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ABSTRACT
Intermittent fevers caused by Plasmodium parasites have been known for
millennia, and have caused untold human suffering. Today, millions of people are
afflicted by malaria each year, and hundreds of thousands die. Historically, the most
successful synthetic antimalarial drug was chloroquine, as it was safe, inexpensive, and
highly efficacious. However, plasmodial resistance to chloroquine now greatly limits its
utility. Previously in our laboratories it has been shown that attachment of a “reversal
agent moiety” to the side chain of chloroquine can result in the restoration of activity
against chloroquine-resistant strains of P. falciparum malaria. In the first part of the
work presented here, a study has been made of the importance of the quinoline ring
substitution pattern to the activity of such reversed chloroquines. The compounds
presented here include those bearing a substituent in the 2-, 5, 6-, 7-, and/or 8- position,
and include those with chloro, bromo, iodo, fluoro, nitro, trifluoromethyl, methyl, and
methoxy substituents. For reversed chloroquines, 2-, 5-, and 8- substituents have been
found to decrease in vitro antiplasmodial activity against P. falciparum relative to 7chloro substitution, whereas 6- and 7- substituted compunds with various substituents
have in many cases similar activity to that of 7-chloro substituted compounds. Little
difference has been observed between 6- and 7- substitution, or between chlorine and a
methyl group in position 6. In most cases these effects on activity are directionally
similar to those observed for chloroquine analogs without an attached reversal agent, but
the magnitude of the effect is generally smaller, suggesting that the activities of reversed
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chloroquines are less affected by modifications to the quinoline ring system than is true
for chloroquine analogs without an attached reversal agent.
The second portion of this work presents an asymmetrical bis-quinoline (PL241)
that is highly active against P. falciparum malaria, with an IC50 of less than 0.1 nM for all
strains tested. Mechanistic studies have been performed in which the substitution
patterns of the two quinoline rings of PL241 are modified in ways that indicate that either
ring system is equally capable of participating in the antimalarial activity of these
compounds. The excellent in vitro antiplasmodial activity of PL241 makes this a
compound of great interest for further development as a potential antimalarial drug.
In the third part of this work, a survey has been made of antimalarial treatments
recommended in the European medical literature from the time of Pliny the Elder (active
in the first century A.D.) through the advent of modern malaria chemotherapy in the early
twentieth century. In the fifteen primary sources utilized in this study, 251 distinct
substances – primarily plants – were identified as having likely been used in the treatment
of malaria. Of the 38 substances that were described in three or more sources, at least
fifteen have been examined by other workers for antiplasmodial activity; in many cases,
they were found to have antiplasmodial activity in vitro or in vivo. However, the
majority of the phytotherapies for malaria identified in this project have not yet been
tested against Plasmodium species, and may provide valuable leads in the search for new
compounds active against drug-resistant malaria.
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Dedication

For Mom, Dad, Michael, and Rolf.

Let the fields and the gliding streams in the valleys delight me.
Inglorious, let me court the rivers and forests.1

1

Virgil: …rura mihi et rigui placeant in vallibus amnes, flumina amem silvasque
inglorius. (Georgics, Book II, Line 485)
iii
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CHAPTER 1

Introduction
But who could revere enough the diligent research of the ancients?
(Pliny, Natural History, Vol. XXVII, II.)2

1.1: Background

Intermittent fevers caused by Plasmodium parasites have been known for
millennia. Examination of Egyptian mummies dating from periods as early as the 1400s
B.C. has revealed Plasmodium parasites (Hawass, 2010; Lalremruata, 2013), and
infection by Plasmodium is believed that to have afflicted mankind for far longer
(Hoeppli, 1959; Hay, 2004; Tanabe, 2010; Prugnolle, 2011). Although the causative
agents and underlying physiological basis of malaria’s effects were only discovered in the
19th and early 20th century (Gilles, 2002), the Ebers Papyrus (ca. 1550 B.C.) refers to
fever with swollen spleen, and malaria symptoms are described in detail in The Yellow
Emperor’s Classic of Internal Medicine (China, age unknown but certainly prior to 400
B.C.; Veith, 1972), in the Atharvaveda (India, ca. 450 B.C.), and by the Greek and Latin
authors (Hippocrates, ca. 400 B.C.; Celsus, 25 B.C. - 50 A.D.; Jones, 1909). Today it is
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Sed antiquorum curam diligentiamque quis possit satis venerari? (Translation by W.H.S.
Jones, 1956.)
1

known that protozoa of the genus Plasmodium cause intermittent fevers, and the resulting
disease is called malaria. At least six Plasmodium species parasitize human beings,
including P. falciparum, P. vivax, P. ovale, P. malariae, P. knowlesi (Strydom, 2014);
recently, an infection by P. cynomologi has also been reported (Ta, 2014). Most malaria
cases are caused by P. falciparum and P. vivax. Although P. falciparum causes the most
fatalities, P. vivax is also a severe problem (Baird, 2014; Quispe, 2014; Price, 2014). In
addition to loss of life, the impact of malaria upon the economic and social welfare of
malaria-endemic nations can scarcely be underestimated (Jones, 1909; WHO, 2013).
Malaria infection is spread between human hosts by the bite of infected female
mosquitoes of the genus Anopheles. In the human host, the parasite initially resides in
the liver, followed by a blood stage. The classical symptom of untreated malaria is the
febrile paroxysm, a dramatic series of chills followed by fever followed by afebrile
periods, although not all victims experience this. The length of time between paroxysms
varies with the species and strain of malaria. In the case of P. falciparum, vivax, and
ovale, the cycle typically lasts 48 hours, while for P. malariae it typically lasts 72 hours
(Warrell, 2002; Schlitzer, 2007; WHO Malaria Report 2013). These are often referred to
in the older literature as tertian and quartan fevers, with fits occurring on the first and
third day (tertian) and on the first and fourth day (quartan; Hoeppli, 1959). Comparison
of genetic analysis of historical materials with historical medical records has provided
additional confirmation that the terms tertian and quartan fever do indeed refer to malaria
(Fornaciari, 2010). If parasitemia is not completely cleared by drug therapy,
recrudescence may occur. In the case of P. vivax and ovale, the liver stage parasites may
2

persist in dormant form so that relapses continue to occur at intervals of months or years
(Warrell, 2002; Schlitzer, 2007).
Malaria today is most prevalent in Africa, Southeast Asia, and South America, but
was formerly common over an even larger range, including much of Europe, Russia, and
North America (Taylor, 1945; Nuttall, Cobbet, and Strangeways-Pigg, 1901; Gilles,
2002). In 2012, the World Health Organization (WHO) estimates that there were 207
million cases, of which an estimated 627,000 were fatal (WHO, 2013). However, the
number of cases and deaths may be higher than estimated by the WHO (Cibulskis, 2011).
Our primary defenses against malaria include control of its vector, the Anopheles
mosquito, and chemotherapy that targets the parasite directly. Work is also underway on
malaria vaccines (Thera, 2012). Antimalarial drugs are used not only to treat cases of
malaria (chemotherapy) but also to prevent them (chemoprophylaxis). Drug resistance is
a severe problem, and there currently exists no class of antimalarial drugs for which
resistance has not been reported. For this reason, the only drug therapies currently
recommended by the WHO in most malaria-endemic regions are combinations of two
drugs from different classes (WHO, 2013).

1.2: The early history of quinoline antimalarials: How chloroquine came to be

In China, treatment of intermittent fevers with quinghao (sweet wormwood,
Artemisia annua L.) has been known at least since the third century A.D. (O’Neill, 2004),
3

but it is often stated that prior to the discovery of cinchona bark in the 16th century, the
West had no really effective cure. Cinchona bark comes from a group of species of
evergreen tree of the genus Cinchona. The trees are native to the western side of South
America and grow there at high altitudes, 5,000-8,000 feet above sea level on average
(Flückiger and Hanbury, 1874; Geerlings, 1999). Different species and varieties contain
widely varying amounts of alkaloids. The most valued species was formerly Cinchona
ledgeriana, also known as Cinchona officinalis 'Ledgeriana', which contains up to 15%
quinine in its bark (Taylor, 1945, Geerlings, 1999). Although the native people may not
have used cinchona bark to treat malaria (and in fact it is generally thought that malaria
did not exist in the New World before the arrival of the Spaniards, although this has been
debated (Guerra, 1977; Yalcindag 2012; de Calda, 2005)), it is said that they were aware
that the bark of the cinchona tree had medicinal properties (Greenwood, 1992). Gaspar
Caldera de Heredia wrote in 1663 that the Spanish Jesuit priests had observed miners in
the province of Quito using an infusion of the bark in water to treat chills resulting from
low temperatures (Guerra, 1977; Jarcho, 1993). The Jesuits are said to have discovered
the antimalarial efficacy of cinchona bark after using it to relieve the chills of intermittent
fevers. The bark was soon imported to Europe. Although the new treatment did not meet
at once with universal acceptance, it gradually became the accepted remedy for
intermittent fevers (Guerra, 1977; Jarcho, 1993). For this and other purposes, huge
quantities were exported to Europe from the South American colonies and later from the
independent South American countries, to the extent that the trees were almost eliminated
in some regions. By the late nineteenth century, cinchona trees were also being
4

cultivated successfully outside of their native habitat on a large scale by the British in
India and by the Dutch in the East Indies. By the early twentieth century, the Dutch
plantations in Java produced the bulk of the world's cinchona bark (Flückiger and
Hanbury, 1874; Taylor, 1945; Greenwood, 1992).
Of the constituents found in cinchona bark, those to which antimalarial activity is
usually ascribed are the crystallizable alkaloids occurring in the largest quantity - quinine,
quinidine, cinchonine, and cinchonidine (Figure 1):

HO
H

H3CO

N

HO
H

N

N

Quinine

HO

N

Cinchonidine

H
H

H3CO

N

HO

H

N

N

N
Quinidine

H

Cinchonine

Figure
1: Cinchona alkaloids
Figure 1: Cinchona
alkaloids.

Of these very closely related compounds, quinine has the best ratio of antimalarial
activity to toxicity (quinidine is more active than quinine but may also be more dangerous
to administer; Chopra, 1938; Wesche, 1990; Warhurst, 2003; White, 2007). Evidence
has also been found that the four alkaloids above act synergistically, and that there may
be other components of cinchona bark that add to this synergistic action (Baranger, 1948;
5

Druilhe,1988; Merkus, 1988; Wesche, 1990; Rasoanaivo, 2011). Quinine was isolated
from cinchona bark in 1820 by Pierre-Joseph Pelletier and Joseph Bienaimé Caventou
(although possibly also earlier), and its chemical formula was determined by Adolph
Strecker in 1854 (Pelletier and Caventou, 1820; Strecker, 1854; Kaufman, 2005). The
structure was elucidated piecewise by Zdenko Hans Skraup (1879), W. Königs (1894),
and Heinrich Hörlein and Paul Rabe (1907) (see Figure 2; Schulemann, 1932):

Meroquin moiety
(Königs, 1894)
N
Rabe-Hörlein (1907)

HO
H3CO

Quinoline moiety
(Skraup, 1879)
N

Figure
Figure 2:
2: Elucidation
Elucidation of
of quinine's
quinine's structure
structure (adapted
(adapted from
from Schulemann,
Schulemann, 1932).
1932)

Administration of purified quinine allowed for better dosage control (since amounts of
alkaloids vary in crude bark) and also may have reduced side effects (nausea, blurred
vision, and depression of the heart were reportedly caused to a greater extent by
cinchonine and quinidine than by quinine (Chopra, 1938)). The bark of C. ledgeriana
contains mostly quinine, while another species, C. succirubra, contains relatively more
quinidine, cinchonin, and cinchonidine, and for a long time continued to be grown in
order to provide supplies of these compounds (Taylor, 1945). Although total synthesis of
quinine has been achieved (Rabe and Kindler, 1918, Woodward and Doering, 1944 and
1945 (see also Smith and Williams, 2008); stereoselective synthesis by Stork, 2001), a
commercially viable synthesis of this complex natural product with four chiral centers
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has never been found.
Despite quinine's value, it had disadvantages. Firstly, the supply of a natural
product - especially one that could grow only under a fairly narrow range of conditions might be threatened (as was feared with the over harvesting of cinchona trees in South
America, and as was experienced by the Germans during World War I and by the Allies
during World War II). Secondly, because of the Dutch monopoly, it was desirable for
other powers to find a replacement for quinine for economic reasons (Greenwood, 1992
and 1995; Slater, 2009). Thirdly, to be really effective, quinine needed be taken several
times per day, and was not without side effects (nausea, tinnitus, reduction in hearing
ability, vertigo, and vision disturbances; Goodman and Gilman, 1985; Mühlens, 1937).
The development of synthetic organic chemistry led to hope of a synthetic substitute for
natural quinine. Synthetic medicaments effective in lowering fevers had already been
discovered by the end of the 19th century - notably, the analgesics and antipyretics,
including Antifebrin (1886) and Phenacetin (1887; Hückel, 1962). However, these were
not effective treatments for malaria (Guttmann and Ehrlich, 1891).
The first encouraging result came in 1891 with the histological stain methylene
blue (Figure 3):
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Histological stains were of interest as possible medicines both because of their known
bacteriocidal activity and because of their selective and specific affinity to certain cell
groups and parts of cells (Guttmann and Ehrlich, 1891; Mietzsch, 1951). Methylene blue
was known to have an affinity for the cells of Plasmodium and was already used in
malaria diagnosis. Paul Ehrlich and Paul Guttmann used methylene blue to treat two
malaria patients with apparent success and no serious side effects (Guttmann and Ehrlich,
1891). In subsequent trials by other researchers, the administration of methylene blue
often failed to give the same encouraging results and in at least one study was invariably
attended by unpleasant side effects (severe stomach pain and vomiting); meanwhile other
researchers confirmed Guttmann and Ehrlich's findings and found no serious side effects
(Lava, 1891; Mya, 1892; and Thayer, 1892, results summarized in Supplement to the
British Medical Journal, 1891 and 1892). The difference in side effects observed
possibly could have been due to the purity of the dye used, in light of the fact that
Guttmann and Ehrlich specify the use of chemically pure methylene blue, whereas
historically the dye has often been used for staining applications at relatively low purity.
Methylene blue was sometimes recommended for treatment of malaria during the early
20th century (Potter's Therapeutics, Materia Medica, and Pharmacy, 1917, contains the
following recommendation: "Methylene blue, next to quinine, has been considered as the
most valuable drug. It is given in 2-grain doses every 4 hours”). More recently, the
clinical efficacy of methylene blue against malaria has been reëxamined (Akoachere,
2005; Meissner, 2006).
The first useful synthetic antimalarials, pamaquine (Plasmochin, Plasmoquine,
8

1924/5), quinacrine (Atebrin, Atabrine, Mepacrine, 1932), chloroquine (Resochin, 1934),
and sontoquine (Sontochin, Nivaquine, 1936), were all developed between the World
Wars by researchers at Farbenfabrik Bayer, Elberfeld (then part of I.G. Farbenindustrie).
All except for quinacrine were quinoline compounds (Figure 4):
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Figure 4: Synthetic antimalarials from the Bayer research team at Elberfeld.
Figure 4: Synthetic antimalarials from the Bayer research team at Elberfeld.

The research team at Elberfeld embarked on structure activity relationship studies having
first quinine and then methylene blue as starting points, with the goal of finding a
synthetic antimalarial with an improved ratio of activity to toxicity. Advances in
techniques of animal testing by Elberfeld's Wilhelm Roehl - a former student of Paul
Ehrlich - allowed the reliable screening of thousands of candidate compounds, and
techniques developed by his successor, Walter Kikuth, together with Lilly MudrowReichenow, allowed even the differentiation between activity against the sexual and
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asexual stages of the parasite (Kikuth, 1942; Andersag, 1948; Slater, 2009). Compounds
successful in animal models (the Plasmodium relictum infection of canaries) were then
tested against human infection. Germany had no colonies at that time and no body of
soldiers and staff in malaria endemic regions, and domestic cases of malaria were by then
rare. Bayer's human testing was therefore contracted to Franz Sioli at the DüsseldorfGrafenberg psychiatric hospital, who was able to administer the drug candidates to
neurosyphilis patients during the normal course of malaria therapy (Slater, 2009).3
The first of the successes to emerge from the Elberfeld malaria project was
pamaquine (Figure 4), synthesized in 1924 (Schulemann, 1932, Andersag, 1948). The
drug was the first successful application of a principle called by its developers "basic
alkylation" (basische Alkylierung; Mauss and Mietzsch, 1933; Schönhöfer, 1965), that
would then be applied successfully in quinacrine, chloroquine, and sontoquine. Extension
of the dimethylamino substituent of methylene blue into a basic side chain - synthesized
by Fritz Schönhöfer and August Wingler - had led to improved activity, but had also
increased toxicity. Attachment of a basic side chain to the quinoline nucleus of quinine
was next attempted by Fritz Schönhöfer. It was initially planned to put the aminoalkyl

3

Malaria therapy, developed by the Austrian doctor Julius Wagner Ritter von Jauregg, was the
only known method of curing late stage syphilis at the time. The patient was infected with
malaria and the high fever was allowed to kill the trypanosomes (although this mechanism of
action has been disputed); the patient was then cured of their malaria with quinine. This
treatment for syphilis was widely practiced in Europe and the United States, and Wagner Ritter
von Jauregg won the 1927 Nobel Prize for his discovery. In addition to saving thousands of lives,
malaria therapy provided scientists in many countries with an invaluable opportunity to test new
medicines for malaria (Covell & Nicol, 1951; Chernin, 1984; Freitas, 2014). Interestingly, the
induction of a high body temperature for the treatment for syphilis, together with guaiacum
therapy, was used at least as early as 1519 (Forrester, 2005), and the disappearance of late stage
syphilis after incidental infection with quartan fever was noted by Jean Fernel in his great work of
philosophical medicine, De Abditis Rerum Causis (On the hidden causes of things; 1542).
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group at the 6-position (replacing the methoxy group of quinine; see Figure 5 for the
numbering system of quinoline compounds); however, when this compound proved too
difficult to purify, Schönhöfer synthesized the 8-amino derivative instead (which could
be steam distilled).
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Figure 5: Quinoline ring numbering system
Figure 5: Quinoline ring numbering system.

The resulting compound had an activity far superior to quinine in bird malaria. A 6methoxy substituent was then introduced by the project leader, Werner Schulemann, by
analogy to quinine; this, too led to a jump in activity, yet the results against human
malaria were disappointing (Schönhöfer, 1965). Further variation of the basic side chain
- to that which would later be used in chloroquine - led at last to Pamaquine (then called
Plasmochin or Plasmoquine) in 1924, the first successful synthetic antimalarial (Figure 6;
Slater, 2009):
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Figure 6: Development of pamaquine (Plasmochin).
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It was moreover reported that the drug was active against the gametocyte stage of
Plasmodium (unlike other known antimalarials), and therefore offered hope that perhaps
malaria could not only be treated, but eradicated by blocking transmission (Schulemann,
1932; Kikuth, 1942). The new compound was also active against the liver stage of P.
vivax malaria and therefore offered a permanent cure to sufferers from relapsing malaria
(Schulemann, 1932; Burrows, 2011). Unfortunately, it had significant toxic side effects,
rendering it less than ideal for long-term administration as a prophylactic. Although it is
often implied today that pamaquine never came into common use due to its toxicity, this
is not entirely true; for instance, in 1942 the drug was manufactured by ICI in Great
Britain in amounts "sufficient for 32 million tablets" (Greenwood, 1995, Slater, 2009).
Researchers at Bayer appreciated that the toxicity of pamaquine was a drawback and later
launched Certuna (also known as Cilional), a related compound discovered by
Schönhofer (Figure 7):
HO
N
HN

N

Figure 7: Certuna (Cilional).
Figure 7: Certuna (Cilional).

Certuna was less toxic, but also less effective than Plasmochin (Chopra, 1938; Slater,
2009), and was never a great success. Plasmochin and Certuna remained the only drugs
active against the gametocyte stage of Plasmodium until being supplanted by the less
12

toxic des-diethyl pamaquine derivative, Primaquine, following World War II (Figure 8;
Slater, 2009, Burrows, 2011). Primaquine was synthesized by Robert C. Elderfield and
coworkers at the University of Michigan (Elderfield, 1946).
H3CO
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NH2

Figure 8: Primaquine.
Figure 8: Primaquine.

In addition to quinolines, acridines - their close chemical relatives - were also of
interest as potential antimalarials. Their development would ultimately lead to the
development of chloroquine, a drug that would save more lives than any other synthetic
antimalarial. Acridine compounds with antibacterial properties were already known. At
Elberfeld, Fritz Mietzsch and Hans Mauss carried over the principle of basic alkylation to
the acridine nucleus (along with a variety of other heterocycles), and discovered
quinacrine (then called Atebrin or Atabrine, also called mepacrine or Italchina).
Quinacrine shared with quinine the point of attachment of its alkylamine residue, and
shared with pamaquine a methoxy group para to the ring nitrogen (Mauss and Mietzsch,
1933) as well as the identical aminoalkylamino side chain. In the third fused ring, meta
to the nitrogen of the middle ring, a chlorine atom was introduced (Figure 9):
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HN
H3CO
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Cl

Figure 9: Quinacrine (Atebrin, Atabrine, Mepacrine).
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That introduction of a chlorine atom might lead to active compounds was
discovered accidentally. During synthetic work on 8-aminoquinolines, Schönhöfer had
used tin (II) hydrochloride reduction to reduce a 6-alkyl-8-nitroquinoline, unaware that
this had sometimes been found to introduce a chlorine atom into the quinoline ring
system. The resulting compound had excellent activity, but turned out to contain
chlorine. This inspired Mauss and Mietzsch to introduce halogens into their acridine
compounds (Schönhöfer, 1965).
Quinacrine was highly successful as an antimalarial, being more active than
quinine and having fewer side effects. Its tolerability made it suitable for prophylactic
use, and it was used extensively for this purpose, although long term use tended to turn
the skin yellow (Mietzsch, 1933, Kikuth, 1942, Greenwood, 1995, Slater, 2009). It was
manufactured in the United States as well as Germany (having been jointly licensed to
Bayer and to its American partner, the Winthrop Chemical Company), although in the
United States there were reports of quinacrine-related psychosis, similar to that later
observed for mefloquine (Slater, 2009). During the Second World War, it was
manufactured by both sides on a large scale (Greenwood, 1995).
During quinacrine’s development, it was observed that the presence or absence of
a 7-chloro substituent had greater influence upon antimalarial activity than did that of the
methoxy group (Andersag, 1948). If one imagines removing the 6-methoxy containing
ring from the structure of quinacrine, one obtains a quinoline compound with the
structure of chloroquine (Figure 10):
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Thus, by analogy to quinacrine, quinoline compounds with the aminoalkyl substituent
opposite the ring nitrogen were made (Andersag and Breitner, 1956). Initially however,
these 4-aminoquinoline compounds could not be made without a substituent in the 2position, and such compounds were inactive against malaria. However, the clever
adaptation of a newly patented synthetic route to kynurenic acid (2-carboxy-4-quinoline,
see Figure 11 below) allowed Hans Andersag to make 4-aminoquinolines with the 2position unsubstituted (Figure 11; Wislicenus, 1889; Hoffmann-LaRoche, 1933;
Andersag, 1948):
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Figure 11: Hans Andersag's synthetic route to 2-unsubstituted 4-aminoquinolines.

Among these he made the 7-chloro-substituted chloroquine (then called Resochin), and
together with Stefan Breitner and Heinrich Jung he made sontoquine shortly thereafter
(Sontochin in German, later also called Nivaquine, Figure 12; Andersag, 1948, Mietzsch,
1951; Andersag, 1956).
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Figure 12: Sontoquine (Sontochin, Nivaquine).
Figure 12: Sontoquine (Sontochin, Nivaquine).

Yet chloroquine was abandoned by Bayer in favor of sontoquine, either because Roehl's
tests found toxicity in animal subjects, or because human toxicity was observed by Sioli
(Slater, 2009; it has been suggested that since the human test subjects were in the late
stages of syphilis, it is possible that unusual physical symptoms would occur that might
be attributed erroneously to the test compound (Riscoe, personal communication)).
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However, chloroquine would soon be rediscovered.
In 1939, the National Research Council of the United States launched an
antimalarial research initiative that by the end of the Second World War had grown into a
massive screening and development program involving industry, government, and
academic research labs alike. The program collaborated with researchers in Britain and
Australia, and screened over 14,000 compounds against malaria, initially identifying
quinacrine as the best compound but later fixing upon chloroquine (Wiselogle, 1946;
Coatney, 1952; Greenwood, 1992; Slater, 2004 and 2009). Both chloroquine and
sontoquine had been patented in the United States by Winthrop, but they were not
included in the screening program until sontoquine was found in the possession of troops
captured at Tunis in 1943. Field trials, conducted by the Australian medical officer Neil
Hamilton Fairley, demonstrated that chloroquine was even more effective than
sontoquine (Greenwood, 1995; Slater, 2009). Chloroquine entered clinical use in 1947.
Because of its efficacy and lack of toxicity - even when administered to pregnant women
and children - chloroquine was the standard antimalarial therapy for decades (Schlitzer,
2007; Slater, 2009).

1.3: Chloroquine resistance

There is substantial evidence that chloroquine acts by interference with the heme
detoxification mechanism of Plasmodium species (Sullivan, 1996; Egan, 2005; Martin,
2009). When in the red blood corpuscle, Plasmodium species obtain nutrients by
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digestion of hemoglobin (Kirk, 2014). During the blood stage of P. falciparum malaria,
the concentration of parasites in the blood has been estimated to be as high as millions of
organisms per milliliter of blood (Dondorp, 2005, Pisciotta, 2007), which can consume
60-80% of the body’s hemoglobin (Francis, 1997). Although the parasite utilizes the
amino acid portion of hemoglobin as a food source, it does not utilize the central oxygenbinding porphyrin of hemoglobin, heme (Slater, 1991). In the acidic, aqueous
environment of the food vacuole, pairs of heme molecules link together into heme dimers
in which the propionate side chain of one molecule coördinates to the iron atom of the
other (Slater, 1991, Egan, 2008). Both free heme and heme dimers are toxic to the
parasite and if allowed to accumulate, would lead to its death by oxidative or osmotic
stress (Francis, 1997, Pisciotta, 2007). To avoid this, the parasite is able to initiate the
crystallization of the heme dimers into an aggregated structure, hemozoin, which is
insoluble in the digestive vacuole and is thus rendered non-toxic (Fitch, 1987, Slater,
1991). The structure of hemozoin is thought to be a large crystal in which the heme
dimers associate by hydrogen bonding (Hänscheid, 2007, Egan, 2008). The process by
which hemozoin formation is initiated, as well as the exact location of its formation, are a
matter of debate, but the process may occur at the surface of lipid droplets within the
acidic, aqueous environment of the digestive vacuole (Jackson, 2004, Oliveira, 2005 (for
other protozoal diseases), 2007, Egan, 2007; Pisciotta, 2007). Once heme has
crystallized, it remains within the digestive vacuole, where it may be stored within lipid
droplets (Pisciotta, 2007). Microscopy of malaria parasites reveals large, dark masses of
crystallized hemozoin, referred to as malaria pigment; observation of malaria pigment in
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the blood of patients with fever has been used since the nineteenth century to diagnose
malaria (Sullivan, 2002). Malaria pigment accumulates in the brain, spleen, and blood
vessels of malaria victims and can be observed upon autopsy without a microscope – the
earliest existing written description of malaria pigment dates to 1771, although its
presence was not connected with malaria until 1849 (Sullivan, 2002, Hänscheid, 2007).
When chloroquine is present in the bloodstream, it passively diffuses into the red
blood corpuscle, into the parasite, and thence into the parasite’s digestive vacuole (Kirk,
2013). Chloroquine’s accumulation in the digestive vacuole has been estimated as one
thousand to several thousand times greater than the concentration in uninfected
erythrocytes (Foley, 1997, Kelly, 2002, Sullivan, 2002). Once inside the vacuole, the
quinoline ring system of chloroquine is thought to bind to the heme dimer, preventing the
formation of hemozoin (Dorn, 1998; Roepe, 2002). The continued presence and
accumulation of drug-bound heme dimers then leads to the parasite's death, possibly by
oxidative and osmotic stress (Sullivan, 1996; Lakshmanan, 2005; Egan, 2005; Martin,
2009) (Figure 13).
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Figure 13: Putative mechanism of chloroquine.

Inhibition of hemozoin formation is not the only possible mechanism of action for
chloroquine, but it is the mechanism for which there is the most evidence. Other
possibilities that have been explored include DNA intercalation, interference with
polyamine biosynthesis, or interference with enzyme activity due to a change in the pH of
the digestive vacuole (Hahn, 1966, Bolte, 1979, Yayon, 1985, Krogstad, 1987,
Schlesinger, 1988). It is quite possible that chloroquine may act by more than one
pathway. In this work, however, it has been assumed that chloroquine’s primary mode of
action is inhibition of hemozoin formation within the digestive vacuole.
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The heavy and widespread use of chloroquine and other antimalarials, as well as
the increased size, density, and mobility of the world's population, gave rise to concern
early on that drug resistant strains of malaria would emerge. By the end of the 1940s,
resistance to the antimalarial proguanil (Figure 14), pamaquine, and even quinine had
been artificially induced in the laboratory, and proguanil resistance had been observed in
the field in Indonesia and Malaysia (Bishop, 1951).
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Figure 14: Proguanil.

In the 1950s, chloroquine resistant strains of P. falciparum were reported in Southeast
Asia and South America (Young, 1961; Rathore, 2005; Packard, 2014). Since that time,
resistance has become widespread (WHO, 2013). Chloroquine resistant parasites exhibit
reduced accumulation of chloroquine within the digestive vacuole (Krogstad, 1987).
Chloroquine resistance in P. falciparum has been linked to one or more mutations
(importantly, K76T) in the transporter PfCRT (Plasmodium falciparum chloroquine
resistance transporter), present in the membrane of the parasite’s digestive vacuole. It is
thought that this mutated transporter is able to export chloroquine out of the vacuole, thus
allowing the heme detoxification process to proceed normally (Fidock, 1996;
Lakshmanan, 2005; Martin, 2009; Roepe, 2011). Additional mutations in other
transporters, such as PfMDR1 (Plasmodium falciparum Multidrug Resistance
Transporter 1) and PfMRP1 (Plasmodium falciparum Multidrug Resistance Protein 1),
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have been linked with chloroquine resistance in some strains of chloroquine resistant
parasites (Kirk, 2013).

1.4: A strategy to overcome chloroquine resistance

An attractive strategy to find new antimalarial compounds is the modification of
existing drugs to which resistance exists in a way that restores their activity against drug
resistant strains. Among other approaches, this can be done by the attachment of a
reversal agent. Reversal agents are drugs that are able to restore the activity of a drug to
which resistance exists, when co-administered. When given together with chloroquine,
the calcium channel blocker Verapamil (normally used to treat high blood pressure,
angina, and cardiac arrhythmia) and the tricyclic antidepressant Desipramine (among
others) have been observed to have this effect (Figure 15; Martin, 1987; Krogstad, 1987;
Bitonti, 1988):

H 3CO
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N
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N
Desipramine

Figure 15: Two known reversal agents for chloroquine resistance in P. falciparum malaria.

Reversal agents appear to work by reducing efflux of chloroquine from the food vacuole
in some manner, perhaps by blocking the chloroquine resistance transporter, PfCRT
(Bray, 2005; Martin, 2009). However, if such a reversal agent were to be coadministered with chloroquine therapeutically, it is possible that the reversal agent drug,
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which has therapeutic activity of its own, might have undesirable effects at the
concentration needed for it to accumulate in the parasite's digestive vacuole. In Dr.
Peyton’s laboratory, it has previously been shown that the combination of a chloroquinelike moiety with a reversal agent-like moiety in a single molecule – which was named a
"reversed chloroquine" (RCQ) compound – may be an effective approach through the
initial compound PL01 (Figure 16), which links a chloroquine-like structure with that of
the anti-depressant Imipramine (Burgess, 2006; Peyton, 2012):
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Figure 16: The reversed chloroquine-type compound PL01 combined features of chloroquine and
imipramine. In vitro antiplasmodial activity is shown as IC50, the concentration required to inhibit
plasmodial growth by 50%.

The hybrid compound had roughly equal activity in vitro against both chloroquine
sensitive and chloroquine resistant strains of P. falciparum,4 and its activity was not at all

4

Antiplasmodial activity is given herein as IC50, the concentration required to inhibit plasmodial
growth by 50%. The strains of P. falciparum used in this work for in vitro testing were D6, a
chloroquine sensitive strain, and Dd2 and 7G8, two chloroquine resistant strains originally
isolated in southeast Asia and Brazil, respectively. In quoting results from other research groups,
when IC50 values are given for compound activity against other P. falciparum strains, it is noted
whether these are chloroquine sensitive (CQS) or chloroquine resistant (CQR) strains.
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diminished relative to that of chloroquine (Burgess, 2006). A structure-activity
relationship study was then performed in which the reversal agent moiety attached to the
4-amino side chain of the 7-chloroquinoline nucleus was varied (see Figure 17 for
representative compounds; Andrews, 2006, Burgess, 2008, Burgess, 2010, Andrews,
2010, Gunsaru, 2010, Peyton, 2012):
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Figure 17: Representative compounds from the initial structure-activity relationship study during which
reversed chloroquine-type compounds were developed.

We believe that reversed chloroquine-type compounds act against P. falciparum
by the same mechanism as chloroquine (i.e. by inhibition of the detoxification of heme by
conversion to hemozoin). This is supported by in vitro studies in which it has been
shown that 7-substituted reversed-chloroquines are able to bind heme, to inhibit the
formation of β-hematin, and to inhibit the formation of hemozoin in P. falciparum
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parasites in vitro (Burgess, 2010). However, it is possible that this may not be the correct
or only mechanism of these compounds.
During this work it was assumed initially that changes in substitution pattern of
the quinoline ring moiety of the reversed chloroquines would only lead to a decrease in
activity relative to the 4-amino-7-chloro substitution pattern seen in chloroquine, since it
has previously been shown for other 4-aminoquinoline antimalarials that the 7-chloro
substitution pattern confers optimal activity (see below). However, as part of a
mechanistic investigation of the reversed chloroquine analogue PL06, the des-chloro
analogue PL64 was synthesized (Figure 18; Burgess, 2008; Burgess, 2010):
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Figure 18: PL06, chloroquine, and their des-chloro analogues

Contrary to what was expected based on the known low activity of des-chloro
chloroquine (PL127, Figure 18), this compound had excellent antiplasmodial activity
against both chloroquine sensitive and chloroquine resistant P. falciparum malaria
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parasites. This indicated that modification of the quinoline ring substitution pattern of
reversed chloroquine-type compounds might, in fact, be a useful line of inquiry (Burgess,
2010).

1.5: The effect of the quinoline ring system substitution patterns on the antimalarial
activity of chloroquine-like compounds

During the original development of chloroquine and sontoquine during the 1930s
and 1940s by researchers at Farbenfabrik Bayer, Elberfeld, 4-aminoquinolines with a
large number of different quinoline ring substitution patterns were tested, but much of the
data on the relative antimalarial efficacy of these compounds was never made public.
The following information may be gleaned from the patent literature and various
publications:

1) From the patent literature, 4-aminoquinolines may have been made and tested with
at least the following substitution patterns (see also Figure 19):
- 2-methyl-6-methoxy (Schulemann, 1929; and Schulemann, 1930)
- 2-methyl (Ibid)
- 7-halo, alkyl, hydroxyl, thiol, alkoxy, alkylmercapto, cyano, thiocyano, amino,
alkylamino, and trifluoromethyl (Andersag, 1939)
- In the 3 position of the above 7-substituted quinolines, alkyl, aryl, aralkyl (Ibid)
- In the 2 position of the above 7- substituted quinolines, an unknown alkyl
substituent, probably methyl (Ibid)
- 7-chloroquinolines with additional substituents from the above in one or more
additional positions (3,5-, 6-, or 5,6-) (Ibid)
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2) Of these, the most effective compounds contained a halogen atom in the 7position. The halogens used included fluorine, chlorine, bromine, and iodine.
Amongst chlorine, bromine, and iodine, roughly equal antimalarial activity was
observed, whereas substitution with fluorine decreased activity. Many other 7substituted compounds were also active.
3) The presence of a methyl group in the 3-position of 7-haloquinolines apparently
did not reduce the efficacy of these compounds. Larger 3-alkyl groups resulted in
reduced efficacy. For other 7-substituted compounds, 3-substitution did not always
result in reduced efficacy and sometimes increased efficacy.
4) An alkyl group in the 2-position resulted in a compound with lowered activity
regardless of any other substituents.
In monographs published by Frederick Y. Wiselogle (1946) and G. Robert
Coatney (1952) on the results of the American-British-Australian wartime screening
project, it is further observed that a substituent in the 8-position also reduces activity.
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Coatney also states that the activity of compounds with a relatively short
aminoalkylamino chain is more susceptible to variation upon modification of the
quinoline ring system substituents than is the activity of compounds with a longer chain.
The advent of chloroquine resistance has inspired research on the effect of
varying quinoline ring substitution of 4-aminoquinolines upon activity against
chloroquine resistant strains (De, 1996; De, 1998; Vippagunta, 1999; Bhattacharjee,
2001; Stocks, 2002; Kaschula, 2002; Madrid, 2005; Hocart, 2011; Pou, 2012; Nsumiwa,
2013). The results of this research can be summarized as follows (see also Figure 20,
below).

somewhat decreases activity
somewhat
decreases
activity

HN

R
tolerated if 7-subsituent
is also present

N
confers
strongly decreases activity
optimal
activity
strongly decreases activity
(moderate
EWG)
N

R=
n

N

(examples)

n = 2 or 3

Figure 20: Effect of quinoline ring substitution pattern on chloroquine analogs
without an attached reversal agent

As for the position of substituents, 7-substitution is optimal whereas moving the
substituent to position 6 results in either diminished or poor efficacy (De, 1996;
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Vippagunta, 1999; Hocart, 2011; Pou, 2012). Substitution in the 2- or 8-position
invariably gives poor efficacy (De, 1996; Madrid, 2005; Hocart, 2011). This is also true
for 5- substitution, but to a lesser extent (Madrid, 2005). With only hydrogen, very poor
efficacy is observed (De, 1996; Vippagunta, 1999; Hocart, 2011). As to the nature of the
substituent, among the halogens some workers have found that chlorine is optimal, while
other workers have found that there is little difference between iodine, bromine, and
chlorine (De, 1998; Vippagunta, 1999; Kaschula, 2002; Hocart, 2011). Fluorine gives
lowered efficacy (De, 1998; Kaschula, 2002; Pou, 2012). Electron-donating groups
(amino, hydroxy, methoxy) in the 7-position generally reduce efficacy, often
dramatically, and a strong electron-withdrawing group (nitro or trifluoromethyl)
frequently reduces efficacy as well. In the case of the 7-trifluoromethyl group, the effect
is not as dramatic and there are notable exceptions (De, 1998; Vippagunta, 1999; Stocks,
2002; Kaschula, 2002; Madrid, 2005; Hocart, 2011; Pou, 2012). Finally, there is some
evidence for resistance reversal relative to chloroquine in the case of 7-iodo substitution,
7-trifluoromethyl substitution, 7-nitro substitution, or simultaneous 3-methyl and 7chloro substitution (the substitution pattern of sontoquine, see Figure 12; De, 1998;
Vippagunta, 1999; Stocks, 2002; Pou, 2012). Additionally, there is evidence that a bulky
substituent in position 7 (phenoxy, Madrid, 2005) or in position 3 (trifluoromethoxy
phenyl, Pou, 2012) may enhance activity against resistant parasites.

The research described above concerns chloroquine analogues without an
attached reversal agent. As discussed in section 1.4, the activity of chloroquine analogs
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with reversal agent attached may be affected differently by changes to the quinoline ring
system substitution pattern. Particularly in light of the results described above for
resistant parasites, a study of the effects of quinoline ring substitution pattern on the
antiplasmodial activity of reversed chloroquine-type compounds seems well warranted.
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CHAPTER 2:
Quinoline Ring-Modified Analogues of Reversed Chloroquine-type Compounds

In the present work, a study has been made of the effect of the quinoline ring
substititution pattern upon the activity of chloroquine analogs with a reversal agent
attached. The 53 compounds synthesized in this work include those bearing a substituent
in the 2-, 5-, 6-, 7-, or 8- position, as well as some disubstituted compounds, and include
those with chloro, bromo, iodo, fluoro, nitro-, trifluoromethyl, methyl, and methoxy
substituents, in addition to unsubstituted compounds (see Appendix B, Table B1 for
structures).
In vitro testing of the new compounds has revealed a wide range of activity
against P. falciparum malaria. The bar graph in Figure 21, below, shows the in vitro
antiplasmodial activities of a selection of the compounds tested against two strains of P.
falciparum (D6, a chloroquine sensitive strain, and Dd2, a chloroquine resistant strain).
As above, antiplasmodial activity is given as IC50, the concentration required to inhibit
plasmodial growth by 50%. For comparison, chloroquine (CQ, far left) is also included.
For methods used to obtain these results, see Experimental Methods, Chapter 5. For
antiplasmodial activities of all ring-modified reversed chloroquine compounds made in
the present work, see Table B1, Appendix B.
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Figure 21: In vitro antiplasmodial activities of a selection of the compounds in the present work against
chloroquine sensitive and chloroquine resistant strains of Plasmodium falciparum. Chloroquine (CQ) is
shown at the far left.

Some of the study compounds performed at least as well as chloroquine, and as well as
the original 7-chloro reversed chloroquine-type compounds, while others had greatly
diminished activity (see Figure 21, and Figure 22, below). The following is a summary
of the results obtained, and a discussion thereof.
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2.1: Results
2.1.1: Effect of a substituent in the 2-, 5-, or 8- position
Compounds with a predominantly electron-withdrawing substituent in the 2- or 8position (either chlorine or a trifluoromethyl group, see PL302 and PL149, figure 22,
below, and others in Table B1, Appendix B) had little activity in the IC50 range tested, in
accord with the findings described above for chloroquine analogues without an attached
reversal agent (Chapter 1, section 1.5). It was not clear however whether this was due to
the lack of a substituent in the 7- position, or to the presence of a substituent in the 2- or
8- position as such. Therefore, compounds were synthesized with 2,7- and 7,8disubstitution (PL398 and PL305). These were also found to have little activity, and so it
seems that it might be the presence of the substituent in these positions that is responsible
for the decrease in activity for 2- and 8- substituted compounds relative to those
substituted with a 7- chloro substituent alone (Figure 22 and Table B1, Appendix B):
HN

N

HN

N

N

N

CF 3

N

N
N

Cl

PL302

PL398
IC 50 660 nMD6, 540 nMDd2

IC 50 >2500D6, 1294 nMDd2
HN

N

CF 3

HN

N

N
N

N

N

N

CF 3

IC 50 > 250

N

Cl

PL149
nMD6,

Cl

>250

nMDd2

PL305
IC 50 108 nMD6, 491 nMDd2

Figure 22: Effect of 2- or 8- substitution compared to 7-substitution and 7,8, or 2,7-disubstitution
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Since only electron-withdrawing substituents were tested initially, it was not
known whether the trend of reduced activity for 2- and 8- substituted compounds would
also be observed for compounds with an electron-donating group in the 2- or 8- position.
Therefore, an 8-methoxy substituted compound (PL390) and two 8-methyl substituted
compounds (PL393 and PL394) were synthesized and tested. Two of these (PL390 and
393) proved to have equally low activity when compared to their analogue containing an
electron-withdrawing group (PL284), while a third molecule with a larger reversal agent
moiety (PL394) had somewhat improved activity, although still far lower than its 7chloro analogue, PL271 (see Figure 23, below and Table B1, Appendix B). Thus, based
on this limited sample, the reduction of activity observed with electron-withdrawing 2and 8- groups seems to extend to electron-donating groups as well, but perhaps to a lesser
extent for compounds with a larger reversal agent moiety.
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N
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N

N
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N

N

PL284

IC 50 465 nMD6, >2500 nMDd2

Cl

N

Cl

PL271

IC 50 66 nMD6, >250 nMDd2

N

PL06
IC 50 1.9 nMD6, 2.6nMDd2

Figure 23: Effect of 8- substitution with a methyl or methoxy substituent, compared with 7- or 8-chlorosubstitution.
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A 7-chloro-2-methyl substituted compound was also tested (PL399). It proved to
have much lower activity than that of its 7-chloro-substituted analogue (PL106), but its
activity was much increased relative to that of the 7-chloro-2-trifluoromethyl- substituted
analogue, PL398 (Figure 24, below, and Table B1, Appendix B). For chloroquine
analogues without an attached reversal agent, a 2-methyl substituent in addition to a 7chloro substituent is also known to lower activity (Andersag, 1948; Wiselogle, 1948;
Vippagunta, 1999; Pou, 2012).

HN

N
N

Cl

N

N

CH 3
PL399

IC 50 = 12 nMD6, 38 nMDd2
HN

HN

N

N
N

N
Cl

N

N

PL 106
(Gunsaru, 2010)

IC 50 = 3.0

nMD6,

6.0

nMDd2

Cl

N

CF 3

N

PL398
IC 50 = 660 nMD6, 540 nMDd2

Figure 24: In a series of 7-chloro substituted compounds, an added 2-methyl substituent decreased activity,
but to a smaller extent than an added 2-trifluoromethyl substituent.

It also was thought desirable to produce 5-substituted compounds for study.
However, a synthetic challenge was presented by the production of a 4-aminoquinoline
compound with a substituent in position 5 alone. In the course of synthesis of the 7substituted 4-chloroquinolines needed to produce the compounds under study, a small
quantity of the 5-substituted regioisomer was usually (but not always) produced during
the initial cyclization step (Figure 25):
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R = F, Br, I,CF 3, Me, OMe

Figure 25: The cyclization step of the Gould Jacobs reaction, a representative quinoline ring-forming
reaction.

However, the isolation of a sufficient quantity of pure 5-regioisomer – which was nearly
always produced in a much smaller quantity than the 7-regioisomer – proved difficult
upon being attempted with several compounds, such as 5- and 7-bromo-4chloroquinoline and 5- and 7-fluoro-4-chloroquinoline, since neither crystallization nor
chromatography provided the 5-regioisomer in pure form (although both methods were
effective in producing the pure 7-regioisomer; see Appendix A). Two 5,7-dichloro
substituted compounds (PL367 and 379, see Table B1, Appendix B, and Figure 26,
below) were therefore produced under the presumption that the results obtained would
give some indication of the impact on activity of the 5- substituent when compared to the
compound with the 7-chloro substituent alone. When tested in vitro, these compounds
proved to have somewhat diminished activity compared to their 7-chloro analogues.
However, the reduction in activity was not nearly as strong as was observed for the 7,8disubstituted analogue, PL306 (Figure 26, below and Table B1, Appendix B):
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IC 50 = 33 nMD6, 67 nMDd2

IC 50 = 217 nMD6, 990 nMDd2

Figure 26: Example of the effect of 5,7-disubstitution compared to 7-substitution and 7,8-disubstitution

These results are in agreement with results obtained by Madrid et al. for 5-substituted
chloroquine analogues with no attached reversal agent and with and without an additional
substituent in position 6 or 7 (Madrid, 2005).
A 2,5-disubstituted compound (PL303) was inadvertantly made during the
attempted synthesis of PL398 (Figure 24 and Table B1, Appendix B). In vitro testing of
this compound revealed that its activity was extremely low, even lower than that of its 2trifluoromethyl substituted analogue (Figure 27, below and Table B1, Appendix B):

Cl HN

HN

N

N
N

N
N

CF 3

PL303
IC 50 = 690 nMD6, 1250 nMDd2

N

CF 3

PL147
IC 50 = 402 nMD6, 639 nMDd2

Figure 27: Activity of 5-chloro-2-trifluoromethyl and 2-trifluoromethyl compounds.
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Interestingly, the 4-chloroquinoline intermediate to this compound, 4,5-dichloro-2(trifluoromethyl)quinoline, was the only 5-regioisomer more readily isolated (by
recrystallization) than its 7- substituted analogue (4,7-dichloro-2(trifuoromethyl)quinoline). These two quinolines proved to be the only 4chloroquinoline intermediates synthesized in the course of this study that had not been
reported and characterized previously in the literature (Figure 28):

Cl

Cl

N

Cl

CF 3

Cl

N

CF 3

Figure 28: Two previously uncharacterized quinolines were made during the course of this work.

2.1.2: Effect of 6- versus 7-substitution

Compounds with a substituent in the 6- position had good activity, in some cases
equal to that of their 7- substituted analogues and in others somewhat diminished (see
Figure 29, below, and Table B2, Appendix B). The former is in contrast to most of the
previous work for compounds without an attached reversal agent.
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IC 50 = 30 nMHaiti 135 (CQS), 250 nMIndochina I (CQR) (De, 1996)
IC 50 = 170 nMNF54 (CQS), 4900 nMK1(CQR) (Vippagunta, 1999)

IC 50 = 13 nMNF54 (CQS), 350 nMK1(CQR) (Vippagunta, 1999)

Figure 29: 6- versus 7-substituted chloroquine analogs with and without an attached reversal agent.

Additionally, a 6,7- dichloro substituted compound (PL307) showed no diminuition of
activity relative to its 7-substituted analogue (PL106), but had improved activity relative
to its 6-substituted analogue, PL283 (Figure 30 and Table B1, Appendix B):

39

HN

N

HN
N

Cl

N

PL106
(Gunsaru, 2010)

N

N

N

HN

N

PL283

IC 50 = 9.2 nMD6, 22 nMDd2

IC 50 = 2.7 nMD6, 1.8 nMDd2
N

Cl

Cl

N

Cl

N
N

N

PL307

IC 50 <2.5 nMD6, <2.5 nMDd2

Figure 30: The effect of 6,7-disubstitution compared to 6- and 7-monosubstitution.

An interesting feature of the results is that for halogen-substituted analogues of PL106
(bearing a single pyridyl ring in their reversal agent moiety), a change in substituent
position from 7 to 6 resulted in a noticeable decrease in activity in the case of chloro- and
bromo-substituted compounds, but this was much less marked in the case of iodosubstituted compounds (Figure 31 and Table B2, Appendix B). This effect was observed
only in the case of PL106 analogues, and not in the case of the PL06 analogues (bearing
the larger diphenylmethyl group in their reversal agent moiety). The latter showed
virtually no diminuition of activity when the position of the halogen was changed from 7to 6-.
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Figure 31: The effect of 6- versus 7- substitution for chloro, bromo, and iodo-substituted analogues of
PL106.

2.1.3: Effect of halogen substituents
With regard to the halogen series (Table B3, Appendix B), substitution of
bromine or iodine for chlorine in a given position (6- or 7-) did not appear to result in any
significant change in in vitro activity within the limits of the assay, although some
bromo- and iodo-substituted compounds had activity too high for the range in which they
were tested (Figure 32 and Table B3, Appendix B):
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Figure 32: Representative bromo- and iodo- substituted compounds

These results are similar to those obtained from much of the previous work on
compounds without an attached reversal agent (Vippagunta, 1999, Kaschula, 2002,
Hocart, 2011, Nsumiwa, 2013). As mentioned previously, substitution with iodine is of
particular interest because there is some evidence for resistance reversal in 7-iodo
analogues of chloroquine (De, 1998).
Compounds with 6-fluoro substitution had somewhat diminished activity relative
to their 6-chloro analogues (Figure 33 and Table B3, Appendix B):
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Figure 33: The effect of 6-chloro versus 6-fluoro substitution

The above results are in agreement with those obtained from work on chloroquine-like
compounds (De, 1998, Hocart, 2011, Nsumiwa, 2013), in which the effects of 7-chloroversus 7-fluoro-substitution are compared. In this work, the synthesis of compounds with
7-fluoro substitution proved more challenging than expected, since the 7-fluoroquinolines
appear to undergo nucleophilic aromatic substitution easily in the presence of amines
(this has been observed previously by Snyder, Freier, Kovacic, and Van Heyningen,
1947). On the basis of the results obtained by other researchers for 7-fluoro substituted
chloroquine analogues without an attached reversal agent, and on the basis of the results
obtained in this study for 6-fluoro substituted compounds, it appeared likely that the
activity of a 7-fluoro-substituted compound would be lower than that observed for the 7chloro-substituted analogue. Therefore, these compounds have not been pursued further.
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2.1.4: Effect of strongly electron-withdrawing groups in position 6 or 7: nitro and
trifluoromethyl substituents

Compounds with strongly electron-withdrawing groups in positions 6 or 7 were
also made and tested (Table B4, Appendix B). Only one nitro-substituted compound was
made (PL282). This compound did not have significantly diminished activity relative to
its 6-chloro analog, PL283. The activity of this compound was also far higher than has
been observed for short-chain 7-nitro-substituted chloroquine analogs without an attached
reversal agent, but similar to that observed for 7-nitro substituted chloroquine analogs
with the side chain of chloroquine (Figure 34 and Table B4, Appendix B). These
compounds cannot be compared directly, since the chloroquine analogues without an
attached reversal agent attached are substituted in the 7-position. On the basis of other
results described herein for 6- and 7-substituted compounds of this type, it seems
probable that a 7-nitro-substituted chloroquine analog with an attached reversal agent
would possess slightly higher activity than the 6-nitro compound.
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Figure 34: The effect of nitro substitution on chloroquine analogues with and without an attached reversal
agent.

Of the trifluoromethyl-substituted compounds, in most cases the activity was not
significantly different from that of the chloro-substituted analogues (although in a few
cases the activity was somewhat lower). This is in contrast to many of the findings for
chloroquine analogues without an attached reversal agent (De, 1996, Kaschula, 2002),
but in agreement with others (Stocks, 2002) (Figure 35, below and Table B4, Appendix
B).
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Figure 35: The effect of trifluoromethyl substitution on chloroquine analogs with and without an attached
reversal agent.
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2.1.5: Unsubstituted compounds and those with an electron-donating group in
position 6 or 7

As mentioned in the introduction, a des-chloro analogue of PL06 (PL64) had been
made previously by Steven Burgess and was the catalyst for this study. During the
course of this study, a des-chloro analog of another compound made by Steven Burgess,
PL69, was also made (PL375). This proved to have unexpectedly low in vitro activity
against P. falciparum compared to that observed for PL64, particularly against the
chloroquine resistant strains, Dd2 and 7G8 (Figure 36, below and Table B5, Appendix
B). HPLC revealed that this compound may have been less pure than had been believed
when this compound was tested in vitro, but this alone seems insufficient to account for
the difference in activity observed, particularly against the chloroquine resistant strains.
However, this compound would need to be re-synthesized, further purified, and re-tested
before any firm conclusions could be made.
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Figure 36: Des-chloro analogues of PL06 and PL69.
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A 6-methyl substituted compound (PL383) proved to have similar activity to that
of the 6-chloro analog, PL270, and to that of the des-chloro analog, PL64 (Figure 37,
below; see also Figure 31, above and Table B5, Appendix B). This is in contrast to
reported activity for chloroquine analogues with a 7-methyl group and without an
attached reversal agent.
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N
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IC 50 = 3.4 nMD6, 7.9 nMDd2

Figure 37: A 6-methyl substituted compound compared to 7-chloro and 7-hydro analogues.

A compound with an electron-donating 7-methoxy substituent (PL391) had diminished
activity relative to that of its 7-choro analog (PL106). However, the decrease in activity
was not so great as has been reported in the literature for chloroquine analogues without
an attached reversal agent (Figure 38):
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Figure 38: The effect of 7-methoxy substitution on chloroquine analogs with and without an attached
reversal agent.

2.2: Significance of the findings

The above results show that the antiplasmodial activity of reversed chloroquinetype compounds is significantly affected by the substitution pattern of the quinoline ring
system. These effects upon activity are directionally similar to those observed for
chloroquine analogs without an attached reversal agent, but are generally smaller, except
in the case of 2- and 8- substituted compounds. In an attempt to understand why the
substitution pattern of the quinoline ring system should affect the antiplasmodial activity
of chloroquine analogues, and to understand why the effect on reversed chloroquine-type
compounds should differ from the effect on chloroquine analogues without an attached
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reversal agent, several possibilities should be considered. Firstly, the quinoline ring
system substitution may affect accumulation of the drug at its site of action, and this
effect may be smaller for compounds with an attached reversal agent. Secondly, the
quinoline ring system substitution may affect the activity of the drug, and this effect may
be smaller for compounds with an attached reversal agent. Thirdly, in the case of
chloroquine resistant parasites, the substitution pattern of the quinoline ring system may
have an impact on drug efflux from the digestive vacuole. Each of these possibilities will
be discussed in turn.

2.2.1 Effect of the quinoline ring system substitution on accumulation of
chloroquine-like drugs in the digestive vacuole by pH trapping

As mentioned previously, the concentration of chloroquine at its site of action, the
parasite’s digestive vacuole, has been estimated to be one thousand to several thousand
times greater than the concentration in uninfected erythrocytes, based on uptake
experiments (Kelly, 2002; Sullivan, 2002). This extraordinary degree of accumulation
has been postulated to occur primarily for two reasons: firstly, because the lower pH of
the digestive vacuole compared to that of the cytosol favors the accumulation of the
weakly basic chloroquine within the digestive vacuole, and secondly, because
chloroquine binds to heme dimers that are present within the vacuole (Yayon, 1985;
Schlesinger, 1988; Bray, 1998; Bray, 1999; Kaschula, 2002). Additionally, although
chloroquine’s entry into the vacuole is generally thought to occur primarily by passive
diffusion of the uncharged drug across the membrane, membrane traversal by charged
50

drug is not inconceivable (Kaschula, 2002). It is further possible that there may be active
transport of some kind, which would constitute a third mechanism of accumulation.
However, if such a mechanism exists, it has not been identified with certainty (Kirk,
2013).
Chloroquine is considered to have two protonatable nitrogens. One is in the
quinoline ring system itself (pKa = 8.1), and the other is the tertiary nitrogen of the side
chain (pKa = 10.2; Figure 39; Martin, 2009):
Chloroquine
HN

Cl

N

N

pKa = 10.2

pKa = 8.1

Figure 39: pKas of chloroquine

The nitrogen in position 4 of the quinoline ring system is thought to be less basic for
reasons that will be explored during the discussion of bis-quinolines. Neutral
chloroquine is able to diffuse freely through the vacuolar membrane, but it is generally
assumed that little diffusion of diprotonated chloroquine through the membrane occurs
(Kaschula, 2002; Warhurst, 2007; Kirk, 2013). The relatively lower pH of the digestive
vacuole as compared to the cytosol therefore favors the accumulation of diprotonated
chloroquine within the vacuole (a mechanism referred to as pH trapping). Prediction of
the extent of accumulation by pH trapping depends upon the pKa values that are used for
chloroquine’s protonatable nitrogens, and upon the difference between the values used
for the vacuolar and cytosolic pH. The precise values used vary within the literature.
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The pH outside of the vacuole is often given as approximately 7.4, whereas the interior of
the vacuole has been estimated to be between pH 4.5 and 5.9 (Martin, 2009; Kirk, 2013).
Based on a vacuolar pH of ~5 and a cytosolic pH of 7.4, Martin et al. calculate that
approximately 83% of the drug outside the vacuole should be present in the diprotonated
form, with approximately 17% monoprotonated, in contrast to approximately 100%
diprotonoated inside of the vacuole (Martin, 2009). On the basis of these values, the drug
would be predicted to accumulate within the digestive vacuole to a small extent by the
mechanism of pH trapping; however, pH trapping alone is insufficient to account for
chloroquine’s remarkable accumulation in the digestive vacuole (Krogstad, 1987;
Sullivan, 2002; Martin, 2009).
The primary cause of chloroquine’s accumulation is thought to be binding to
heme dimers (Krogstad, 1987; Bray, 1998; Bray, 1999). This mechanism of accumulation
is intimately associated with the drug’s mode of action, which is thought to begin with
reversible binding to heme (Dorn, 1998).
The quinoline ring system substitution pattern is postulated to have an impact on
drug accumulation both through pH trapping and through binding to heme (the effect on
heme binding will be discussed together with antiplasmodial activity, below; Egan, 2000;
Kaschula, 2002). As stated above, accumulation of chloroquine by pH trapping would be
significantly affected by the pKas of chloroquine’s protonatable nitrogens. It has been
shown that the substitution pattern of the quinoline ring system strongly affects the pKa
of the ring nitrogen (pKa1), as well as the nitrogen of the alkylamino side chain (pKa 2;
Kaschula, 2002). Values of pKa1 and pKa2 for variously substituted chloroquine-like
52

compounds have been determined experimentally by Kaschula et al. (2002), and vary by
as much as two pKa units from molecule to molecule, depending on the ring substituent.
It is interesting that the quinoline ring substituent should have an effect not only upon the
pKa of the quinoline ring nitrogen, but upon the side chain nitrogen as well. The effect
on the side chain nitrogen evidently occurs through space rather than through bonds.
Kaschula et al. (2002) have speculated that for shorter-chain chloroquine analogues, this
effect would be more pronounced than for chloroquine analogues with longer and bulkier
chains. Longer side chains may spend more time away from the quinoline ring system
and may even be sterically prevented from approaching the ring system or its substituent.
It has been pointed out by Kaschula et al. (2002) that this may account for the
observation that the antiplasmodial activity of 4-aminoquinolines with a shorter alkyl
chain is more vulnerable to modification of the quinoline ring system than that of 4aminoquinolines with a longer chain (Coatney, 1953, Kaschula, 2002, Nsumiwa, 2013).
By extension, this may be the explanation for the observation in this work that for
chloroquine analogs with an attached reversal agent, many modifications of the quinoline
ring system substitution pattern have relatively little impact on activity as compared to
that observed for chloroquine analogues without an attached reversal agent. The long and
bulky reversal agent side chain may hold the protonatable nitrogen of the side chain far
enough away from the quinoline ring system to negate an effect of the latter upon side
chain nitrogen pKa. However, because the impact of pH trapping on accumulation is
believed to be relatively small, the importance of quinoline ring system substitution to
antiplasmodial activity cannot be explained by pH trapping alone. Moreover, it is
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probable that the differences in pKa between compounds with certain substitution
patterns in the present study are less than would be predicted on the basis of their activity,
if differences in accumulation due to pH trapping were the only cause of the variations in
activity observed. For the compounds under study, however, pKa values have not been
determined.

2.2.2. Effect of quinoline ring system substitution on heme binding and β-hematin
inhibition

For chloroquine and chloroquine-like drugs, the binding site of the heme dimer is
believed to be the quinoline ring system itself (Egan, 2000). The structure of the bound
drug-heme complex in vivo is not known, but it is often envisioned as a π-π stacking
interaction between the aromatic ring systems of the porphyrin and the quinoline (Leed,
2002; Stocks, 2002; Crespo, 2010). The side chain is thought to have little involvement
in this binding, for reasons that will be discussed later. Binding of the drug to heme is
thought to be an important step in inhibition of the formation of hemozoin and hence, the
antimalarial activity of quinoline drugs (Dorn, 1998). In vitro models have been
extensively studied both for heme binding (either as the heme monomer or as the heme
dimer) and for inhibition of the formation of hemozoin (as inhibition of the formation of
β-hematin, the chemically identical in vitro analogue of the biomineral hemozoin; Fitch,
1987; Slater, 1991; Dorn, 1998; Egan, 2000). In the course of these studies it has been
found that heme binding strength does not always correlate to β-hematin inhibition –
compounds capable of inhibiting the formation of β-hematin exhibit strong heme binding
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ability, but heme binding ability alone does not predict whether a compound will inhibit
the formation of β-hematin (Egan, 2000; Kaschula, 2002). Quinoline compounds with a
wide variety of substitution patterns have been shown to bind to heme in aqueous
solution (Vippagunta, 1999; Egan, 2000; Kaschula, 2002), but there is a much greater
variation in ability to inhibit the formation of β-hematin (Egan, 2000; Kaschula, 2002).
Thus, it has been proposed by Egan (2000) that while the quinoline ring system itself is
responsible for binding to heme, the inhibition of formation of hemozoin is modulated by
the substitution pattern of the ring system. If the quinoline ring system always binds to
the heme dimer in a similar position, regardless of its substituents, this effect could be
due to the ability of the substituent to block the site at which the association between
dimers occurs, preventing hemozoin from forming. The large effects on antiplasmodial
activity observed upon variation of the nature of the quinoline ring substituent
(electronegativity, lipophilicity, steric bulk) or variation of its position on the quinoline
ring would make sense if such a substituent-specific blocking were occurring. Another
explanation might be that the positioning of the quinoline ring system with respect to
heme is changed by altering the position and nature of the substituent. Perhaps the 7choro substituent is correctly placed and has the right stereoelectronic character to stop
the biomineralization from occurring (Vippagunta, 1999; Kaschula, 2002).

2.2.3 Effect of the side chain on activity: beyond pH trapping?

It would at first seem likely that the side chain would also exert an effect on heme
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binding and inhibition of hemozoin formation. In the case of chloroquine it has been
suggested previously that the side chain is involved in binding to the heme dimer by
association of the protonated side chain nitrogen of chloroquine with the propionate
moieties of heme (O’Neill, 1997). In the case of quinoline methanols (quinine and
mefloquine), which are thought to work similarly to 4-aminoquinolines (at least in part),
portions of the side chain are thought to be important for heme binding (Alumasa, 2011).
Additionally, it has been observed that chloroquine associates more strongly with heme
in vitro as compared to chloroquine analogs with the same quinoline ring substitution
pattern, but a shorter side chain (Egan, 2000). In the context of the observation that the
antiplasmodial activity of chloroquine-like compounds with longer side chains is less
vulnerable to modification of the quinoline ring system substitution pattern, and in the
context of the present work in which it is shown that chloroquine analogues with an
attached reversal agent are even less vulnerable to side chain modification, it is worth
considering that a longer side chain may have a relatively larger impact on heme binding
and perhaps on inhibition of hemozoin formation. Conceivably, the larger side chain
might alter the binding geometry of the quinoline ring system to heme, affecting
inhibition of hemozoin formation, or the chain itself might block the site of hemozoin
formation. However, because of the extreme variations in side chain structure that are
possible without affecting antiplasmodial activity, it is thought that the side chain is not
directly involved in these compounds’ mechanism of action. This is true both for the
alkylamine side chain of chloroquine analogues and for the reversal agent moeity of
chloroquine analogues with an attached reversal agent. In the course of work performed
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by others in our group (Burgess, 2008; Andrews, 2010; Burgess, 2010; Gunsaru, 2010) it
has been observed that the reversal agent moiety of reversed chloroquine-type
compounds can be widely varied without affecting in vitro antiplasmodial activity
(Figure 40):
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Figure 40: Variability of the reversal agent moeity of reversed chloroquine-type compounds

A structurally-related molecule with similarly high in vitro potency against chloroquine
resistant Plasmodium falciparum was published by Ryckebush and coworkers in 2003
(Figure 41):
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Figure 41: A chloroquine analogue closely related to the above reversed chloroquine-type compounds, also
with high activity against chloroquine resistant parasites.

On the other hand, the above reversed chloroquine-type compounds all bear a lipophilic
group on their alkylamino side chain, whether aromatic or saturated. As there is
substantial evidence that hemozoin formation occurs at the interface of lipid droplets
within the digestive vacuole (Jackson, 2004; Oliveira, 2005 (for other protozoal
diseases); Pisciotta, 2007; Egan, 2007), it is possible that in addition to any reversal agent
activity that these groups may have, they also favor the presence of the reversed
chloroquine compound at the lipid droplet interface. Conceivably, the protonated side
chain might stand outside of the lipid droplet, while the lipophilic group might stand
inside. Alternatively, deprotonated molecules might accumulate inside of the lipid
droplet, constituting an additional mechanism of accumulation (this may be true for
chloroquine analogues without an attached reversal agent as well; Warhurst, 2007). In
any case, whether or not the side chain is involved in the mechanism of action of
aminoquinolines, it is an important modulator of resistance, as will be discussed below
(section 2.2.5).
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2.2.4: The relationship between accumulation and inhibition of hemozoin formation

It has been observed repeatedly in the literature that the ability of a 4aminoquinoline compound to inhibit the formation of β-hematin formation in vitro does
not unequivocally predict in vitro antiplasmodial activity (Vippagunta, 1999; Egan, 2000;
Kaschula, 2002). Chloroquine analogues with high in vitro antiplasmodial activity have a
high ability to inhibit the formation of β-hematin, but not all compounds that inhibit the
formation of β-hematin have high in vitro antiplasmodial activity. This lack of
correlation has been explained by invoking the variation in accumulation by pH trapping
of the various compounds involved. In a study by Kaschula et al. (2002), β-hematin
inhibitory activity, and in vitro antiplasmodial activity were determined for a series of
variously substituted short-chain chloroquine analogs. Among others, the series of
compounds in that study included those in which the quinoline ring system was
substituted in the 7-position with a halogen, with a nitro group, with hydrogen, and with a
methoxy group. It was observed that compounds with a halogen substituent (chlorine,
bromine, or iodine) had good β-hematin inhibitory activity and good in vivo activity.
Compounds bearing a strong electron-withdrawing group (nitro or trifluoromethyl) had
excellent β-hematin inhibitory activity, but poor in vitro antiplasmodial activity.
Compounds with an electron-donating methoxy group, as well as those without an
attached substituent, had much lower β-hematin inhibitory activity, and their in vitro
antiplasmodial activity was low as well. However, their antiplasmodial activity was not
as low as might be predicted from their β-hematin inhibitory activity alone, if β-hematin
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inhibition and antiplasmodial activity were directly correlated. Side chain and quinoline
ring nitrogen pKa for the study compounds were determined experimentally, and were
used to estimate accumulation due to pH trapping relative to that of chloroquine (as
described above in the discussion of pH trapping, section 4.3.1). Upon adjusting the in
vitro β-hematin inhibitory activity of the study compounds for accumulation, a good
correlation was obtained between accumulation-corrected β-hematin inhibitory activity
and in vitro antiplasmodial activity. It therefore appeared to the authors of that study that
the halogen-substituted compounds presented the best compromise between accumulation
and β-hematin inhibitory properties, leading to their superior activity relative to
compounds with other substituents. As mentioned above (section 4.3.1), accumulation of
chloroquine at its site of action may occur largely due to heme binding, with
accumulation due to pH trapping playing a relatively minor role. Yet in contrast to βhematin inhibitory activity, heme binding ability (as determined in vitro) varies
comparatively little amongst variously substituted chloroquine analogues. If the
conclusions of Kaschula and coworkers are correct, and the differences in in vitro
antiplasmodial activity are partly explained by differences in accumulation due to pH
trapping, then it is interesting that the latter should play such a comparatively important
role, though constituting a relatively small proportion of total accumulation (Kaschula,
2002). Another explanation might be that accumulation is related not only to heme
binding but to hemozoin inhibition as well, such that for some reason compounds that
inhibit hemozoin formation accumulate more strongly; however, if so, this has not been
elucidated.
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The compounds in the study described above were substituted only in the 7position of the 4-aminoquinoline ring system, so it was not clear from that study whether
the results would be the same for other substitution patterns. Additionally, as observed
by Kaschula and coworkers, the impact of the quinoline ring system substitution upon the
pKa of the 4-aminoquinoline side chain nitrogen may partially depend on side chain
length, and this may help explain why the antiplasmodial activity of compounds with a
longer side chain is relatively less impacted by quinoline ring system substitution than
shorter chain compounds. It is therefore of interest that in many cases, compounds
substituted in the 2- and 8- position seem to have the same strong, negative effect on
activity regardless of side chain length and type, including the reversed chloroquine-type
antiplasmodials in the present study. If the deleterious effect of this substitution pattern
on activity were due to a change in the pKa of the side chain nitrogen, leading to reduced
accumulation by pH trapping, then it would be anticipated that 2- and 8- substituted
compounds with a longer side chain would be more active relative to those with a shorter
side chain. If one assumes that the conclusions made by Kaschula and coworkers are
correct, a possible explanation might be that 2- and 8- substituted compounds are so poor
at inhibiting the formation of hemozoin that accumulation is irrelevant. If this is true, it
would be interesting to learn whether the effect of the 2- or 8-substituent is primarily a
steric or an electronic one. Based on the results in the present work, it appears that in
position 8 the effect is at least partially a steric one, as the 8-methoxy and one of the 8methyl substituted compounds performed as poorly as 8-trifluoromethyl substituted
compounds; however, an 8-methyl-substituted compound with a larger reversal agent
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moiety did not perform as poorly (see Figure 23). Comparing the two compounds in the
present study with a 2-methyl versus a 2-trifluoromethyl group (Figure 24), it was seen
that the 7-chloro-2-methyl substituted compound synthesized in the present study had
weak but improved activity relative to its 2-trifluoromethyl analogue. However, this does
not necessarily mean that the effect of the substituent in position 2 is an electronic one,
since the trifluoromethyl group is also more sterically demanding than the methyl group
(Bégué, 2008). Synthesis and testing of a compound with a smaller electron-withdrawing
group or a larger electron-donating group in position 2 might help to decide this question.

It seems probable that neither an effect on accumulation nor an effect on the
ability to inhibit the formation of hemozoin can be the sole reason for the importance of
the quinoline ring system substitution pattern. Rather, it appears that both accumulation
and hemozoin inhibitory activity are likely to be involved.
2.2.5. Modulation of resistance

In the literature it has often been observed that modification of the chloroquine
side chain has a powerful effect on the resistance profile of chloroquine analogues (De,
1996; Stocks, 2002). Changes in chain length and bulk generally confer improved
activity against chloroquine resistant parasites relative to activity against chloroquine
sensitive parasites (referred to as resistance index).5 The chloroquine resistance

5

Effect on resistant parasites, or cross resistance, is often discussed in terms of the resistance
index, the ratio of activity against chloroquine resistant (CQR) and chloroquine sensitive (CQS)
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transporter or transporters seem to have evolved in such a way that they are able to
specifically recognize the side chain of chloroquine. This has been exploited in the
development of AQ-13 (De, 1996), F2Bu (Stocks, 2002), and ferroquine (Brocard, 1995;
Dive, 2008), amongst others (Figure 42):
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Figure 42: Altering side chain length of chloroquine analogues restores activity against chloroquine
resistant parasites.

In contrast, it has generally been observed in the literature that modifications of the
quinoline ring system itself have a negative impact on activity without enhancing the
resistance index. As stated above in the review of previous work, exceptions to this are
known. For the substitution pattern of sontoquine (Vippagunta, 1999; Pou, 2012), and
for compounds with a larger quinoline ring substituent such as an iodo, phenoxy, or
trifluoromethoxyphenyl group (De, 1998; Madrid, 2005; Pou, 2012), an improved
resistance index has been observed. Additionally, for some smaller substituents (nitro,
cyano) some improvement in the resistance index has been observed also (Nsumiwa,
2013). Therefore it appears that the assumption that the quinoline ring system has no
impact on resistance is not entirely correct – the chloroquine resistance transporter may
have some ability to recognize the 7-chloroquinoline moiety of chloroquine as well as its

strains. Thus, a drug with lower overall activity than chloroquine may still show an improved
resistance profile in terms of its ratio of activity against CQS and CQR parasites.
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side chain. For the bulkier ring substituents at least, it is also possible that the compound
simply does not fit the transporter – perhaps the compound is pushed into a less favorable
conformation for binding (Pou, 2012).
For the compounds in the present study, it was not possible to observe the impact
of the quinoline ring system substitution pattern on the resistance index, since a
resistance-reversing side-chain was already in place. Enhancement of activity against
resistant parasites relative to sensitive parasites was not observed upon modification of
the quinoline ring system. However, it occasionally appeared that modification of the
quinoline ring system decreased activity against chloroquine resistant parasites relative to
activity against chloroquine sensitive parasites (Figure 43):
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Figure 43: Apparent cross-resistance with chloroquine was observed for some ring-modified reversed
chloroquine-type compounds

Significantly lower activity against chloroquine resistant parasites than against
chloroquine sensitive parasites was most commonly observed in the case of 8-substituted
compounds. The causes of this phenomenon are unclear at the present time. It is
possible that this modification to the quinoline ring system somehow negates the effect of
the reversal agent in preventing efflux (although this seems far fetched), or perhaps it is
related to non-resistance-related mutations in the resistant parasites which somehow
affect the hemozoin inhibition properties of these particular compounds. It might be
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informative to determine whether this apparent cross-resistance is reversed by a reversal
agent, such as verapamil.
Nevertheless, it appears that in many cases the 7-chloro substituent of reversed
chloroquine-type compounds can be altered without adversely affecting either activity or
resistance profile. If reversed chloroquine-type compounds were to be used as drugs, it is
possible that modification of the quinoline ring system might serve as an additional
protection against the development of resistance.

2.3: Summary of the present work, and future directions

Fifty three reversed chloroquine-type compounds have been synthesized in which
the 7-chloro substituent is changed to another electron-withdrawing substituent in the 2-,
5-, 6-, 7-, and 8- positions of the quinoline ring system, to a methyl substituent in position
2-, 6- or 8-, or to a methoxy substituent in position 7- or 8- (see Table B1, Appendix B).
For this class of compounds, 2-, 5-, and 8- substituents appear to decrease in vitro
antiplasmodial activity against P. falciparum relative to 7-chloro substitution, whereas 6and 7- substituted compounds have similar activity to that of 7-chloro substituted
compounds except in the case of nitro-, fluoro-, and methoxy-substituted compounds.
These effects on activity are directionally similar to those observed for chloroquine
analogues without an attached reversal agent, but the magnitude of the effect is smaller.
The results of this study support and extend the conclusions of Coatney and others that
the importance of the quinoline ring system substitution pattern to antiplasmodial activity
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may be smaller for chloroquine analogues with a longer side chain. Furthermore, the
results obtained for 2-and 8- substituted compounds may indicate that the deleterious
effect of these substituent positions on the antiplasmodial activity of 4-aminoquinoline
compounds may be primarily a steric rather than an electronic one.
To complete this series, 7-fluoro, 7-nitro, 7-methyl and 6-methoxy substituted
compounds should be made. The 3-position is of particular interest by analogy to
sontoquine, which Andersag reported as having similar activity to chloroquine, and for
which Vippagunta (1999) and Pou (2012) have found evidence of resistance reversal
relative to chloroquine. Additionally, bulky electron-donating substituents would be of
interest (such as phenoxy, tert-butoxy, trifluoromethoxy, or pentafluorosulfanyloxy (OSF5), as would the bulky, lipophilic, electron-withdrawing pentafluorosulfanyl group (SF5). As far as is known, the pentafluorosulfanyl group is of a metabolic stability
comparable to the trifluoromethyl group, and is analogous in its electron-withdrawing
effect, but its larger size and increased lipophilicity should offer intriguing differences in
biological activity (Welch, 2007 and 2009; Kirsch, 2007).6 Additionally, compounds
substituted with a bulkier substituent in position 2 or 8 would be of interest in order to
determine whether this would decrease activity still further than has been observed with
the study compounds. This might indicate whether the observed effect is due to steric or
other factors. Finally, it would be of interest to determine pKa values for a selection of
6

In recent years the pentafluorosulfanyl group has met with increasing interest as a new
substituent for bioactive molecules (Stump, 2009; Welch, 2007; Micheli, 2010; Wipf, 2009),
especially since the methods used to incorporate it into organic molecules have improved
(although regrettably few SF5-containing organic building blocks and reagents used to introduce
it are commercially available). This substituent has been incorporated into the quinoline ring
system of mefloquine analogues synthesized at the Walter Reed Army Institute (Wipf, 2009; Mo,
2010).
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the study compounds in order to determine whether, in fact, the side chain pKa is indeed
less strongly effected by the quinoline ring system substitution pattern than has been
observed for chloroquine analogues without an attached reversal agent, and in order to
determine the effect of substituents in various positions upon pKa. If indeed the pKa of
the side chain nitrogen is less strongly affected in these molecules than in shorter chain
chloroquine analogues, it would also be of interest to determine the conformation adopted
by some of these molecules as salts in acidic aqueous solution, which might be possible
by two-dimensional NMR spectroscopy (NOESY).
The results of this study show that the substitution pattern of the quinoline ring
system of reversed chloroquine type antiplasmodials is much more flexible than that
observed for chloroquine analogs without an attached reversal agent. In the light of
findings by other workers that some quinoline ring system substitution patterns offer an
improved resistance index relative to the 7-chloro substitution pattern of chloroquine, it is
possible that modification of the quinoline ring system substitution pattern of reversed
chloroquine-type compounds would provide enhanced protection against the emergence
of resistance. At present, however, it is not known whether these compounds are equally
active in vivo.
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CHAPTER 3
Asymmetrical bis-quinolines with antiplasmodial activity

In the second portion of this work, a novel type of asymmetrical bis-quinoline has
been developed that has unusually high antiplasmodial potency. In this chapter, the
subject of bis-quinolines as antimalarials will first be introduced (Section 3.1,
Background). This will be followed by a description of the asymmetrical bis-quinolines
made in this work, followed by a discussion of their in vitro antiplasmodial activity and
potential for further development (Sections 3.2-3.5).

3.1: Background
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Figure 44: Piperaquine, a bis-quinoline antimalarial

Like the mono-(4-amino)quinoline compounds discussed in the previous chapters,
the class of bis-(4-amino)quinolines includes many compounds with antiplasmodial
activity. The bis-quinoline antimalarial piperaquine (above, Figure 44), is a long-acting
component of dihydroartemisinin-piperaquine, one of the five artemisinin combination
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therapies recommended by the World Health Organization to treat P. falciparum malaria
(WHO Report, 2013). Piperaquine was originally synthesized at the French chemical
firm, Rhône-Poulenc. In the original patents for this compound, submitted by RhônePoulenc in 1962 (France, granted in 1965) and subsequently in Belgium (granted in
1963), examples are given not only for the synthesis of piperaquine but also a variety of
analogues (Figure 45):
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Figure 45: Some bis-quinolines used as examples in the original patents for piperaquine by Rhône-Poulenc.

Piperaquine attracted the interest of Chinese researchers, who synthesized it in 1965.7
Following successful clinical trials performed during the early 1970s it was widely used
in China both as a treatment and as prophylaxis for P. falciparum and vivax malaria
(Davis, 2005; Schlitzer, 2007; Warhurst, 2007; Chen, 2014).

7

It has sometimes been stated that piperaquine was synthesized independently in China (Davis,
2005, and citing authors); however, in the reference given for this information by Davis and coauthors, I could not find a statement to this effect. In the above I have followed Chen (2014) and
Warhurst (2007).
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Piperaquine is believed to work by a mechanism similar to that of chloroquine
and other 4-aminoquinolines (Warhurst, 2007); however, it retains activity against many
chloroquine-resistant strains, perhaps because its large size prevents its being exported by
the chloroquine resistance transporter (Vennerstrom, 1992; Basco, 2003; Davis, 2005;
Naudé, 2005; Pascual, 2012). However, piperaquine resistance is now common in some
parts of Asia, particularly the areas of China in which piperaquine was heavily used
following its introduction (Schlitzer, 2007; Chen, 2014). The mechanism of piperaquine
resistance is not known, and attempts to associate resistance to piperaquine with
mutations known to confer resistance to other quinoline antimalarials have produced
conflicting results (Muangnoicharoen, 2009; Briolant, 2010; Eastman, 2011; Hao, 2013;
Pasual, 2013). Disturbingly, the development of resistance to the combination
dihydroartemisinin-piperaquine has been reported in southeast Asia (Saunders, 2014).
In addition to piperaquine itself, a diverse range of other bis-4-aminoquinoline
compounds have been shown to have antiplasmodial activity (Figure 46, following page).
Like piperaquine, these compounds tend to be active against chloroquine-resistant strains
(Rhône-Poulenc, 1962; Elslager, 1969; Makler, 1990; Vennerstrom, 1992; Raynes, 1995;
Vennerstrom, 1998; Ayad, 2001; Ryckebusch, 2003; Khan, 2009; Ribeiro, 2013; Tomar,
2013).
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Figure 46: A range of bis-(4-amino)quinoline compounds with antiplasmodial activity
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3.2: A novel, asymmetrical bis-quinoline: PL241

During the initial structure-activity relationship study in which reversed
choroquine-type compounds were developed (Burgess, 2008; Burgess, 2010), the
compound PL69 was produced (Figure 47):

HN

N

N
N
H

Cl

N

PL69

N

Figure 47: PL69, a reversed chloroquine-type antimalarial synthesized by Steven J. Burgess (2008)

The original synthetic method for PL69 required the use of the following compound
(PL67) as an intermediate (Figure 48):
HN

Cl

N
PL67

NH 2

N

Figure 48: PL67, an intermediate originally used to produce PL69

In the present work, at the suggestion of Steven Burgess, PL67 was used to
synthesize a bis-quinoline compound, as follows (Figure 49):
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Figure 49: In this work, PL67 was used to produce the novel bis-quinoline, PL241.

The new compound had extremely high in vitro activity against chloroquine sensitive and
chloroquine resistant strains of P. falciparum. With an IC50 of less than 0.1 nM for all
strains tested, its activity was superior to any compound previously synthesized in our
laboratory, as well as to that of piperaquine (Figure 50):
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Figure 50: In vitro antiplasmodial activity of PL241 compared to that of piperaquine

PL241 is noticably different from piperaquine. Firstly, it is asymmetrical.
Secondly, in contrast to piperaquine’s piperazine ring system, PL241 contains a 474

aminopiperidine moiety directly attached to one of its quinoline rings. This structural
motif has previously been incorporated into other quinoline compounds with
antiplasmodial activity, including a recently published bis-quinoline conjugated with
squaric acid (Wiselogle, 1948; Madrid, 2006; Hocart, 2011; Ribeiro, 2013; Figure 51):
N

N
SN 13,425
Wiselogle, 1948

HN

O

Cl

HN

N

Madrid, 2006
Cl

Shown to have
activity against P.
vivax in man.

N

O

O

N

N

Cl

HN

N

Hocart, 2011
Cl

N

IC 50 = 9.5 nMHaiti 135 (CQS),
5.5 nMIndochina 1 (CQR)

Ribeiro, 2013
HN

Cl

N

NH

IC 50 = 105 nM W2 (CQR)
Cl

Figure 51: (4-Piperidyl)-4-aminoquinolines previously shown to have antiplasmodial activity.

The third important difference between piperaquine and PL241 is that the
nitrogen in position 4 of each of the quinoline ring systems of PL241 is secondary rather
than tertiary. This is significant in view of the frequent observation that for mono-(4amino)quinolines and related antiplasmodials, the presence of a tertiary rather than a
secondary nitrogen in position 4 of the quinoline ring system lowers antiplasmodial
potency. This is true not only for chloroquine analogues without an attached reversal
agent (Wiselogle, 1948; Warhurst, 2007), but for reversed chloroquine-type compounds
as well (Figure 52; Burgess, 2008):
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Figure 52: A tertiary nitrogen in position 4 of the quinoline ring system lowers antiplasmodial potency.

This phenomenon was originally observed in the case of 8-aminoquinoline
antimalarials and acridines. In the course of a mechanistic study upon the quinoline and
acridine antimalarials atebrine (quinacrine), plasmochin (pamaquine), and certuna
(cilional), Schönhöfer and coworkers synthesized an N,N,N-trisubstituted derivative of
the active antimalarial, atebrine (Schönhöfer, 1942). The N,N,N-trisubstituted compound
was devoid of antimalarial activity (Figure 53):

Atebrine (Quinacrine)
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N

HN

H 3CO

O
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H
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N

H 3CO
N

Cl

N

Cl

Figure 53: Atebrine and its N,N,N-trisubstituted analogue (Schönhöfer, 1942).

It was remarked by Schönhöfer that the introduction of a second substituent on the amino
group para to the acridine ring nitrogen would prevent the following tautomerization
from occurring (Figure 54):
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Figure 54: Tautomerization of atebrine predicted by Schönhöfer to have significance for antimalarial
potency (1942)

In the context of this and other observations, Schönhöfer speculated that the form of the
drug active in vivo might be that in which it has transiently rearranged to the above
structure.
In the case of 4-aminoquinolines, which are closely related to acridines,
disubstitution of the amino group para to the ring nitrogen would also block
tautomerization. It is now believed that the site of action of quinoline (and acridine)
antimalarials is the parasite’s acidic digestive vacuole, where the quinoline ring is
expected to be protonated. The tautomerization shown above has been revisited as
resonance stabilization of positive charge on the ring nitrogen resulting from protonation
(Egan, 2000; Figure 55):
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Figure 55: Resonance stabilization of the positive charge on the protonated ring nitrogen of chloroquine
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It has also been found by Egan (2000) that within the series including 2-, 3-, 4-, 5, 6-, and 8-aminoquinoline, the only quinolines able to bind strongly to heme are those for
which the above resonance stabilization is possible, to wit, the 2- and 4-aminoquinolines.
The ability to stabilize a positive charge on the ring nitrogen leads to increased basicity in
the 2- and 4-aminoquinolines, and therefore presumably to increased accumulation in the
digestive vacuole. It is also possible that the altered electronic properties of the
protonated, resonance-stabilized structure lead to improved heme binding ability (Egan,
2000).
It would at first appear that the resonance stabilization shown above would be
equally effective for tertiary 4-aminoquinolines. However, it has been suggested by
Warhurst (2007) in the case of piperaquine that steric hindrance between the proton in
position 5 of the quinoline ring system and the piperazine methylene results in twisting of
the substituted 4-amino group out of the plane of the ring, so that resonance stabilization
is decreased. This would result in reduced basicity of the ring nitrogen for tertiary
compounds, leading to reduced accumulation in the digestive vacuole. Experimental
determination of the pKas of piperaquine has shown that it is indeed less basic than
chloroquine (Warhurst, 2007).
In view of the observation for the general class of 4-aminoquinolines that the
presence of a tertiary quinoline-4-amino group leads to reduced antiplasmodial activity, it
is curious that piperaquine, with its two tertiary quinoline-4-amino groups, should have
high activity. The reason for this is unknown. Assuming that piperaquine’s mode of
action is the same as that of chloroquine, Warhurst (2007) has predicted that while
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piperaquine’s accumulation in the aqueous acidic vacuole should be somewhat less than
that of chloroquine, its accumulation in the lipid portions of the vacuole is expected to be
much greater (based on the empirically determined pKas and cLogP of both compounds;
Warhurst, 2007). This may be significant in view of the evidence that hemozoin may
form at the surface of or inside of lipid droplets within the digestive vacuole (Warhurst,
2007; Pisciotta, 2007; Egan, 2007). It is also conceivable that the availability of two
heme binding sites in piperaquine compensates in part for lower accumulation relative to
that of chloroquine, with its single heme binding site. Finally, if the importance of the
mesomerism described above lies in its effect upon the electronic nature – and therefore
binding ability – of the quinoline ring system of 4-aminoquinolines in general, then it is
conceivable that piperaquine may be a special case in which the presence of the specific
combination of the bulky aminoalkyl motif and second quinoline ring system results in a
binding geometry altered in such a way that it is different from that of other 4aminoquinolines but provides equally strong heme binding and inhibition of hemozoin
formation.
Whatever the reasons behind piperaquine’s high activity, the fact that PL241 has
improved activity over that of piperaquine may indicate that the presence of a tertiary
amine is indeed detrimental to 4-aminoquinoline antimalarials and that piperaquine’s
activity represents a compromise between the detriment of the tertiary 4-amino group and
other more favorable properties. PL241 may possess the positive features of piperaquine
with the additional advantage of the secondary quinoline-4-amino group.
An interesting feature of bis-quinoline compounds is that they retain activity
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against many chloroquine-resistant strains of P. falciparum malaria. To explain
piperaquine’s activity against chloroquine resistant strains, it has been suggested that due
to the increased bulk and lipophilicity of piperaquine relative to that of chloroquine, the
bis-quinoline is unable to be exported through the Plasmodium falciparum chloroquine
resistance transporter, PfCRT (Warhurst, 2007). This is similar to the explanation that
has been advanced for the activity of reversed chloroquine-type antimalarials, and it has
been remarked that piperaquine might be thought of as a reversed chloroquine-type
antimalarial (Burgess, 2008). This also applies to PL241, which is structurally similar to
the reversed chloroquine PL69 (Figure 56):
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Figure 56: PL69, a reversed chloroquine type compound, compared to the structures of piperaquine and
PL241

Piperaquine is a symmetrical molecule, but PL241 is not. In view of this, it is
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uncertain whether the quinoline rings of PL241 are equally important to the antimalarial
activity or whether one ring has weaker antimalarial activity and is perhaps acting
primarily as a reversal agent (as we believe occurs with the N-(dipyridin-2ylmethylene)piperidin-4-amine group in the case of PL69, above). To help determine
this, a short mechanistic study was performed.

3.3: A short mechanistic study: The effect of inactivating groups upon the activity of
PL241

To determine whether the two quinoline ring systems of PL241 are equally
important to its antimalarial activity, several PL241 analogues were made and tested in
vitro against Plasmodium falciparum. In the first two analogues, the 7-chloro substituent
of one quinoline ring system was changed to an 8-trifluoromethyl group, a substitution
pattern that was expected to be inactivating based on the work described in Chapter 2 for
quinoline ring-modified reversed chloroquine-type compounds. It was anticipated that if
one of the ring systems is more important to antimalarial activity than the other, then
substitution of this ring with an 8-trifluoromethyl group would result in a diminuition of
in vitro activity. The results obtained are shown below (Figure 57; see also Appendix B,
Table B6). For comparison, PL69 is also shown, together with its 8-trifluoromethylsubstituted analogue, PL269, as well as PL241:8

8

With the exception of PL241, the bis-quinolines in this project were not tested against the
chloroquine resistant strain Dd2, but only against 7G8, another chloroquine resistant strain of P.
falciparum malaria.
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Figure 57: 8-trifluoromethyl-substituted PL241 analogues, shown with PL241, PL69, and its 8trifluoromethyl-substituted analogue, PL269.

Within the range of the test, the activities of both 8-trifluoromethyl-substituted PL241
analogues were equivalent to that of the parent drug. These results may be interpreted to
mean that neither quinoline ring system is of primary importance to the antimalarial
activity of PL241. However, whether the 8-trifluoromethyl group would in fact be
inactivating in the context of these compounds was unknown. Therefore, an additional
PL241 analogue was synthesized in which both rings were substituted with an 8trifluoromethyl group (Figure 58):
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Figure 58: A PL241 analog with two 8-trifluoromethyl-substituted quinoline ring systems.

The activity of the bis-8-trifluoromethyl PL241 analogue was substantially decreased
relative to that of PL241. Therefore it seems probable that the 8-trifluoromethyl
substitution is indeed an inactivating substitution pattern for compounds of this type, as
with reversed chloroquine-type compounds. Taken together with the results above for
PL241 analogues with a single 8-trifluoromethyl substitution, these results suggest that
either quinoline ring system is equally capable of participating in the antimalarial action
of PL241.
It is notable that for the bis-8-trifluoromethyl substituted PL241 analogue, PL341,
the decrease in activity observed for the chloroquine sensitive parasites was not as great
as that observed for other 8-substituted reversed chloroquine-type antimalarials when
compared to their 7-substituted analogues (see PL69 and PL269, Figure 57, above).
Possibly, this might be attributable to a slightly different binding pattern induced by the
larger side chain of these compounds (including the second quinoline ring system).
For the chloroquine resistant parasites, the activity of the bis-8-trifluoromethyl
analogue of PL241 was much lower. Regrettably, the magnitude of this effect cannot be
compared to the effect on the activity of 8-trifluoromethyl substituted reversed
chloroquine-type compounds tested against resistant parasites, since the assays used to
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test the latter did not test in the same range (all had IC50 >250 nM).
Finally, it is of interest that the same phenomenon of apparent cross resistance is
observed here as for most of the 8-substituted reversed chloroquine-type antimalarials
(see Figure 43). Again, it would be informative to determine whether this apparent crossresistance is reversible by verapamil (and thus whether it relates to increased efflux of the
8-substituted compounds from the digestive vacuole, or to another, unknown
mechanism).

3.4: A second short mechanistic study: The effect of exchanging chlorine for
hydrogen

In Chapter 1, it was noted that the activity of chloroquine analogues without an
attached reversal agent is detrimentally affected by removal of the 7-chloro substituent,
but that this is not always true for reversed chloroquine-type compounds (see Figure 18).
Previous work in Dr. Peyton’s laboratory has examined the importance of the 7-chloro
substituent to the class of bis-quinolines. Analogues of piperaquine and a related bisquinoline, PL192, have been made in which chlorine has been exchanged for hydrogen
(Figure 59; Gunsaru, 2010):
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Figure 59: Piperaquine analogues made during previous work, in which chlorine has been exchanged for
hydrogen (Gunsaru, 2010). Also shown is chloroquine with its 7-hydro analogue (Burgess, 2008).

Similarly to the case of reversed chloroquine-type compounds, no significant
difference in activity was observed between piperaquine and its bis-7-hydro analogue,
PL174 (Figure 59, above). PL192 differs from piperaquine in the arrangement of its
aminoalkyl motif, such that both quinoline ring systems have a secondary rather than
tertiary 4-amino group. In contrast to what was observed for piperaquine, and in contrast
to what has been observed for some reversed chloroquine-type compounds, PL255 (the
des-chloro analogue of PL192; Figure 59, above) showed a diminuition in activity
compared to PL192 (Gunsaru, 2010). However, it was not known whether this effect
would generalize to other bis-quinolines containing secondary quinoline-4-amino groups.
To help determine this, analogues of PL241 were made in which either or both
quinoline ring systems were substituted with hydrogen in position 7 (Figure 60; see also
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Appendix B, Table B6):
HN

N
NH

Cl

N

PL241
N

Cl

IC 50 = 0.063 nMD6, 0.014 nM 7G8
HN

N

HN

N

NH
Cl

N

NH

PL337

N

PL338

N
IC 50 <2.5

nMD6,

<2.5

N
IC 50 <2.5

nM 7G8
HN

nMD6,

<2.5

Cl

nM 7G8

N
NH

N
PL339
N
IC 50 = 17 nMD6, 28 nM 7G8

Figure 60: Analogues of PL241 in which chlorine has been exchanged for hydrogen.

As was observed in the case of the 8-trifluoromethyl substituted PL241 analogues,
substitution of a single 7-chloroquinoline ring system with 7-hydroquinoline did not
result in any reduction in activity within the range of the assay. However, exchange of
both rings for 7-hydroquinolines resulted in a reduction of activity similar to that seen for
the bis-8-trifluoromethyl PL241 analogue, indicating that in the case of PL241, removal
of the 7-chloro substituent is detrimental to antiplasmodial activity. This limited study
provides further support to the tentative conclusion from Gunsaru’s work (2010) that the
activity of bis-quinoline compounds with secondary quinoline-4-amino groups is more
sensitive to the removal of chlorine than is that of compounds more similar to
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piperaquine, with tertiary quinoline-4-amino groups. The reasons for this remain unclear.
It would be of interest to know whether the weak activity of other tertiary 4aminoquinoline antiplasmodials is insensitive to the removal of the 7-chloro group, or
whether the effect is specific to piperaquine. It would also be of interest to determine the
effect of removing chlorine from only one quinoline ring system of PL192 (see Figure
59).

3.5 The future of PL241: A potential antimalarial drug?

The excellent in vitro antiplasmodial activity of PL241 makes this a compound of
great interest for further development as a potential antimalarial drug, particularly if it
were to be found that it is active against piperaquine-resistant strains of Plasmodium.
However, for bis-quinolines as well as for other classes of compounds, high in vitro
activity does not always predict high activity in vivo (Vennerstrom, 1998), and even a
compound with high activity in vivo may not be a suitable drug. Considered as a
potential drug, PL241 has some features that are cause for concern. Firstly, toxicity may
be an issue. In the course of this work, an initial in vitro test to determine the possible
toxicity of PL241 was performed using mouse spleen lymphocytes (see Appendix B,
Table B7). Toxicity is given as LC50, the concentration required to kill 50% of the cells.
PL241 was found to be substantially more toxic (LC50 = 190) than chloroquine (LC50 =
12400), and also more toxic than the reversed chloroquine-type compounds tested
(representative LC50 = 6500 for PL69). However, the antiplasmodial activity of PL241 is
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substantially better than that of chloroquine – at least in vitro – so it is possible that could
be administered at a much lower dose, below the threshold of toxicity. The therapeutic
index (ratio of activity to toxicity) of PL241 using the mouse spleen lymphocyte assay
compares favorably to that of chloroquine (3500 versus 122). A second concern is the
known low water solubility of PL241, even as the phosphate salt. Low aqueous solubility
could present a problem in terms of biological absorption. The use of a solubilizing
counterion, such as mesylate or lactate (Stahl, 2003a), or a special formulation (Stahl,
2003b) might alleviate this problem, but the former might not do enough to improve
solubility while the latter would unacceptably increase cost. It is possible that PL241
might turn out to be is more absorbable in vivo than might be predicted (it may be worth
noting that the predicted cLogP (octanol-water partition coefficient, a predictor of water
solubility) of PL241 is 7.0 (ChemBioDraw), compared to 6.5 predicted for piperaquine).
However, at this early stage, the best approach might be to modify the structure of PL241
such that the drug properties would be improved without excessively compromising
activity. For example, in view of the easy synthetic variability of the quinoline ring
system, together with the results shown above for ring-modified reversed chloroquinetype compounds, it may be possible to add solubilizing substituents to the quinoline ring
system without unacceptably compromising activity (Wermuth, 2003).
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CHAPTER 4
A survey of historical therapies used in Europe to treat intermittent fevers

The mere treatment of this subject undoubtedly increases the admiration
that I at least feel for the men of old; the greater the number of plants
waiting to be described, the more one is led to revere the careful research
of the ancients and their kindness in passing on the results.
(Pliny, Natural History, Vol. VII, 1.)9

4.1: Introduction to the project
Malaria has been with us for many centuries, perhaps for all of human history
(Hoeppli, 1959; Hay, 2004; Hawass, 2010; Fornaciari, 2010). Its former range was much
larger than it is today, including much of Europe (Nuttall, 1901; Russell, 1955; Hay,
2004). The following chapter will survey selected therapies used in Europe to treat
malaria prior to and along with cinchona bark, from the time of Pliny the Elder (active in
the first century A.D.) through the advent of modern malaria chemotherapy in the early
twentieth century. The substances utilized for treatment were primarily plant remedies
(phytotherapies). The remedies include what may be considered traditional or folk
medicine, as well as official or scientific medicine. These two categories are not distinct,
and for the purposes of this survey they have been considered together.
There has been much interest in the traditional phytotherapies used to treat

9

Crescit profecto apud me certe tractatu ipso admiratio antiquitatis, quantoque maior copia
herbarum dicenda restat, tanto magis adorare priscorum in invendiendo curam, in tradendo
benignitatem subit. (Translation by W.H.S. Jones., 1956.)
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malaria in the parts of the world where malaria is currently endemic. Thousands of
articles and books have been published on this subject (see for example Dharani, 2010;
Zhu, 2012; Singh, 2011; Soejarto, 2012; Koch, 2005). However, with the exception of
cinchona, the historical malaria therapies used in Europe prior to the development of
modern antimalarial chemotherapy have attracted relatively little interest. The reasons
for this may be fourfold. Firstly, malaria has not been considered endemic to most of
Europe for nearly a century (Hay, 2004). In many formerly malaria endemic regions,
malaria has been absent for far longer, as has been discused by Nuttall, Cobbett, and
Strangeways-Pigg (1901). Naturally enough, the possibility that native European
antimalarial phytotherapies might have existed is not often considered. Secondly,
historical phytotherapies are often dismissed as folk medicine. Scientists, medical
practitioners, and even historians within the European tradition have typically considered
modern medicine to be contradictory and incompatible with folk medicine, which is often
regarded with amusement and scorn (Cameron, 2006; De Vos, 2010). It is no longer
considered acceptable in scholarship to ridicule and dismiss traditional remedies used in
other parts of the world, but this attitude is more rarely applied to the traditional medicine
of one’s own culture. Thirdly, in part because of the historical attitude of dismissal
towards traditional remedies, and partly also because of the lapse in time since malaria
has been prevalent in Europe, much of the European traditional medicine that was
formerly used to treat malaria has been forgotten. It is no longer part of the daily lives of
most of the population. Fourthly, there is a notion extremely prevalent in the literature
that no antimalarial remedy worthy of the name existed in Europe until the appearance of
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cinchona bark in the 17th century. Cinchona bark is generally thought of as having taken
over relatively quickly as the malaria treatment of choice, as if in a vacuum. In reality,
this was far from true (Jarcho, 1993; Adams, 2011). The prevalence of this belief has
helped to obscure a large number of antimalarial remedies that existed in the past.
The examination of early treatments for malaria and other diseases is not only of
historical interest. Both quinine and the artemisinins were originally discovered by
isolation of active constituents from plants used to treat malaria.

Especially now that

there is so much interest in finding novel scaffolds that are not yet subject to drug
resistance, it is likely that phytochemical sources of interest could surface from a serious
examination of the old literature. Recently, Adams, Zimmerman and coworkers have
screened 61 plants used in the European materia medica for in vitro antiplasmodial
activity (Adams, 2011; Zimmerman, 2013). Thirty-four of the plants were discovered by
inspection of eight German language herbals from the 16th and 17th century, while the
remainder were plants with known medicinal activity. Of the plants mentioned in the
Renaissance herbals, Adams, Zimmerman and coworkers found that many had some
degree of antiplasmodial activity. In view of this, it can no longer be assumed that
cinchona bark was the only malaria remedy used in Europe that had antimalarial efficacy.
Moreover, it appears likely that a search of the historical medical literature may yield
useful leads for the treatment of drug-resistant malaria.

In the present project, fifteen European primary sources have been searched for
malaria remedies. The remedies that were found are presented in tabular form, followed
91

by a brief discussion. The sources used begin with Pliny the Elder, whose Natural
History was written in the first century A.D., and end with Mrs. M. Grieve, whose
Modern Herbal was published in 1931. When possible, these sources were read in their
native language, but due to the inability of the author to read ancient Greek, Latin,
Middle Welsh, or Anglo Saxon, translations were sometimes used. The fifteen sources
used in this project are described briefly below. In the course of the project, several
additional sources were examined without finding reference to any disease that could
clearly be identified as malaria; the names of these sources are also briefly noted below.

Pliny the Elder: Plinii Naturalis Historiae (1st century A.D.)

Pliny the Elder, born in 23 A.D, was a Roman official and encyclopedist known
for his love of reading and interest in the natural sciences. In 79 A.D. he was killed by
toxic fumes from the eruption of Vesuvius, having sailed to the nearby Stabiae to observe
the results of the eruption (Rackham, 1938). His best-known work, Plinii Naturalis
Historiae (Natural History by Pliny), includes sections on the treatment of various
ailments and on the medical uses of plants. The edition used in this project is that
translated into English by H. Rackham, W.B.S. Jones, and D.E. Eichholz, divided into ten
volumes originally published during the years 1938 through 1957.
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Dioscorides: Herbal (1st century A.D.)

Dioscorides’ herbal describes the medical uses of herbs, animals, and minerals. It
was written in Greek by Pedanius Dioscorides, a Greek physician active in Rome during
the reign of Nero, 54-68 A.D. (Gunther, 1934; Major; 1954; Grant, 1970; Cameron,
2006); he was roughly contemporary with Pliny the Elder. Dioscorides’ Herbal remained
a standard medical work through the 1700s, having been translated into Latin early in its
history (as Materia Medica). Although its large size made it unavailable to many
physicians due to the expense of producing a copy, excerpts and epitomes were widely
available and it is frequently referred to in the older medical literature (Cameron, 2006).
The English botanist John Goodyer translated the Herbal into English during the years
1652-1655, and this translation was finally published in 1934, with amended translations
of species names, by Robert T. Gunther. A reprint of the 1934 edition has been used as a
reference here.

Alexander of Tralles: A work on fevers (525-605 A.D.)

Alexander of Tralles (525-605) was a Byzantine physician who died in Rome. He
wrote several medical works in Greek, including a treatise on fevers. In the latter he
often gives scathing critiques of the methods of treatment used by other physicians,
including Galen (whom, however, he greatly admired). An augmented edition of his
works, translated into Latin, was widely used during the Middle Ages (Cameron, 2006).
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The edition used in this work is a reprint of the 1878 translation from Greek into German
by T. Puschmann.

The Herbarium of Pseudo Apuleius (Anglo Saxon version, 10th century or earlier)

In its Latin original, the Herbarium of Pseudo Apuleius (Herbarium) was a widely
used health handbook on the European continent. It is a collection of three works. The
first of these is a short work on the uses of the herb betony (probably Stachys officinalis
(L.) Trevis.) by a Roman physician, Antonius Musa. The second book is a series of
herbal remedies, organized by ailment and ascribed to Apuleius Platonicus (this portion
of the text is thought to have originated in the 6th or 7th century A.D.; Anderson, 1977).
The final book is a Latin epitome of Dioscorides. The Herbarium was translated into
Anglo-Saxon from Latin at an unknown date, no later than the 10th century (Cameron,
2006). Together with other works, the Herbarium was translated from Anglo Saxon into
English by the Reverend Thomas Oswald Cockayne, and published as a three volume set
entitled Leechdoms, Wortcunning, and Starcraft of Early England (1864-1866).10 Of the
included works, only the three books of the Herbarium include remedies for a disease
that can be identified with relative certainty as malaria, despite the fact that malaria may
have existed in Britain at that time (Nuttall, 1901). Although the Herbarium is a
translation of a work that survives in Latin and (in the case of Dioscorides) in ancient
Greek, it is nevertheless valuable to examine the Anglo Saxon text. Firstly, the
10

The same author also published a series entitled The Shrine: A Collection of Occasional Papers on Dry
Subjects.
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translation into Anglo Saxon may reflect usage by a wider number of physicians in the
British Isles (viz, literate physicians without knowledge of Latin or Greek; as pointed out
by Cameron, it is significant that no fewer than four Anglo Saxon copies of the
Herbarium of Pseudo Apuleius survive today). Secondly, as noted above, its inclusion of
remedies for a disease that can be identified as malaria may be unique among the
surviving Anglo Saxon texts. Finally, the Anglo Saxon translator or translators often
rendered Latin plant names that he did not recognize as the names of local plants. The
plants selected may reflect to some extent existing local usage (Cameron, 2006).

Hildegard of Bingen: Causae et Curae (12th century)

Causaue et Curae is a health handbook written in Latin by Hildegard of Bingen
(1098-1179), a Benedictine abbess at Disibodenberg and later, Rupertsberg in RheinlandPfalz. She personally attended and treated the sick, including not only members of her
religious community but of the community at large; she also supervised the abbey’s herb
garden. Much of her writing and music survives today. Although most of her writings
are on subjects theological and mystical, Hildegard of Bingen was greatly interested in
natural history, particularly the medicinal uses of plants (Anderson, 1977; Pawlik, 1989).
Causae et Curae is partly based on historical medicine, partly on observation, and partly
on Christian theology. It was transcribed many times during the centuries after its
composition, and influenced the writings of future German botanists (Anderson, 1977).
The edition used here was translated into English by Patrick Madigan (1994).
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The Physicians of Myddfai (Prior to 1234)

The text of the Physicians of Myddfai (Meddygon Myddfai) is a compilation of
prescriptions collected and written down in Middle Welsh by Rhiwallon of Myddfai,
court physician to the South Welsh prince, Rhys Gryg (died 1234). The collection is
presumed to include much older material. A transcription of the text was included in the
Red Book of Hergest (Llyfr Coch Hergest), collected in 1382, and has survived in this
form up to the present day (Henderson, 1994; Breverton, 2012). The classic 1861
English translation by John Pughe unfortunately could not be obtained, and therefore a
more recent translation by Terry Breverton was used.

Bartholomæus Anglicus: De proprietatibus rerum (Prior to 1283)

Bartholomæus Anglicus (Bartholomew the Englishman) was a Franciscan teacher
active in Paris and Saxony during the 13th century. He may possibly have been the
protégé of Albertus Magnus (Anderson, 1977). His De proprietatibus rerum (On the
properties of things) was written in Latin prior to 1283. It is an early encyclopedia that
includes a section on the medicinal uses of plants. The work originally may have been
intended as an educational text for evangelical friars; however, it gained wide popularity
in the ensuing centuries and was translated into French, English, Dutch, Spanish, and
possibly Bavarian (Anderson, 1977; Keen, 2007). The edition used in this project is a
reprint of the 1398 translation into English by John Trevisa.
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Otto Brunfels: Contrafayt Kreüterbůch (1532) and Ander Teyl des Teütschen
Contrafayten Kreüterbůchs (1537)11

The Contrafayt Kreüterbůch (1532, Straßburg) is an early example of a new type
of herbal that would become common in the ensuing centuries. Unlike many
contemporary medical texts, it is written in German rather than Latin (it is a translation of
the Latin Herbarium Vivae Eicones, 1530, by the same author); in the ensuing years,
many more herbals would be written in the native language of their country (Arber,
1912). The Kreüterbůch is renowned especially for its naturalistic woodcuts by Hans
Weiditz, who based his woodcuts on drawings directly from plant specimens.
Illustrations in earlier books were primarily copies of earlier illustrations, and tended to
be conceptual or decorative rather than naturalistic (Arber, 1912; Collins, 2000). Herbals
of the years following the Contrafayt Kreüterbůch began to include illustrations based on
observation of plant specimens (Arber, 1912). In its text, the Kreüterbůch draws
substantially on earlier authors, including Dioscorides and Pliny, and provides
information about the astrological character of the plants, followed by information on
how to find and use them. Much effort is spent in trying to identify local plants as those
spoken of by Dioscorides (Anderson, 1977). The author, Otto Brunfels (circa 14891534), was a former monk who subsequently converted to Protestantism; after working as
a preacher and a schoolmaster, he studied to become a physician (Isely, 1994). A

11

Here, as elsewhere, historical spelling has been preserved whenever possible.
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facsimile reprint of the 1532 edition of the Contrafayt Kreüterbůch, including the
posthumously published Ander Teyl des Teütschen Contrafayten Kreüterbůchs (1537),
was used in this project.

Hieronymus Bock: Kreutterbůch (1572)

In contrast to many earlier and contemporary medical works, the 1539
Kreutterbůch of Heironymus Bock (also known as Tragus; 1498-1554) focuses on the
empirical identification and uses of local plants, rather than on the identification of local
plants as those described by ancient physicians (Anderson, 1977). The book was
originally written in German, not Latin, and the style is colloquial (Arber, 1912). The
author seems to take delight in relating superstitions about plants, only to disprove or
reject them. Hieronymus Bock studied medicine, and later supervised the gardens of the
Count Palatine Ludwig; subsequently he became a Lutheran pastor (Anderson, 1977). A
facsimile of the 1572 edition of the Kreůterbuch was used in this project.

John Gerard, Dr. Priest, and Thomas Johnson: The Herball or Generall Historie of
Plantes (1597 and 1633)

The Herball or Generall History of Plantes, one of the best loved of all English
botanical works, originated as a translation of Pemptades by the Belgian botanist
Rembert Dodoens (1517-1585). The original translator, a certain Dr. Priest, died before
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being able to ready his translation for publication. The publisher, John Norton, enlisted
the assistant of the botanist John Gerard (1545-1612), a surgeon and well known
horticulturist (Jackson, 1950). It is possible that Gerard merely rearranged the work
before publication (Arber, 1912; Anderson, 1977), but it is also possible that he
substantially revised and augmented it with his own work (Isely, 1994; Jackson, 1950); in
any case, The Herball was published in 1597 without crediting Dr. Priest. An enlarged
and improved edition was published in 1633 by Thomas Johnson (Arber, 1912;
Anderson, 1977). Facsimile versions of both editions were used in this project.

Nicolas Culpepper, Peter Cole, and Joseph Blagrave: The English Physician (1677)

The London physician and astrologer Nicolas Culpepper (1616-1654) was a noted
proponent of astrological botany, wherein ailments and remedies are related to various
planetary influences; in various forms, this doctrine was both controversial and popular
throughout the Middle Ages and ensuing centuries, up to the present day (Anderson,
1977). Culpepper was also known for giving medical advice to the poor without fee
(Lee, 1950). In 1649, Culpepper caused dismay and outrage among the London College
of Physicians by publishing an unauthorized English translation of their Pharmacopeia
(as The London Physical Directory; Anderson, 1977; Arber, 1912). Although described
by Culpepper’s opponents as “very filthily done”, this book was terrifically popular and
appeared in numerous editions. In 1653, together with Peter Cole, Culpepper published
The English Physician, a book of remedies from 369 English herbs. This book too had
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enormous popularity and continued to appear in various editions in the decades after
Culpepper’s death from consumption in 1654 (Lee, 1950). The version used in this
project is a facsimile of an enlarged 1677 edition published by Joseph Blagrave.

William Coles: Adam in Eden, or, Nature’s Paradise: The History of Plants, Fruits,
Herbs, and Flowers. (1657)

The English botanist William Coles (sometimes spelled Cole; 1626-1662)
published his great botanical work, Adam in Eden, or, Nature’s Paradise, in 1657. Many
of the remedies given relate to the doctrine of signatures, the theory that the shapes of
plants indicate their medical uses (e.g. the walnut for disorders of the brain).
Giambattista Porta is credited with much of the formal development of this theory as it
existed in early modern Europe (in his Phytognomonica, 1588), but the doctrine of
signatures has existed in various forms for far longer and in many parts of the world
(Arber, 1912; Bennet, 2007). Coles is credited with further development of the doctrine
of signatures in his work. He was also the author of another work, The Art of Simpling
(1656). In this project, a fascimile of the 1657 edition of Adam in Eden was used.

William Salmon: A Family Dictionary (1696)

William Salmon (1644-1713) practiced medicine in London, sold prescriptions,
including his own patent medicines, and practiced astrology and alchemy. He published
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many medical works, including a translation of Sydenham’s Practice of Physic
(sometimes referred to today for its descriptions of malaria), as well as works on other
subjects including theology and travel; he had at one time traveled to New England
(Moore, 1950). His Family Dictionary is a domestic handbook, including medical
advice, recipes, and instructions for making alcoholic beverages, perfumes, and various
medicines. Many of the prescriptions are intended for home manufacture, but others
describe patent medicines obtainable at William Salmon’s practice. The Family
Dictionary is of special interest because it is avowedly directed not at medical
practitioners but at the literate layman. The edition used in this project was a facsimile of
the expanded second edition, originally published in 1696.

Robert John Thornton: A New Family Herbal (1814)

Robert John Thornton (1783-1837) was a physician, botanist, and lecturer on
medical botany. He published two botanical works, including both the New Family
Herbal and another work called A New Illustration of the Sexual System of Linnaeus; the
beautiful and expensive plates in the latter book unfortunately led to the financial ruin of
the author (University of Cambridge Alumni Database, 2009-2011). Despite its name,
the New Family Herbal appears to be intended not only for lay people but for physicians
as well. Its entries generally include a botanical description, a history of medical use
(often including use by country people), a discussion of current usage, and detailed
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advice on dosage and administration. A facsimile of the expanded second edition (1814)
was used in this project.

Mrs. M. Grieve: A Modern Herbal (1931)

The herbalist and historian Maude Grieve (1858-1941) published her A Modern
Herbal in 1931. Part primary source and part work of history, the book contains the
following types of information on hundreds of herbs: firstly, information on historical
usage gathered from dozens of primary sources, secondly, folklore and information on
use by country people, and thirdly, information on current production and use by
herbalists, including cultivation, dosage, method of administration, and chemical
constituents when available. A useful feature of the book is its list of many common or
country names of plants, without which this project would have been much more
difficult. A service index of Latin names of plants was added in 1940, but the book lacks
an index by usage, and does not contain a list of the works consulted (although names of
sources are given within the text). Neverthelesss, the Modern Herbal is frequently
referred to by historians and herbalists, and has been reprinted many times. In this
project, a reprint from 1996 was used.

The following is a list of works consulted in which malaria remedies were not found, or
in which malaria could not be identified with relative certainty:

Theophrastes: On the Nature of Plants (370-285 B.C.)
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Marcellus: De Medicamentus Liber (On medicaments; 4th-5th century)
Isidore of Seville: The medical writings (d. 636; Sharpe, 1964)
Bald’s Leechbook (circa 950 A.D.)
Leechbook III (perhaps circa 950 A.D.)
Lacnunga (Later than 950 A.D.; Cockayne, 1864-6; Cameron, 2006)
Jean Fernel: De Abditis Rerum Causis (On the hidden causes of things; 1542)

4.2: Tables of the historical remedies found in this survey

Following are the remedies for malaria that were discovered in this survey, in the
form of two tables. Table 4.1 provides the plants and other substances encountered,
organized when possible by Latin name. Plant names used are those currently
recommended by the Royal Botanic Garden at Kew (The Plant List, 2013). Some of the
substances listed in Table 4.1 were part of more complex remedies; when this is true, the
reader is referred to Table 4.2, in which complex remedies are given, organized by the
source in which they were found.
A significant difficulty encountered in the course of the project was the accurate
identification of malaria in the sources. The variety of the terminology used to describe
different diseases and symptoms, as well as the different understanding of the causes of
disease, often makes it difficult to determine whether the illness that is being described is
malaria or not. The word “malaria” was not commonly used to describe the disease
itself until the beginning of the twentieth century, although it was associated with the
disease-causing agent during the nineteenth century, and had been used to describe
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unhealthful marsh air for centuries earlier (Russell, 1955; Jarcho, 1993)12. For the
purpose of this survey the following terms have been regarded as likely to refer to
malaria: ague or cold ague, intermittent fever or intermittent, remitting fever, periodic
fever, quartan or quartan fever, tertian or tertian fever, aestivoautumnal fever, Dreitägiges
Fieber (three-day fever), and Viertägiges Fieber (four-day fever). The terms fever or
chills when taken alone were not considered likely to refer to malaria, nor was swelling
of the spleen (although a recognized symptom of chronic malaria; Jones, 1909)13, as these
symptoms are common to multiple ailments. The term quotidian fever was also rejected,
although it may also describe malaria (Jones, 1909). Unless a hot ague was specified,
ague was accepted as likely to refer to malaria despite the fact that the term “ague” is
known to have been used for any acute fever during some periods (Nuttall, 1901;
MacArthur, 1954). The vocabularly used in a given source is provided in the table, so
that the reader may make his own distinctions. Naturally, there is substantial possibility
for error in the identification of disease, particularly when dealing with translated
materials. Due to time and language limitations, it had to be assumed that the translator –
in many cases a medical historian – had made his best effort to translate medical
terminology correctly. It is quite possible that not every remedy listed here was in fact
used to treat malaria, and it is very likely that some remedies were rejected
inappropriately.

12

Russell (1955) and Jarcho (1993) provide a useful discussion of the origins of the term,
malaria; these authors and others have shown that it does not originate with the physician
Francesco Torti, as is sometimes stated.
13
According to the Oxford English Dictionary (1971), the term “ague cake” was formerly used to
describe enlargement and hardening of the spleen.
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The second primary difficulty encountered was the identification of the
substances used. Plants in particular are often difficult to identify with certainty, as they
have changed their names and classifications many times over the course of millennia
(Singer, 1961; De Vriend, 1984). Some plants that are described in ancient texts may not
exist today (Vehling, 1977). In many cases, especially in the older texts, the
identification provided can only be an informed suggestion. A more complex situation
arises when using texts that are themselves historical translations of earlier documents,
intended for contemporary use as medical texts. In these cases, it is extremely probable
that many of the plants that were unknown to the translator were identified as local or
imported plants that were not, in fact, those intended by the original author (De Vriend,
1984; Cameron, 2006). Nevertheless, as these mistranslated plants were presumably then
used to treat malaria, they were considered valuable for this project in themselves; no
attempt was made to correct false identifications made in historical translations that were
used as medical books in their own right. This category includes the following: the
translation of Dioscorides by John Goodyer (1655), the De Proprietatibus Rerum of
Bartholomæus Anglicus, translated by John Trevisa (1283), and the Herbarium of Pseudo
Apuleius, translated into Anglo Saxon during the tenth century or earlier. Several of the
other sources, such as Otto Brunfels’ Contrafayt Kreüterbůch, also contain translations of
remedies from other texts, such as Dioscorides and Pliny.
Not all of the plants in the sources were European natives, or cultivated in the
region of the source describing them. Imported plants were nevertheless included here.
Some of these plants, such as ginger (Zingiber officinale Roscoe) and black pepper (Piper
105

nigrum L.), are used to treat malaria on other continents, and in some cases their
antimalarial activity has been studied (Willcox, 2004; Kamaraj 2012). The plants in
Table 4.1 were roughly categorized as being either imported or available somewhere in
Europe (whether native or cultivated, and not necessarily in the region of the source).
In the older literature, a distinction was made between tertian and quartan fevers,
and this distinction has been preserved in the table. The distinction may be that between
malaria caused by Plasmodium falciparum, vivax, and ovale, leading to the occurrence of
the fit on every other day, and malaria caused by Plasmodium malariae, leading to the
occurrence of the fit on every third day (Hoeppli, 1959; Adams, 2011). It is recognized
today as in the past that not every remedy is appropriate for every form of malaria. The
manner in which remedies are prepared and administered is also given in Table 4.1. The
possible importance of this will be addressed below.

KEY TO THE TABLES
Abbreviations used for sources:
Pl - Pliny the Elder: Plinii Naturalis Historiae (1st century A.D.)
D - Dioscorides: Herbal (1st century A.D.)
AvT - Alexander of Tralles: A work on fevers (525-605 A.D.)
HAP - The Herbarium of Pseudo Apuleius (Anglo Saxon version, 10th century or earlier)
HvB - Hildegard of Bingen: Causae et Curae (12th century)
Myd - The Physicians of Myddfai (Prior to 1234)
BA - Bartholomæus Anglicus: De proprietatibus rerum (Prior to 1283)
OB - Otto Brunfels: Contrafayt Kreüterbuch (1532) and Ander Teyl des Teütschen
Contrafayten Kreüterbůchs (1537)
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HB - Hieronymus Bock: Kreutterbůch (1572)
Co - William Coles: Adam in Eden, or, Nature’s Paradise: The History of Plants, Fruits,
Herbs, and Flowers. (1657)
JG - John Gerard, Dr. Priest, and Thomas Johnson: The Herball or Generall Historie of
Plantes (1597) and (1633)
Cu - Nicolas Culpepper, Peter Cole, and Joseph Blagrave: The English Physician (1677)
Sa - William Salmon: A Family Dictionary (1696)
Th - Robert John Thornton: A New Family Herbal (1814)
Gr - Mrs. M. Grieve: A Modern Herbal (1931)
A small h in parentheses after a source, e.g. Gr (h), indicates that source is not referring to a
treatment contemporary with itself, but to a historical treatment.
Further abbreviations:
Afr. – Africa
Aust. – Australia
Boi. – Boiled
Dec. – Decoction
Dist. – Distillate or distilled
Eur. – Europe (cultivated or native)
Ext. – External or topical
Extr. – Extract
Inf. – Infusion
Ingred. – Ingredients
Int. – Internal
Med. – Mediterranean
Mid. E. – Middle East
N. Afr. – North Africa
New W. – New World
Powd. – Powder or powdered
Purg. – Purgative
Tincture – tinct.
Unsp. – unspecified
With – w/
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Table 1: Historical remedies used to treat malaria
Scientific name

Common
name

Achillea millefolium
L.

Aconitum napellus L.
Acorus calamus L.?
Adiantum capillusveneris L.
Aegopodium
podagraria L.
Aesculus
hippocastanum L.
Agrimonia eupatoria
L.

Ailanthus altissima
(Mill.) Swingle
Ajuga chamaepitys
(L.) Schreb.
Allium
ampeloprasum L.
Allium sativum L.
Alnus glutinosa (L.)
Gaertn.
Aloe vera (L.)
Burm.f.
Alpinia galanga (L.)
Willd., A.
officinarum Hance
Alstonia constricta
F. Muell.
Alstonia scholaris
(L.) R. Br.
Anacyclus pyrethrum
(L.) Lag.

Availability

Source

Specificity

Yarrow

Eur.

Gr (h),
HvB

Ague (Gr), Threeday fever (HvB)

Wolfbane, Monkshood
Bitter flag

Eur.
Eur.

Th
Gr (h)

Intermittent fevers
Intermittent fevers

Method/part of
plant
Int., dec. herb
(Gr (h)); Int.,
HvB 1
Int., w/ caution
(dried leaves
or inspissated
juice)
Root, Gr 1

Maidenhair

Eur.

AvT

Herb Gerard

Eur.

JG

Quartan agues (JG)

Int., AvT 13
Int., root
powd. in wine
before fit, to
cure (JG)

Horse chestnut

Eur.

Agrimony

Eur.

Gr
Gr (h),
Cu

Tree of heaven

Eur.,
Asia

Gr

Intermittent fevers
Agues, tertian,
quartan
Malaria ("the
action of the trees
in malarial districts
is considered to
resemble that of
Eucalyptus"
(elsewhere
recommended to
treat intermittent
fevers)

Yellow bugle

Eur.

Gr

Agues

Leek

Eur.

AvT

Tertians

Garlic

Eur.

Pl, Th

Quartans

Alder

Eur.

Gr

Agues

Aloe

Afr.

Sa

China root (galangal,
galingale)

Eur.,
Asia
Aust
.

Cu,
HvB

Agues
Agues, quotidian or
intermittent (Cu),
Three-day fever
(HvB)

Gr

Agues

Asia

Gr

Eur.

JG

Malarial fever
Agues of long
standing

Alstonia bark
Dita bark
Pellitory of Spain,
Spanish chamomile

Int., inf. Bark
Int., dec. or
juice of herb

Int., inf. Bark
Int., powd. or
inf. Leaves
Int., AvT 14
Int., one head,
Pl 3
Int., dec. bark
Int., Sa 3 or
Sa 4
Int., boi. in
wine, water, or
broth (Cu), Int.
HvB 2
Int., powd.
Bark
Int., inf. of
bark
Int., root,
against
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shivering

Anacyclus pyrethrum
(L.) Lag.

Anagallis arvensis L.
Anchusa officinalis
L., Alkanna
tinctoria (L.)
Tausch, Anchusa
azurea Mill.
Anemone nemorosa
L.
Anethum gravelans
L.
Angelica
archangelica L.

Angostura trifoliata
(Willd.) T.S.Elias
Anthemis chia L., A.
rosea Sm.

Eur.

OB

Longstanding
fevers w/ shivering
and cold
("langwyrigen
feberen so mit
shauderen/ zytteren
und kelte angond").

Eur.

HAP
(?),
Mdf

Agues (cold fever)
(HAP), Intermittent
fevers (Mdf)

Eur.

JG, D,
Pl (h)

Agues and diseases
of spleen (JG),
Tertians, quartans
(D, Pl)

Wood anemone

Eur.

Gr (h),
Pl (h)

Agues (tertian)
(Gr), Tertian and
quartan (Pl)

Dill

Eur.

AvT

Bertram

Scarlet pimpernel

Alkanet, bugloss, or
wild bugloss

Angelica

Angostura
Anthemis

Eur.

New
W.
Mid.
E.

Sa

Gr
D

Aristolochia rotunda
L.

Birthwort, Smearwort

Eur.

JG,
HAP

Agues (lingering),
tertians (JG)
Agues (shaking
and shivering of),
hardness of spleen
(JG), Fevers (not
specific) (HAP)

Aristolochia
serpentaria L.

Snakeroot

New
W.

Gr, Th

Intermittent fevers
(Gr, Th)

Armoracia rusticana
P.Gaertn., B.Mey. &
Scherb.

Horse radish, Dittander
or Pepperwort

JG

Quartan Agues
(purgative)

Apium graveolans L.

Celery

Eur.

AvT,
JG

Agues, prevent and
cure (Sa)
"Some doctors
prefer Angostura
Bark to Cinchona
for use in fever
cases"
Recurring fevers
(D)

Int.
Ext., boi.. in
oil, before fit
(HAP), Ext.
Mdf 1, Int.
Mdf 2
Int. dec. root,
w/ mead or
honeyed water
(JG), Herb boi.
in wine (D),
pith, amulet
(Pl).
Int. root,
leaves, juice
(Gr), Amulet
(Pl)
Int., dec. herb
Int., root
powd. Sa 5

inf. of powd.
bark

Int., Juice in
syrup (JG),
Int., AvT 13
Int., Dried and
burnt (the
smoke is
inhaled)
Int., dried
roots (Gr), Th
3
Int., syrup
made from
rinds in vinega
r& honey, as
purgative
(vomiting)
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(JG)
Int., flowers
Ext.?, with oil
to remove
shivering of
fits (JG), Ext.,
annoint
backbone to
prevent fit (Gr,
h)
Dec. herb
(AvT (h)), Ext.
(AvT), Int.
Mdf 3, Int.
powd. dried
flowers (Gr
(h)), dec. herb
(Th), Int. dec.
powd.,or
juice, or inf. in
wine (Co)
Young
flowering tops,
shoots

Arnica montana L.

Mountain arnica

Eur.

Th

Intermittent fevers

Artemisia abrotanum
L.

Southernwood

Eur.

JG, Gr
(h)

Agues

Wormwood

Eur.

AvT,
AvT
(h),
Mdf,
Gr, Th,
Co

Quartans (AvT),
Tertians (AvT),
Intermittent fevers
(Mdf, Th), Agues
(Gr (h)),
Intermittent agues
(Co)

Sea wormwood
Pontic wormwood,
Roman wormwood

Eur.

JG

Eur.

JG

Intermittent fevers
(Gr)
Agues (lingering),
Tertians

Eur.

Gr,
Mdf,
Th

Intermittent fevers
(Gr, Mdf), Ague
(Th)

Eur.

Th

Intermittent fevers

Eur.

OB,
JG,
Co, Gr
(h)

Lingering and
quartan fevers
(OB), Quartans,
agues of long
continuance (JG),
Agues (Gr from
Cu, Co)

Eur.

HB

Quartans (HB)

Roots, inf. or
boi. (purgative
by vomiting)
(JG), Int., Gr.
4; Ext., Co 6;
Int., inf. leaves
& roots in
wine (Co)
Int., whole
plant stewed in
wine

Candy carrot

Eur.

AvT

Quartans

Int., AvT 15

Macedonian parsely

Eur.

AvT

Int., AvT 11

Oats
Field daisy, common
daisy, English daisy

Eur.

AvT

Quartans
Tertians, possibly
quartans

Eur.

JG

Agues

Artemisia absinthium
L.
Artemisia maritima
L.
Artemisia pontica L.

Artemisia vulgaris L.
Arum maculatum L.

Asarum europaeum
L.
Asplenium
scolopendrium L.
Athamanta cretensis
L.
Athamanta
macedonia (L.)
Spreng.
Avena sativa L.
Bellis perennis L.

Mugwort
Arum, Cuckoo's Pint,
Wake Robin

European wild ginger
(Asarabacca,
Haselwurz, Hazelwort)
Hart's tongue
(Hirzzung, Wald
Asplenon)

Int., juice and
inf. of herb
(Gr, Th), Ext.,
Mdf 2

Int., gruel
Int., dec. in
water (JG)
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Sa, Gr,
JG

Berberis vulgaris L.
Betula pubescens
Ehrh.

Barberry

Eur.

Birch

Eur.

Bidens tripartita L.
Bituminaria
bituminosa (L.)
C.H.Stirt.
Blechnum sp.

Water agrimony

Eur.

Gr
Gr (h),
Cu

Trifolium, trefoil, pitch
trefoil
Blechnum

Med.
Eur.

D
HvB

Agues (Sa),
intermittent fevers
(Gr)

Int., inner bark
boi. in wine
(Sa), Int.,
powd. bark
(Gr)

Intermittent fevers

Inner bark

Agues (tertian)
Tertians, Quartans
Three-day fever

Herb
Int., leaves or
seeds in wine
(D)
Int. HvB 1
Int., whole
plant stewed in
wine (HB), Int.
Mdf 2

Borago officinalis L.
Calendula officinalis
L. and others

Borage

Eur.

HB,
Mdf

Marigold

Eur.

JG, Gr

Tertians, Quartans
(HB), Intermittent
fevers (Mdf)
Pestilential agues
(JG), Ague (Gr)

Capparis spinosa L.

Capers

Eur.

JG, D

Quartans (JG)

Shepherd's Purse
Capsicum, Guinea
pepper, Chilli pepper
Caraway

Eur.

Co

Ague (to prevent
the fits)

Eur.

Th
Mdf

Intermittent fevers
Intermittent fevers

Sweet chestnut

Eur.

Gr

Agues

Eur.

JG,
HB,
Gr,
OB,
Co

Eur.

JG, Sa,
Gr (h)

Eur.

JG,
AvT,
Gr, Th,
Co

Capsella bursapastoris (L.) Medik.
Capsicum annuum L.
Carum carvi L.
Castanea vesca
Gaertn.

Centaurea benedicta
(L.) L.
Centurium erythraea
Rafn

Chamaemelum
nobile (L.) All.

Blessed thistle (Cardo
Benedict, Holy thistle)

Centaury

Chamomile, Roman
chamomile

Quartan (JG, HB,
OB, Co), Ague
(Co), Intermittent
fevers (Gr)
Lingering agues
(JG), Tertians (Sa),
Intermittent fevers
(Gr)
Agues (Co), Agues
in children, cold
Agues (JG),
Quartans (AvT),
Intermittent fevers

Any (JG)
Int., w/ food
(JG)
Int., juice of
the herb w/
wine
Int., seeds
Int., Mdf 2
Int., dec.
leaves
Int., hot, boi.
in wine, extr.
of leaves (JG),
powd. in wine
(HB), inf. of
herb as
diaphoretic
(Gr) Int.,
powd. or dec.
of the herb in
posset for any
ague; extr. for
quartan ague
(Co)
Int., dec. (JG,
Sa), Herb and
leaves (Gr)
Int. boi. in
posset ale
(JG), Ext.
(AvT), Int.,
inf. of flowers
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Chelidonium majus
L.
Chionanthus
virginicus L.
Cichorium endiva
L.?
Cicorium intybus L.

Cinchona sp.
Cinnamomum verum
J.Presl and C. cassia
(L.) J.Presl
Cistus creticus L. ?

Citrullus colocynthis
(L.) Schrad.

(Gr, Th)

(Gr, Th), Th 1
(Th), dec.
flowers (Co)
Int., herb juice
Int., extr. of
dried root bark

Greater celandine
Fringe tree (Old Man's
Beard)

Eur.
New
W.

Th (h)

Intermittent fevers

Gr

Intermittent fevers

Endive
Chicory

Eur.
Eur.

AvT
Gr (h)

Tertians, quartans
Agues

Peruvian bark,
cinchona

New
W.

Sa,
Gr?,
Th

Agues (Sa),
Febrifuge (Gr),
Intermittent fevers
(Th)

Cinnamon
Ladanum (Labdanum)

Asia
Med.

Sa
Pl

Agues
Tertians

Mid.
E.

AvT,
HB
(h), Pl,
BA

Colocynth

Quartans (HB,
AvT, Pl, BA),
Tertians (HB, Pl)

Agues (JG),
Antiperiodic (Gr),
Remittent fever
(Th)

Citrus limon (L.)
Osbeck
Citrus medica L.

Lemon
Citron

Eur.
Eur.

JG, Gr,
Th
AvT

Clinopodium nepeta
(L.) Kuntze
subsp.glandululosum

Mountain mint, lesser
calamint

Eur.

JG, Gr
(h), Cu

Agues

Myrrh

Mid.
E.,
N.
Afr.

D, Sa,
Cu

Agues, esp.
Quartans (D, Cu),
Ague or quartan
ague (Sa)

Commiphora myrrha
(Nees.) Engl. and
others

Stalks
Int., Gr 2
Int., bark in
wine,
sweetened
(Sa), Int., dec.
of bark (Gr,
Th)
Int., Sa 2 or
Sa 3
Int., fruit AvT
7, Int., seeds
(HB), Ext.,
seeds, amulet
(Pliny)
Int., fruit juice
w/ aqua vitae
at approach of
fit; Int., dist.
Fruit; Int., dec.
fruit (Gr), Int.,
juice, saturated
w/ salt (Th)
Peels
Int., alone or
w/ mead or
honeyed water
to remove
shivering, Ext.
boi. in salad
oil to remove
shivering (JG)
Int. w/ pepper
and water (D),
Int. Sa 3, in
wine for
quartan (Sa),
Int. two hours
before the fit
to prevent
shaking; For
quartans, in
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muscadine
before the fit,
to provoke
sweating (Cu)
Hemlock

Eur.

AvT

Quartans (provoke
sleep to reduce
severity of fit)

Larkspur

Eur.

HAP

Quartans

Field bindweed

Eur.

D

Intermittent fevers

Convolvulus
Scammonia L.

Scammony or purging
bindweed

Eur.

Sa, JG,
AvT

Tertians (JG, AvT),
quartans (AvT)

Coriandrum sativum
L.

Coriander

Pl, OB

Tertians

Cornus florida L.

American boxwood

Eur.
New
W.

Gr

Cornus sericea L.

Red American osier

New
W.

Crocus sativus L.
Croton eluteria (L.)
W.Wright

Saffron
Cascarilla, Willowleaved croton

Eur.
New
W.

Sa
Th

Intermittent fevers
"Active properties
similar to those
found in Peruvian
bark"
Agues (tertian)
(Sa)
Agues/Remitting
fevers

Cucumis melo L.

Melon

Eur.

AvT

Quartans (some)

Gourd or cucumber
Turmeric

Eur.
Asia

BA,
JG (h)
Thr

Agues (BA, JG)
Intermittent fevers

Zedoary

Asia

Gr

Antiperiodic
Long tertians (JG),
Quartans (JG,
AvT), agues in
children (JG, Sa,
Gr)
Tertians, quartans
(AvT)

Conium maculatum
L.
Consolida regalis
Gray?
Convolvulus arvensis
L.

Cucurbitae sp.
(various)
Curcuma longa L.
Curcuma zedoaria
(Christm.) Roscoe

Cuscuta epithymum
L. and others
Cydonia oblonga
Mill.

Gr

Dodder, Hell weed

Eur.

JG, Sa,
AvT,
Gr (h)

Quince

Eur.

AvT

Int., AvT 16
Int., juice w/
pepper, for
three days.
Ext. w/ oil
JG 3 (JG),
Int., Sa 3 and
Sa 4 (Sa), Int.,
juice as a mild
purgative; or
AvT 9
Int., grains, or
Ext. in
ointment to
forehead (Pl)
Int., root bark

Int., Sa 4
Int., bark
Int., as part of
cooling diet
Int., roasted or
fried (BA);
Placed in bed
w/ a sleeping
infant sick w/
ague, to cure
(JG)
Int., powd.
Int., alone or
w/ aloe
Int., that
growing upon
brambles (JG),
that growing
on thyme, AvT
7 and (Sa)
Int.
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Cynoglossum
officinale L.

Drosera anglica
Huds.
Dysphania
ambrosioides (L.)
Mosyakin &
Clemants
Eucalyptus globulus
Labill.
Eupatorium
perfoliatum L.
Euphorbia esula L.
Ferula assa-foetida
L.

Hound's tongue

Eur.

HAP,
Pl

English sundew

Eur.

Sa

Quartans

Int., root boi.in
water (HAP),
Int. (Pl)
Ext., dist.
water of plant
applied to the
pulse for 6
hours

Gr

Malaria

Int., the
volatile oil

Gr

Intermittent fever

Int., extr.

Gr

Intermittent fevers

Eur.
Mid.
E.

OB
Cu

Quartans
Agues (the shaking
fit), Quartans (Cul)

Herb
Int., powd.,
OB 2
Int., Cu 1 and
Cu 2

Sa,
AvT

Agues

Int., Sa 3, Int.
AvT 1

D

Intermittent fevers

American wormseed
Eucalyptus
Boneset/Thoroughwort
Leafy spurge,
Wolffsmilch
Asafoetida (Asafetida),
Devil's dung

New
W.
Aust
.
New
W.

Tertians, Quartans
(HAP, Pl)

Ferula gummosa
Bois., F. galbanifera
(Mill.) W.D.J.Koch?
Ferula persica
Willd.

Galbanum
Ferula of Media

Mid.
E.
Mid.
E.

Filipendula ulmaria
(L.) Maxim.

Meadowsweet, Queen
of the meadow

Eur.

JG, Gr

Foeniculum vulgare
Mill.

Fennel

Eur.

Mdf,
Pl

Quartans (JG, Gr)
Intermittent fevers
(Mdf), Quartans
(Pl)

Fraxinus excelsior L.

Ash

Eur.

Gr

Intermittent fevers

JG,
Mdf

Quartans (JG),
Intermittent fevers
(Mdf)

Int., the liquor
Int., flowers
boi. in wine
(JG)
Int., Mdf 2
(Mdf), Int., Pl
2
Int., dec. of
bark
Int., dec. herb,
syrup of juice,
dist. water of
herb (JG), Int.,
Mdf 3

Gr

Antiperiodic

Int., leaves

Fumaria officinalis
L.
Garrya fremontii
Torr.
Gelsemium
sempervirens (L.)
J.St.-Hil.
Gentiana lutea L.,
Gentiana purpurea
L.
Gentiana
quinquefolia Hill.
Gentianella amarella
(L.) Harry Sm.

Fumitory
Californian Fever Bush

Eur.
New
W.

Gelsemium (yellow
jasmine)

New
W.

Gr

Intermittent fevers

Yellow gentian, purple
gentian

Eur.

Gr, Th,
Co

Intermittent fevers
(Gr, Th), Agues
(Co)

Five-flowered gentian

Eur.

Gr

Intermittent fevers

Autumn gentian

Eur.

Cu

Agues

Int., inf. of
root
Int., root Gr 3
or Thr 4, Int.,
inf. herb in
wine (Co)
Int., tinct. of
root
Int. dist. water
of herb, or root
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Intermittent fevers
(Gr, Th), Agues,
esp. tertians (Sa)

in liquid (Cu)
Int., dec. or
inf. of powd.
root or herb
(Gr), Int., root
or herb boi. in
water or posset
before fit (Sa),
Root powd.
(Th)

Avens
Ground ivy (Gill-overthe-ground)

Eur.

Gr, Sa,
Th

Eur.

Mdf

Intermittent fevers

Int., Mdf 2

Hedge hyssop

Eur.

Thr

Autumnal fevers

Helianthus annuus
L.

Sunflower

Eur.

Gr

Intermittent fevers

Heliotropum
europaeum L. ?

Heliotrope

Eur.

Pl

Tertians, Quartans
(Pl)

Black hellebore, wild
black hellebore, Great
oxheel, Setterwort or
bearfoot, "Christwurz
or Nieswurz" (OB)

Eur.

JG,
OB,
Pl, Co,
BA

Quartans (as
purgative) (JG,
OB, Pl, Co, BA)

Int., Thr 5
Int., tinct. of
the seed in
ethanol
3 or 4 grains of
seed in wine
for tertians and
quartans
respectively
(Pl)
Strong
purgative, only
for strong
bodies (JG),
As purgative,
w/ caution
(OB, Pl, Co root)

Hawkweed

Eur.

Gr (h)

Agues

Hippurus vulgaris L.

Horsetail

Eur.

D

Intermittent fevers

Hordeum distichon
L.

Barley

Eur.

AvT

Tertians and
possibly quartans

Geum urbanum L.
Glechoma hederacea
L.
Gratiola officinalis
L.

Helleborus niger L.
Hieracium murorum
L.

Humulus lupulus L.

Hops, Wild hops

Eur.

JG,
OB

Agues (lingering),
spleen stoppages
(JG), Quartans
(OB)

Hybanthus
calceolaria (L.)
Oken
Hyoscyamus niger

Ipecacuanha
Henbane and other

New
W.
Eur.

Th
AvT

Intermittent fevers
Quartans

Herb
Drunk w/ wine
one hour
before the fit
Int. (barley
water or gruel
[Gerstenschlei
msaft])
Leaves, tender
stalks, &
flowers, boi. in
whey (JG),
OB 1 (OB)
Int., a small
amount before
the fit OR to
cause vomiting
at the end of
the cold stage.
Int., AvT 5;
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L., H. albus L.
Hypericum
androsaemum L.

Hypericum coris L.

Hypericum
perforatum L.
Hypericum
tomentosum L.
Hypericum
triquetrifolium
Turra, Hypericum
barbatum Jacq.
Hyssopus officinalis
L.
Ilex aquifolium L.
Ilex verticillata (L.)
A.Gray
Inula conyza
(Griess.) DC.
Ipomoea jalapa (L.)
Pursh and I.
pandurata (L.) G.
Mey

hyoscyamus sp.

AvT 16

Tutsan

Eur.

Mdf

Intermittent fevers

Heath-leaved St. John's
Wort, Aaron's beard

Eur.

HAP

Quartans

St. John's wort

Eur.

Sa, HB

Woolly St. John's Wort

Eur.

JG

Hypericum sp.

Eur.

Hyssop

Eur.

D, Pl
AvT
(h)

Holly

Eur.
New
W.

Black American alder
Fleabane (HAP,
identification
uncertain), Spikenard
(AvT)

Jalap bindweed

Agues (quartan or
tertian) (Sa),
Tertians, Quartans
(HB)
Tertians and
quartans
Tertians, Quartans
(D), Quartans (Pl)

Gr

Intermittent fevers

Gr

Intermittent fevers

Eur.

HAP?,
AvT

Agues (cold fever)
(HAP), Quartans
(AvT)

New
W.

Sa

Agues
Quartans (AvT),
Shaking fits of
ague (Co)

Iris x germanica L.,
I. pallida Lam. and
others

Iris (Flower de Luce,
Orris)

Eur.

AvT,
Co

Juglans nigra L.

Walnut

Eur.

Co, Gr

Agues (Co, Gr)

Juniperus communis
L.

Juniper

Eur.

Sa, BA

Agues (Sa),
Quartans (BA)

Justicia adhatoda L.
Lactuca sativa L.
Lamium purpureum

Malabar nut
Lettuce
Lamium (Dead nettle)

India
Eur.
Eur.

Gr
AvT
Gr (h),

Intermittent fevers
Tertians, quartans
Quartans (Gr, Co),

Ext., Mdf 1
Pounded, and
drunk in wine.
Int., warm dec.
of leaves and
seeds before
the fit (Sa),
Int. (HB)
Drink w/ wine
(JG from D)
Int., w/ wine
(D), Int. as a
component of
Pl 1
Int., AvT 10
Int., inf. or
dec. of powd.
Leaves
Int., dec. of
bark
boi. in oil and
applied Ext.
(HAP), Int.,
AvT 8

Int., Sa 3
Int., AvT 1,
Int., dec. of
roots w/ honey
(Co)
Int., root bark
powd. and
infused into
vinegar (Co),
Juice of green
walnut husks
(Gr)
Int., the extr.
Sa 3, Taken
every day
(BA)
Int. leaves,
flowers, fruit,
root
Stalks
Int.? (Gr), As
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L.
Laserpitum
(identification
uncertain, possibly
Thapsia garganica
or silphion, or
Narthex silphium,
but probably extinct)
Laurus nobilis L.
Levisticum officinale
W.D.J.Koch
Liquidambar
orientalis Mill.
Magnolia acuminata
(L.) L. and M.
virginiana L.
Malva sylvestris L.
or Althaea officinalis
L.
Mandragora
officinarum L.
Many sp.
Marchantiophyta sp.,
unidentified (possiby
various)
Melissa officinalis L.
Mentha spicata L.,
Mentha x piperita L.

Mentha pulegium L.
Menyanthes
trifoliata L.

Pl, Co

Tertians, quartans
(Pl)

an amulet (Pl),
Int., the
flowers (Co)

Magydare, Laser,
Laserwort, Silphium

Eur.,
Mid.
E.

JG, Pl

Agues (shaking
and shivering of)
(JG), Quartans (JG,
Pl)

Bay

Eur.

Gr (h)

Agues

Lovage

Gr (h)

Agues

Storax (Liquidambar)

Eur.
Mid.
E.

Int., JG 2, Pl
3
Int., inf. of
berries
Int., dec. of
herb (Gr from
Cu)

AvT

Quartans

Int., AvT 1

Magnolia

New
W.

Gr

Malaria

Int., bark of
stem and root

Mallow

Eur.

Mdf

Intermittent fevers

Mandrake

Eur.
Mid.
E.

AvT

Quartans

Ext., Mdf 1,
Int., Mdf 2
Int., the bark
AvT 6

BA

Quartans

Sap or resin

Stone liverwort
Melissa, Lemon balm,
"Muterkraut,
Pfaffenkraut"

Eur.

JG

Tertians

Eur.

OB

Mint

Eur.

Sa

Quartans
Agues (quartan)
(Sa)

HAP,
AvT
(h), Pl,
Co
Gr,
Thr

Tertians
Agues (Gr),
Tertians and

Balsam

Pennyroyal (Dwarf
dwostle)
Bogbean (Buckbean,
Water trefoil)

Eur.
Eur.

Int., the herb
Int., Sa 2
Ext., twigs in
wool, wound
about the head,
for headache
caused by fit
(HAP), Ext.,
or smell,
wrapped in
wool, before
fit, or place
under
bedclothes
(Pl); AvT 10,
Co 3
Leaves, finely
powd. (Gr),
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quartans (Thr)

Leaves, finely
powd., inf. or
extr. (Thr)
Int., dec. in
rooster broth
Int., Sa 3, w/
other unsp.
ingred. (Gr)
Int., seed, w/
wine
Root, boi. in
posset, to
cause vomiting
(at beginning
of disease)

Mercurialis perrenis
L.

Dog's mercury

Eur.

Gr (h)

Myristica fragrans
Houtt.
Myrrhis odorata (L.)
Scop.

Nutmeg, Mace
Hartswort or Seseli
(Cicely?)

Asia

Sa, Gr

Ague
Agues (Sa),
Intermittent fevers
(Gr)

Eur.

JG

Agues

Narcissus
pseudonarcissus L.

Daffodil

Eur.

Nepeta cataria L.

Catnip (Katzenkraut)

Eur.

Cu, Gr
(h)
HB,
OB

Agues, esp.
Tertians (Cu)
Tertians (HB),
Quartans (OB)

Tobacco

New
W.

Sa, Co

Agues (Co), Agues
(especially tertian)
(Sa)

Nigella, Fennel flower

Eur.

Co

Tertians, quartans

Water dropwort

Gr

Intermittent fevers

Int., seeds in
wine before fit
Int., powd.
Fruits

AvT
AvT
(h)

Quartans

Int., AvT 1

Nicotiana tabacum
L.
Nigella sativa L,
Nigella damascena
L., and others
Oenanthe aquatica
(L.) Poir.
Opopanax chironium
Koch

Opoponax

Eur.
Eur.,
Mid.
E.

Origanum vulgare L.

Oregano

Eur.

Paeonia officinalis
L.

Papaver somniferum
L.
Passiflora
maliformis L. & P.
suberosa L.
Pastinaca sativa L.
Persicaria amphibia
(L.) Delarbre
Persicaria bistorta
(L.) Samp.
Petroselinum
crispum (Mill.) Fuss

Peony

Eur.

Int., juice (HB)
Int., dist. water
of herb w/
sugar before fit
(Co), Ext. Sa
1

Int., AvT 10

D,
HAP

Quartans, and
fevers that come w/
shivering (D),
Tertians and
quartans (HAP)

Herb, amulet
(D); Ext., juice
w/ rose oil
(HAP)
Int., AvT 12;
AvT 16 (to
provoke sleep,
thus reducing
severity of fit)

Opium

Eur.,
Asia

AvT

Quartans (internal
pains of); Provoke
sleep to reduce
severity of fit

Granadilla
Parsnip

New
W.
Eur.

Gr
Gr

Intermittent fevers
Intermittent fevers

Int., leaf juice
Int., seeds

Amphibious persicaria

Eur.

Mdf

Intermittent fevers

Ext., Mdf 1

Bistort

Eur.

Gr (h)

Intermittent fevers

Root, Gr 1

Parsely

Eur.

Gr

Intermittent fevers

Int., dec. seeds
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Peucedanum
ostruthium (L.)
W.D.J. Koch
Phoenix dactylifera
L.
Pimpinella anisum
L.

Masterwort

OB,
Co,
HB

Quartan agues
(Co), Quotidians
(OB)
Agues, compound
and long

Dates

Eur.
Mid.
E.

Anise

Eur.

Co
AvT,
Pl

Intermittent fevers
(D, Thr)

Quartans (Pl)

Piper nigrum L.

Pepper

Asia

D,
AvT
(h),
Thr

Pistacia lentiscus L.
Pisum sativum L.,
Cicer arietinum L.,
or Lathyrus odoratus
L. (unlikely)

Mastic

Mid.
E.

AvT

Quartans

Zyßeren erbsen (Pea,
chick pea, or sweet
pea?)

Eur.

OB

Quartans, Tertians

Eur.

D,
HAP,
OB,
HB,
Thr,
Pl, Gr,
AvT

Tertians (HAP, D,
OB, HB, Thr, Pl),
Quartans (D, OB,
HB), Intermittent
fevers (Gr)

Eur.

D, Gr
(h), Pl

Intermittent fevers
(D, Gr), Tertians
(Pl)

Eur.

Gr,
HB,
Co

Agues (Gr),
Quartans (HB, Co)

Plantago major L.
and P. lanceolata L.

Plantain, waybread
(Wegerich,
Spitzwegerich)

Polygonum aviculare
L.

Knotgrass

Polypodium vulgare
L.

Common polypody
(oak fern, Engelfuß,
Steinfarn)

Int., root inf.
(OB), Root
(Co)
Int., in wine
Int., AvT 14,
Int., Pl 2
Int. or Ext.
(D), Int. AvT
1 or AvT 9,
Int., large dose
to cure (Thr)
Int., gum, AvT
7; Int.,
flowers, AvT 8
Int., legumes
boi. in water
Int. roots in
wine (D), Int.
sprouts in
water or wine,
fasting, before
fit (HAP), Int.
roots in wine
and water; Int.
dist.; Int. herb
juice (OB),
Int., roots boi.
in wine; Int.
root dist. (HB)
Reported by
others (Thr),
Int. root juice
or the pounded
root in water
or honey water
before fit (Pl),
Int., fluid extr.
of leaves, root,
flower spikes
(Gr)
Int. w/ wine
before fit (D),
Int., juice (Gr),
Amulet against
tertians (Pl)
Int., dist. water
of roots &
leaves (Gr,
HB), Int., herb
dec. or inf.
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Potentilla anserina
L.

Gr

Ague

Tormentil

Co,
Gr, Th

Agues (Co),
Intermittent fevers
(Gr, Th)

Potentilla reptans L.
Prunus laurocerasus
L.
Prunus sp.,
unidentified

Cinquefoil

Eur.

JG, D,
Gr, Pl,
Co

Tertians, quartans
(JG, D, Pl),
Intermittent fevers
(Gr [h]), Ague (Co)

Cherry laurel
Flanders or Kentish
cherries

Eur.

Th

Agues

Eur.

JG

Agues

Prunus spinosa L.

Sloe tree

Eur.

Th

Agues

Pulicaria
dysenterica (L.)
Bernh.

Fleawort and Never
dying fleawort

Eur.

JG, Cu

Tertians (JG)

Potentilla erecta (L.)
Raeusch.

Punica granatum L.
Quercus robur L.
and others
Raphanus
raphanistrum subsp.
sativus (L.) Domin

Rheum rabarbarum
L.

Silverweed

Eur.

Pomegranate

Eur.

JG, Gr

Agues (JG),
Intermittent fevers
(Gr)

Common oak, Oak

Eur.

Th, Gr

Intermittent fevers
(Th, Gr)

Radish

Eur.

HvB

Three-day fever

D, Sa,
JG

Intermittent fevers
(D), Agues (Sa),
Lingering agues
(JG)

Rhubarb

Eur.

(Co); Co 4
Int., dried
powd. leaves,
roots
Int., herb
steeped
overnight in
wine and dist.
(Co), Gr 3;
large dose
(Thr); Thr 4
Int., root juice,
JG 4; int.,
herb, D 1; Int.,
herb in wine or
vinegar (Co),
Int., leaves,
either as D or
in honey water
w/ pepper (Pl)
Int., dist. water
of leaves
Int., fruit
Int., bark
powd.
Int., JG 3;
Seed boi. in
water or
infused, dec.
or inf.
(purgative and
cooling) (JG)
Int., sour seeds
(JG), Int.,
powd. rind of
fruit (Gr)
Int., bark (Th),
Int., bark extr.
(Gr)
Int. HvB 2
Int. w/ wine
(D); Int., root
boi. in posset
before fit (Sa),
Int., leaves inf.
in ale (strong
purgative)
(JG); Int.,
Roots JG 1
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Ricinus communis L.

Satyrion royall, Palma
christi, Castor bean

Eur.

JG

Quartan

Rosa sp.
Rubia tinctorum L.
Rubus sp.

Rose
Madder
Brier

Eur.
Eur.
Eur.

Cu, Sa,
Gr (h)
HvB
HvB

Agues (Cu, Sa, Gr
(h), BA)
Four-day fever
Four-day fever

Rumex acetosa L.

Garden sorrel, Sheep
sorrel

Eur.

Gr (h),
JG

Agues (JG), fiery
fits of ague (Gr)

Rumex acetosella L.

Sorrel, Knobbed sorrel,
Sheep sorrel and others

Eur.

JG

Agues

Ruscus aculeatus L.

Butcher's broom

Eur.

Mdf

Intermittent fevers

Agues (JG),
Intermittent fevers
(D), Agues,
especially tertian
(Sa, Co), Shaking
of ague (Sa, Gr,
Co)

Ruta graveolans L.

Rue, Herb Grace

Eur.

JG, D,
AvT,
Sa, Co,
Gr (h)

S. paniculata Mill.

English saxifrage

Eur.

JG

Salix alba L.

Eur.

Gr, Th

Salix caprea L.
Salix x fragilis L.

White willow
Great round-leaved
willow
Crack willow

Eur.
Eur.

Th
Th

Salvia officinalis L.

Sage

Eur.

Sa, Gr

Intermittent fevers
Intermittent fevers
Agues (especially
tertian) (Sa), Ague
(Gr)

Eur.

Cu,
Mdf,
OB

Agues (Cu),
Intermittent fevers
(Mdf), Quartans
(OB)

Sambucus ebulus L.

Dwarf elder

Agues
Antiperiodic (Gr),
Intermittent fevers
(Th)

(JG)
Int., roots,
crushed w/
wine before fit
(as purgative)
Int., syrup of
dried red roses
(Cu, Gr); Int.
Sa 2; Ext., oil
(BA)
Int. HvB 3
Int. HvB 3
Int., dec.
leaves w/
unsp. Ingred.
(JG)
Int., dec.
leaves w/
unsp. Ingred.
(JG)
Ext., Mdf 1;
Int., Mdf 2
Int., possibly
seed in wine
(D); Int. AvT
3; dec. (Sa, Gr
(h)); Int., dec.,
to relieve
shaking of
ague (Sa),
Ext., Sa 6;
Int., Co 5;
dec. of
leaves/flowers
(Co)
Int., dec. in
wine
Int., dec. bark
or powd. Root
Int., bark
Int., bark
Ext., Sa 6
Int., flowers in
water, spirit, or
vinegar, &
cover up to
sweat (Cu);
Int., seed or
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Sambucus nigra L.

Elder

Eur.

Mdf

Intermittent fevers
(Mdf)

Santalum album L.

Sandalwood (white and
yellow)

India

Cu

Agues, hot fits of

Sassafras albidum
(Nutt.) Nees

Sassafras or Ague tree

New
W.

JG, Cu

Tertians (JG)

Costus

India

D,
AvT,
Cu

Agues, Quartans
(AvT), Cold fits of
ague (Cu)

Common scullcap

Eur.

Gr

Tertians

Saussurea costus
(Falc.) Lipsch.
Scutellaria
galericulata L.

Sedum acre L.
Sedum roseum (L.)
Scop. ?
Sempervivum
tectorum L.
Senna alexandrina
Mill.
Sideritis sp.

flower & bark
oil, to vomit
(Cu); syrup of
the berries,
buds, or bark
(for children;
Cu); dec. in
honey and
vinegar, on
intermitting
days (Cu);
crystallized
salt of elder
(Cu); Cu 4;
Ext. Mdf 1;
Int. juice OB
2
Int., root bark
Mdf 2
Ext., applied
w/ rosewater
to the temples
Int. wood inf.,
for days
together (JG);
dec. of wood ?
(Cu)
Ext. w/ oil,
before fit (D),
Int., AvT 2,
Ext., w/ oil to
warm during
cold fit (Cu)
Int., juice or
herb inf.
Int., extr. juice
w/ vinegar or
other liquor, as
purgative
(vomiting)
(JG)

Wall pepper

Eur.

JG

Aaron

Eur.

Sa

Quartans and other
agues of long
standing
Agues (quartan)
(Sa)

Houseleek

Eur.

Co

Quartans, lingering
agues (Co, Th)

Senna, Alexandrian
senna
Sideritis, Ironwort,
Greek mountain tea

N.
Afr.

Co

Quartans (Co)

Int., Sa 2
Int., juice w/
vinegar or
posset (Co)
Int., dec. or
inf. of leaves
(Co)

Eur.

Pl

Tertians

Int., w/ oil?
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Silphium laciniatum
L.
Silybum marianum
(L.) Gaertn.
Simaba cedron
Planch.
Sinapis alba L.
Sison amomum L.
Solidago virgaurea
L.

Stachys officinalis
(L.) Trevis.
Symphytum
officinale L.
Syringa vulgaris L.
Syzygium
aromaticum (L.)
Merr. & L.M. Perry
Tanacetum
balsamita L.?

Tanacetum
parthenium (L.)
Sch.Bip.

Tanacetum vulgare
L.
Taraxacum
campylodes G.E.

Rosin-weed
Milk thistle
Cedron
White mustard
Bastard stone parsely
Saracen's Confound
(Heidnisch Wundkraut)

New
W.

Gr

Intermittent fevers

Eur.
New
W.

Gr, Co
Gr

Ague (Gr (h), Co)
Intermittent
fevers/Antiperiodic

Eur.
Eur.

D
AvT

Intermittent fevers
Quartans

Eur.

Cu

Agues, continual

Int., dec. or
powd. (Co),
inf. (Gr)
Int., inf. of
powd. seeds
Int., dried, in
beverage (D)
Int., AvT 8
Int., herb boi.
in wine
Dried leaves
(JG), Int. Sa 2
(Sa), Int., Co
3 (Co), Int., in
hydromel, or
specifically for
quartans, Pl 1
(Pl)

Betony

Eur.

JG, Sa,
OB,
Co, Pl

Comfrey

Eur.

JG

Lilac

Eur.

Gr

Agues (JG, Sa),
Quotidians,
tertians, quartans
(OB), Quartans
(Co) Tertians and
quartans (Pl)
Agues (to temper
the heat)
Antiperiodic/Malar
ia

Cloves

Asia

Sa, Co,
HvB

Agues (Co, Sa),
Three-day fever
(HvB)

Balsam herb

Eur.

HvB

Three-day fever

Feverfew

Eur.

JG, Gr
(h), Pl
(?)

Agues (JG, Gr),
Tertians (Pl)

Tansy

Eur.

Gr, Co

Agues

Int., HvB 2
Int., in
beverage (JG);
Ext., w/ bay
salt and powd.
glass, wrist
plaster (JG),
Bound to the
wrists (Gr),
Int., a leaf in
water (Pl, but
ident. of plant
uncertain)
Int., herb extr.
(Gr), Ext.,
juice applied
to wrists and
soles of feet
during hot fit
(Co)

Dandelion

Eur.

Mdf

Intermittent fevers

Int., Mdf 3

Int. JG 1 (JG)
Leaves, fruit
Int., the oil
(Co), Int., Sa
3, Int., as a
component of
HvB 2
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Haglund
Terminalia bellerica
(Gaertn.) Roxb., T.
chebula Retz., T.
citrina Roxb. ex
Fleming, and others
Teucrium
chamædrys L.

Myrobalans or
Mirobalans

Asia

Co

Tertians, quartans,
long continued
agues (Co)

Wall germander

Eur.

Gr

Intermittent fevers

Teucrium scordium
L.

Water germander

Eur.

HAP,
Gr

Tertians,
Quotidians (HAP),
Intermittent fevers
(Gr)

Thuja occidentalis L.

Yellow cedar (arbor
vitae)

Eur.

Gr

Intermittent fevers

Thymus serpillum L.

Wild thyme, Thyme
marjorum

Eur.

Agues

Garden thyme

Eur.

JG
JG,
BA

Thymus vulgaris L.
Trifolium
bituminosum
Garsault, Trifolium
odoratum, or
Trigonella caerulea
(L.) Ser.
Trigonella caerulea
(L.) Ser.?
Trigonella caerulea
(L.) Ser.?
Trigonella fœnumgræcum L.
Tussilago farfara L.
?
Urtica dioica L.

Verbena officinalis
L.

Int., fruits
Int., herb
Ext., tied about
the body
(HAP), Int.,
dried herb inf.
(Gr)
Int., dec.
recently dried
leafy twigs

Quartans (JG, BA)

Int., boi. in
wine
Int.?, flower
(BA)

Stinking trefoil or
Treacle Cleaver,
Siebengezeit

Eur.

JG,
HB

Tertians, Quartans
(JG, HB)

Int., leaves w/
wine or seeds
(JG), Int., dec.
herb (HB)

Sweet trefoil or balsam

Eur.

Co

Tertians, Quartans

Int., dec. herb

Sweet trefoil or balsam

Co

Tertians, Quartans

Int., dec. herb

Fenugreek

Eur.
Eur.,
Asia,
Mid.
E.

Gr

"Said to be equal to
quinine in
preventing fevers"

Int., seeds

Coltsfoot?

Eur.

HvB

Three-day fever

Stinging nettle

Eur.

Gr

Ague

Eur.

D, Sa,
OB,
Co, Pl,
Gr

Agues (D), Tertian
(Sa, OB, Co, Pl),
Quartans (Co, Pl),
Intermittent fevers
(Gr)

Vervain, verbena
(Eisenkraut)

Int. HvB 2
Int., seeds and
flowers in
wine (Gr)
Stand before
the patient w/
the branches
during the
shivering fit
(D), Int. (?),
the herb (Sa,
Co), Int., water
of the leaves
(OB); dec.
leaves or roots
(OB); Int.,
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Verbena supina L.

Supine vervain

Eur.

D

Tertians, Quartans

Viola lutea Huds.

Wall flower, mountain
pansy

Eur.

JG

Agues

Viola odorata L.

Violet

Eur.

Gr, JG

Viola tricolor L.

Heart's ease, or Pansies

Eur.

JG, Gr
(h)

Ague (Gr (h))
Agues (especially
in infants &
children)

Vitis vinifera L.
Zanthoxylum
americanum Mill.
Zingiber officinale
Roscoe

Grape

Eur.
New
W.

AvT

Quartans (some)

Gr

Agues

HvB

Three-day fever

Ziziphus jujuba Mill.

Beade Tree, Jujube tree

Asia
Eur.,
Asia

JG

Agues (JG)

Prickly ash
Ginger

herb in wine
(Pl), Int.,
leaves and
flowering
heads (Gr)
Int., herb in
beverage
Ext., crushed
leaves w/ bay
salt bound
about the
wrists (JG)
Int., syrup of
flowers (Gr
(h))
Int.
Int., as part of
cooling diet
Int., dec. bark
Int. HvB 2;
Int., Cu 3
Int., dec. bark
JG 5

Non-plant remedies
and ingredients:
Agaricus or Boletus
sp. (various)
Amber
Annelida sp.

Agarics or boletes
(unsp.)
Amber
Earthworms

Eur.
Eur.
Eur.

D, Cu
Sa
D

Agues
Agues
Tertians

Antimony

Antimony

Eur.

Sa

Agues

Araneae sp.

Spiders

Eur.

D

Tertians, Quartans

Brachyura sp.

Eur.

Sa

Agues (quartan)
(Sa)

Castor fiber

Crab
Beaver (source of
castoreum)

Eur.

AvT

Quartans

Cimex lectularius ?

Bed bugs

Eur.

D

Quartans

Int. in wine
before fit (D),
Int., Cu 3
Int., Sa 3
Ext., ground
Int., dist. w/
sugar, give in
wine before
fit, 2-3 times
to cure (Sa);
Sa 5
Ext., paste, for
tertian; amulet
for quartan (D)
Int., the eye
Sa 2; Int.,
powd. black
tips of claws in
any liquid (Sa)
Int., AvT 4,
AvT 5
Seven of them
w/ beans,
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Gallus gallus

Rooster

Eur.

D

Agues (lingering)

Polypores growing
on Larix sp.

Shelf fungi growing on
larch

Eur.

JG, Sa,
AvT,
Gr,
Co, Pl

Sulfur

Spirit of sulfur

Eur.

Sa

Agues (JG, Sa),
agues (lingering)
(JG), tertians (AvT,
Co, Pl),
Antiperiodic (Gr),
Quartans (Pl)
Agues (tertian)
(Sa)

Eur.

D, HB
(h), Gr
(h),
OB (h)

Quartans (D, HB,
OB)

Worms (unidentified
sp.) in Dipsacus
fullonum L.

Worms in the heads of
teasel (also teazle)

before the fit
Int., broth, D
2
Mixed w/
unsp. ingred.
(JG), Int., Sa
3, w/
rosewater,
honey &
vinegar (AvT),
Int.,to check
sweating (Gr),
w/ oxymel or
as Co 1, Co )
Int., Sa 4
Amulet, the
worms bound
up in a purse,
hung at the
neck or arm
(D, OB, Gr,
HB)

Table 2: Compound remedies
Name of
compound
AvT 1

Specificity
Quartans

AvT 2

Quartans

AvT 3

Quartans

AvT 4
AvT 5

Quartans
Quartans

AvT 6

Quartans

AvT 7

Quartans

AvT 8

Quartans
Tertians,
quartans
Quartans
Quartans

AvT 9
AvT 10
AvT 11

Components
Storax, myrrh, opoponax, iris, pepper, galbanum, poppy juice.
Saffron, opium, galbanum, cassia-cinnamon, storax, myrrh,
castoreum, costus, pepper, spikenard, honey.
Kyrenaischer saft (Cyrenian liquid, identity uncertain), pepper,
myrrh, rue.
Castoreum, poppy, myrrh, white pepper, Kyrenaischer saft
(Cyrenian liquid, identity uncertain).
Opoponax, opium, castoreum, henbane seeds.
Poppy seeds and juice, white henbane, liquorice juice, storax,
anise, saffron, castoreum, mandrake bark.
Wormwood, colocynth, aloe, gum mastic, dodder growing on
thyme.
Myrrh, spikenard, saffron, castoreum, opium, amomum (exact
species unknown), anise, Macedonian parsely, celery seed, mastic
flowers, cassia, white pepper, black pepper, storax, Sison
amomum, Sesel (unidentified), sage, honey.
Scammony, larch agaric, rosewater, honey, pepper.
Pennyroyal, oregano, hyssop, and barley water
Macedonian parsely, scammony, larch agaric, and white pepper
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AvT 12
AvT 13
AvT 14
AvT 15
AvT 16
Co 1
Co 2
Co 3
Co 4
Co 4
Co 5
Cu 1
Cu 2
Cu 3
Cu 4
D1
D2
JG 1

JG 2
JG 3
JG 4
JG 5
JG 6

JG 7
Gr 1
Gr 2
Gr 3
Gr 4

Quartans
(Internal
pains)
Tertians,
quartans
Tertians,
quartans
Quartans
Quartans
Ague and
cold shaking
Ague and
cold shaking
Quartans
Quartans
Agues
Shaking fit
of ague
Shaking fit
of ague
Quartan
Ague
Ague
Quartans,
tertians,
quotidians
Agues,
lingering
Agues (to
temper the
heat)
Agues
(shaking and
shivering of),
Quartans
Tertians
Tertians,
quartans
Agues
Agues
Agues of
long
standing (as
strong
purgative)
Intermittent
fevers
Agues
Intermittent
fevers
Agues

Opium with saffron, opium, cassia, storax, myrrh, and galbanum
resin
Roots of celery and maidenhair, cooked until soft
Anise, celeriac, leek leaves, honey, and vinegar
Candy carrot seeds, with pepper, in hot water
Opium, henbane, and hemlock.
Sliced larch agaric, ginger, rock salt, polypodium, damask rose
infusion, sugar
Hiera Picta (aloe juice, boiled down and powdered, with the bark
of white cinnamon, Canella alba), larch agaric, aloe, honey, roses
Betony and pennyroyal in decoction, with mead
Common polypody with whey, honeyed water, barley water, or
chicken broth with thyme, beet, and mallows
European wild ginger, let sit in sun with laudanum
Decoction of rue with dried dill herb and flowers
Asfoetida, myrrh, pepper and frankincense
Asfoetida, pepper, ginger, and rue
Agaricus or boletus sp. with ginger, honey, and vinegar
Rob of elder with blessed thistle, followed by vinegar
Cinquefoil drunk with hydromel or diluted wine, and a little
pepper; three leaves for tertian, four for quartan, and one for
quotidian
Broth of an old rooster with sea colewort, mercury, cnicum
(Carthamus tinctorius), or polypodium (Polypodium vulgare)
Syrup made from comfrey, liquorice, poleroot, pinenuts, jujubes,
mallow seed, poppies, sugar, and honey

Laserpitum, wine, pepper, and white frankincense
Scammony with apple and fleawort or prunes
Cinquefoil root juice drunk in mead or honeyed water, or wine
with pepper
Beade tree bark with fumitory and mirobalans
Wrist plaster with wall flower or with feverfew and ground glass

Bastard rhubarb roots boiled in water of blessed thistle, with
honey, taken before the fit on two or three separate occasions
Bistort root and calamus root
Chicory and endive (historic)
Gentian with astringents such as tormentil or galls
European wild ginger, let sit in sun with laudanum
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HvB 3

Three-day
fever
Three-day
fever
Four-day
fever

Mdf 1

Intermittent
fevers

HvB 1
HvB 2

Mdf 2
Mdf 3
OB 1
OB 2
Pl 1
Pl 2
Pl 3
Sa 1
Sa 2
Sa 3
Sa 4
Sa 5
Sa 6
Thr 1
Thr 2
Thr 3
Thr 4
Thr 5

Intermittent
fevers
Intermittent
fevers
Quartans
Quartans
Quartans
Quartans
Quartans
Agues, esp.
tertians
Agues
Agues
Agues
Agues
Agues
Intermittent
fevers
Intermittent
fevers
Intermittent
fevers
Intermittent
fevers
Autumnal
fevers

Blechnum and yarrow, boiled in wine and strained
Balsam herb, small coltsfoot, cloves, galangal, ginger, radish, and
wine
Madder, brier bush, fallow root (unidentified), and wine, heated
with red-hot steel
Mugwort, dwarf elder, tutsan, amphibious persicaria, pimpernel,
butcher's broom, elder bark, mallow boiled together and added to
the patient's bath
Moss, ground ivy, elder or caraway, mallow, fennel, pimpernel,
butcher's broom, borage, and young leaves of the earth nut, boiled
together and mixed with the juice of elder root bark and fermented
with goat's or cow's whey. After taking, consume apple, honey, or
wood sorrel to remove the taste.
Fumitory, infusion with dandelion in the morning, then
wormwood infusion at noon
Hops seethed in wine, "mit hirtzzung und senet bletter"
The juice of dwarf elder with powdered leafy spurge
Betony powdered with hypericum seed and panaces (an
unidentified herb)
Fennel and anise in vinegar and honey
Garlic, one head with silphium (see laserpitum) in dry wine
Tobacco, rue, sage, bay salt, and vinegar (wrist plaster)
Betony, aaron roots, crabs' eyes, cinnamon, sugar of roses, mint
Scammony, myrrh, aloe, galbanum, jallop, white agaric, nutmeg,
amber, cinnamon, cloves, and juniper
Scammony, saffron, aloe, spirit of wine, and spirit of sulfur
Antimony, angelica, and canary wine (as vomitory)
Wrist plaster of rue, sage, tobacco, bay salt, and vinegar
Powdered chamomile flowers, salt of wormwood, and antimony
(given as diaphoretic)
Dried arum root, rhubarb, and tartarus vitriolatus
Cinchona with snake root added to increase the efficacy
Gentian with astringents such as tormentil or galls
Gentian with hedge hyssop
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4.3: Discussion

In the fifteen sources used, 251 substances were identified as having likely been
used in the treatment of malaria. Of these, 239 are plants; the remaining twelve include
sulfur, antimony, unidentified fungi, and animal ingredients. Not all of the remedies in
the table were intended to remove disease; many were intended to palliate symptoms,
while others may have been added to compound remedies in order to improve their taste,
appearance, or perceived value. It was often impossible to determine whether a given
remedy or ingredient was intended to cure the disease or for one of these other purposes.
Nevertheless, it is probable that a large portion of the substances in the table were
intended to cure malaria. Some substances appear repeatedly and may be of special
interest from a medicinal chemistry standpoint; these will be discussed in more detail
below.
From the table, it will be seen that some of the remedies are what would today be
considered as food rather than medicine. As in the Chinese and Ayurvedic medical
traditions, the Greek and Roman physicians considered diet to be of paramount
importance to the maintenance of health and prevention of disease. It was believed that
one of the causes of disease was an immoderate or imbalanced diet, sometimes to the
extent that a disorder might be caused or cured by the consumption of particular food
items (Celsus, 1960; Phillips, 1973). The medieval physicians also held strongly to this
belief (Major, 1954; Gottfried, 1986), and specific dietary recommendations are not
always extricable from medicament. As an example, in his section on medicinal plants,
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Bartholomæus Anglicus (writing before 1283) gives the following information about the
cucurbit:
And it is to hem that hauen the feuer agu bothe mete an medicyne yrostid
other fryed; for he purgeth the matiere by vryne and laxeth, and abateth
the hetes and comforteth the sike.14 (Bartholomæus Anglicus, translated
by John Trevisa, 1398.)
It is certainly possible that some of the foods given in the dietary prescriptions may have
contained compounds active against malaria, or may perhaps have contributed to the
efficacy of other remedies; however, this portion of the table is perhaps of more historical
than medicinal chemistry interest.
Several of the remedies listed in the table are meant to be carried or worn as
amulets against malaria. It is not commonly believed today that amulets could have had
other than a psychological effect in treatment or prevention of disease (Cameron, 2006).
Indeed, the sources used in this project often describe amulets with some degree of
skepticism. The colorful nature of some of these remedies may have led to their
perpetuation in the literature. For example, the following use of the worms found in the
heads of teasel (Dipsacum fullonum L.) appears in four of the sources examined:

But ye worms of ye heads being bound up in a purse, & hanged about the
neck or the arme, are sayd to cure such as have quartanes. (Dioscorides,
Book III, 13.; Goodyer.)

14

In the above quotation, as well as others by Bartholomæus Anglicus, the runic letter for the
sound “th” has been rendered as th.
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From Goodyer’s translation, Dioscorides appears to be relating this superstition at
a slight distance. In fact, each of the sources including this remedy evinces some degree
of scepticism. For example, Hieronymus Bock mentions it thus:

Dioscorides writes that the worms that are sometimes found in the interior
of this thistle are good for quartan fever, wrapped up and carried about the
neck. I have not tried it – I have certainly found the worms.15
(Hieronymus Bock, Kreutterbůch, 1572 edition)
Aside from those remedies overtly intended for use as amulets, there are ritual
components in many of the other prescriptions found in the sources. A frequent example
is the instruction that for a tertian fever, one should use a plant with three stems, or take
three leaves or roots, or cut at the third joint, and that for a quartan fever, one should use
a plant with four stems, or take four leaves or roots, or cut at the fourth joint. This
appears at least four times in Pliny’s Natural History, including the following
descriptions of the use of cinquefoil (possibly Potentilla reptans L.) and vervain
(Verbena officinalis L.):
Some have prescribed doses of three cinquefoil leaves for tertians, of four
for quartans, and of more for the other fevers; others prescribe for all three
oboli with pepper in hydromel. Vervain in wine indeed is a remedy for
fever even of beasts of burden, but for tertians the plant must be cut at the
third joint, and for quartans at the fourth. (Pliny, Book XXVI, Chapter
LXXI., translated by W.H.S. Jones.) 16

15

Dioscorides schreibet/ das die würmlin so etwann im marck diser distel funden werden/ seien
gůt für das feber quartana eingewickelt unnd am halß getragen/ ich habs nicht erfaren/ die
würmlin hab ich wol funden. (Translation mine.)
16

Quinquefolii folia quidam terna tertianis dedere, quaterna quartanis, plura ceteris, alii
omnibus tres obolos cum pipere ex aqua mulsa. Verbenaca quidem et iumentorum febribus in
vino medetur, sed in tertianis a tertio geniculo incisa, quartanis a quarto.
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In addition to their possible magical purpose and psychological value, apparent
ritual elements in a remedy may have contributed to the activity of the remedies in other
ways. As an example, the following is Hildegard of Bingen’s prescription for a four-day
fever:
A person who suffers from a four-day fever should take madder, the same
weight of brier bush, and three times this combined amount of fallow root
and boil them in wine. Then pour clear, very good wine into a basin and
plunge a heated, glowing-hot piece of steel into it; plunge the heated steel
into the wine in this basin a second time. Do it ten times with the same
wine and the same steel. After that, take the wine in which you boiled the
plants, pour it into the heated wine into which you have plunged the hot
steel bar, cause the whole thing to boil up one more time, and when the
fever begins again, drink it immediately, and keep it up until you are
healthy. (Hildegard of Bingen, Translation by P. Madigan, 1994)
The manner of heating is of interest. Although at first it seems ritualistic, it would likely
result in the presence of iron salts in the resulting liquid. As malaria is known to cause
anemia (Greenwood, 2005), it is possible that this method of heating might have helped
the patient to recover more quickly.
However, the majority of the remedies listed are plants or combinations of plants
intended to be of primarily medicinal rather than dietary or magical use against malaria.
Of these, most (approximately 65%) are referred to in only a single source. From the
sheer number of different substances that were recommended at various times, it is hard
to escape a conclusion that most of the remedies were not very effective (Cameron,
2006). However, approximately 35% of the remedies are referred to repeatedly. A
scientific examination of these plants for antimalarial activity might be of particular
value. Only a portion of the plants listed here have been examined previously for
antimalarial activity.
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Of the 251 entries in Table 4.1, 38 substances were referred to in three or more
sources (Table 4.3, below). Of these, at least fifteen have previously been examined for
antiplasmodial activity; in many cases, they were found to have antiplasmodial activity in
vitro or in vivo. A small selection of the plants in Table 4.3 will be discussed in more
detail below.

Table 4.3: Remedies listed in three or more historical sources

Scientific name

Common name

Number of

Activity

references in

observed

survey

Tested for malaria?

(Yes/No)

Anchusa officinalis L., Alkanna
tinctoria (L.) Tausch, Anchusa

Ozbilgin (2014)

azurea Mill.

Alkanet, bugloss

3

(Alkanna tinctoria)

No

Artemisia absinthium L.

Wormwood

6

Zimmerman (2012)

Yes

Milhau (1997)
Zimmerman (2012)
Bamunuarachchi
Artemisia vulgaris L.

Mugwort

3

(2013)

Asarum europaeum L.

European wild ginger

4

Not found

Berberis vulgaris L.

Barberry

3

Not found

Centaurea benedicta (L.) L.

Blessed thistle

5

Not found

Centurium erythraea Rafn

Centaury

3

Danzel (1948)

Chamomile

5

Fujisaki (2012)

Yes

Chamaemelum nobile (L.) All.,
Matricaria chamomilla L.

No

Saunders (1783)
Peruvian bark,
Cinchona sp.

Vaughan (1795)

cinchona

3

(and many others)

Schrad.

Colocynth

4

Not found

Citrus limon (L.) Osbeck

Lemon

3

Not found

Clinopodium nepeta (L.)

Mountain mint, lesser

3

Not found

Yes

Citrullus colocynthis (L.)
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Kuntze subsp.glandululosum

calamint

Commiphora myrrha (Nees.)
Engl. and others

Myrrh

3

Not found

Convolvulus scammonia L.

Scammony

3

Not found

Dodder, Hell weed

4

Not found

Cuscuta epithymum L. and
others

Zimmerman (2012)
Gentiana lutea L., Gentiana

Yellow gentian,

See also Riscoe

purpurea L.

purple gentian

3

(2005)

Yes

Geum urbanum L.

Avens

3

Zimmerman (2012)

Yes

Helleborus niger L.

Black hellebore

5

Not found

Lamium (Dead
Lamium purpureum L.

nettle)

3

Not found

Mentha pulegium L.

Pennyroyal

4

Not found

W.D.J. Koch

Masterwort

3

Zimmerman (2012)

Piper nigrum L.

Pepper

3

Kamaraj (2012)

Peucedanum ostruthium (L.)
Yes

Plantain, waybread
Plantago major L. and P.

(Wegerich,

Sangian (2013) (P.

lanceolata L.

Spitzwegerich)

7

lanceolata)

Polygonum aviculare L.

Knotgrass

3

Not found

Yes

Common polypody
(oak fern, Engelfuß,
Polypodium vulgare L.

Steinfarn)

3

Not found

Potentilla erecta (L.) Raeusch.

Tormentil

3

Zimmerman (2012)

Potentilla reptans L.

Cinquefoil

5

Not found

Rheum rabarbarum L.

Rhubarb

3

Not found

Rosa sp.

Rose

3

Not found

Ruta graveolans L.

Rue, Herb Grace

6

Not found

Sambucus ebulus L.

Dwarf elder

3

Zimmerman (2012)

Lipsch.

Costus

3

Not found

Stachys officinalis (L.) Trevis.

Betony

5

Not found

Syzygium aromaticum (L.)

Cloves

3

Fujisaki (2012)

Yes

Yes

Saussurea costus (Falc.)

Yes
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Merr. & L.M. Perry
Tanacetum parthenium (L.)
Sch.Bip.

Feverfew

3

Zimmerman (2012)

Yes
Yes

Vervain, verbena,
Verbena officinalis L.

Eisenkraut

6

Zimmerman (2012)

Polypores growing on Larix sp.

Shelf fungi on larch

6

Not found

Worms (unidentified sp.) in

Worms in teasel

Dipsacus fullonum L.

heads

4

Not found

Artemisia absinthium L. and Artemisia vulgaris L.

In this survey, wormwood (Artemisia absinthium L.) and mugwort (Artemisia
vulgaris L.) were recommended to treat intermittent fevers by six and three sources
respectively. These plants are widely naturalized throughout various continents,
including the United States. Their use to treat malaria is intriguing, since they are
relatives of Artemisia annua (qinghao), the source of the antimalarial artemisinin
(qinghaosu); the additional Artemisia species A. abrotanum L. (southernwood), A.
ponticum L. (Roman wormwood), and A. maritima L. (sea wormwood) are also
mentioned in the sources as having antimalarial acitivity. Both A. absinthium and A.
vulgaris have been tested for antimalarial properties, and activity has been found both in
vitro and in vivo (Plasmodium berghei in a mouse model; Milhau, 1997; Zimmerman,
2012; Bamunuarachchi, 2013 and others). There has, however, been a report that a
traveler to West Africa attempted to use Artemisia vulgaris L. as antimalarial
prophylaxis, and contracted malaria (Kurtzhals, 2005).

135

Berberis vulgaris L.

Barberry (probably Berberis vulgaris L.), a Eurasian shrub producing edible berries, is
recommended to treat intermittent fevers in three of the sources surveyed. Although it
appears that this species of barberry may not have been screened as an antimalarial, the
roots of this plant are known to produce berberine, a compound with antiplasmodial
activity. Both this and other barberries are used in natural medicine in many parts of the
world (Duke, 1985; Hutchens, 1991; Bahar, 2014).

Citrus limon (L.) Osbeck

The rind or juice of lemon (perhaps Citrus limon (L.) Osbeck) was recommended to treat
intermittent fevers by three of the sources in the survey. Although the lemon does not
appear to have been assayed for activity against Plasmodium, the peel and juice of other
species of citrus have been found to have antiplasmodial activity. In a mouse study, the
juice of grapefruit was found to confer some degree of protection against infection by
rodent malaria (P. berghei; Oreagba, 2008), and acridones with antimalarial activity have
been isolated from the peel of Citrus grandis (Fujioka, 1989). Ascorbic acid (present in
lemon juice) has also been found to potentiate the antimalarial activity of the oxidant
drug, exifone (Winter, 1997).
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Helleborus niger L. and others:

Hellebore (including Helleborus niger L., Christmas Rose) was described in nearly all of
the sources in this survey, and is one of the few medicaments recommended by
Hippocrates (460-370 B.C., translated by Jones, 1957) and Celsus (25 B.C. – 50 A.D.,
translated by Spencer, 1960). Although an Old World plant, it is grown in the United
States as an ornamental. It was formerly used in herbal medicine as a drastic purgative,
but at the time of Celsus it was already considered quite dangerous and not appropriate
for all patients – its use causes nausea and diarrhea, and larger doses cause vomiting,
narcosis and coronary arrest (Gerard, 1597; Duke, 1985; Frohne, 2005). Five of the
sources in this survey recommended the use of hellebore in intermittent fevers. However,
each author urges caution in its use. Bartholomæus Anglicus gives the following
warning:

Dias and othre auctors meneth that it is a ful violent herbe and schal be
ytake redily and warly, for he greueth and son[e]st ageins many yueles if it
is vnredily ytake to ony person… he destroyeth the feuere quarteyn…
(Bartholomæus Anglicus, translated by John Trevisa.)
Gerard has the following:
Blacke Hellebor purgeth downwards flegme, choler, and also blacke
choler especially, and all melancholike humors, yet not without trouble
and difficultie. Therefore it is not to be giuen but to robustious and strong
bodies, as Mesues teacheth. A purgation of blacke Hellebor is good for
mad and furious men, for melancholike, dull, and heauie persons, for those
that are troubled with the falling sicknesse, for lepers, for them that are
sicke of a quartaine ague, and briefly for all those that are troubled with
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blacke choler, and molested with melancholie. (John Gerard and Dr.
Priest, 1597)
Although hellebore was intended to purge disease-causing humors, it is possible that this
plant may contain compounds that are active against Plasmodium species. As this plant
apparently has not been assayed for antimalarial activity, it may be another
phytochemical source of interest.

Plantago major L. and Plantago lanceolata L.

The plantains (waybread, or Wegerich, and ribwort, or Spitzwegerich) are
recommended to treat intermittent fevers in seven of the sources surveyed, more
frequently than any other plant. These edible plants are present on several continents,
and both species are common in the Pacific Northwest as an introduced species. The
plantains are used in traditional medicine in many parts of the world (Duke, 1985).
Sangian and coworkers (2013) have recently reported that an ethanolic extract of P.
major had mild antiplasmodial activity in vitro (IC50 = 40 µg/mL). Therefore, further
examination of both P. lanceolata L. and P. major L. appears promising, particularly as
these plants are readily available.
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Potentilla reptans L.

Cinquefoil, tentatively identified as Potentilla reptans L., was recommended to treat
intermittent fevers by five of the sources in this survey. However, it does not appear to
have been assayed for antimalarial activity. A related species, Potentilla discolor, is used
in Chinese medicine to treat malaria (Yang, 2010).

4.4: Further notes on historical remedies, and a word of caution for medicinal
chemists

While the approach of looking for active compounds in medicinal plants is
intriguing from the perspective of medicinal chemistry, it is attended by certain dangers
from an anthropological or historical point of view. There is a large difference between
an herbal remedy administered in the recommended form within in its cultural context,
and a purified compound given as a pharmaceutical drug. It must not be concluded that
because a plant extract does not have in vitro antiplasmodial activity that the remedy was
useless. In vitro and even in vivo testing of plant extracts may provide misleading results
for several reasons. Firstly, the importance of psychological factors in determining the
efficacy of medical treatment must not be underestimated. Secondly, whole plants may
contain active constituents that are degraded under the conditions of the techniques used
to extract them. In view of this it is important to consider the recommended method of
administration of the remedy. Thirdly, more than a single constituent may be important to
the antimalarial activity of a plant remedy. Multiple active constituents may be present
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that act either separately or synergistically, or it may be that compounds are present that
have little antimalarial activity of their own, but potentiate the activity of the active
constituents. The latter may be true in the case of qinghao (sweet wormwood, Artemisia
annua L.), the source of the antimalarial compound artemisinin (qinghaosu). Mice fed
whole plant Artemisia annua have been observed to have far higher levels of artemisinin
in their blood than those fed an equivalent amount of purified artemisinin (Weathers,
2011), and in a mouse model of malaria it has also been observed that whole-plant
Artemisia annua has higher antimalarial activity than would be expected on the basis of
its content of artemisinin (Elfawal, 2012). It has therefore been suggested that other
compounds are present in the whole plant that act synergistically with artemisinin; these
compounds may be removed when artemisinin is purified. Flavones isolated from
Artemisia annua, such as artemetin and casticin (Figure 61, below), have been observed
to potentiate the in vitro antiplasmodial activity of artemisinin (Elford, 1987; Liu, 1992;
Rasoanaivo, 2011).
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H 3CO
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OH
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H 3CO
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H 3CO
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OH O

OH O

Artemetin

Casticin

Figure 61: Artemisinin and two flavones believed to potentiate its antimalarial activity: artemetin

and casticin.
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Synergistic activity has also been observed in the case of cinchona alkaloids (Baranger,
1948; Druilhe, 1988; Rasonaivo, 2011). For the same reason, it is also important to
remember that many of the remedies in the table were not intended to be given alone.
Some of the compound remedies identified in the course of this project may have had
antimalarial activity due to the synergistic action of constituents in several different
ingredients.
The sources used in this project generally provide the method in which a remedy
should be prepared and administered, often in great detail. As with modern
pharmaceutical preparations, this may have had a significant effect on efficacy. Some
plants were recommended for fresh use, while others were recommended for use in a
dried state; the state of the plant certainly would affect the constituents, but the
determination of active constituents in fresh plant matter presents great challenges.
Remedies intended for internal use are most often administered in liquid form. The most
common liquids used are water, wine (usually white wine is specified), vinegar, ale, and
milk. The prescriptions were sometimes heated – at times using sunlight – and other
times not. Heating in wine or vinegar would have a high likelihood of extracting active
principles; it is conceivable that the prescriptions that are not meant to be heated may
contain active constituents that would be destroyed by heat. Honey is a frequent
component of remedies. It is easy to assume that this was simply added to improve the
taste of an otherwise less palatable remedy, but the possibility that its presence increased
the efficacy of the remedy cannot be neglected. Writing in 1951, W.H.S. Jones has
observed the following:
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There is at least one ingredient of the Plinian remedies that must have
been of great value. Honey appears again and again in both potions and
external applications, full use being made of its healing powers. The
superseding of honey by sugar has been by no means an unmixed blessing.
(W.H.S. Jones, introduction to Pliny, volume VI, 1951.)
More recently, honey has attracted considerable interest for its possible activity as an
antibacterial, antiinflammatory, antidiabetic, and anticancer agent (Alvarez-Suarez, 2013;
Carina, 2014; Erujawa, 2014).
Finally, as mentioned above, some remedies are not single herbs (simples), but
combinations of two or more herbs. Compound medicines, sometimes including more
than ten different substances, are often encountered. William Coles, the author of The
Art of Simpling, makes the following remark about compound remedies in the
introduction to his Adam in Eden:

And now let me tell the ingenious Reader, and by him others, that if those
of these times would but be, by a joynt Concurrence, as industrious to
search into the Secrets of the Nature of Herbs, as some of the former, and
make tryall of them as they did, they should no doubt find the force of
Simples many times no leße effectual, then that of the Compounds, to
which this present Age is too too much addicted… Thus have I broken the
Nut of Herbarisme, do thou take out the Kernel and eate it and much good
may it do thee. (William Coles)
It cannot be assumed that all of the materials in a compound remedy were expected to
have antimalarial activity of their own – some might have been intended to treat various
symptoms or to improve the flavor and appearance of the remedy. It must be suspected
that at times, rare or expensive ingredients such as ground pearls, myrrh, saffron, or
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crab’s eyes were added for no other reason than to increase the perceived value of the
remedy (e.g. Salmon, 1696). A medicinal chemistry approach to the compound
medicines might be to test the components individually, and then as the compound, to
determine whether the components act synergistically; however, this would be quite
laborious.

4.5: Conclusions

It may be seen from the results of this project, and those of other workers, that
cinchona bark was far from being the only remedy for malaria used in Europe prior to the
advent of modern antimalarial chemotherapy. The results of antiplasmodial testing by
other workers (Table 4.3) have shown that at least some of the treatments used may have
been effective. However, the majority of the phytotherapies for malaria identified in this
project have not yet been tested against Plasmodium species. Despite the cautions above,
the results obtained by other workers indicate that this approach may provide valuable
leads for medicinal chemists. Moreover, this project has examined only a fraction of the
surviving historical literature on the treatment of malaria. A more comprehensive project
might be of great historical value. The following are the words of the historian Theodor
Puschmann, writing in 1878:

The history of a science is that science itself. The knowledge of its past
gives understanding of its present. The doctor who neglects historical
studies becomes an empiricist; he will fall into many errors, undertake
many fruitless studies, because he has not learned to avoid the mistakes of
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his predecessors, and because he has become used to measuring facts by the
narrow measuring stick of the time period to which he belongs.
Theodor Puschmann, 1878 (Vorwort, Alexander
of Tralles: Original-Text und Übersetzung.)17

But, as Bartholomæus Anglicus has said, “be this ynowe at this tyme”.18

17

Die Geschichte einer Wissenschaft ist diese Wissenschaft selbst. Die Kenntniss ihrer
Vergangenheit gibt das Verständniss ihrer Gegenwart. Der Arzt, welcher die
historischen Studien vernachlässigt, wird zum Empiriker; er wird manchen Irrweg
einschlagen, manche fruchtlose Arbeit unternehmen, weil eir nicht gelernt hat, die Fehler
seiner Vorgänger zu vermeiden, und weil er sich gewöhnt hat, die Thatsachen mit dem
Massstab des engen Zeitraumes zu messen, dem er angehört. (Historical spelling
preserved. English translation mine.)
18
Bartholomæus Anglicus, in On the Properties of Things. (Translation into English by
John Trevisa, 1398, reprinted in 1975; p. 984.)
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CHAPTER 5:

Experimental Methods

5.1.: General synthetic methods
Described below are the general synthetic methods used to make the compounds
described in this work. For specific synthetic details for each compound, including
characterization data, see Appendix A: Specific synthetic methods and characterization
data. For in vitro antiplasmodial activity and cytotoxicity data, see Appendix B: Tables
of in vitro antiplasmodial activity and cytotoxicity. For sample NMR data (for PL241),
see Appendix C: Sample NMR spectra: PL241.
5.1.1.: Synthesis of drug candidates and intermediates: Quinoline-ring modified
reversed chloroquine-type compounds
Substituted 4-chloroquinolines with hydrogen in the 2-position were made by the GouldJacobs reaction, followed by chlorination with phosphorus oxychloride (Figure 62;
Claisen, 1897; Gould, 1939; Price, 1946):
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Gould-Jacobs Reaction:
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O
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Claisen, R.L.; Hasse, E., Justus Liebigs Annalen der Chemie, 1897, 297, 1-98
Gould, R.G. Jr.; Jacobs, W.A., J. Am. Chem. Soc., 1939, 61, 2890-2895
Price, C.C.; Roberts, R.M., J. Am. Chem. Soc., 1946, 1204-1208
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Figure 62: Synthesis of 4-chloroquinolines by the Gould-Jacobs reaction, followed by chlorination with
phosphorus oxychloride.

4-chloroquinolines containing a trifluoromethyl group in the 2-position were made by
the Conrad-Limpach reaction, followed by phosphorus oxychloride chlorination (Figure
63; Conrad, 1887; Reynolds, 1955):

Conrad-Limpach Reaction:
O
R

+

pTSA

EtO

NH 2
R = H, Cl, OMe
R' = CH 3, CF 3

O

R'

R
Benzene,
Dean and Stark
water separator,
reflux

Conrad, M.; Limpach, L., Ber., 1887, 20, 944-98; 1891, 24, 2990-2;
Reynolds, G.A.; Hauser, C.R., Organic Syntheses
Collective Vol 3., 1955, 374-5 and 593-4
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Figure 63: Synthesis of 2-trifluoromethyl-4-chloroquinolines by the Conrad-Limpach reaction, followed by
phosphorus oxychloride chlorination.

In most cases the resulting substituted 4-chloroquinolines were then allowed to undergo
solvolysis with 3-amino-1-propanol to give 4-amino alcohols, and the hydroxyl group
was then converted to a methanesulfonyl group (Figure 64; Burgess, 2006; Burgess,
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2008; Burgess, 2010):

HN

Cl
R

H 2N
R'

N

OH

OH
90oC

R = H, F, Cl, Br, I, NO 2, CF 3, Me, OMe
R' = H, CH 3, CF 3

R

R'
N

HN

MsCl, TEA
THF, DCM, or
CHCl 3, 0oC

R

OMs
R'

N

Burgess, S. J., Kelly, J.A., Shomloo, S., Wittlin, S., Brun, R.,
Liebmann, K., Peyton, D.H., J. Med. Chem., 2010, 53, 6477-6489

Figure 64: Reaction of 4-chloroquinolines with 3-amino-1-propanol, followed by activation of the resulting
alcohol by methanesulfonyl chloride.

Finally, the resulting compounds were allowed to react with an appropriate secondary
amine to yield either the final products (Group 1, Figure 65, below) or an imine that was
then reduced with sodium borohydride to yield the final product (Group 2, Figure 65,
below). The secondary amines required to produce the compounds in Figure 65, Group
1, were purchased, but in the case of the secondary amine required to produce compounds
shown in Figure 65, Group 2, the secondary amine was first synthesized as shown below
(Figure 65; Burgess, 2006; Burgess, 2010; Gunsaru, 2010):
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Figure 65: Reaction of mesyl alcohols with secondary amines to produce the final products.

In one case, a different method was used to produce a final product starting from the 4chloroquinoline; this is detailed below (PL142, Method 2, Appendix A, p. 257). In most
cases, final products were purifiable by recrystallization, though column chromatography
was sometimes necessary.
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5.1.2: Synthesis of asymmetrical bis-quinoline type compounds

The synthesis of the asymmetrical bis-quinoline compounds required the synthesis of two
different quinoline starting materials. One quinoline starting material was identical to
that shown above (Figure 64, far right). The other was produced by reaction of the
appropriate 4-chloroquinoline with 3-carbethoxy-4-aminopiperidine in phenol (Andersag,
1948; Surrey, 1951; De, 1998), followed by removal of the carbethoxy group by heating
with aqueous sodium hydroxide in ethanol (Figure 66; Iwasaki, 1994):
O
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Figure 66: Synthesis of one starting material for asymmetrical bis-quinoline compounds.

Reaction of the two quinoline starting materials under the same conditions shown above
then provided the desired bis-quinoline (Figure 67; Burgess, 2006; Burgess, 2010):
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Figure 67: Synthesis of asymmetrical bis-quinoline compounds.

A different, less satisfactory synthetic method was initially used to produce PL241. This
is detailed below (Appendix A, p. 323).
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As with the reversed chloroquine-type compounds in section 5.1.1, the bisquinolines could in most cases be purified by recrystallization. However, column
chromatography was necessary in a few cases.

5.1.3: Characterization of products

Final products were characterized by NMR (1H, 13C, COSY, HSQC, NOESY, and 19F if
applicable), melting point, HPLC, and LC/MS (details of methods used below).
Intermediates not previously reported in the literature were characterized by 1H NMR,
melting point (for purified products), and occasionally HPLC and LC/MS. For sample
NMR spectral interpretations for final products, see pages 187, 193, 213, 220, 256, 262-3
and 316. For example NMR spectra, see Appendix C: Sample NMR data: PL241.
Nearly all 4-chloroquinoline starting materials were synthesized from the corresponding
aniline in several steps (only 4-chloro-2,8-(ditrifluoromethyl)quinoline and 4,7dichloroquinaldine were purchased). The intermediates in these syntheses are reported as
individual steps below, but the products generally were not characterized (NMR was
sometimes used, and in most cases this spectral data is reported below). As these
reactions are well understood and ample characterization data exists in the literature for
the 4-quinolones and 4-chloroquinolines produced, it was found convenient to limit
characterization by NMR and melting point to the 4-chloroquinoline, which is the starting
point for the novel compounds. Of the 4-chloroquinoline intermediates, only two had
not previously been characterized in the literature. These were 4,5-dichloro-2150

(trifluoromethyl)quinoline and 4,7-dichloro(2-trifluoromethyl)quinoline. These were
characterized by 1H, 13C, 19F, and 2D NMR, melting point, and GC/MS.
1

H, 13C, COSY, HSQC, HMBC, and 19F, NMR experiments were run on a Bruker

400 MHz or 600MHz spectrometer. HPLC was performed using UV detection at 254
and 325 nm, using a Varian ProStar 325 UV/vis dual wavelength detector. Two HPLC
methods were used. For HPLC Method A, a SUPELCO Ascentis RP-Amide 5µm, 4.6
mm x 150 mm column was used, eluting with a gradient of 95:5 to 30:70 water with
0.1% formic acid (v/v)/acetonitrile. For HPLC method C, a SUPELCO Ascentis C18
5µm, 4.6 x 150 mm column was used, eluting with a gradient from 95:5 to 5:95 water
with 0.1% formic acid (v/v)/acetonitrile. High resolution mass spectrometry was
performed on a Bruker micrOTOF-Q instrument. Results were obtained using
electrospray ionization (ESI) in the positive mode, at a flow rate of 0.4 mL/min. with 1:1
methanol-water. Gas chromatography-mass spectrometry (GC-MS) was performed using
a Hewlett Packard HP5890 Series II gas chromatograph with a 30-m DB5 column. The
oven temperature was set at 130° for 2 minutes, and then increased to 300°C at the rate of
30°C per minute. This instrument was used with the kind permission of Dr. Michael
Riscoe of the Portland Veterans Affairs Medical Center.

5.2: In vitro studies on inhibition of P. falciparum parasite growth

The antiplasmodial activities of the compounds in this study were determined by Dr. Jane
Xu Kelly and Dr. Yuexin Li of the Portland Veteran’s Affairs Medical Center by
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methods described previously (e.g. Burgess, 2010; Pou, 2012). The following three
strains of P. falciparum were used: 1) a chloroquine-sensitive strain, D6, 2) a chloroquine
resistant strain, Dd2, originally isolated from southeast Asia 3) a second chloroquine
resistant strain, 7G8, originally isolated from Brazil. The parasites were maintained
continueously in culture, and asynchronous cultures were used for testing. Samples of
the cultures were diluted to 0.2% parasitemia and 0.2% hemocrit using uninfected red
blood cells and complete cell growth medium (RPMI-1640 with 0.5% Albumax II).
Chloroquine was used as a positive control. Solutions of chloroquine and the test
compounds were made at 10mM in DMSO. These solutions were diluted into complete
cell growth medium. In 96-well microplate, the stock solutions were diluted with
complete cell growth medium to provide triplicate wells at concentrations between 0 to
10-4 M, each having a final volume of 100µL. A given assay was performed using
concentrations either in the range of 0.025 nM to 250 nM, or 2.5 nM to 2500 nM. The
plates were then incubated under standard culture conditions for 72 hours before
harvesting. The SYBR Green-I fluorescence-based method (Smilkstein, 2004) was used
to read the plates, using a 96-well plate fluorescence reader (Gemini-EM, Molecular
devices) with respective excitation and emission wavelengths of 497 and 520nm.
Fluorescence was plotted against the logarithm of drug concentration. IC50 values were
then obtained by curve fitting by nonlinear regression analysis, using Prism (Graph Pad)
software. The IC50 obtained for the chloroquine positive control was then used to
“normalize” the IC50 values obtained for the test compounds to the following chloroquine
IC50 values: 6.9 nMD6, 102 nMDd2, and 108 nM7G8 (Burgess, 2010). An example of the
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formula used to obtain the normalized value for the IC50 of a given test compound is
shown here for the case of strain D6, using 6.9 nM as the control value for chloroquine’s
IC50 against strain D6:

Normalized IC50 of test compound against D6 = (6.9/IC50 of chloroquine against D6) ×
IC50 of test compound against D6.

From the variability in IC50 values obtained in different tests on the same compounds
over a period of several years, the uncertainty in the obtained values is estimated to be
±30% (based on results for three randomly chosen compounds).

--------Happy the Man, who, studying Nature's Laws,
Thro’ known Effects can trace the secret Cause.
Virgil, Georgics II, line 49019, rendered by John Dryden (1697).
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Note: Line 698 in Dryden’s text. Latin text reads as follows: Felix, qui potuit rerum
cognoscere causas, atque metus omnis et inexorabile fatum subiecit pedibus strepitumque
Acherontis avari. See Virgil (1999), Virgil: Eclogues, Georgics, Aenid, with an English
translation by H. Rushton Fairclough, revised by G.P. Goold. Cambridge, MA: Harvard
University Press.
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APPENDIX A: Specific synthetic methods and characterization data
The following synthetic methods are organized by quinoline ring substitution pattern (for
the monoquinolines), followed by a separate section for bis-quinolines and their starting
materials. For an overview of the compounds included, see the Table of Contents, page
vii. For an overview of the synthetic methods used to make the compounds described
herein, and a description of the methods used to obtain the characterization data, see
Chapter 5, sections 5.1-2. Again, note that characterization data has often been omitted
for those quinolone intermediates that have been previously well characterized in the
literature. To find the synthetic method for a final product by its code number (PL
number), see Table A1, below.
Table A1: Compounds listed by code number (PL number)
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A.1. Chloroquinolines
A.1.1: 6-chloroquinolines

3-carbethoxy-6-chloro-4-quinolone (Price, 1946; Riegel, 1946)
O

O

Cl

OEt
N
H

para-Chloroaniline (10.05 g, 78.8 mmol) and diethyl ethoxymethylene malonate (17.03
g, 78.8 mmol) were heated in refluxing Dowtherm A (70 mL) for 25 minutes. After
cooling, the reaction mixture was diluted with hexanes (150 mL) and vacuum filtered,
rinsing well with additional hexanes, to recover the product as an off-white, crystalline
solid (18.32 g, 92%).
3-carboxy-6-chloro-4-quinolone (Price, 1946; Riegel, 1946)
O

O

Cl

OH
N
H

3-carbethoxy-6-chloro-4-quinolone (18.32 g, 72.8 mmol) in 200 mL of 10% caustic soda
was allowed to reflux, stirring, for 3 hours. The hot reaction mixture was poured into 500
mL water and acidified with concentrated muriatic acid. After cooling, vacuum filtration
yielded a white solid. This was allowed to air dry, and was used without further
purification or drying.
6-chloro-4-quinolone (Price, 1946; Riegel, 1946)
O
Cl
N
H
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3-carboxy-6-chloro-4-quinolone from the above reaction (presumed to contain residual
water) was heated in Dowtherm A (100 mL) at reflux for 40 minutes. After cooling, the
reaction mixture was diluted with 100 mL hexanes and vacuum filtered to yield a
sawdust-colored solid. NMR indicated that reaction was not complete. The solid was
again suspended in Dowtherm (100 mL) and returned to reflux for a further 15 minutes.
Upon cooling, the reaction mixture was diluted with hexanes (150 mL) and vacuum
filtered, rinsing well with additional hexanes, to recover the product as a greenish-tan,
crystalline solid (13.93 g, used without further purification).
4,6-dichloroquinoline (Price, 1946; Riegel, 1946; Tarbell, 1946)
Cl
Cl
N

6-chloro-4-quinolone from the above reaction (13.93 g of crude material) and phosphorus
oxychloride (40 mL) were heated at a gentle reflux for 5 hours. After cooling, the
reaction mixture was poured gradually onto ice and then cautiously basified with 50%
caustic soda. This was diluted to 3.3 L with water and divided into three equal portions,
each of which was extracted with chloroform (100 mL, followed by 3 x 30 mL). The
pooled chloroform layers from all extractions were dried (MgSO4) and evaporated under
reduced pressure with warming to yield a pale tan solid (13.48 g, 86% from parachloroaniline, mp = 102.3-103.6°C (lit. 104°C (Tarbell, 1946)).
1

H NMR δ (ppm)(CHCl3-d): 8.78 (1 H, d, J = 4.71 Hz), 8.23 (1 H, d, J = 2.34 Hz), 8.07
(1 H, d, J = 8.98 Hz), 7.72 (1 H, dd, J = 8.98, 2.33 Hz), 7.52 (1 H, d, J = 4.70 Hz).
3-(6-chloroquinolin-4-ylamino)propanol

HN

OH

Cl
N

4,6-dichloroquinoline (5.00 g, 25.2 mmol) and 3-amino-1-propanol (12.0 mL, 157 mmol)
were heated at 85°C for 2 days, whereupon TLC indicated that reaction was complete.
The hot reaction mixture was then poured into water (150 mL), while stirring vigorously.
After resting 20 minutes, the resulting precipitate was recovered by vacuum filtration,
followed by air drying and partial recrystallization from ethyl acetate to provide the
desired product as fine, tan, crystalline solid (5.20 g, 87%, mp = 165.4-166.8°C).
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1

H NMR δ (ppm)(DMSO-d6): 8.40 (1 H, d, J = 5.37 Hz), 8.38 (1 H, d, J = 2.38 Hz), 7.78
(1 H, d, J = 8.95 Hz), 7.60 (1 H, dd, J = 8.95, 2.30 Hz), 7.23 (1 H, br t, J = 5.31 Hz), 6.49
(1 H, d, J = 5.42 Hz), 4.60 (1 H, t, J = 5.06 Hz), 3.55 (2 H, m), 3.28-3.35 (water signal
overlaps m, ~2 H), 1.79-1.87 (2 H, m).
1

H NMR δ (ppm)(CHCl3-d): 8.52 (1 H, d, J = 5.34 Hz), 7.90 (1 H, d, J = 8.96 Hz), 7.68
(1 H, d, J = 2.26 Hz), 7.55 (1 H, dd, J = 8.96, 2.24 Hz), 6.42 (1 H, d, J = 5.36 Hz), 5.80 (1
H, br s), 3.97 (2 H, t, J = 5.45 Hz), 3.47-3.48 (2 H, m), 2.00-2.08 (2 H, m).
3-(6-chloroquinolin-4-ylamino)propyl methanesulfonate
HN

OMs

Cl
N

3-(6-chloroquinolin-4-ylamino)propanol (4.20 g, 17.7 mmol) and triethylamine (3.71 mL,
26.6 mmol) in dry THF (100 mL) were cooled to below 0°C on ice/salt. Methanesulfonyl
chloride (1.58 mL, 20.3 mmol) was added dropwise. After stirring for 30 minutes on ice,
there remained some undissolved solid that had the appearance of starting material. An
additional 50 mL THF were added, followed by additional triethylamine (1.2 mL, 8.6
mmol) and methanesulfonyl chloride (0.50 mL, 6.4 mmol), and stirring was continued for
a further 40 minutes, whereupon TLC indicated that reaction was not complete (a sample
of the reaction mixture indicated completion, but a sample incorporating the undissolved
solid indicated the presence of unreacted starting material). The reaction mixture was
filtered to remove the solid material. The filtrate was diluted with ethyl acetate (25 mL)
and washed with 35 mL saturated sodium bicarbonate; after separating, the aqueous layer
was extracted with ethyl acetate (3 x 10 mL). The pooled organic layers were dried
(MgSO4) and evaporated under reduced pressure with warming to give the desired
product as a yellow solid (4.16 g, 75%).
PL270: N-(3-(4-benzhydrylpiperazin-1-yl)propyl)-6-chloroquinolin-4-amine)

HN

N

Cl

N
N

PL270

185

3-(6-chloroquinolin-4-ylamino)propyl methanesulfonate (2.03 g, 6.45 mmol), N(diphenylmethyl)piperazine (1.67 g, 6.62 mmol), and triethylamine (1.32 mL, 9.57
mmol) were heated at reflux in acetonitrile (22 mL) for 22 hours. TLC then indicated
that reaction was complete. The solvent was removed by evaporation under reduced
pressure with warming. The residue was partitioned between 100 mL chloroform and 35
mL water; after separation, the aqueous layer was extracted with chloroform (3 x 15 mL).
The pooled organic layers were dried (MgSO4) and evaporated under reduced pressure
with warming. The residue was partially recrystallized from 95% ethanol, and then fully
recrystallized from chloroform to yield the desired product as a white, crystalline solid
(0.21 g, 0.4%, mp = 212-214°C).
1

H NMR δ (ppm)(CHCl3-d): 8.49 (1 H, d, J = 5.28 Hz), 8.01 (1 H, d, J = 2.30 Hz), 7.90
(1 H, d, J = 8.98 Hz), 7.75 (1 H, br t, J = 3.94 Hz), 7.58 (1 H, dd, J = 8.98, 2.25 Hz), 7.457.49 (4 H, m), 7.27-7.28 (4 H, m), 7.16-7.18 (2 H, m), 6.31 (1 H, d, J = 5.32 Hz), 4.48 (1
H, s), 3.34 (2 H, td, J = 5.39, 0.00 Hz), 2.64 (10 H, br s overlaps t, J = 5.16 Hz), 1.92 (2
H, apparent p, J = 5.27 Hz).
13

C NMR δ (ppm)(CHCl3-d): 151.5, 150.0, 147.0, 143.1, 131.6, 129.7, 128.6, 127.9,
127.0, 120.1, 120.0, 119.9, 98.8, 76.1, 59.3, 54.1, 52.1, 45.0, 23.2.
HPLC (method C) tR = 11.33 min (95% pure). MS (ESI): m/z 471.2301 M + H
(calculated 471.2310).
PL283: 6-chloro-N-(3-(4-(pyridin-2-yl)piperazin-1-yl)propyl)quinolin-4-amine

HN

N

Cl

N
N

PL283

N

3-(6-chloroquinolin-4-ylamino)propyl methanesulfonate (1.00 g, 3.2 mmol), 1-(2pyridyl)piperazine (0.65 g, 4.0 mmol), potassium carbonate (0.66 g, 4.8 mmol), and a
catalytic amount of potassium iodide were heated at 75°C in acetonitrile (15 mL) for 28
hours. TLC then indicated that reaction was complete. The solvent was removed under
reduced pressure with warming, and the residue was shaken with ethyl acetate (30 mL)
and water (20 mL). Some material remained insoluble, and was removed by vacuum
filtration. The filtrate was separated, and the aqueous layer was extracted with ethyl
acetate (3 x 10 mL). The pooled ethyl acetate layers were dried over MgSO4 and
evaporated under reduced pressure with warming to yield a solid. This was combined
with the solid material that had been removed from the extraction by filtration. This
material was recrystallized from a mixture of ethyl acetate and 95% ethanol (6:1, 15 mL)
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to provide the desired product as large, golden crystals (0.66 g, 54%, mp = 175.6177.5°C).
1

H NMR δ (ppm)(CHCl3-d): 8.51 (1 H, d, J = 5.31 Hz, Q-C2-H), 8.23-8.23 (1 H, m, PyH6 (from N, counterclockwise)), 7.94 (1 H, d, J = 2.31 Hz, Q-C5-H), 7.86 (1 H, d, J =
8.93 Hz, Q-C8-H), 7.62 (1 H, t, J = 4.05 Hz, Q-NH), 7.51 (1 H, ddd, J = 8.54, 7.15, 2.02
Hz, Py-H4), 7.46 (1 H, dd, J = 8.93, 2.27 Hz, Q-H7), 6.70 (1 H, d, J = 8.54 Hz, Py-H3),
6.67 (1 H, dd, J = 7.16, 4.93 Hz, Py-H5), 6.35 (1 H, d, J = 5.35 Hz, Q-C3-H), 3.78 (4 H,
m, Pip CH2CH2-Py), 3.41 (2 H, td, J = 5.37, 0.00 Hz, QNHCH2), 2.70-2.71 (6 H, m, Pip
CH2CH2-Py, ~2.71; QNHCH2CH2CH2, ~2.70), 2.01 (2 H, apparent p, J = 5.28 Hz,
CH2CH2CH2).
13

C NMR δ (ppm)(CHCl3-d): 159.7, 151.5 (Q-C2), 149.8, 148.0 (Py-C6 from N,
counterclockwise), 146.9, 137.5 (Py-C4), 131.5 (Q-C8), 130.0, 129.5 (Q-C7), 119.9,
119.8 (either 119.9 or 119.8 is Q-C5), 115.4, 113.7 (Py-C5), 107.2 (Py-C3), 98.7 (Q-C3),
59.1 (QNHCH2CH2CH2Pip), 53.6 (Pip CH2CH2-Py), 45.2 (Pip CH2CH2-Py), 44.6
(QNHCH2CH2CH2), 23.4 (QNHCH2CH2CH2).
MS (ESI): m/z 382.17990 M + H (calculated 382.17930)
HPLC (method A) tR = 5.09 min (98% pure).

PL397: 6-chloro-N-(3-(4-(4-fluorophenyl)piperazin-1-yl)propyl)quinolin-4-amine

HN

N

Cl

N
N

PL397

F

3-(6-chloroquinolin-4-ylamino)propyl methanesulfonate (1.00 g, 3.2 mmol), 1-(4fluorophenyl)piperazine (0.60 g, 3.3 mmol), potassium carbonate (0.66 g, 4.8 mmol), and
a catalytic amount of potassium iodide were heated at 75°C in acetonitrile (15 mL) for 28
hours. TLC then indicated that reaction was complete. The solvent was removed under
reduced pressure with warming, and the residue was shaken with ethyl acetate (30 mL)
and water (20 mL). A yellow solid remained insoluble, and was removed by vacuum
filtration. The filtrate was separated, and the aqueous layer was extracted with ethyl
acetate (3 x 10 mL). The pooled ethyl acetate layers were dried over MgSO4 and
evaporated under reduced pressure with warming to yield a golden, crystalline solid. The
solid material removed from the extraction by filtration was recrystallized from a mixture
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of ethyl acetate and 95% ethanol (6:1, 20 mL) to yield a golden, crystalline solid (0.51 g,
40%, mp = 183.4-184.8°C).
1

H NMR δ (ppm)(CHCl3-d): 8.51 (1 H, d, J = 5.31 Hz), 7.93 (1 H, d, J = 2.24 Hz), 7.87
(1 H, d, J = 8.93 Hz), 7.57 (1 H, br t, J = 3.95 Hz), 7.48 (1 H, dd, J = 8.94, 2.24 Hz), 6.946.99 (4 H, m), 6.34 (1 H, d, J = 5.35 Hz), 3.40 (2 H, td, J = 5.77, 4.06 Hz), 3.36 (4 H, m),
2.77 (4 H, m), 2.72 (2 H, t, J = 5.15 Hz), 2.00 (2 H, apparent p, J = 5.36 Hz).
19

F NMR δ (ppm)(CHCl3-d): -124.7 (m).

13

C NMR δ (ppm)(CHCl3-d): 158.2, 156.6, 151.4, 149.8, 147.7 (d, JF = 2.05 Hz?), 146.9,
131.5, 129.9, 129.5, 119.8 (d, JF = 6.08 Hz?), 118.3 (d, JF = 8.49 Hz?), 115.5 (d, JF =
22.01 Hz?) 98.7, 59.1, 53.9, 50.2, 44.7, 23.4.
MS (ESI): m/z 399.17560 M + H (calculated NUMBER)
HPLC (method A) tR = 8.41 min (>99% pure).

PL382: 6-chloro-N-(3-(4-(4-methoxyphenyl)piperazin-1-yl)propyl)quinolin-4-amine

HN

N

Cl

N
N

PL382

O

3-(6-chloroquinolin-4-ylamino)propyl methanesulfonate (1.00 g, 3.2 mmol), 1-(4methoxyphenyl)piperazine (0.64 g, 3.3 mmol), potassium carbonate (0.66 g, 4.8 mmol),
and a catalytic amount of potassium iodide were heated at 75°C in acetonitrile (15 mL)
for 28 hours. TLC then indicated that reaction was complete. The solvent was removed
under reduced pressure with warming, and the residue was partitioned between
chloroform (20 mL) and water (20 mL). After separation, the aqueous layer was
extracted with further chloroform (3 x 7 mL), and the pooled organic layers were dried
over MgSO4 and evaporated under reduced pressure with warming. The residue was
recrystallized by boiling in excess 95% ethanol, followed by slow concentration to 3 mL
at room temperature. This afforded the desired product as tan crystals (0.40 g, 26%, mp
= 198.5-199.0°C).
1

H NMR δ (ppm)(CHCl3-d): 8.51 (1 H, d, J = 5.31 Hz), 7.95 (1 H, d, J = 2.30 Hz), 7.87
(1 H, d, J = 8.94 Hz), 7.57 (1 H, t, J = 3.99 Hz), 7.48 (1 H, dd, J = 8.93, 2.26 Hz), 6.97188

6.98 (2 H, m), 6.85-6.86 (2 H, m), 6.34 (1 H, d, J = 5.35 Hz), 3.79 (3 H, s), 3.39 (2 H, td,
J = 5.79, 4.06 Hz), 3.33 (4 H, m), 2.76 (4 H, m), 2.71 (2 H, t, J = 5.20 Hz), 1.99 (2 H,
apparent p, J = 5.39 Hz).
13

C NMR δ (ppm)(CHCl3-d): 154.1, 151.4, 149.9, 146.9, 145.5, 131.5, 130.0, 129.6,
119.9, 119.8, 118.8, 114.4, 98.7, 59.2, 55.6, 54.0, 50.7, 44.7, 23.4.
MS (ESI): m/z 411.19454 M + H (calculated 411.19462)
HPLC (method A) tR = 8.51 min (69% pure).

A.1.2: 8-chloroquinolines

3-carbethoxy-8-chloro-4-quinolone (Price, 1946; Tarbell, 1946)

O

O
OEt

Cl

N
H

ortho-Chloroaniline (5.35 mL, 51.2 mmol) and diethyl ethoxymethylene malonate (10.1
mL, 50.3 mmol) were heated in refluxing Dowtherm A (70 mL) for 30 minutes. After
cooling, the reaction mixture was diluted with hexanes (150 mL) and vacuum filtered,
rinsing with further hexanes (200 mL), followed by acetone (100 mL). The product was
obtained as a beige, powdery solid (11.32 g, 89%).
1

H NMR δ (ppm)(DMSO-d6): 11.91 (1 H, br s), 8.43 (1 H, s), 8.14 (1 H, dd, J = 8.10,
1.38 Hz), 7.91 (1 H, dd, J = 7.72, 1.38 Hz), 7.43 (1 H, t, J = 7.92 Hz), 4.24 (2 H, q, J =
7.10 Hz), 1.29 (3 H, t, J = 7.10 Hz)
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3-carboxy-8-chloro-4-quinolone (Price, 1946; Tarbell, 1946)
O

O
OH

Cl

N
H

3-carbethoxy-8-chloro-4-quinolone (11.32 g, 45.0 mmol) was heated at reflux in 200 mL
of 10% caustic soda for 1 hour. The hot reaction mixture was poured into 300 mL water,
then made acidic by the addition of concentrated muriatic acid. After cooling, vacuum
filtration yielded a white solid. This was allowed to air dry for 48 hours followed by
drying in a vacuum oven at 50ºC for 5 hours. The resulting cream-colored solid (10.40
g, containing residual water) was used without further drying in the ensuing reaction.
1

H NMR δ (ppm)(DMSO-d6): 14.88 (1 H, br s), 13.00 (1 H, br s), 8.67 (1 H, s), 8.28 (1
H, dd, J = 8.18, 1.34 Hz), 8.10 (1 H, dd, J = 7.74, 1.35 Hz), 7.61 (1 H, dd, J = 8.17, 7.74
Hz).

8-chloro-4-quinolone (Price, 1946; Tarbell, 1946):
O

Cl

N
H

3-carboxy-8-chloro-4-quinolone from the above reaction (10.40 g, containing residual
water) was heated in Dowtherm A (50 mL) at reflux for 40 minutes. After cooling, the
reaction mixture was diluted with 100 mL hexanes and allowed to sit for 48 hours,
followed by vacuum filtration, rinsing with further hexanes (200 mL) followed by a
mixture of acetone and hexanes (1:1, 50 mL). This gave a beige solid (8.27 g, used
without further purification in the following reaction).
1

H NMR δ (ppm)(DMSO-d6): 11.39 (1 H, s), 8.07 (1 H, dd, J = 8.10, 1.39 Hz), 7.85-7.85
(2 H, m), 7.33 (1 H, t, J = 7.88 Hz), 6.13 (1 H, dd, J = 7.49, 1.00 Hz).
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4,8-dichloroquinoline (Price, 1946; Tarbell, 1946; Riegel, 1946):
Cl

N
Cl

8-chloro-4-quinolone from the above reaction (7.27 g, no more than 40 mmol) and 20.0
mL phosphorus oxychloride (220 mmol) were heated at 70ºC for 2.5 hours, followed by
heating at 110ºC for 1 hour. After cooling, the reaction mixture was poured cautiously
into ice water (300 mL), stirring vigorously. After 30 minutes, the aqueous mixture was
made basic to litmus by the addition of concentrated sodium hydroxide. After cooling,
this mixture was diluted to 2 L and divided into two portions. Each portion was extracted
with chloroform (100 mL followed by 3 x 15 mL), and the pooled organic layers from
both extractions were dried (MgSO4) and evaporated under reduced pressure with
warming to yield a pale beige solid (6.83 g, 67% from ortho-chloroaniline, mp = 159.1160.1°C (lit. 155-6°C (Tarbell, 1946)).

3-(8-chloroquinolin-4-ylamino)propanol

HN

OH

N
Cl

4,8-dichloroquinoline (3.00 g, 15 mmol) and 3-amino-1-propanol (5.95 mL, 7.8 mmol)
were heated in a 10 mL Biotage microwave vial at 130°C for 15 minutes, whereupon
TLC indicated that some starting material remained; heating at 130°C was continued for
an additional 15 minutes. The hot reaction mixture was then poured into water (100 mL)
with good stirring. After standing 18 hours, the solid product was recovered by vacuum
filtration, followed by recrystallization from a mixture of ethyl acetate and 95% ethanol
(55 mL, approximately 10:1). The desired product was isolated as gleaming, beige,
crystalline flakes (2.35 g, 66%, mp = 155.0-155.7°C).
1

H NMR δ (ppm)(DMSO-d6): 8.47 (1 H, d, J = 5.35 Hz), 8.19 (1 H, dd, J = 8.51, 1.28
Hz), 7.79 (1 H, dd, J = 7.44, 1.20 Hz), 7.37 (1 H, dd, J = 8.45, 7.44 Hz), 7.32 (1 H, br t, J
= 5.38 Hz), 6.55 (1 H, d, J = 5.41 Hz), 4.61 (1 H, t, J = 5.07 Hz), 3.55 (2 H, m), 3.34-3.35
(water signal overlaps m, ~2 H), 1.80-1.85 (2 H, m).
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1

H NMR δ (ppm)(CHCl3-d): 8.65 (1 H, d, J = 5.34 Hz), 7.75 (1 H, dd, J = 7.47, 1.24 Hz),
7.65 (1 H, dd, J = 8.46, 1.25 Hz), 7.30 (1 H, dd, J = 8.44, 7.48 Hz), 6.45 (1 H, d, J = 5.37
Hz), 6.03 (1 H, br t, J = 4.71 Hz), 3.97 (2 H, t, J = 5.41 Hz), 3.48 (2 H, m), 2.04-2.06 (2
H, m).

3-(8-chloroquinolin-4-ylamino)propyl methanesulfonate

HN

OMs

N
Cl

3-(8-chloroquinolin-4-ylamino)propanol (1.00 g, 42 mmol) and triethylamine (0.88 mL,
63 mmol) in dry THF (100 mL) were cooled to below 0°C on ice/salt. Methanesulfonyl
chloride (0.38 mL, 49 mmol) was added dropwise. After stirring for 1 hour on ice,
reaction appeared complete by TLC; however, additional methanesulfonyl chloride (0.11
mL, 0.65 mmol) was added and stirring was continued for a further 30 minutes. The
reaction mixture was then diluted with ethyl acetate (30 mL) and washed with saturated
sodium bicarbonate (25 mL); after separating, the aqueous layer was extracted with ethyl
acetate (3 x 7 mL). The pooled organic layers were rinsed with brine (10 mL), dried
(MgSO4) and evaporated under reduced pressure with warming to give the desired
product as a pale yellow, waxy solid (0.72 g, 54%).
1

H NMR δ (ppm)(CHCl3-d): 8.66 (1 H, d, J = 5.20 Hz), 7.73-7.80 (1 H, m), 7.36 (1 H, t,
J = 8.01 Hz), 6.49 (1 H, d, J = 5.12 Hz), 4.42 (2 H, t, J = 5.64 Hz), 3.59 (2 H, m), 3.06 (3
H, s), 2.19-2.20 (2 H, m).
1

H NMR δ (ppm)(DMSO-d6): 8.48 (1 H, d, J = 5.78 Hz), 8.29 (1 H, d, J = 8.52 Hz), 7.877.90 (2 H, m), 7.47 (1 H, t, J = 8.00 Hz), 6.68 (1 H, d, J = 5.85 Hz), 4.36 (2 H, t, J = 6.16
Hz), 3.47 (3 H, m), 2.10-2.11 (2 H, m).
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PL271: N-(3-(4-benzhydrylpiperazin-1-yl)propyl)-8-chloroquinolin-4-amine

HN

N
N

N
Cl

PL271

3-(8-chloroquinolin-4-ylamino)propyl methanesulfonate (0.68 g, 2.2 mmol), N(diphenylmethyl)piperazine (0.56 g, 2.2 mmol), potassium carbonate (0.47 g, 3.4 mmol),
and a catalytic amount of potassium iodide were heated at reflux in acetonitrile (50 mL)
for 20 hours. TLC then indicated that reaction was complete. The reaction mixture was
diluted with 5 mL water, and the solvent was removed by evaporation under reduced
pressure with warming. The residue thus obtained was partitioned between chloroform
(35 mL) and water (50 mL). After separation, the aqueous layer was extracted with
chloroform (3 x 7 mL). The pooled organic layers were dried (MgSO4) and concentrated
under reduced pressure with warming, and the resulting pale yellow solid was boiled in
50 mL 95% ethanol; the clear, yellow supernatent was decanted from a small amount of
insoluble material. After cooling and crystallization, the desired product was isolated by
vacuum filtration (a shimmering, white, crystalline solid, 0.43 g, 42%, mp = 206-208°C).
1

H NMR δ (ppm)(CHCl3-d): 8.62 (1 H, d, J = 5.30 Hz, Q-C2-H), 7.83 (1 H, dd, J = 8.42,
1.29 Hz, Q-C7-H or Q-C5-H, probably C7), 7.76 (1 H, dd, J = 7.40, 1.21 Hz, Q-C5-H or
Q-C7-H, probably C5), 7.64 (1 H, br t, J = 4.00 Hz, Q-N-H), 7.42-7.46 (4 H, m, Ph-H x
4, ortho), 7.27-7.33 (4 H, m, Ph-H x 4, meta), 7.21-7.22 (2 H, m, Ph-H x 2, para), 7.17 (1
H, dd, 8.40, 7.40 Hz, Q-C6-H), 6.36 (1 H, d, J = 5.34 Hz, Q-C3-H), 4.36 (1 H, s,
CH(Ph)2), 3.36 (2 H, td, J = 5.80, 4.01 Hz, Q-NHCH2CH2CH2), 2.64 (10 H, br s overlaps
t, J = 5.41 Hz, CH2 x 4 (piperazine) and Q-NHCH2CH2CH2), 1.93 (2 H, apparent p, J =
5.41 Hz, Q-NHCH2CH2CH2).
13

C NMR δ (ppm)(CHCl3-d): 151.7 (Q-C2), 150.9 (Q-C, possibly Q-C4 (HMBC to
QNHCH2)), 144.9 (Q-C), 142.2 (Ph-C, ipso), 133.7 (Q-C), 129.1 (Q-C5 or possibly C7,
7.76), 128.6 (Ph-C, meta), 128.1 (Ph-C, ortho), 127.1 (Ph-C, para), 123.5 (Q-C6), 120.4
(Q-C7 or possibly C5, 7.83), 120.1 (Q-C), 98.9 (Q-C3), 76.4 (CH(Ph)2), 58.8 (QNHCH2CH2CH2), 53.9 (CH2 x 2, piperazine), 51.8 (CH2 x 2, piperazine), 44.6 (QNHCH2CH2CH2), 23.4 (Q-NHCH2CH2CH2).
MS (ESI): m/z 471.2300 M + H (calculated 471.2310).
HPLC (method C) tR = 10.93 min (98% pure).
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PL284: 8-chloro-N-(3-(4-(pyridin-2-yl)piperazin-1-yl)propyl)quinolin-4-amine

HN

N
N

N

N

PL284

Cl

3-(8-chloroquinolin-4-ylamino)propyl methanesulfonate (1.65 g, 5.2 mmol), 1-(2pyridyl)piperazine (0.85 g, 5.2 mmol), and potassium carbonate (1.09 g, 7.9 mmol) in
acetonitrile (15 mL) were allowed to reflux for 3 days. Precipitation was evident, and so
the reaction mixture was vacuum filtered, rinsing extensively with water, and then with 1
mL 95% ethanol. The resulting cream-colored, sparkling solid proved to be the desired
product (0.49 g, 25%, mp = 164.5-165.7°C).
1

H NMR δ (ppm)(CHCl3-d): 8.65 (1 H, d, J = 5.34 Hz), 8.23-8.25 (1 H, m), 7.80 (1 H,
dd, J = 8.44, 1.30 Hz), 7.69 (1 H, dd, J = 7.46, 1.25 Hz), 7.51-7.55 (1 H, m), 7.39 (1 H, br
t, J = 4.22 Hz), 7.17 (1 H, dd, J = 8.42, 7.46 Hz), 6.67-6.68 (2 H, m), 6.41 (1 H, d, J =
5.38 Hz), 3.65-3.70 (4 H, m), 3.41 (2 H, td, J = 5.95, 4.20 Hz), 2.65-2.70 (6 H, m), 2.00
(2 H, apparent p, J = 5.59 Hz).
13

C NMR δ (ppm)(CHCl3-d): 159.4, 151.7, 150.8, 148.1, 145.0, 137.7, 133.8, 129.2,
123.7, 120.4, 119.5, 113.8, 107.1, 99.1, 58.7, 53.5, 45.3, 44.4, 23.7.
MS (ESI): m/z 382.18024 M + H (calculated 382.17930)
HPLC (method A) tR = 3.68 min (97% pure).

A.1.3: 5,7-dichloroquinolines
3-carbethoxy-5,7-dichloro-4-quinolone (Price, 1946; Surrey, 1946)
Cl

O

O
OEt

Cl

N
H
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3,5-dichloroaniline (8.11 g, 50.1 mmol) and diethyl ethoxymethylene malonate (10.04
mL, 50.1 mmol) were heated in refluxing Dowtherm A (65 mL) for 30 minutes. After
cooling, the reaction mixture was diluted with hexanes (100 mL) and vacuum filtered,
rinsing with hexanes (300 mL) and acetone (75 mL), to recover the product as a
sparkling, pearly white solid (11.42 g, 80% yield).

3-carboxy-5,7-dichloro-4-quinolone (Price, 1946; Surrey, 1946)
Cl

O

O
OH

Cl

N
H

3-carbethoxy-5,7-dichloro-4-quinolone (11.37 g, 39.7 mmol) in 500 mL of 10% caustic
soda was allowed to reflux, stirring, for 6 days, at which point solid was still present.
The orange reaction mixture was decanted from the reaction solids and made acidic by
the addition of concentrated muriatic acid. Further 10% caustic soda was added to the
reaction flask and reflux was continued for an additional 24 hours, whereupon it was
found that all solid material had dissolved; this too was poured into 100 mL water and
made acidic by the addition of concentrated muriatic acid. The two acidified reaction
mixtures were combined and filtered. The resulting pale pink solid was allowed to air
dry, and was used in the ensuing reaction without further purification (21.23 g, containing
residual water). NMR indicated that this contained some decarboxylated material,
approximately 13% of the total quinolone content.
1

H NMR δ (ppm)(DMSO-d6): Major peaks: 15.06 (1 H, s), 8.93 (1 H, s), 7.80 (1 H, d, J =
2.06 Hz), 7.74 (1 H, d, J = 2.04 Hz).

5,7-dichloro-4-quinolone (Price, 1946; Surrey, 1946)
Cl

Cl

O

N
H

3-carboxy-5,7-dichloro-4-quinolone from the above reaction (containing residual water
as well as some decarboxylated material) was heated in Dowtherm A (80 mL) at 255°C
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for 40 minutes. After cooling, the reaction mixture was diluted with 75 mL hexanes and
vacuum filtered, rinsing with 150 mL additional hexanes; the resulting solid was then
boiled in 50 mL hexanes for 1 hour. After standing overnight, vacuum filtration of this
mixture afforded the desired product as a faintly pink, powdery solid (8.01 g).
1

H NMR δ (ppm)(DMSO-d6): 7.85 (1 H, dd, J = 7.50, 5.67 Hz), 7.52 (1 H, d, J = 2.07
Hz), 7.36 (1 H, d, J = 2.06 Hz), 6.01 (1 H, d, J = 7.44 Hz).

4,5,7-trichloroquinoline (Price, 1946; Surrey, 1946)
Cl

Cl

Cl

N

Phosphorous oxychloride (20.6 mL, 221 mmol) was cautiously added to 5,7-dichloro-4quinolone from the above reaction (8.01 g, 37.4 mmol), followed by heating at reflux for
21 hours. After cooling, the reaction mixture was poured gradually onto ice, then
gradually made basic to litmus with solid caustic potash. This was diluted with water to
1 L and combined with 50 mL chloroform. Some material remained undissolved, and
was recovered by vacuum filtration; the filtrate was separated, and the aqueous layer was
extracted with chloroform (5 x 15 mL). The pooled chloroform layers from all
extractions were combined, dried (MgSO4) and evaporated under reduced pressure with
warming to yield a caramel-colored, crystalline solid. NMR indicated that this was the
desired 4,5,7-trichloroquinoline (1.26 g, 15%, mp = 107.0-109.0°C (lit. 105-6°C (Surrey,
1946)). NMR indicated that the solid recovered from filtration (7.59 g) also contained
the desired quinoline, together with approximately 10% of unreacted 5,7-dichloro-4quinolone starting material.
1

H NMR δ (ppm)(CHCl3-d): 8.72 (1 H, d, J = 4.69 Hz), 8.06 (1 H, d, J = 2.21 Hz), 7.66
(1 H, d, J = 2.21 Hz), 7.51 (1 H, d, J = 4.68 Hz).
1

H NMR δ (ppm)(DMSO-d6): 8.87 (1 H, d, J = 4.71 Hz), 8.19 (1 H, d, J = 2.23 Hz), 7.99
(1 H, d, J = 2.23 Hz), 7.83 (1 H, d, J = 4.72 Hz).
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3-(5,7-dichloroquinolin-4-ylamino)propanol

Cl HN

Cl

OH

N

4,5,7-trichloroquinoline (3.01 g, 12.9 mmol) and 3-amino-1-propanol (5.93 mL, 77.5
mmol) were heated in a Carius vessel at 90°C for 3 hours. TLC then indicated that
reaction was complete. The hot reaction mixture was poured into 100 mL water, with
vigorous stirring. After standing overnight, the resulting solid was recovered by vacuum
filtration, followed by air-drying (2.01 g, 59%, mp = 119.3-120.1°C).
1

H NMR δ (ppm)(DMSO-d6): 8.41 (1 H, d, J = 5.53 Hz), 7.78 (1 H, d, J = 2.30 Hz), 7.56
(1 H, br t, J = 2.32 Hz), 6.56 (1 H, d, J = 5.59 Hz), 4.77 (1 H, t, J = 4.91 Hz), 3.59 (2 H,
m), 3.32-3.37 (water signal overlaps m, ~2 H), 1.80-1.87 (2 H, m).

3-(5,7-dichloroquinolin-4-ylamino)propyl methanesulfonate

Cl HN

Cl

OMs

N

3-(5,7-dichloroquinolin-4-ylamino)propanol (2.00 g, 7.41 mmol) and triethylamine (1.5
mL, 11 mmol) in dry THF (100 mL) were cooled to below 0°C on ice/salt.
Methanesulfonyl chloride (0.66 mL, 8.5 mmol) was added dropwise. After stirring for 30
minutes, TLC indicated that reaction was complete. The reaction mixture was diluted
with ethyl acetate (30 mL) and washed with 100 mL saturated sodium bicarbonate. The
aqueous layer was extracted with ethyl acetate (3 x 10 mL), and the pooled organic layers
were dried (MgSO4) and evaporated under reduced pressure with warming to give the
desired product as a pale yellow solid (2.65 g, containing residual solvent and
triethylamine). This material was used without purification in the ensuing reactions.
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PL379: N-(3-(4-benzhydrylpiperazin-1-yl)propyl)-5,7-dichloroquinolin-4-amine

Cl HN

N
N

Cl

N
PL379

3-(5,7-dichloroquinolin-4-ylamino)propyl methanesulfonate (0.52 g crude material from
the above reaction, no more than 1.5 mmol), N-(diphenylmethyl)piperazine (0.39 g, 1.5
mmol), potassium carbonate (0.31 g, 2.2 mmol), and a catalytic amount of potassium
iodide were heated at reflux in acetonitrile (24 mL) for 24 hours, whereupon TLC
indicated that reaction was complete. The solvent was removed under reduced pressure
with warming, and the residue was partitioned between chloroform (60 mL) and water
(40 mL). After separation, the aqueous layer was extracted with chloroform (3 x 15 mL),
dried (MgSO4) and evaporated under reduced pressure with warming. The residue was
recrystallized from 15 mL ethyl acetate to yield the desired product as pale golden
crystals (0.25 g, 34% from 3-(5,7-dichloroquinolin-4-ylamino)propanol, mp = 125.4128.1°C).
1

H NMR δ (ppm)(CHCl3-d): 8.41 (1 H, d, J = 5.51 Hz), 7.83 (1 H, d, J = 2.26 Hz), 7.397.43 (5 H, m), 7.32 (1 H, d, J = 2.26 Hz), 7.25-7.27 (solvent signal overlaps m, ~4 H),
7.17-7.19 (2 H, m), 6.37 (1 H, d, J = 5.56 Hz), 4.23 (1 H, s), 3.29 (2 H, td, J = 6.70, 4.93
Hz), 2.49 (10 H, m), 1.90 (2 H, apparent p, J = 6.82 Hz).
13

C NMR δ (ppm)(CHCl3-d): 151.8, 151.3, 151.0, 142.7, 133.4, 129.1, 128.8, 128.5,
128.0, 127.1, 127.0, 114.9, 100.1, 76.3, 56.2, 53.7, 51.9, 42.1, 25.5.
MS (ESI): m/z 505.19286 M + H (calculated 505.19203)
HPLC (method A) tR = 10.75 min (>99% pure).
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PL367: 5,7-dichloro-N-(3-(4-(pyridin-2-yl)piperazin-1-yl)propyl)quinolin-4-amine

Cl HN

N
N

Cl

N

PL367

N

3-(5,7-dichloroquinolin-4-ylamino)propyl methanesulfonate (1.62 g, 4.64 mmol), 1-(2pyridyl)piperazine (0.79 g, 4.8 mmol), potassium carbonate (0.96 g, 6.9 mmol), and a
catalytic amount of potassium iodide were heated at reflux in acetonitrile (48 mL) for 5
days. The solvent was then removed under reduced pressure with warming, and the
residue was partitioned between chloroform (60 mL) and water (40 mL). After
separation, the aqueous layer was extracted with chloroform (3 x 15 mL), dried (MgSO4)
and evaporated under reduced pressure with warming. The residue was recrystallized by
dissolution in excess boiling ethyl acetate, followed by concentration to 10 mL at room
temperature. Filtration afforded the desired product as a cream colored solid. The
mother liquor was further concentrated to yield a second crop of the same material (total
yield 1.19 g, 63% from 3-(5,7-dichloroquinolin-4-ylamino)propanol, mp = 101.5103.3°C).
1

H NMR δ (ppm)(CHCl3-d): 8.44 (1 H, d, J = 5.50 Hz), 8.20-8.20 (1 H, m), 7.84 (1 H, d,
J = 2.25 Hz), 7.48 (1 H, ddd, J = 8.57, 7.12, 2.01 Hz), 7.33 (2 H, br d, J = 2.30 Hz), 6.636.65 (2 H, m), 6.42 (1 H, d, J = 5.55 Hz), 3.57 (4 H, m), 3.31-3.41 (2 H, m), 2.59 (4 H,
m), 2.56 (2 H, t, J = 6.82 Hz), 1.98 (2 H, apparent p, J = 6.79 Hz).
13

C NMR δ (ppm)(CHCl3-d): 159.5, 151.9, 151.3, 151.0, 148.0, 137.5, 133.5, 129.1,
128.8, 127.2, 114.9, 113.4, 107.1, 100.2, 56.2, 53.3, 45.2, 42.0, 25.5.
MS (ESI): m/z 416.14101 M + H (calculated 416.14033)
HPLC (method A) tR = 6.50 min (99% pure).
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A.1.4: 6,7-dichloroquinolines

3-carbethoxy-6,7-dichloro-4-quinolone (Price, 1946; Surrey, 1946)
O

O

Cl
Cl

OEt
N
H

3,4-dichloroaniline (6.00 g, 37.0 mmol) and diethyl ethoxymethylene malonate (7.42 mL,
37.0 mmol) were heated in refluxing Dowtherm A (100 mL) for 30 minutes. After
cooling, the reaction mixture was diluted with hexanes (200 mL) and vacuum filtered to
recover the solid product (9.11 g, 86% yield).
3-carboxy-6,7-dichloro-4-quinolone (Price, 1946; Surrey, 1946)
O
Cl
Cl

O
OH

N
H

3-carbethoxy-6,7-dichloro-4-quinolone (9.11 g, 31.8 mmol) in 100 mL of 10% caustic
soda was allowed to reflux, stirring, for 20 hours. Solid was still present, and additional
10% caustic soda (400 mL) was added. Reflux was continued for a further 20 hours,
after which no solid remained in the reaction. The hot reaction mixture was poured into
water (200 mL) and made acidic by the addition of concentrated HCl. After resting
overnight, the white precipitate was recovered by vacuum filtration and allowed to air
dry. The resulting off-white powder appeared by NMR to contain the 6,7- and 5,6dichloro regioismers in a proportion of approximately 95:5. This material was used
without further purification in the following reaction (9.11 g, also containing residual
water).
1

H NMR δ (ppm)(DMSO-d6): Major peaks: 8.76 (1 H, s), 8.26 (1 H, s), 7.90 (1 H, s).
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6,7-dichloro-4-quinolone (Price, 1946; Surrey, 1946)
O
Cl
Cl

N
H

3-carboxy-6,7-dichloro-4-quinolone from the above reaction (9.11 g, containing residual
water) was heated in Dowtherm A (100 mL) at 255°C for 50 minutes. After cooling, the
reaction mixture was diluted with 100 mL hexanes and vacuum filtered to yield a
sawdust-colored solid (8.16 g). This material was used without further purification in the
following reaction.
1

H NMR δ (ppm)(DMSO-d6): 8.11 (1 H, s), 7.90 (1 H, d, J = 5.94 Hz), 7.60 (1 H, s), 5.86
(1 H, d, J = 5.95 Hz).

4,6,7-trichloroquinoline (Price, 1946; Surrey, 1946)
Cl
Cl
Cl

N

Phosphorus oxychloride (50 mL, 536 mmol) was added cautiously to 6,7-dichloro-4quinolone from the above reaction (12.43 g of crude material). This was equipped with
stacked air condensers and allowed to heat, stirring, at 105°C for 24 hours. After cooling,
the reaction mixture was poured gradually into 700 mL ice water and then cautiously
basified with solid caustic soda. This was diluted to 2.3 L and combined with 400 mL
chloroform. Some material remained undissolved, and was recovered by vacuum
filtration; the remaining material was separated into three equal portions, each of which
was treated in the following manner: after separation of the layers, the aqueous layer was
extracted with chloroform (3 x 20 mL). The pooled chloroform layers from all
extractions were combined, dried (MgSO4) and evaporated under reduced pressure with
warming to yield a cream-colored solid. NMR indicated that this was the primarily the
desired 4,6,7-trichloroquinoline, containing 5,6,7-trichloroquinoline in a proportion of
approximately 1:6 (see below for spectrum). The desired compound was obtained by
recrystallization from 1:1 chloroform:hexanes (4.48 g including 4 crops, 52% from 3,4dichloroaniline, beige crystals, mp = 155.5-158.2°C (lit. 154-155°C (Surrey, 1946)).
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1

H NMR δ (ppm)(CHCl3-d), prior to recrystallization, containing both regioisomers in a
proportion of approximately 6:1: 8.79 (6 H, d, J = 4.72 Hz), 8.72 (1 H, d, J = 4.67 Hz),
8.35 (6 H, s), 8.26 (6 H, s), 8.01 (1 H, d, J = 9.06 Hz), 7.80 (1 H, d, J = 9.06 Hz), 7.58 (1
H, d, J = 4.68 Hz), 7.51 (6 H, d, J = 4.71 Hz).
1

H NMR δ (ppm)(CHCl3-d), after recrystallization: 8.78 (1 H, d, J = 4.72 Hz), 8.34 (1 H,
s), 8.26 (1 H, s), 7.51 (1 H, d, J = 4.72 Hz).
3-(6,7-dichloroquinolin-4-ylamino)propanol (Method 1)

Cl
Cl
Cl

N

H 2N

OH

Carius vessel
90oC, 3 days

HN

OH

Cl
Cl

N

4,6,7-trichloroquinoline (0.91 g, 3.9 mmol) and 3-amino-1-propanol (1.79 mL, 23.4
mmol) were heated at 90°C for 3 days. The hot reaction mixture was then poured into
250 mL water, while stirring vigorously. After standing overnight, the resulting
precipitate was recovered by vacuum filtration, followed by air drying and partial
recrystallization from ethyl acetate (0.62 g of a beige solid, 59%, mp = 220-222°C).
1

H NMR δ (ppm)(DMSO-d6): 8.61 (1 H, s), 8.41 (1 H, d, J = 5.44 Hz), 7.98 (1 H, s), 7.36
(1 H, s), 6.51 (1 H, d, J = 5.50 Hz), 4.57 (1 H, t, J = 5.08 Hz), 3.54 (2 H, m), 3.32 (water
signal overlaps m, ~2 H), 1.81-1.82 (2 H, m).
1

H NMR δ (ppm)(CHCl3-d): 8.52 (1 H, d, J = 5.36 Hz), 8.07 (1 H, s), 7.80 (1 H, s), 6.41
(1 H, d, J = 5.39 Hz), 5.86 (1 H, br s), 3.98 (2 H, t, J = 5.41 Hz), 3.48 (2 H, td, J = 6.23,
4.78 Hz), 2.06 (2 H, apparent p, J = 2.98 Hz).

3-(6,7-dichloroquinolin-4-ylamino)propanol (Method 2)

Cl
Cl
Cl

N

H 2N

OH

Microwave
130 oC, 15 minutes

HN

OH

Cl
Cl

N

4,6,7-trichloroquinoline (0.25 g, 1.1 mmol) and 3-amino-1-propanol (1.00 mL, 13 mmol)
were combined in a 0.5-2 mL Biotage microwave vial and heated at 130°C for 15
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minutes, whereupon TLC indicated that reaction was complete. The hot reaction mixture
was poured into 50 mL water, while stirring vigorously. After standing 20 minutes, the
resulting precipitate was recovered by vacuum filtration, followed by air drying to
provide the desired product as a beige, powdery solid (0.26 g of a beige solid, 87%).

3-(6,7-dichloroquinolin-4-ylamino)propyl methanesulfonate

HN

OMs

Cl
Cl

N

3-(6,7-dichloroquinolin-4-ylamino)propanol (0.62 g, 2.3 mmol) and triethylamine (0.48
mL, 3.4 mmol) in dry THF (50 mL) were cooled to below 0°C on ice/salt.
Methanesulfonyl chloride (0.21 mL, 2.7 mmol) was added dropwise. After stirring for 1
hour on ice, TLC indicated that reaction was complete; nevertheless, additional
methanesulfonyl chloride (0.02 mL, 0.3 mmol) was added and stirring was continued for
a further 15 hours. The reaction mixture was then washed with 100 mL saturated sodium
bicarbonate. The aqueous layer was extracted with ethyl acetate (3 x 10 mL), and the
pooled organic layers were rinsed with 10 mL brine, then dried (MgSO4) and evaporated
under reduced pressure with warming to give the desired product as a tan solid (0.71 g,
87%).
1

H NMR δ (ppm)(DMSO-d6): 8.61 (1 H, s), 8.44 (1 H, d, J = 5.45 Hz), 8.01 (1 H, s), 7.43
(1 H, s), 6.55 (1 H, d, J = 5.51 Hz), 4.35 (2 H, t, J = 6.18 Hz), 3.41 (2 H, m), 3.20 (3 H,
s), 2.07-2.08 (2 H, m).
PL307: 6,7-dichloro-N-(3-(4-(pyridin-2-yl)piperazin-1-yl)propyl)quinolin-4-amine

HN

N

Cl
Cl

N
N

PL 307

N

3-(6,7-dichloroquinolin-4-ylamino)propyl methanesulfonate (0.71 g, 2.0 mmol), 1-(2pyridyl)piperazine (0.35 g, 2.1 mmol), potassium carbonate (0.41 g, 3.0 mmol), and a
catalytic amount of potassium iodide were heated in refluxing acetonitrile (21 mL) for 3
days. The solvent was removed under reduced pressure with warming, and the residue
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was partitioned between chloroform (30 mL) and water (30 mL). After separation, the
aqueous layer was extracted with further chloroform (3 x 7 mL), and the pooled organic
layers were dried (MgSO4) and evaporated under reduced pressure with warming to yield
a brown solid. This was taken up in excess boiling 95% ethanol and allowed to
concentrate slowly at room temperature. The resulting amber crystals proved to be the
desired product (0.27 g, 33%, mp = 221-223°C).
1

H NMR δ (ppm)(CHCl3-d): 8.49 (1 H, d, J = 5.36 Hz), 8.23-8.23 (1 H, m), 8.02 (2 H, d,
J = 11.61 Hz), 7.80 (1 H, t, J = 3.94 Hz), 7.52 (1 H, ddd, J = 8.53, 7.17, 2.02 Hz), 6.71 (1
H, d, J = 8.54 Hz), 6.68 (1 H, dd, J = 7.17, 4.93 Hz), 6.31 (1 H, d, J = 5.40 Hz), 3.77 (4 H,
m), 3.40 (2 H, td, J = 5.36, 0.01 Hz), 2.71-2.72 (6 H, m), 1.96-2.01 (2 H, m).
13

C NMR δ (ppm)(CHCl3-d): 159.7, 152.4, 149.7, 148.0, 147.5, 137.6, 133.0, 133.0,
130.8, 128.3, 121.9, 118.4, 113.9, 107.3, 98.7, 59.2, 53.6, 45.3, 44.7, 23.2.
MS (ESI): m/z 416.14087 M + H (calculated 416.14033)
HPLC (method A) tR = 6.86 min (>99% pure).

A.1.5: 7,8-dichloroquinolines
3-carbethoxy-7,8-dichloro-4-quinolone (Price, 1946; Surrey, 1946)
O

O
OEt

Cl
Cl

N
H

2,3-dichloroaniline (25.85 g, 160 mmol) and diethyl ethoxymethylene malonate (31.65
mL, 160 mmol) were heated in refluxing Dowtherm A (100 mL) for 40 minutes. After
cooling, the reaction mixture was diluted with 30-60° petroleum æther (150 mL) and
vacuum filtered, rinsing well with additional petroleum æther, to recover the product as
an off-white solid (37.10 g, 81% yield).

3-carboxy-7,8-dichloro-4-quinolone (Price, 1946; Surrey, 1946)
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O

O
OH

Cl
Cl

N
H

3-carbethoxy-7.8-dichloro-4-quinolone (37.10 g, 130 mmol) in 400 mL of 10% caustic
soda was allowed to reflux, stirring, for 20 hours. Solid was still present, and therefore
40 mL 50% caustic soda was added to the reaction, followed by 200 mL water. Note:
upon cooling somewhat, the reaction mixture solidified; upon returning to reflux, much
of the solid again dissolved. Reflux was continued for a further 1.5 hours. Since a small
amount of solid still remained, the reaction was vacuum filtered while hot, rinsing with
hot water. The filtrate was brought to a simmer (to dissolve material that had solidified
upon cooling), and acidified with concentrated hydrochloric acid while hot. After
cooling, vacuum filtration yielded a white solid, product A. Meanwhile, the solid from
filtration of the basic reaction mixture returned to the reaction vessel and again heated at
reflux in a further 400 mL 10% caustic soda. After 1.5 hours, all material had dissolved,
and so the reaction mixture was acidified while hot by the addition of concentrated
hydrochloric acid. Upon cooling, filtration again yielded an off-white solid (product B).
Product A appeared to contain a large amount of salt (by taste and flame test) and
residual water. Only product B, which appeared to be the desired material by NMR, was
used in the next reaction (15.75 g, 47%).
1

H NMR δ (ppm)(DMSO-d6): 13.08 (1 H, br s), 8.66 (1 H, s), 8.24 (1 H, d, J = 8.80 Hz),
7.81 (1 H, d, J = 8.80 Hz).

7,8-dichloro-4-quinolone (Price, 1946; Surrey, 1946)
O

Cl
Cl

N
H

3-carboxy-7,8-dichloro-4-quinolone (15.75 g, 61.0 mmol) was decarboxyated in two
portions (I and II). Portion I was heated in Dowtherm A (100 mL) at reflux for 1 hour.
Upon cooling, the reaction mixture was diluted with 30-60° petroleum æther (150 mL)
and vacuum filtered, rinsing well with additional petroleum æther. Portion II was heated
in Dowtherm A (100 mL) at reflux for 40 minutes; upon cooling, NMR indicated that
decarboxylation was not complete. The reaction was returned to reflux and inadvertently
heated for 4 hours. After cooling, the reaction mixture was diluted with 30-60°
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petroleum æther (150 mL) and vacuum filtered, rinsing well with further petroleum
æther. The products from decarboxylation of portions I and II were combined (a tan
crystalline solid, 12.31 g, 94%).
1

H NMR δ (ppm)(DMSO-d6): 11.51 (1 H, br s), 8.06 (1 H, d, J = 8.73 Hz), 7.88 (1 H, dd,
J = 7.56, 6.02 Hz), 7.55 (1 H, d, J = 8.73 Hz), 6.15 (1 H, dd, J = 7.54, 1.10 Hz).
1

H NMR δ (ppm)(DMSO-d6): 11.51 (1 H, br d, J = 5.93 Hz), 8.06 (1 H, d, J = 8.73 Hz),
7.88 (1 H, dd, J = 7.55, 6.02 Hz), 7.55 (1 H, d, J = 8.73 Hz), 6.15 (1 H, dd, J = 7.54, 1.10
Hz).

4,7,8-trichloroquinoline (Price, 1946; Surrey, 1946)

Cl

Cl

N
Cl

7,8-dichloro-4-quinolone (12.31 g, 57.5 mmol) was allowed to heat, stirring, in
phosphorus oxychloride (41 mL, 440 mmol) at a gentle reflux for 24 hours. After
cooling, the reaction mixture was poured gradually onto ice (with good stirring) and then
made basic with 10% caustic soda (final volume 900 mL). This was extracted with
chloroform (4 x 75 mL). The combined chloroform extracts were dried (MgSO4) and
evaporated under reduced pressure with warming to yield a cream-colored solid (9.18 g,
69%, mp = 126.0-126.8°C (lit. 125-126°C).
1

H NMR δ (ppm)(CHCl3-d): 8.93 (1 H, d, J = 4.70 Hz), 8.14 (1 H, d, J = 9.09 Hz), 7.71
(1 H, d, J = 9.09 Hz), 7.58 (1 H, d, J = 4.71 Hz).

3-(5,7-dichloroquinolin-4-ylamino)propanol

HN

Cl

OH

N
Cl
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4,7,8-trichloroquinoline (4.50 g, 19.4 mmol) and 3-amino-1-propanol (8.80 mL, 115
mmol) were heated at 110°C for 24 hours. The hot reaction mixture was then poured into
250 mL water, while stirring vigorously. The resulting precipitate was recovered by
vacuum filtration, followed by air drying and partial recrystallization from ethyl acetate.
NMR indicated that a small amount of 3-amino-1-propanol remained, and so the product
was ground finely and again partially recrystallized from ethyl acetate to yield the desired
product as a tan solid (4.42 g, 84%).
1

H NMR δ (ppm)(DMSO-d6): 8.49 (1 H, d, J = 5.44 Hz), 8.23 (1 H, d, J = 9.15 Hz), 7.60
(1 H, d, J = 9.08 Hz), 7.46 (1 H, t, J = 5.32 Hz), 6.58 (1 H, d, J = 5.50 Hz), 4.60 (1 H, t, J
= 5.03 Hz), 3.54 (2 H, m), 3.34 (water signal overlaps m, ~2 H), 1.82 (2 H, m).

3-(7,8-dichloroquinolin-4-ylamino)propyl methanesulfonate

HN

Cl

OMs

N
Cl

3-(7,8-dichloroquinolin-4-ylamino)propanol (4.42 g, 16.3 mmol) and triethylamine (3.35
mL, 24.0 mmol) in dry dichloromethane (100 mL) were cooled to below 0°C on ice/salt.
Methanesulfonyl chloride (1.60 mL, 20.6 mmol) was added dropwise. After stirring for 1
hour on ice, additional triethylamine (1.0 mL, 7.2 mmol) and methanesulfonyl chloride
(0.50 mL, 6.4 mmol) were added and stirring was continued for a further 30 minutes,
whereupon TLC indicated that reaction was complete. The reaction mixture was washed
with 120 mL saturated sodium bicarbonate; after separating, the aqueous layer was
extracted with dichloromethane (3 x 15 mL). The pooled organic layers were dried
(MgSO4) and evaporated under reduced pressure with warming to give the desired
product as a yellowish tan solid (4.63 g, 82%,).
1

H NMR δ (ppm)(DMSO-d6): 8.51 (1 H, d, J = 5.42 Hz), 8.24 (1 H, d, J = 9.17 Hz), 7.63
(1 H, d, J = 9.09 Hz), 7.49 (1 H, t, J = 5.36 Hz), 6.62 (1 H, d, J = 5.49 Hz), 4.35 (2 H, t, J
= 6.18 Hz), 3.40 (2 H, m), 3.20 (3 H, s), 2.04-2.11 (2 H, m).
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PL305: N-(3-(4-benzhydrylpiperazin-1-yl)propyl)-7,8-dichloroquinolin-4-amine

HN

N
N

Cl

N
Cl

PL 305

3-(7,8-dichloroquinolin-4-ylamino)propyl methanesulfonate (1.80 g, 5.15 mmol), N(diphenylmethyl)piperazine (1.38 g, 5.47 mmol), and potassium carbonate (0.74 g, 5.4
mmol were heated at 75°C in acetonitrile (15 mL) for 9 days. TLC then indicated that
reaction was complete. The solvent was removed by evaporation under reduced pressure
with warming. The residue was partitioned between chloroform (40 mL) and water (35
mL); after separation, the aqueous layer was extracted with additional chloroform (3 x 10
mL). The aqueous layer contained a tan precipitate that remained undissolved during
extraction; this was recovered by vacuum filtration. NMR indicated that this was
predominantly the desired product. The pooled organic layers were dried (MgSO4) and
evaporated under reduced pressure with warming to yield a miniscule quantity of
unpromising yellow oil; this was subsequently discarded. The solid material recovered
from extraction was recrystallized by dissolution in excess boiling ethyl acetate, followed
by slow concentration at room temperature to yield the desired product as a tan,
crystalline solid (1.72 g, 66%, mp = 171.5-173.2°C).
1

H NMR δ (ppm)(CHCl3-d): 8.60 (1 H, d, J = 5.34 Hz), 7.79 (1 H, br t, J = 3.96 Hz), 7.68
(1 H, d, J = 9.03 Hz), 7.41-7.45 (4 H, m), 7.30-7.36 (4 H, m), 7.24-7.29 (solvent peak
overlaps m, ~2 H), 7.15 (1 H, d, J = 8.99 Hz), 6.34 (1 H, d, J = 5.39 Hz), 4.46 (1 H, s),
3.35 (2 H, td, J = 5.78, 3.94 Hz), 2.65 (10 H, br s overlaps t, J = 5.31 Hz), 1.93 (2 H,
apparent p, J = 5.33 Hz).
13

C NMR δ (ppm)(CHCl3-d): 152.4, 151.0, 146.1, 141.7, 133.5, 131.6, 128.5, 128.3,
127.3, 124.8, 120.3, 118.4, 99.1, 75.8, 59.0, 54.0, 51.5, 44.8, 23.1.
MS (ESI): m/z 505.19271 M + H (calculated 505.19203)
HPLC (method A) tR = 10.82 min (99% pure).
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PL306: 7,8-dichloro-N-(3-(4-(pyridin-2-yl)piperazin-1-yl)propyl)quinolin-4-amine

HN

N
N

Cl

N

N
PL 306

Cl

3-(7,8-dichloroquinolin-4-ylamino)propyl methanesulfonate (1.80 g, 5.15 mmol), 1-(2pyridyl)piperazine (0.90 mL, 5.5 mmol), and potassium carbonate (0.71 g, 7.8 mmol)
were heated at 75°C in acetonitrile (15 mL) for 3 days. TLC then indicated that reaction
was complete. The solvent was removed under reduced pressure with warming, and the
residue was boiled in 100 mL water for 20 minutes. Upon cooling, the solid was
recovered by vacuum filtration and partially recrystallized from ethyl acetate, followed
by full recrystallization from 95% ethanol to provide the desired product as a sparkling,
beige solid (0.53 g, 25%).
1

H NMR δ (ppm)(CHCl3-d): 8.64 (1 H, d, J = 5.38 Hz), 8.24-8.24 (1 H, m), 7.73 (1 H, d,
J = 9.04 Hz), 7.54-7.54 (1 H, m), 7.50 (1 H, s), 7.31 (1 H, d, J = 9.00 Hz), 6.69-6.70 (2 H,
m), 6.42 (1 H, d, J = 5.42 Hz), 3.68 (4 H, m), 3.43 (2 H, td, J = 5.93, 4.14 Hz), 2.69-2.70
(6 H, m), 2.01 (2 H, apparent p, J = 5.52 Hz).
13

C NMR δ (ppm)(CHCl3-d): 159.3, 152.4, 150.9, 148.1, 146.1, 137.7, 133.6, 131.9,
125.1, 119.8, 118.4, 113.9, 107.2, 99.3, 58.8, 53.5, 45.4, 44.5, 23.5.
MS (ESI): m/z 416.14033 M + H (calculated 416.14061)
HPLC (method A) tR = 6.52 min (96% pure).
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A.2. Haloquinolines other than chlorine
A.2.1: 6-fluoroquinolines
3-carbethoxy-6-fluoro-4-quinolone (Price, 1946; Snyder, 1947)

O

O

F

OEt
N
H

para-Fluoroaniline (26.39 g, 0.237 mol) and diethyl ethoxymethylene malonate (48.0
mL, 0.238 mol) in Dowtherm A (100 mL) were allowed to heat gradually, stirring, to
255°C, at which temperature the reaction was allowed to remain for 35 minutes. After
cooling, the reaction mixture was diluted with 35-60° petroleum æther (200 mL) and
vacuum filtered to obtain the product as a tan, powdery solid (45.83 g, 82%).

6-fluoro-4-quinolone (Price, 1946; Snyder, 1947)

O
F

O
OEt

N
H

1) 10% NaOH,
F
reflux
2) HCl

O

O

O
F
OH

N
H

Dowtherm A
255oC

N
H

The above product (45.83 g, 0.195 mol) in 400 mL of 10% caustic soda was allowed to
reflux, stirring, for 2 hours, at which point all solid material had dissolved. After partial
cooling, the reaction was poured gradually and with good stirring into 300 mL 6M
muriatic acid. The resulting off-white precipitate was recovered by vacuum filtration.
After air-drying, the above product was heated in Dowtherm A (100 mL) at 255°C for 40
minutes. After cooling, the reaction mixture was diluted with 100 mL 35-60° petroleum
æther and vacuum filtered. The product was obtained as a tan, powdery solid (30.11 g,
95%).
1

H NMR δ (ppm)(DMSO-d6): 11.98 (1 H, br s), 7.93 (1 H, dd, J = 7.35, 5.92 Hz), 7.72 (1
H, dd, J = 9.43, 2.99 Hz), 7.65 (1 H, dd, J = 9.00, 4.71 Hz), 7.56 (1 H, ddd, J = 9.09, 8.22,
3.00 Hz).
19

F NMR δ (ppm)(DMSO-d6): -118.1 (m).
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4-chloro-6-fluoroquinoline (Price, 1946; Snyder, 1947)
Cl
F
N

Phosphorus oxychloride (80 mL, 860 mmol) was cautiously added to 6-fluoro-4quinolone (30.11 g, 185 mmol). The reaction was allowed to heat, stirring, at 110°C for
18 hours. After cooling, the reaction mixture was poured gradually onto ice and then
made basic (pH 10) with solid caustic potash. This resulted in formation of white
precipitate, which was recovered by filtration and allowed to air dry (19.16 g, 57% mp =
60.7-65.3°C (lit. 76.5-77°C). Note: Four years elapsed between synthesis of this product
and determination of melting point. The product had been stored in a sealed bottle in a
dark drawer during this time.
1

H NMR δ (ppm)(CHCl3-d): 8.76 (1 H, d, J = 4.71 Hz), 8.14 (1 H, dd, J = 9.24, 5.33 Hz),
7.86 (1 H, dd, J = 9.41, 2.83 Hz), 7.54-7.55 (2 H, m).
19

F NMR δ (ppm)(CHCl3-d): -110.6 (m).

3-(6-fluoroquinolin-4-ylamino)propanol

HN

OH

F
N

4-chloro-6-fluoroquinoline (10.01 g, 55.1 mmol) and 3-amino-1-propanol (25.29 mL, 331
mmol) were heated at 110°C for 24 hours. The hot reaction mixture was poured into 750
mL water, gradually and with good stirring. The resulting precipitate was isolated by
vacuum filtration, and then partially recrystallized from ethyl acetate. Filtration afforded
the desired product as a tan solid (9.74 g, 80%, mp =159.1-160.1°C).
1

H NMR δ (ppm)(DMSO-d6): 8.38 (1 H, d, J = 5.32 Hz), 8.04 (1 H, dd, J = 11.15, 2.85
Hz), 7.83 (1 H, dd, J = 9.21, 5.84 Hz), 7.49-7.50 (1 H, m), 7.04 (1 H, br t, J = 5.28 Hz),
6.47 (1 H, d, J = 5.37 Hz), 4.58 (1 H, t, J = 5.07 Hz), 3.55 (2 H, td, J = 6.13, 5.03 Hz),
3.33 (water signal overlaps m, ~2 H), 1.82 (2 H, apparent p, J = 6.65 Hz).
19

F NMR δ (ppm)(DMSO-d6): -116.6 (m).
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1

H NMR δ (ppm)(CHCl3-d): 8.52 (1 H, d, J = 5.30 Hz), 7.96 (1 H, dd, J = 9.19, 5.61 Hz),
7.35-7.36 (2 H, m), 6.42 (1 H, d, J = 5.32 Hz), 5.70 (1 H, s), 3.97 (2 H, t, J = 5.44 Hz),
3.48 (2 H, m), 2.04-2.06 (2 H, m).
MS (ESI): m/z 221.10864 M + H (calculated 221.10847)
HPLC (method A) tR = 6.98 min (86% pure). Second peak tR = 7.77 min (13%). Note:
Four years elapsed between synthesis of this product and testing by HPLC. The product
had been stored in a sealed bottle in a dark drawer during this time.

3-(6-fluoroquinolin-4-ylamino)propyl methanesulfonate

HN

OMs

F
N

3-(6-fluoroquinolin-4-ylamino)propanol (3.00 g, 13.6 mmol) and triethylamine (3.00 mL,
21.5 mmol) in dry chloroform (125 mL) were cooled to below 0°C on ice/salt.
Methanesulfonyl chloride (1.22 mL, 15.7 mmol) was added dropwise. After stirring for
an hour on ice, TLC indicated that reaction was complete. The reaction mixture was
shaken with 25 mL saturated sodium bicarbonate, followed by extraction of the aqueous
layer with three 10 mL portions of chloroform. The pooled organic layers were washed
with 10 mL water, dried over anhydrous magnesium sulfate, and evaporated under
reduced pressure with warming. This afforded the desired product as a pale yellow,
powdery solid (3.78 g, 93%).

PL285: N-(3-(4-benzhydrylpiperazin-1-yl)propyl)-6-fluoroquinolin-4-amine

HN

N

F

N
N

PL285
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3-(6-fluoro quinolin-4-ylamino)propyl methanesulfonate (1.81 g, 6.07 mmol), N(diphenylmethyl)piperazine (1.62 g, 6.42 mmol), and potassium carbonate (1.26 g, 9.12
mmol) were heated in refluxing acetonitrile (22 mL) for 5 hours. The reaction mixture
was vacuum filtered, rinsing extensively with water, and then with 1 mL 95% ethanol.
This afforded the desired product as a sparkling, cream-colored solid (2.12 g, 77%, mp =
201-203°C).
1

H NMR δ (ppm)(CHCl3-d): 8.49 (1 H, d, J3,2 = 5.26 Hz, Q-C2-H), 7.96 (1 H, dd, J7,8 =
9.23, JF = 5.61 Hz, Q-C8-H), 7.71 (1 H, dd, JF = 10.02, J7,5 = 2.79 Hz, Q-C5-H), 7.62 (1
H, br t, JCH2,NH = 3.94 Hz, Q-C4-NH), 7.47-7.49 (4 H, m, Ph-H, ortho), 7.43 (1 H, ddd,
J8,7 = 9.23, JF = 8.02, J5,7 = 2.75 Hz, Q-C7-H), 7.24-7.31 (solvent signal overlaps m, ~4
H, Ph-H, meta), 7.15-7.22 (2 H, m, Ph-H, para), 6.31 (1 H, d, J2,3 = 5.31 Hz, Q-C3-H),
4.36 (1 H, s, CH(Ph)2), 3.35 (2 H, td, JCH2,CH2 = 5.71, JNH,CH2 = 3.98 Hz, Q-C1NHCH2CH2CH2), 2.58 (10 H, br s overlaps t, center at 2.64 ppm, JCH2,CH2 = 8.82 Hz, PipCH2 x 4 and Q-C1-NHCH2CH2CH2), 1.92 (2 H, apparent p, JCH2 x 2, CH2 = 5.31 Hz, Q-C1NHCH2CH2CH2).
19

F NMR δ (ppm)(CHCl3-d): -117.1 (m).

13

C NMR δ (ppm)(CHCl3-d): 160.8, 158.3 (d, JF = 244.47 Hz , Q-C6), 150.6 (d, JF = 1.95
Hz, Q-C2), 150.2 (d, JF = 4.19 Hz, Q), 145.4 (Q), 142.9 (Ph-C, ipso), 132.1 (d, JF = 8.91
Hz, Q-C8), 128.6 (Ph-C, meta), 127.9 (Ph-C, ortho), 127.0 (Ph-C, para), 119.6 (d, JF =
8.64 Hz, Q), 118.5 (d, JF = 24.30 Hz, Q-C7), 105.3 (d, JF = 21.88 Hz, Q-C5), 98.3 (QC3), 76.7 (CH(Ph)2), 59.0 (Q-C1-NHCH2CH2CH2), 53.9 (Pip-C x 2, adjacent to
NHCH2CH2CH2), 52.1 (Pip-C x 2, adjacent to CH(Ph)2), 44.8 (Q-C1-NHCH2CH2CH2),
23.3 (Q-C1-NHCH2CH2CH2).
MS (ESI): m/z 455.26087 M + H (calculated 455.26055)
HPLC (method A) tR = 10.21 min (98% pure).

PL286: 6-fluoro-N-(3-(4-(pyridin-2-yl)piperazin-1-yl)propyl)quinolin-4-amine

HN

N

F

N
N

PL286

N

3-(6-fluoroquinolin-4-ylamino)propyl methanesulfonate (1.97 g, 6.60 mmol), 1-(2pyridyl)piperazine (1.34 g, 8.21 mmol), and potassium carbonate (1.26 g, 9.12 mmol)
were heated in refluxing acetonitrile (16 mL) for 4 days. The solvent was removed under
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reduced pressure with warming, and the residue was partitioned between water (25 mL)
and ethyl acetate (35 mL). After separation the aqueous layer was extracted with
additional ethyl acetate (3 x 10 mL), and the pooled organic layers were dried (MgSO4)
and evaporated under reduced pressure with warming. The residue was dissolved in
excess boiling ethyl acetate. This was then allowed to concentrate slowly at room
temperature. Filtration afforded the desired product as pale yellow needles (0.40 g, 17%,
mp = 145.3-146.6°C).
1

H NMR δ (ppm)(CHCl3-d): 8.51 (1 H, d, J = 5.30 Hz), 8.23 (1 H, dd, J = 4.96, 1.87 Hz),
7.94 (1 H, dd, J = 9.22, 5.58 Hz), 7.51-7.52 (2 H, m), 7.33 (1 H, ddd, J = 9.20, 7.93, 2.75
Hz), 7.09 (1 H, br t, J = 4.20 Hz), 6.67-6.69 (2 H, m), 6.38 (1 H, d, J = 5.32 Hz), 3.72 (4
H, m), 3.42 (2 H, td, J = 5.94, 4.30 Hz), 2.68-2.70 (6 H, m), 2.01-2.03 (2 H, m).
19

F NMR δ (ppm)(CHCl3-d): -116.0 (m).

MS (ESI): m/z 366.20932 M + H (calculated 366.20885)
HPLC (method A) tR = 2.66 min (81% pure). (Additional peaks elute at 1.64 min, 13%,
and 7.68 min, 5%.)

A.2.2: 7-fluoroquinolines

3-carbethoxy-5- and 7-fluoro-4-quinolone (Price, 1946; Snyder, 1947)
F

O

O

O
OEt

N
H

O
OEt

+
F

N
H

meta-Fluoroaniline (11.64 g, 105 mmol) and diethyl ethoxymethylene malonate (21.04
mL, 105 mmol) in Dowtherm A (100 mL) were allowed to heat gradually, stirring, to
255°C, at which temperature the reaction was allowed to remain for 30 minutes. After
cooling, the reaction mixture was diluted with 35-60° petroleum æther (200 mL) and
vacuum filtered to obtain a cream-colored, powdery solid (21.19 g, 86%).
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5- and 7- fluoro-3-carboxy-4-quinolone (Price, 1946; Snyder, 1947)
F

O

O

O
OH

OH

+

N
H

O

F

N
H

A portion of the above product (11.80 g, 50.2 mmol) in 250 mL of 10% caustic soda was
allowed to reflux, stirring, for 1.75 hours, at which point all solid material had dissolved.
After cooling to room temperature, the reaction was poured into 300 mL deionized water
and triturated with concentrated muriatic acid until no more precipitate formed. The
resulting off-white precipitate was recovered by vacuum filtration. The off-white solid
obtained after air-drying (11.12 g, presumed to contain residual water) was used without
further drying or purification in the ensuing reaction.

5- and 7-fluoro-4-quinolone (Price, 1946; Snyder, 1947)
F

O

O

+
F

N
H

N
H

The above product (10.39 g, presumed to contain residual water) was heated in
Dowtherm A (60 mL) at 255°C for 1.5 hours. After cooling, the reaction mixture was
diluted with 35-60° petroleum æther (100 mL) and vacuum filtered. The product was a
beige solid (7.92 g, 97% from 3-carbethoxy-5- and 7-fluoro-4-quinolone).

4-chloro-5- and 7-fluoroquinoline (Price, 1946; Snyder, 1947)

F

Cl

Cl

+
N

F

N

Phosphorus oxychloride (40 mL, 430 mmol) was cautiously added to 5- and 7-fluoro-4quinolone (7.92 g, 45 mmol). This mixture was allowed to heat, stirring, at 100°C for 1
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hour and 45 minutes. After cooling, the reaction mixture was poured gradually onto ice
and then made basic (pH >10) with solid caustic potash. The resulting white precipitate
was recovered by filtration and allowed to air dry. NMR indicated that this product was a
mixture of 4-chloro-5-fluoroquinoline and 4-chloro-7-fluoroquinoline, as expected.
Separation of the 7- and 5-fluoro regioisomers by recrystallization from hexanes was not
successful. The regioisomers were therefore separated by chromatography on alumina,
eluting with 98:2 hexanes:ethyl acetate followed by 93:7 hexanes:ethyl acetate. The
desired 4-chloro-7-fluoroquinoline was recovered as a white, crystalline solid with a
flowery odor, similar to that of 4,7-dichloroquinoline (4.99 g, 57%, mp = 74.9-75.6°C
(lit. 73.5-74°C (Snyder, 1947)), Rf = 0.1 (basic alumina, hexanes)).
1

H NMR δ (ppm)(CHCl3-d): 8.79 (1 H, d, J = 4.74 Hz), 8.26 (1 H, dd, J = 9.27, 5.91 Hz),
7.77 (1 H, dd, J = 9.77, 2.57 Hz), 7.48 (1 H, d, J = 4.65 Hz), 7.44-7.44 (1 H, m).
19

F NMR δ (ppm)(CHCl3-d), 1H-decoupled: -108.30.

Note: Reaction of the above material with 3-amino-1-propanol gave a mixture of
products due to replacement of the 7-fluoro substituent with 3-amino-1-propanol in
addition to the expected substitution of the 4-chloro substituent. Replacement of the 7fluoro substituent of 4-chloro-7-fluoroquinoline by amines has been observed previously
(Snyder, 1947). In the case of the above compound, the 7-substituted product was
removed by chromatography. Once purified, mesylation of the 4-substituted product
resulted in partial substitution of the 7-fluoro substituent by the triethylamine base used
in the reaction. Due to the small yield of both products, the project was placed on hold.
The easy replacement of the 7-fluoro substituent by amines, even tertiary amines,
suggested possible avenues for the synthesis of 4,7-diamino-substituted quinolines, but
these have not yet been pursued.

A.2.3: 6-bromoquinolines
3-carbethoxy-6-bromo-4-quinolone (Price, 1946; Lin, 1978)
O
Br

O
OEt

N
H

para-Bromoaniline (13.53 g, 78.7 mmol) and diethyl ethoxymethylene malonate (15.9
mL, 78.7 mmol) in Dowtherm A (60 mL) were allowed to heat gradually, stirring, to
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255°C, at which temperature the reaction was allowed to remain for 1.25 hours. After
cooling, the reaction mixture was diluted with 30-60º petroleum æther and vacuum
filtered, rinsing with additional petroleum æther, then with acetone. This afforded a
sparkling, cream-colored solid (17.56 g, 75%).

3-carboxy-6-bromo-4-quinolone (Price, 1946; Lin, 1978)
O

O

Br

OH
N
H

3-carbethoxy-6-bromo-4-quinolone (17.56 g, 59.3 mmol) in 250 mL of 10% caustic soda
was heated at reflux, stirring, for 1.5 hours, at which point all solid material had
dissolved. The hot reaction mixture was poured into 500 mL water and acidified by
addition of concentrated muriatic acid. The resulting white precipitate was isolated by
vacuum filtration. After air-drying, mass of product obtained was 16.38 g (product
presumed to contain water; yield not calculated). The product was used without further
drying or purification in the next step.
6-bromo-4-quinolone (Price, 1946; Lin, 1978)
O
Br
N
H

The above product (16.38 g, presumed to contain water) was decarboxylated in two
portions. Each portion was heated in Dowtherm A (50 mL) at 255°C for 1.25 hours.
After cooling, the reaction mixture was diluted with 35-60° petroleum æther and vacuum
filtered to recover the solid product as a pearlescent, pale beige solid. In both cases,
NMR indicated that this material was the decarboxylated product (13.40 g).
1

H NMR δ (ppm)(DMSO-d6): 11.94 (1 H, d, J = 5.86 Hz, Q-N1-H), 8.16 (1 H, d, J = 2.43
Hz, Q-C5-H), 7.95 (1 H, dd, J = 7.37, 5.19 Hz, Q-C2-H), 7.79 (1 H, dd, J = 8.79, 2.48 Hz,
Q-C7-H), 7.53 (1 H, d, J = 8.82 Hz, Q-C8-H), 6.08 (1 H, d, J = 7.38 Hz, Q-C3-H).
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4-chloro-6-bromoquinoline (Price, 1946; Lin, 1978)

Cl
Br
N

The above product (13.40 g, no more than 59.3 mmol) was heated at reflux in 42 mL
phosphorus oxychloride for 2 hours. TLC indicated that the reaction was complete, and
the reaction was therefore poured gradually into ice water, followed by basification with
solid caustic potash (final volume 500 mL). After cooling, the resulting precipitate was
collected by vacuum filtration and allowed to air dry (10.82 g, ~75%, mp = 113.3114.8°C (lit. 111-112°C).
1

H NMR δ (ppm)(CHCl3-d): 8.80 (1 H, d, J = 4.73 Hz. Q-C2-H), 8.41 (1 H, d, J = 2.19
Hz, Q-C5-H), 8.02 (1 H, d, J = 8.96 Hz, Q-C8-H), 7.86 (1 H, dd, J = 8.96, 2.18 Hz, QC7-H), 7.53 (1 H, d, J = 4.73 Hz, Q-C3-H).

3-(6-bromoquinolin-4-ylamino)propanol

HN

OH

Br
N

4-chloro-6-bromoquinoline (5.00 g, 20.6 mmol) and 3-amino-1-propanol (15.50 mL, 203
mmol) were heated at 100°C in a Carius vessel for 3 hours, whereupon TLC indicated
that the reaction was complete. The hot reaction mixture was then poured into 200 mL
water, while stirring vigorously. After standing overnight, the resulting precipitate was
recovered by vacuum filtration, followed by air drying and partial recrystallization from
25 mL ethyl acetate (3.46 g of a beige solid, 60%, mp = 176.3-177.8°C).
1

H NMR δ (ppm)(DMSO-d6): 8.51 (1 H, s), 8.40 (1 H, d, J = 5.38 Hz), 7.71 (2 H, d, J =
1.24 Hz), 7.24 (1 H, br t, J = 5.27 Hz), 6.49 (1 H, d, J = 5.43 Hz), 4.58 (1 H, t, J = 5.08
Hz), 3.55 (2 H, m), 3.30-3.32 (water signal overlaps m, ~2 H), 1.82 (2 H, apparent p, J =
6.68 Hz).
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1

H NMR δ (ppm)(CHCl3-d): 8.54 (1 H, d, J = 5.38 Hz), 7.85-7.85 (2 H, m), 7.68 (1 H,
dd, J = 8.95, 2.12 Hz), 7.27 (solvent signal overlaps m, ~1 H), 6.44 (1 H, d, J = 5.40 Hz),
3.97 (2 H, t, J = 5.46 Hz), 3.48 (2 H, m), 2.05 (2 H, m).

3-(6-bromoquinolin-4-ylamino)propyl methanesulfonate

HN

OMs

Br
N

3-(6-bromoquinolin-4-ylamino)propanol (3.16 g, 11.2 mmol) and triethylamine (2.35
mL, 16.8 mmol) in dry THF (100 mL) were cooled to below 0°C on ice/salt.
Methanesulfonyl chloride (1.00 mL, 12.9 mmol) was added dropwise. After stirring for 1
hour on ice, TLC indicated that reaction was not complete; additional methanesulfonyl
chloride (0.15 mL, 1.9 mmol) were therefore added. After a further hour of stirring, TLC
indicated that reaction was complete. The reaction mixture was diluted with ethyl acetate
(10 mL) and washed with saturated sodium bicarbonate (100 mL). The aqueous layer
was then extracted with additional ethyl acetate (3 x 10 mL), and the pooled organic
layers were rinsed with water (10 mL), dried (MgSO4), and evaporated under reduced
pressure with warming to give the desired product as a pale yellow solid (3.32 g, 83%).
1

H NMR δ (ppm)(DMSO-d6): 8.52 (1 H, s), 8.43 (1 H, d, J = 5.41 Hz), 7.73 (2 H, m),
7.29-7.41 (1 H, m), 6.54 (1 H, d, J = 5.47 Hz), 4.35 (2 H, t, J = 6.21 Hz), 3.37-3.38 (water
signal overlaps m, ~2 H), 3.20 (3 H, s), 2.08 (2 H, m).

PL308: N-(3-(4-benzhydrylpiperazin-1-yl)propyl)-6-bromoquinolin-4-amine

HN

N

Br

N
N

PL308

3-(6-bromoquinolin-4-ylamino)propyl methanesulfonate (1.59 g, 4.43 mmol), N(diphenylmethyl)piperazine (1.17 g, 4.65 mmol), potassium carbonate (0.91 g, 6.7
mmol), and a catalytic amount of potassium iodide were heated in refluxing acetonitrile
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(15 mL) for 24 hours, whereupon substantial precipitate was noted to have formed. A
further 20 mL acetonitrile was added (to improve stirring), and reflux was continued for a
further 4 days. TLC then indicated that reaction was complete. The solvent was then
removed under reduced pressure with warming, and the residue was partitioned between
chloroform (30 mL) and water (40 mL). After separation, the aqueous layer was
extracted with further chloroform (3 x 7 mL), and the pooled organic layers were rinsed
with brine (10 mL), dried (MgSO4) and evaporated under reduced pressure with warming
to yield a pale brownish yellow solid. This material was partially recrystallized from 20
mL 95% ethanol to provide the desired product as fine, white crystals (1.58 g, 69%, mp =
209-210°C).
1

H NMR δ (ppm)(CHCl3-d): 8.50 (1 H, d, J = 5.32 Hz, Q-C2-H), 8.13 (1 H, d, J = 2.15
Hz, Q-C5-H), 7.83 (1 H, d, J = 8.97 Hz, Q-C8-H), 7.70 (2 H, br dd, J = 8.78, 2.31 Hz, QC7-H overlaps Q-C4-NH), 7.46-7.48 (4 H, m, Ph-CH ortho), 7.25-7.32 (solvent signal
overlaps m, ~4 H, Ph-CH-meta), 7.17 (2 H, m, Ph-CH para), 6.32 (1 H, d, J = 5.37 Hz,
Q-C3-H), 4.56 (1 H, s, CH(Ph)2), 3.34 (2 H, td, J = 5.67, 3.95 Hz, Q-NH-CH2CH2CH2),
2.63-2.65 (10 H, br s overlaps t, J = 5.23 Hz, Pip-CH2 x 4 and Q-NH-CH2CH2CH2), 1.92
(2 H, apparent p, J = 5.26 Hz, Q-NH-CH2CH2CH2).
13

C NMR δ (ppm)(CHCl3-d): 151.6 (Q-C2), 149.9 (Q), 147.2 (Q), 143.1 (Ph-C ipso),
132.2 (Q-C7), 131.7 (Q-C8), 128.6 (Ph-C meta), 127.9 (Ph-C ortho), 127.0 (Ph-C para),
123.2 (Q-C5), 120.5 (Q), 117.8 (Q), 98.8 (Q-C3), 75.9 (CH(Ph)2), 59.4 (Q-NHCH2CH2CH2), 54.2 (Pip-C-C-NCH(Ph)2), 52.0 (Pip-C-C-NCH(Ph)2), 45.1 (Q-NHCH2CH2CH2), 23.2 (Q-NH-CH2CH2CH2).
MS (ESI): m/z 515.18091 M + H (calculated 515.18049)
HPLC (method A, 15 min) tR = 11.02 min (84% pure).

PL309: 6-bromo-N-(3-(4-(pyridin-2-yl)piperazin-1-yl)propyl)quinolin-4-amine

HN

N

Br

N
N

PL309

N

3-(6-bromoquinolin-4-ylamino)propyl methanesulfonate (1.66 g, 4.62 mmol), 1-(2pyridyl)piperazine (0.78 g, 4.85 mmol), potassium carbonate (0.95 g, 6.93 mmol), and a
catalytic amount of potassium iodide were heated in refluxing acetonitrile (15 mL) for 24
hours. Due to the formation of a precipitate, stirring was poor, and a further 20 mL of
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acetonitrile was therefore added. Reflux was continued for a further 4 days. The solvent
was then removed under reduced pressure with warming, and the residue was partitioned
between chloroform (30 mL) and water (40 mL). After separation, the aqueous layer was
extracted with further chloroform (3 x 7 mL), and the pooled organic layers were rinsed
with brine (10 mL), dried (MgSO4) and evaporated under reduced pressure with warming
to yield a yellowish tan solid. This material was taken up in excess boiling 95% ethanol
and allowed to concentrate gradually at room temperature; the resulting pale golden
crystals were recovered by vacuum filtration (1.17 g, 57%, mp = 186.1-187.9°C).
1

H NMR δ (ppm)(CHCl3-d): 8.52 (1 H, d, J = 5.33 Hz), 8.22-8.22 (1 H, m), 8.10 (1 H, d,
J = 2.18 Hz), 7.79 (1 H, d, J = 8.93 Hz), 7.71 (1 H, br t, J = 4.09 Hz), 7.59 (1 H, dd, J =
8.92, 2.14 Hz), 7.51 (1 H, ddd, J = 8.53, 7.15, 2.04 Hz), 6.71 (1 H, d, J = 8.55 Hz), 6.66
(1 H, ddd, J = 7.17, 4.89, 0.84 Hz), 6.34 (1 H, d, J = 5.36 Hz), 3.81 (4 H, m), 3.41 (2 H,
td, J = 5.38, 0.01 Hz), 2.71-2.72 (6 H, m), 2.01 (2 H, apparent p, J = 5.40 Hz).
13

C NMR δ (ppm)(CHCl3-d): 159.7, 151.6, 149.7, 148.0, 147.1, 137.5, 132.1, 131.6,
123.1, 120.4, 117.8, 113.7, 107.3, 98.7, 59.3, 53.6, 45.2, 44.7, 23.4.
MS (ESI): m/z 426.12947 M + H (calculated 426.12878)
HPLC (method A) tR = 5.97 min (99% pure).

A.2.4: 7-bromoquinolines
3-carbethoxy-7-bromo-4-quinolone (Price, 1946)

O

O
OEt

Br

N
H

meta-Bromoaniline (11.92 g, 69.3 mmol) and diethyl ethoxymethylene malonate (14.00
mL, 69.3 mmol) in Dowtherm A (60 mL) were allowed to heat gradually, stirring, to
255°C, at which temperature the reaction was allowed to remain for 60 minutes. After
cooling, the reaction mixture was diluted with 30-60º petroleum æther, then vacuum
filtered, rinsing with additional petroleum æther, followed by acetone to give an offwhite, powdery solid (13.67 g, 67%).
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3-carboxy-7-bromo-4-quinolone (Price, 1946)

O

O
OH

Br

N
H

3-carbethoxy-7-bromo-4-quinolone (13.67 g, 46.2 mmol) in 130 mL of 10% caustic soda
was heated at reflux, stirring, for 1 hour, at which point all solid material had dissolved.
The hot reaction mixture was poured into 1.2 M muriatic acid (400 mL). The resulting
white precipitate was isolated by vacuum filtration. After air-drying, 13.00 g of a white
solid was obtained (containing residual water). The product was used without further
drying or purification in the next step.

7-bromo-4-quinolone (Price, 1946; Conroy, 1949)
O

Br

N
H

The above product (13.00 g, containing residual water) was heated in refluxing
Dowtherm A (200 mL) for 1 hour. After cooling, the reaction mixture was diluted with
35-60° petroleum æther and vacuum filtered to recover the solid product as a pearlescent,
tan solid (10.94 g, containing residual solvent; yield not calculated).
4-chloro-7-bromoquinoline (Price, 1946; Conroy, 1949)
Cl

Br

N

The above product (10.94 g, no more than 46.2 mmol) was heated at reflux in phosphorus
oxychloride (45 mL) for 2 hours. TLC indicated that the reaction was complete, and the
reaction was therefore poured gradually onto ice, followed by basification with solid
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caustic potash (final volume 500 mL). After cooling, the resulting precipitate was
collected by vacuum filtration and allowed to air dry. NMR indicated that this material
was 4-chloro-7-bromoquinoline containing approximately 10% 4-chloro-5bromoquinoline. The pure 7-bromo regioisomer was obtained by recrystallization from
95% ethanol (7.02 g, 42% from m-bromoaniline, mp = 107.3-108.9°C (lit. 105-106°C
(Conroy, 1949)).
1

H NMR δ (ppm)(CHCl3-d): 8.78 (1 H, d, J = 4.72 Hz), 8.32 (1 H, d, J = 1.96 Hz), 8.11
(1 H, d, J = 8.95 Hz), 7.74 (1 H, dd, J = 8.96, 1.96 Hz), 7.51 (1 H, d, J = 4.71 Hz).

3-(7-bromoquinolin-4-ylamino)propanol

HN

Br

OH

N

4-chloro-6-bromoquinoline (3.00 g, 12.4 mmol) and 3-amino-1-propanol (5.98 mL, 78.2
mmol) were heated at 100°C for 4.5 hours, whereupon TLC indicated that the reaction
was complete. The hot reaction mixture was poured into water (200 mL), while stirring
vigorously. After standing overnight, the resulting precipitate was recovered by vacuum
filtration, followed by air drying and partial recrystallization from 20 mL ethyl acetate
(2.29 g of a tan, crystalline solid, 66%, mp = 162.3-163.2°C).
1

H NMR δ (ppm)(DMSO-d6): 8.39 (1 H, d, J = 5.40 Hz), 8.18 (1 H, d, J = 9.01 Hz), 7.94
(1 H, d, J = 2.11 Hz), 7.55 (1 H, dd, J = 8.95, 2.14 Hz), 7.30 (1 H, t, J = 5.33 Hz), 6.48 (1
H, d, J = 5.46 Hz), 4.59 (1 H, t, J = 5.01 Hz), 3.55 (2 H, m), 3.30-3.32 (2 H, m), 1.82 (2
H, apparent p, J = 6.68 Hz).
1

H NMR δ (ppm)(CHCl3-d): 8.51 (1 H, d, J = 5.36 Hz), 8.12 (1 H, d, J = 2.02 Hz), 7.56
(1 H, d, J = 8.91 Hz), 7.46 (1 H, dd, J = 8.90, 2.03 Hz), 6.40 (1 H, d, J = 5.38 Hz), 5.92 (1
H, s), 3.97 (2 H, t, J = 5.42 Hz), 3.46-3.47 (2 H, m), 2.01-2.08 (2 H, m).
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3-(7-bromoquinolin-4-ylamino)propyl methanesulfonate

HN

Br

OMs

N

3-(7-bromoquinolin-4-ylamino)propanol (0.58 g, 2.06 mmol) and triethylamine (0.44
mL, 3.16 mmol) in dry tetrahydrofuran (70 mL) were cooled to below 0°C on ice/salt.
Methanesulfonyl chloride (0.18 mL, 2.32 mmol) was added dropwise. After stirring for
1.5 hours on ice, TLC indicated that reaction was not complete; additional
methanesulfonyl chloride (0.03 mL, 0.4 mmol) were therefore added. After a further 18
hours of stirring at room temperature, TLC indicated that reaction was complete. The
reaction mixture was washed with saturated sodium bicarbonate (100 mL), and the
aqueous layer was extracted with ethyl acetate (3 x 10 mL). The pooled organic layers
were rinsed with brine (15 mL), dried over MgSO4, and evaporated under reduced
pressure with warming to give the desired product as a cream-colored solid (0.68 g,
92%).
1

H NMR δ (ppm)(DMSO-d6): 8.41 (1 H, d, J = 5.40 Hz), 8.20 (1 H, d, J = 8.99 Hz), 7.96
(1 H, d, J = 2.10 Hz), 7.59 (1 H, dd, J = 8.94, 2.13 Hz), 7.38 (1 H, t, J = 5.38 Hz), 6.53 (1
H, d, J = 5.46 Hz), 4.35 (2 H, t, J = 6.19 Hz), 3.37-3.38 (water overlaps m, ~2 H), 3.20 (3
H, s), 2.08 (2 H, apparent p, J = 6.61 Hz).

PL310: N-(3-(4-benzhydrylpiperazin-1-yl)propyl)-7-bromoquinolin-4-amine

HN

N
N

Br

N

PL310

3-(7-bromoquinolin-4-ylamino)propyl methanesulfonate (0.68 g, 1.89 mmol), N(diphenylmethyl)piperazine (0.50 g, 1.98 mmol), potassium carbonate (0.39 g, 2.82
mmol), and a catalytic amount of potassium iodide were heated in refluxing acetonitrile
(25 mL) for 24 hours, whereupon TLC indicated that reaction was complete. The solvent
was removed under reduced pressure with warming, and the residue was partitioned
between chloroform (30 mL) and water (30 mL). After separation, the aqueous layer was
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extracted with further chloroform (3 x 7 mL), and the pooled organic layers were rinsed
with brine (10 mL), dried (MgSO4) and evaporated under reduced pressure with warming
to yield a tan, crystalline solid. Recrystallization from 95% ethanol provided the desired
product as lustrous, pale yellow crystals (0.29 g, 30%, mp = 185.5-187.3°C).
1

H NMR δ (ppm)(CHCl3-d): 8.48 (1 H, d, J = 5.34 Hz), 8.10 (1 H, d, J = 2.03 Hz), 7.70
(1 H, d, J = 8.93 Hz), 7.60 (1 H, br t, J = 4.05 Hz), 7.44 (4 H, d, J = 7.55 Hz), 7.29-7.37
(4 H, m), 7.26 (solvent signal overlaps m, ~3 H), 6.29 (1 H, d, J = 5.39 Hz), 4.44 (1 H, s),
3.34 (2 H, td, J = 5.79, 4.03 Hz), 2.64 (10 H, br s overlaps t, J = 5.58 Hz), 1.92 (2 H, m, J
= 5.37 Hz).
13

C NMR δ (ppm)(CHCl3-d): 152.1, 150.6, 149.4, 141.8, 132.0, 128.5, 128.2, 127.2,
127.1, 122.8, 122.5, 117.8, 98.5, 75.8, 59.0, 54.0, 51.5, 44.5, 23.2.
MS (ESI): m/z 515.18133 M + H (calculated 515.18049)
HPLC (method A) tR = 10.54 min (99% pure)

PL311: 7-bromo-N-(3-(4-(pyridin-2-yl)piperazin-1-yl)propyl)quinolin-4-amine

HN

N
N

Br

N

PL311

N

3-(6-bromoquinolin-4-ylamino)propyl methanesulfonate (1.42 g, 3.95 mmol), 1-(2pyridyl)piperazine (0.84 g, 5.15 mmol), potassium carbonate (0.81 g, 5.86 mmol), and
acetonitrile (16 mL) were heated at reflux for 5 days, whereupon substantial precipitate
was noted to have formed. The precipitate was recovered from the reaction mixture by
vacuum filtration, rinsing with 60 mL water; this precipitate was recrystallized from 95%
ethanol to yield the desired product as golden crystals (0.37 g, 22%, mp = 169.7171.4°C).
1

H NMR δ (ppm)(CHCl3-d): 8.51 (1 H, d, J = 5.35 Hz), 8.24-8.24 (1 H, m), 8.11 (1 H, d,
J = 2.03 Hz), 7.72 (1 H, d, J = 8.91 Hz), 7.54-7.54 (1 H, m), 7.36 (1 H, dd, J = 8.87, 2.04
Hz), 7.30 (1 H, br t, J = 4.21 Hz), 6.68-6.69 (2 H, m), 6.36 (1 H, d, J = 5.39 Hz), 3.67 (4
H, m), 3.42 (2 H, td, J = 5.46, 0.02 Hz), 2.65-2.70 (6 H, m), 2.00 (2 H, apparent p, J =
5.60 Hz), 1.93 (1 H, s).
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13

C NMR δ (ppm)(CHCl3-d): 159.3, 152.1, 150.5, 149.4, 148.1, 137.7, 132.1, 127.4,
122.9, 121.9, 117.8, 113.8, 107.1, 98.7, 58.6, 53.5, 45.4, 44.2, 23.7.
MS (ESI): m/z 426.12955 M + H (calculated 426.12878)
HPLC (method A) tR = 5.78 min (>99% pure).

A.2.5: 6-iodoquinolines
3-carbethoxy-6-iodo-4-quinolone (Price, 1946; Lin, 1978)
O

O

I

OEt
N
H

para-Iodoaniline (13.24 g, 60.5 mmol) and diethyl ethoxymethylene malonate (13.05 g,
60.4 mmol) in Dowtherm A (100 mL) were allowed to heat gradually, stirring, to 255°C,
at which temperature the reaction was allowed to remain for 25 minutes. After cooling,
the reaction mixture was diluted with 150 mL hexanes, then vacuum filtered, rinsing with
hexanes (200 mL) followed by acetone (70 mL) to give a lustrous, pearl-gray solid (19.37
g, 93%).

3-carboxy-6-iodo-4-quinolone (Price, 1946; Lin, 1978)
O
I

O
OH

N
H

3-carbethoxy-6-iodo-4-quinolone (19.37 g, 56.5 mmol) in 250 mL of 10% caustic soda
was heated just under reflux, stirring, for 24 hours. At the end of this time, a small
amount of undissolved solid was removed by vacuum filtration (0.53 g after drying, this
was presumed to be unsaponified starting material). The filtrate was made acidic by
addition of concentrated muriatic acid. The resulting pure white precipitate was recovered
from the pale yellow filtrate by vacuum filtration. After air-drying, 18.80 g of product
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was obtained (containing residual water). This material was used without further drying
or purification in the next step.
1

H NMR δ (ppm)(DMSO-d6): 15.04 (1 H, br s), 13.58 (1 H, s), 8.92 (1 H, s), 8.57 (1 H, d,
J = 2.00 Hz), 8.18 (1 H, dd, J = 8.73, 2.03 Hz), 7.65 (1 H, d, J = 8.73 Hz).

6-iodo-4-quinolone (Price, 1946; Lin, 1948)
O
I
N
H

The above product (18.80 g, containing residual water) was heated in Dowtherm A (125
mL) at 255°C for 25 minutes. After cooling, NMR indicated that the reaction had not
gone to completion; it was therefore heated for an additional 25 minutes at 255°C. After
cooling, the reaction mixture was diluted with 100 mL 35-60° petroleum æther and
vacuum filtered to recover the solid product (15.70 g, presumed to contain residual
solvent; yield not calculated). This was used without purification in the next step.

4-chloro-6-iodoquinoline (Price, 1946; Lin, 1978)

Cl
I
N

The above product (15.62 g, presumed to contain residual solvent) was heated in
phosphorus oxychloride (60 mL, 640 mmol) for 1 hour at 100ºC, followed by 20 hours at
70ºC, and finally 2 hours at 100ºC. TLC indicated that the reaction was complete, and
the dark reaction mixture was therefore poured gradually onto ice, followed by
basification with concentrated caustic soda. After cooling, the aqueous mixture (diluted
to 2.7 L) was divided into three portions. Each portion was extracted with chloroform
(50 mL, then 5 x 15 mL), and the pooled organic layers were dried (MgSO4) and
evaporated under reduced pressure with warming to yield an off-white, powdery solid
(14.24 g, 81% from starting aniline, mp 137-139ºC (lit. 138-139.5ºC (Lin, 1978)).
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1

H NMR δ (ppm)(CHCl3-d): 8.78 (1 H, d, J = 4.69 Hz, Q-C2-H), 8.62 (1 H, d, J = 1.96
Hz, Q-C5-H), 8.02 (1 H, dd, J = 8.83, 1.94 Hz, Q-C7-H), 7.84 (1 H, d, J = 8.83 Hz, QC8-H), 7.50 (1 H, d, J = 4.69 Hz, Q-C3-H).

3-(6-iodoquinolin-4-ylamino)propanol

HN

OH

I
N

4-chloro-6-iodoquinoline (7.00 g, 24.2 mmol) and 3-amino-1-propanol (10.90 g, 145
mmol) were heated at 95°C in a Carius vessel for 24 hours. The reaction mixture still
contained solid material. Temperature was increased to 140°C for 1 hour, with no visible
change, and then to 160°C. After a further hour, no solid was visible, and TLC indicated
that the reaction was complete. The reaction was allowed to cool to 110°C, and the hot
reaction mixture was then poured into 200 mL water. After standing 1 hour, the resulting
precipitate was recovered by vacuum filtration, followed by air-drying (7.55 g of a
yellow solid, 95%, mp = 177.0-179.4°C).
1

H NMR δ (ppm)(DMSO-d6): 8.65 (1 H, d, J = 1.91 Hz), 8.38 (1 H, d, J = 5.37 Hz), 7.84
(1 H, dd, J = 8.80, 1.87 Hz), 7.54 (1 H, d, J = 8.80 Hz), 7.24 (1 H, br t, J = 5.27 Hz), 6.47
(1 H, d, J = 5.43 Hz), 4.58 (1 H, t, J = 5.07 Hz), 3.54 (2 H, m), 3.26-3.33 (2 H, m), 1.82
(2 H, m).

3-(6-iodoquinolin-4-ylamino)propyl methanesulfonate

HN

OMs

I
N

3-(6-iodoquinolin-4-ylamino)propanol (3.50 g, 10.7 mmol) and triethylamine (2.23 mL,
16.1 mmol) in 100 mL dry tetrahydrofuran were cooled to below 0°C on ice/salt.
Methanesulfonyl chloride (0.96 mL, 12.3 mmol) was added dropwise. After stirring for 3
hours on ice, TLC indicated that reaction was not complete. Additional methanesulfonyl
chloride (0.15 mL, 1.9 mmol) was added. After a further 30 minutes, the reaction was
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sealed and refrigerated for 18 hours. TLC then indicated that no quinoline starting
material remained. The reaction mixture was diluted with ethyl acetate (30 mL) and
shaken with saturated NaHCO3 (45 mL). After separation, the organic layer was washed
with water (3 x 10 mL), then dried (MgSO4) and evaporated under reduced pressure with
warming (extract A). The initial aqueous layer was extracted with further ethyl acetate (3
x 15 mL), and this ethyl acetate was pooled, dried (MgSO4), and also evaporated under
reduced pressure with warming (extract B). Comparison of extracts A and B indicated
that neither contained a significant amount of triethylamine, and that extract B contained
6% of the total yield (i.e. additional extractions of the aqueous layer increase yield
without increasing the amount of triethylamine contamination of the product, and it is not
worthwhile to rinse the organic layers with water to remove residual triethylamine).
Extracts A and B were combined (a yellow solid, 3.92 g, 90%).
1

H NMR δ (ppm)(DMSO-d6): 8.65 (1 H, d, J = 1.91 Hz), 8.41 (1 H, d, J = 5.36 Hz), 7.86
(1 H, dd, J = 8.80, 1.86 Hz), 7.55 (1 H, d, J = 8.80 Hz), 7.29 (1 H, s), 6.51 (1 H, d, J =
5.42 Hz), 4.35 (2 H, t, J = 6.21 Hz), 3.33 (water overlaps m, ~2 H), 3.20 (3 H, s), 2.08 (2
H, apparent p, J = 6.61 Hz).

PL317: N-(3-(4-benzhydrylpiperazin-1-yl)propyl)-6-iodoquinolin-4-amine

HN

N

I

N
N
PL 317

3-(6-iodo quinolin-4-ylamino)propyl methanesulfonate (1.96 g, 4.82 mmol), N(diphenylmethyl)piperazine (1.28 g, 5.07 mmol), potassium carbonate (1.00 g, 7.23
mmol), and a catalytic amount of potassium iodide were heated in refluxing acetonitrile
(50 mL) for 24 hours. TLC then indicated that reaction was complete. The solvent was
removed by evaporation under reduced pressure with warming, diluting with 35 mL
water at the end. This material was then extracted with ethyl acetate (25 mL). Some
material remained insoluble, and so the aqueous layer was extracted with
dichloromethane (25 mL); residual undissolved material was removed by vacuum
filtration. The aqueous layer was then extracted with a further ethyl acetate (3 x 10 mL),
and the pooled organic layers were dried (MgSO4) and evaporated under reduced
pressure with warming to yield an ochre solid. The insoluble material from extraction
was dissolved in excess boiling 95% ethanol and allowed to evaporate gradually to 200
mL (at room temperature); filtration afforded the desired product as large, lustrous,
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golden crystals. The mother liquor was further concentrated to yield a second crop of
crystals (1.37 g in total, 51%, mp = 208-210°C ).
1

H NMR δ (ppm)(CHCl3-d): 8.50 (1 H, d, J = 5.34 Hz), 8.25 (1 H, d, J = 1.89 Hz), 7.87
(1 H, dd, J = 8.87, 1.85 Hz), 7.68 (1 H, d, J = 8.87 Hz), 7.51 (1 H, br t, J = 4.04 Hz), 7.467.48 (4 H, m), 7.27-7.27 (solvent peak overlaps m, ~ 4 H), 7.14-7.21 (2 H, m), 6.32 (1 H,
d, J = 5.39 Hz), 4.68 (1 H, s), 3.34 (2 H, td, J = 5.68, 4.01 Hz), 2.63 (10 H, br s overlaps t,
J = 5.25 Hz), 1.92 (2 H, apparent p, J = 5.29 Hz).
13

C NMR δ (ppm)(CHCl3-d): 151.7, 149.6, 147.6, 143.1, 137.7, 131.8, 129.2, 128.6,
127.9, 127.0, 121.2, 99.0, 89.1, 75.5, 59.4, 54.3, 52.0, 45.1, 23.3.
MS (ESI): m/z 563.16755 M + H (calculated 563.16662)
HPLC (method A) tR = 10.91 min (99% pure).

PL318: 6-iodo-N-(3-(4-(pyridin-2-yl)piperazin-1-yl)propyl)quinolin-4-amine

HN

N

I

N
N

PL 318

N

3-(6-iodoquinolin-4-ylamino)propyl methanesulfonate (1.96 g, 4.82 mmol), 1-(2pyridyl)piperazine (0.87 g, 5.33 mmol), and potassium carbonate (1.00 g, 7.23 mmol)
were heated in refluxing acetonitrile (50 mL) for 28 hours. The solvent was removed
under reduced pressure with warming, and the residue was diluted with water (35 mL)
and filtered. The solid material was dissolved in excess boiling solvent (25% ethanol,
75% ethyl acetate) and allowed to concentrate slowly at room temperature to 22 mL.
Filtration afforded the desired product as small, amber crystals (1.25 g, 55%, mp = 193.5194.5°C).
1

H NMR δ (ppm)(CHCl3-d): 8.51 (1 H, d, J = 5.34 Hz), 8.27 (1 H, d, J = 1.91 Hz), 8.208.22 (1 H, m), 7.75 (1 H, dd, J = 8.85, 1.88 Hz), 7.71 (1 H, t, J = 4.02 Hz), 7.65 (1 H, d, J
= 8.84 Hz), 7.49 (1 H, ddd, J = 8.56, 7.14, 2.02 Hz), 6.73 (1 H, d, J = 8.57 Hz), 6.64 (1 H,
dd, J = 7.14, 4.92 Hz), 6.33 (1 H, d, J = 5.38 Hz), 3.84 (4 H, m), 3.40 (2 H, td, J = 5.73,
4.03 Hz), 2.70-2.71 (6 H, m), 2.00 (2 H, apparent p, J = 5.35 Hz).
13

C NMR δ (ppm)(CHCl3-d): 159.6, 151.7, 149.5, 147.9, 147.5, 137.5, 137.4, 131.6,
129.3, 121.0, 113.6, 107.4, 98.7, 88.8, 59.4, 53.7, 45.2, 44.8, 23.3.
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MS (ESI): m/z 474.11508 M + H (calculated 474.11492)
HPLC (method A) tR = 6.55 min (>99% pure).

A.2.6: 7-iodoquinolines
3-carbethoxy-5- and 7-iodo-4-quinolone (Price, 1946; Conroy, 1949)
I

O

O

O
OEt

O
OEt

+

N
H

I

N
H

meta-Iodoaniline (11.14 g, 52.1 mmol) and diethyl ethoxymethylene malonate (10.28
mL, 51.3 mmol) in Dowtherm A (125 mL) were allowed to heat gradually, stirring, to
255°C, at which temperature the reaction was allowed to remain for 30 minutes. After
cooling, the reaction mixture was vacuum filtered (without dilution), rinsing with 10 mL
Dowtherm A, then with 35-60° petroleum æther (200 mL), and finally with acetone (70
mL) to give an off-white, powdery solid (19.25 g). NMR indicated that the 7- and 5iodo regioisomers were present in a proportion of approximately 9:1. This material was
used without purification in the ensuing reactions.
5- and 7- iodo-3-carboxy-4-quinolone (Price, 1946; Conroy, 1949)
I

O

O

O
OEt

N
H

O
OEt

+
I

N
H

The above product (19.25 g, ≤ 52.1 mmol) in 450 mL of 10% caustic soda was allowed to
reflux, stirring, for 3 hours, at which point all solid material had dissolved. After cooling
to room temperature, some solid appeared, and so the reaction was reheated before being
poured into 450 mL deionized water and acidified with concentrated muriatic acid. After
cooling, the resulting white precipitate was recovered by vacuum filtration (14.41 g, used
without analysis in the ensuing reaction).
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5- and 7-iodo-4-quinolone (Price, 1946; Conroy, 1949)

I

O

O

+
I

N
H

N
H

Without further drying, the above product (14.41 g) was heated in Dowtherm A (75 mL)
at 255°C for 50 minutes. After cooling, the reaction mixture was diluted with 100 mL
35-60° petroleum æther and vacuum filtered. The solid product was used without
analysis in the next reaction.
4-chloro-7-iodoquinoline (Price, 1946; Conroy, 1949)

Cl

I

N

Phosphorus oxychloride (30 mL, 320 mmol) was cautiously added to the product from
the above reaction (12.43 g). The mixture was heated at 105°C for 4 hours, followed by
heating at 70°C for 14 hours. After cooling, the reaction mixture was poured gradually
into ice water (700 mL) and then made basic (pH 10) with solid caustic soda. The
resulting inhomogeneous mixture was diluted with water to 1.1 L and extracted in three
equal portions. Each was extracted with chloroform (100 mL, followed by 3 x 30 mL),
and the combined organic layers were dried (MgSO4) and evaporated under reduced
pressure with warming to yield a pale brown solid (9.60 g, 64% from the aniline, mp =
100.4-102.3°C (lit. 101-102°C (Conroy, 1949)). NMR indicated that none of the 5-iodo
regioisomer was present.

3-(7-iodoquinolin-4-ylamino)propanol

HN

I

OH

N
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4-chloro-7-iodoquinoline (3.00 g, 10.4 mmol) and 3-amino-1-propanol (4.76 mL, 62.2
mmol) were heated at 85°C in a Carius vessel for 20 hours. TLC indicated that the
reaction was complete, and so the hot reaction mixture was poured into 100 mL water
(stirring well). After standing 1 hour, the resulting precipitate was recovered by vacuum
filtration, followed by air drying (3.28 g of an ochre solid, 96%, mp = 172.1-173.9°C).
1

H NMR δ (ppm)(DMSO-d6): 8.36 (1 H, d, J = 5.38 Hz), 8.15 (1 H, d, J = 1.83 Hz), 8.00
(1 H, d, J = 8.86 Hz), 7.68 (1 H, dd, J = 8.78, 1.88 Hz), 7.26 (1 H, br t, J = 5.37 Hz), 6.48
(1 H, d, J = 5.44 Hz), 4.59 (1 H, t, J = 5.04 Hz), 3.54 (2 H, m), 3.27-3.32 (water signal
overlaps m, ~2 H, m), 1.81 (2 H, apparent p, J = 6.66 Hz).
1

H NMR δ (ppm)(CHCl3-d): 8.50 (1 H, d, J = 5.35 Hz), 8.36 (1 H, d, J = 1.79 Hz), 7.64
(1 H, dd, J = 8.78, 1.81 Hz), 7.41 (1 H, d, J = 8.81 Hz), 6.40 (1 H, d, J = 5.37 Hz), 3.96 (2
H, t, J = 5.43 Hz), 3.47 (2 H, m), 2.04-2.04 (2 H, m).
MS (ESI): m/z 329.01435 M + H (calculated 329.01496)
HPLC (method A) tR = 8.66 min (98% pure).

3-(7-iodoquinolin-4-ylamino)propyl methanesulfonate

HN

I

OMs

N

3-(7-iodoquinolin-4-ylamino)propanol (1.00 g, 3.05 mmol) and triethylamine (0.64 mL,
4.6 mmol) in 100 mL dry tetrahydrofuran were cooled to 5°C in an ice bath.
Methanesulfonyl chloride (0.26 mL, 3.4 mmol) was added dropwise. After stirring for 30
minutes, TLC indicated that reaction was not complete. Additional triethylamine (0.27
mL, 1.9 mmol) and methanesulfonyl chloride (0.07 mL, 0.9 mmol) were added. After a
further 45 minutes, TLC indicated that reaction was complete. The reaction mixture was
diluted with 25 mL ethyl acetate and shaken with 30 mL saturated NaHCO3. The
aqueous layer was diluted with 15 mL water to dissolve a small amount of precipitate that
formed. After separation of the layers, the aqueous layer was extracted with 3 x 10 mL
ethyl acetate, and the pooled organic layers were dried (MgSO4) and evaporated under
reduced pressure with warming to yield a grayish yellow solid, containing residual ethyl
acetate and triethylamine. This material was used without purification in the ensuing
reaction.
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1

H NMR δ (ppm)(CHCl3-d): 8.50 (1 H, d, J = 5.36 Hz), 8.38 (1 H, d, J = 1.79 Hz), 7.69
(1 H, dd, J = 8.80, 1.80 Hz), 7.50 (1 H, d, J = 8.84 Hz), 6.44 (1 H, d, J = 5.40 Hz), 5.56 (1
H, s), 4.41 (2 H, t, J = 5.66 Hz), 3.57 (2 H, m), 3.06 (3 H, s), 2.16-2.18 (2 H, m). Minor
peaks due to triethylamine and ethyl acetate were also present.
PL392: 7-iodo-N-(3-(4-(pyridin-2-yl)piperazin-1-yl)propyl)quinolin-4-amine

HN

N
N

I

N

PL392

N

3-(7-iodoquinolin-4-ylamino)propyl methanesulfonate (no more than 2.2 mmol,
containing residual triethylamine and ethyl acetate), 1-(2-pyridyl)piperazine (0.38 g, 2.3
mmol), and potassium carbonate (0.45 g, 2.2 mmol) were heated in refluxing acetonitrile
(25 mL) for 13 hours. The reaction mixture was diluted with 5 mL water, and the solvent
was removed under reduced pressure with warming; the residue was partitioned between
chloroform (150 mL) and water (125 mL). After separation, the aqueous layer was
extracted with additional chloroform (3 x 10 mL), and the pooled organic layers were
dried (MgSO4) and evaporated under reduced pressure with warming to yield a golden
oil. This was recrystallized from 20 mL ethyl acetate/95% ethanol (9:1) to yield the
desired product as yellow crystals (0.58 g, 56% from 3-(7-iodoquinolin-4ylamino)propanol, mp = 176.5-177.1°C).
1

H NMR δ (ppm)(CHCl3-d): 8.50 (1 H, d, J = 5.34 Hz), 8.35 (1 H, d, J = 1.74 Hz), 8.238.25 (1 H, m), 7.57 (1 H, d, J = 8.80 Hz), 7.54-7.54 (2 H, m), 7.28 (1 H, br t, J = 4.42
Hz), 6.67-6.71 (2 H, m), 6.36 (1 H, d, J = 5.38 Hz), 3.67 (4 H, m), 3.41 (2 H, td, J = 5.97,
4.24 Hz), 2.67-2.68 (6 H, m), 2.00 (2 H, apparent p, J = 5.61 Hz).
13

C NMR δ (ppm)(CHCl3-d): 159.3, 151.9, 150.5, 149.5, 148.1, 138.8, 137.7, 132.7,
121.8, 118.3, 113.8, 107.2, 107.1, 98.8, 94.8, 58.7, 53.5, 45.4, 44.3, 23.7.
MS (ESI): m/z 474.11539 M + H (calculated 474.11492)
HPLC (method A) tR = 6.43 min (97% pure).
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A.3.: Nitroquinolines, trifluoromethyl quinolines, and 7-chloro-2-methylquinolines
A.3.1: 6-nitroquinolines
3-carbethoxy-6-nitro-4-quinolone (Price, 1946; Riegel, 1946)

O

O

O2N

OEt
N
H

para-Nitroaniline (5.00 g, 36.2 mmol) and diethyl ethoxymethylene malonate (7.25 mL,
36.2 mmol) were heated on a boiling water bath for 40 minutes. Crystallization of the
crude reaction mixture from methanol afforded the condensation product as greenish-gray
crystals. This material was heated in refluxing Dowtherm A (125 mL) for 30 minutes.
After cooling, the reaction mixture was diluted with 35-60° petroleum æther (200 mL)
and vacuum filtered to recover the solid product (6.96 g, 74% yield).

3-carboxy-6-nitro-4-quinolone (Price, 1946; Riegel, 1946)
O
O2N

O
OH

N
H

3-carbethoxy-6-nitro-4-quinolone (6.96 g, 26.5 mmol) in 55 mL of 10% caustic soda was
allowed to reflux, stirring, for 30 minutes, at which point all solid material had dissolved.
After partial cooling, the brilliant orange, semisolid reaction mixture was poured into
water (200 mL); after heating to 60°C to dissolve the solid, the mixture was acidified
with 10% muriatic acid. The resulting tan precipitate was isolated by vacuum filtration
(the filtrate was now colorless). After air-drying, the product was used without further
purification in the ensuing reaction.
1

H NMR δ (ppm)(DMSO-d6): 14.59 (1 H, br s, COOH), 13.78 (1 H, br s, Q-N1-H), 9.05
(1 H, s, Q-C2-H), 8.98 (1 H, d, J = 2.64 Hz, Q-C5-H), 8.63 (1 H, dd, J = 9.16, 2.66 Hz,
Q-C7-H), 8.02 (1 H, d, J = 9.16 Hz, Q-C8-H).
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6-nitro-4-quinolone (Price, 1946; Baker, 1946)
O
O2N
N
H

3-carboxy-6-nitro-4-quinolone from the above reaction was decarboxylated in two
portions as follows. Approximately half of the above product was heated in Dowtherm A
(100 mL) at 255°C for 30 minutes. After cooling, the reaction mixture was diluted with
100 mL 35-60° petroleum æther and vacuum filtered. The remaining 3-carboxy-6-nitro4-quinolone was treated in the same manner and the products from the two reactions were
combined (4.77 g, 95% from 3-carbethoxy-6-nitro-4-quinolone).
1

H NMR δ (ppm)(DMSO-d6): 12.28 (1 H, br d, J = 5.26 Hz, Q-N1-H), 8.84 (1 H, d, J =
2.71 Hz, Q-C5-H), 8.42 (1 H, dd, J = 9.15, 2.73 Hz, Q-C7-H), 8.05 (1 H, dd, J = 7.52,
5.24 Hz, Q-C2-H), 7.73 (1 H, d, J = 9.16 Hz, Q-C8-H), 6.19 (1 H, d, J = 7.53 Hz, Q-C3H).

4-chloro-6-nitroquinoline (Price, 1946; Baker, 1946)

Cl
O2N
N

6-nitro-4-quinolone (4.77 g, 25.1 mmol) was heated in 25 mL phosphorus oxychloride
for 1.5 hours at reflux. Upon cooling to room temperature, the reaction mixture was
poured gradually onto ice (stirring vigorously). The aqueous mixture (400 mL) was then
extracted (without basifying) with four 50 mL portions of DCM, and the pooled organic
layers were rinsed with 50 mL brine. The yellow organic layers contained a black
precipitate. This was removed by vacuum filtration, followed by drying of the filtrate
over MgSO4 and evaporation under reduced pressure with warming to yield a cream
colored powder with an odor resembling that of 4,7-dichloroquinoline (3.35 g, 64%, mp
= 138.5-144.5°C (lit. 141-141.5°C (Baker, 1946)). Note: It is probably that the yield
could have been improved if the aqueous mixture had been basified before extraction.
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1

H NMR δ (ppm)(CHCl3-d): 9.21 (1 H, d, J = 2.52 Hz, Q-C5-H), 8.97 (1 H, d, J = 4.72
Hz, Q-C2-H), 8.55 (1 H, dd, J = 9.23, 2.51 Hz, Q-C7-H), 8.29 (1 H, d, J = 9.22 Hz, QC8-H), 7.67 (1 H, d, J = 4.71 Hz, Q-C3-H).

3-(6-nitroquinolin-4-ylamino)propanol

HN

OH

O2N
N

4-chloro-6-nitroquinoline (2.82 g, 13.5 mmol) and 3-amino-1-propanol (15.0 mL, 196
mmol) were heated at 90°C for 1.5 hours, followed by further heating at 130°C for 20
minutes. TLC then indicated that the reaction was complete. The hot reaction mixture
was poured into 200 mL water, gradually and with good stirring. Vacuum filtration,
followed by air-drying, afforded the desired product as a sparkling, ochre solid (2.76 g,
83%).
1

H NMR δ (ppm)(DMSO-d6): 9.37 (1 H, d, J = 2.52 Hz, Q-C5-H), 8.51 (1 H, d, J = 5.56
Hz, Q-C2-H), 8.31 (1 H, dd, J = 9.25, 2.48 Hz, Q-C7-H), 7.95 (1 H, br t, J = 5.25 Hz, QC4-NH), 7.90 (1 H, d, J = 9.25 Hz, Q-C8-H), 6.61 (1 H, d, J = 5.61 Hz, Q-C3-H), 4.59 (1
H, t, J = 5.07 Hz, OH), 3.55 (2 H, td, J = 6.13, 5.06 Hz, Q-NHCH2CH2CH2), 3.38 (2 H,
td, J = 7.04, 5.39 Hz, Q-NHCH2CH2CH2), 1.84 (2 H, apparent p, J = 6.64 Hz, QNHCH2CH2CH2).

3-(6-nitroquinolin-4-ylamino)propyl methanesulfonate

HN

OMs

O2N
N

3-(6-nitroquinolin-4-ylamino)propanol (2.76 g, 11.2 mmol) and triethylamine (2.36 mL,
16.9 mmol) in 100 mL dry chloroform were cooled to below 0°C on ice/salt.
Methanesulfonyl chloride (1.01 mL, 13.0 mmol) was added dropwise. After stirring for
an hour on ice, additional methanesulfonyl chloride (0.5 mL, 6.43 mmol) was added.
After a further 30 minutes, TLC indicated that no quinoline starting material remained.
The reaction was vacuum filtered to remove a precipitate, and the filtrate was shaken
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with 45 mL saturated NaHCO3. After separation, the aqueous layer was extracted with
further chloroform (3 x 10 mL), and the pooled organic layers were washed with 10 mL
brine, dried (MgSO4), and evaporated under reduced pressure with warming. This
afforded a bright yellow semisolid with the odor of triethylamine (approximately 3 g,
yield not calculated). This material was used without further purification.
1

H NMR δ (ppm)(DMSO-d6): 9.38 (1 H, d, J = 2.53 Hz, Q-C5-H), 8.55 (1 H, d, J = 5.55
Hz, Q-C2-H), 8.33 (1 H, dd, J = 9.24, 2.48 Hz, Q-C7-H), 7.97 (1 H, t, J = 5.25 Hz, Q-C4NH), 7.92 (1 H, d, J = 9.24 Hz, Q-C8-H), 6.65 (1 H, d, J = 5.61 Hz, Q-C5-H), 4.37 (2 H,
t, J = 6.20 Hz, CH2CH2CH2OMs), 3.44 (2 H, td, J = 6.90, 5.34 Hz, CH2CH2CH2OMs),
3.21 (3 H, s, CH3), 2.11 (2 H, apparent p, J = 6.58 Hz, CH2CH2CH2OMs). Minor peaks
due to the presence of residual triethylamine were also present.
PL282: 6-nitro-N-(3-(4-(pyridin-2-yl)piperazin-1-yl)propyl)quinolin-4-amine

HN

N

O2N

N
N

PL 282

N

3-(6-nitroquinolin-4-ylamino)propyl methanesulfonate (0.36 g, 1.1 mmol), 1-(2pyridyl)piperazine (0.23 g, 1.4 mmol), and potassium carbonate (0.23 g, 1.7 mmol) in
acetonitrile (15 mL) were allowed to reflux for 3 days. The reaction mixture was vacuum
filtered, rinsing extensively with water, and then with 1 mL 95% ethanol. The canaryyellow, crystalline solid thus obtained proved to be the desired product (0.24 g, 55%, mp
= 175.5-177.4°C).
1

H NMR δ (ppm)(CHCl3-d): 8.88 (1 H, d, J = 2.48 Hz), 8.63 (1 H, d, J = 5.50 Hz), 8.218.21 (1 H, m), 8.00 (1 H, d, J = 9.25 Hz), 7.92 (1 H, br t, J = 3.99 Hz), 7.52 (1 H, ddd, J =
8.56, 7.15, 2.01 Hz), 6.70 (1 H, d, J = 8.56 Hz), 6.66 (1 H, dd, J = 7.13, 4.94 Hz), 6.46 (1
H, d, J = 5.54 Hz), 3.80 (4 H, m), 3.47 (2 H, td, J = 5.83, 4.10 Hz), 2.72 (6 H, m), 2.05 (2
H, apparent p, J = 5.44 Hz).
13

C NMR δ (ppm)(CHCl3-d): 159.5, 154.2, 152.0, 151.4, 147.9, 143.5, 137.6, 131.3,
122.6, 118.0, 117.9, 113.6, 107.2, 99.7, 59.1, 53.8, 45.0, 44.9, 23.3.
MS (ESI): m/z 393.20411M + H (calculated 393.20335)
HPLC (method A) tR = 2.97 min (89% pure). Additional peaks elute at 1.66 min, 7%,
and 2.20 min, 3%.
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A.3.2: 2-trifluoromethylquinolines
2-trifluoromethyl-4-quinolone (Conrad, 1887; Conrad, 1891; Reynolds, 1955;
Steinacker Dey, 1965)

O

N
H

CF 3

Ethyl-4,4,4-trifluoroacetoacetate (13.0 g, 70.6 mmol) and aniline (6.44 mL, 70.7 mmol)
were allowed to heat at 125ºC in a retort for 1.5 hours. TLC and NMR indicated that
reaction was not complete. The reaction mixture was combined with benzene (100 mL)
and a catalytic amount of para-toluenesulfonic acid and allowed to heat for 2 hours at
reflux in a flask equipped with a Dean and Stark water separator topped with a watercooled Liebig condenser. TLC then indicated that reaction was complete. The solvent
was therefore removed by evaporation under reduced pressure with warming. The
residue was allowed to heat in Dowtherm A (110 mL) to 255ºC, and allowed to remain at
this temperature for 70 minutes. The cooled reaction mixture was diluted with 35-60º
petroleum æther (150 mL), and the solid product was recovered by vacuum filtration
(6.28 g of a cream-colored solid, 42%).

4-chloro-2-(trifluoromethyl)quinoline (Steinacker Dey, 1965)

Cl

N

CF 3

2-trifluoromethyl-4-quinolone (6.00 g, 22.2 mmol) and phosphorus oxychloride (45.0
mL, 483 mmol) were allowed to heat at 110°C for 75 minutes. After cooling, the reaction
mixture was gradually poured into ice water (200 mL, adding additional ice as needed to
control the resulting exothermic reaction) with vigorous stirring. After resting 18 hours,
the aqueous mixture was made basic by the addition of solid caustic potash. Upon
cooling, the solid product was recovered by vacuum filtration (5.53 g). This material was
recrystallized from 95% ethanol (17 mL) to provide the desired product as tan crystals
with a flowery scent (5.13 g, 79%, mp = 32.9-34.1°C (lit. 38-40°C (Steinacker Dey,
1965)).
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1

H NMR δ (ppm)(CHCl3-d): 8.31 (1 H, dd, J = 8.45, 1.36 Hz), 8.26 (1 H, d, J = 8.51 Hz),
7.89 (1 H, ddd, J = 8.51, 6.91, 1.44 Hz), 7.84 (1 H, s), 7.79 (1 H, ddd, J = 8.44, 6.92, 1.22
Hz).
19

F NMR δ (ppm)(CHCl3-d): -67.6.

3-(2-(trifluoromethyl)quinolin-4-ylamino)propanol

HN

N

OH

CF 3

4-chloro-2-(trifluoromethyl)quinoline (2.65 g, 11.4 mmol) and 3-amino-1-propanol (7.00
mL, 91.5 mmol) were allowed to heat at 90°C for 1 hour. The hot reaction mixture was
then poured into 100 mL water, stirring vigorously. After standing 1 hour, the resulting
precipitate was recovered by vacuum filtration, followed by air-drying (2.99 g of a white
powder, 97%, mp = 162.3-163.7°C).
1

H NMR δ (ppm)(DMSO-d6): 8.31 (1 H, d, J = 8.47 Hz), 7.89 (1 H, d, J = 8.42 Hz), 7.697.77 (2 H, m), 7.56 (1 H, t, J = 7.64 Hz), 6.76 (1 H, s), 4.62 (1 H, t, J = 5.07 Hz), 3.55 (2
H, m), 3.42 (2 H, m), 1.80-1.88 (2 H, m).
19

F NMR δ (ppm)(DMSO-d6): -66.6.

3-(5-chloro-2-trifluoromethylquinolin-4-ylamino)propyl methanesulfonate

HN

N

OMs

CF 3

3-(2-trifluoromethylquinolin-4-ylamino)propanol (2.58 g, 9.5 mmol) and triethylamine
(1.99 mL, 14 mmol) in anhydrous tetrahydrofuran (100 mL) were cooled to below 0°C
on ice/salt. Methanesulfonyl chloride (0.85 mL, 11 mmol) was added dropwise. After
stirring for 90 minutes on ice, TLC indicated that the reaction was complete. The
reaction mixture was diluted with ethyl acetate (20 mL) and washed with saturated
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sodium bicarbonate (30 mL). The aqueous layer was extracted with ethyl acetate (3 x 7
mL), and the pooled organic layers were rinsed with brine (10 mL), dried (MgSO4), and
evaporated under reduced pressure with warming to give a tan solid (2.73 g, 82%).
1

H NMR δ (ppm)(DMSO-d6): 8.32 (1 H, d, J = 1.63 Hz), 7.90 (1 H, d, J = 8.43 Hz), 7.737.75 (2 H, m), 7.57-7.58 (1 H, m), 6.79 (1 H, s), 4.36 (2 H, t, J = 6.16 Hz), 3.48 (2 H, m),
3.20 (2 H, s), 2.06-2.16 (2 H, m).

PL147 (PL301): N-(3-(4-benzhydrylpiperazin-1-yl)propyl)-2trifluoromethylquinolin-4-amine

HN

N
N

N

CF 3
PL147

3-(2-trifluoromethylquinolin-4-ylamino)propyl methanesulfonate (1.36 g, 3.9 mmol), 1(diphenylmethyl)piperazine (1.03 g, 4.1 mmol), and potassium carbonate (0.81 g, 5.9
mmol) were heated at reflux in anhydrous acetonitrile (22 mL) for 18 hours. TLC then
indicated that reaction was complete. The solvent was removed under reduced pressure
with warming, and the residue was partitioned between chloroform (25 mL) and water
(25 mL). After separation, the aqueous layer was extracted with further chloroform (3 x
10 mL), and the pooled organic layers were dried (MgSO4) and evaporated under reduced
pressure with warming to yield a beige solid. This material was recrrystallized from 95%
ethanol to provide the desired product as pale beige crystals (0.91 g, 46%, mp = 191.8193.7°C).
1

H NMR δ (ppm)(CHCl3-d): 8.06 (1 H, dd, J = 8.50, 1.15 Hz), 7.99 (1 H, br t, J = 3.96
Hz), 7.95 (1 H, dd, J = 8.45, 1.30 Hz), 7.71 (1 H, ddd, J = 8.52, 6.82, 1.29 Hz), 7.45-7.45
(4 H, m), 7.39 (1 H, ddd, J = 8.42, 6.82, 1.25 Hz), 7.30-7.32 (4 H, m), 7.19-7.27 (2 H, m),
6.61 (1 H, s), 4.36 (1 H, s), 3.42 (2 H, td, J = 5.78, 3.98 Hz), 2.62-2.63 (10 H, br s
overlaps t, J = 5.45 Hz), 1.95 (2 H, apparent p, J = 5.34 Hz).
19

F NMR δ (ppm)(CHCl3-d): 0.5, -68.1.
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13

C NMR δ (ppm)(CHCl3-d): 152.1, 149.1 (q, JF = 33.1 Hz, Q-C2-CF3), 147.5, 142.2,
130.5, 129.8, 128.6, 128.0, 127.1, 125.6, 120.9, 120.7, 119.1, 93.6, 76.5, 58.9, 53.9, 51.8,
44.7, 23.1.
MS (ESI): m/z 505.25791 M + H (calculated 505.25736)
HPLC (method A) tR = 14.42 min (91% pure).

PL302: 2-trifluoromethyl-N-(3-(4-(pyridin-2-yl)piperazin-1-yl)propyl)quinolin-4amine

HN

N
N

N

CF 3

N
PL302

3-(2-trifluoromethylquinolin-4-ylamino)propyl methanesulfonate (1.36 g, 3.9 mmol), 1(2-pyridyl)piperazine (0.75 g, 4.1 mmol), and potassium carbonate (0.81 g, 5.9 mmol)
were heated at reflux in anhydrous acetonitrile (23 mL) for 42 hours. The solvent was
then removed under reduced pressure with warming to provide a thick, yellow oil that
solidified upon standing. This material was recrystallized from 95% ethanol to provide
the desired product as fine, off-white crystals (0.54 g, 33%, mp = 146.2-146.8°C).
1

H NMR δ (ppm)(CHCl3-d): 8.24-8.24 (1 H, m), 8.06 (1 H, d, J = 8.47 Hz), 7.91 (1 H, d,
J = 8.42 Hz), 7.72 (1 H, br t, J = 4.19 Hz), 7.64 (1 H, ddd, J = 8.49, 6.84, 1.35 Hz), 7.54
(1 H, ddd, J = 8.52, 7.17, 2.02 Hz), 7.38-7.38 (1 H, m), 6.68-6.72 (2 H, m), 6.67 (1 H, s),
3.71 (4 H, m), 3.50 (2 H, td, J = 5.44, 0.01 Hz), 2.70-2.71 (6 H, m), 2.04 (2 H, apparent p,
J = 5.51 Hz).
13

C NMR δ (ppm)(CHCl3-d): 159.4, 152.0, 148.1, 147.5, 137.7, 130.6, 129.9, 125.9,
120.4, 119.1, 113.8, 107.1, 93.8, 58.8, 53.5, 45.3, 44.5, 23.5.
19

F NMR δ (ppm)(CHCl3-d): -68.6.

MS (ESI): m/z 416.20605 M + H (calculated 416.20566)
HPLC (method A) tR = 8.07 min (97% pure).
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A.3.3: 6-trifluoromethylquinolines
3-carbethoxy-6-trifluoromethyl-4-quinolone (Ressurreição, 2013)

O

O

F 3C

OEt
N
H

meta-Trifluoromethyl aniline (25.48 g, 160 mmol) and diethyl ethoxymethylene malonate
(32 mL, 160 mmol) in Dowtherm A (150 mL) were allowed to heat gradually, stirring, to
255°C, at which temperature the reaction was allowed to remain for 30 minutes. After
cooling, the reaction mixture was diluted with 35-60° petroleum æther (200 mL) and
vacuum filtered, giving 38.94 g of a cream-colored, fine, crystalline solid (38.94 g, 86%).
1

H NMR δ (ppm)(DMSO-d6): 12.62 (1 H, d, J = 6.25 Hz), 8.66 (1 H, d, J = 6.47 Hz),
8.41 (1 H, d, J = 2.02 Hz), 8.03 (1 H, dd, J = 8.68, 2.20 Hz), 7.83 (1 H, d, J = 8.66 Hz),
4.24 (2 H, q, J = 7.10 Hz), 1.29 (3 H, t, J = 7.10 Hz).
19

F NMR δ (ppm)(DMSO-d6): -60.7.

3-carboxy-6-trifluoromethyl-4-quinolone (Price, 1946; Ressurreição, 2013)
O
F 3C

O
OH

N
H

3-carbethoxy-6-trifluoromethyl-4-quinolone (38.94 g, 0.136 mol) in 400 mL of 10%
caustic soda was allowed to reflux, stirring, for 1.5 hours, at which point all solid material
had dissolved. After cooling partially, the reaction was poured into 5 M HCl (350 mL)
with good stirring. The resulting off-white precipitate was recovered by vacuum
filtration, followed by air-drying (34.72 g, containing residual water).
1

H NMR δ (ppm)(DMSO-d6): 8.10 (1 H, s), 7.88 (1 H, s), 7.31 (1 H, dd, J = 8.76, 2.06
Hz), 7.10 (1 H, d, J = 8.77 Hz).
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6-trifluoromethyl-4-quinolone (Price, 1946; Ressurreição, 2013)
O
F 3C
N
H

3-carboxy-6-trifluoromethyl-4-quinolone (34.72 g, containing residual water) was heated
in Dowtherm A (200 mL) at 255°C for 1.5 hours. After cooling, the reaction mixture was
diluted with 200 mL 35-60° petroleum æther and vacuum filtered. The product was a
tan, fine, crystalline solid, 27.01 g (94%).
19

F NMR δ (ppm)(CHCl3-d): -63.0.

4-chloro-6-(trifluoromethyl)quinoline (Price, 1946; Ressurreição, 2013)
Cl
F 3C
N

Phosphorus oxychloride (40 mL, 430 mmol) was cautiously added to 6-trifluoromethyl4-quinolone (27.01g, 127 mmol), followed by heating at 110°C for 1.5 h. At the end of
this time TLC indicated that the reaction had gone to completion. After cooling, the
reaction mixture was gradually added to 300 mL ice water. Without basifying, this
aqueous solution was extracted with chloroform (200mL, then 3 x 50 mL). Upon drying
over MgSO4 and evaporation under reduced pressure with warming, yield from this was
8.72g. Further extraction with dichloromethane (3 times 75 mL) followed by drying over
MgSO4 and evaporation under reduced pressure with warming gave an additional 4.40 g
of the product, a tan, crystalline material with a sweet and pleasing aroma, similar to that
of 4,7-dichloroquinoline. Total yield is 13.12 g (0.057 mol, 45% yield).
1

H NMR δ (ppm)(CHCl3-d): 8.94 (1 H, d, J = 4.83 Hz), 8.59 (1 H, s), 8.38 (1 H, d, J =
8.85 Hz), 8.00 (1 H, dd, J = 8.84, 1.98 Hz), 7.68 (1 H, d, J = 4.83 Hz).
19

F NMR δ (ppm)(CHCl3-d): -63.3.
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3-(6-(trifluoromethyl)quinolin-4-ylamino)propanol

HN

OH

F 3C
N

4-chloro-6-(trifluoromethyl)quinoline (8.58 g, 37 mmol) and 3-amino-1-propanol (17.0
mL, 222 mmol) were heated at 90°C for 2 hours, at the end of which time TLC indicated
that the reaction had gone to completion. The reaction mixture was poured into water
(500 mL), and the resulting precipitate was recovered by vacuum filtration, followed by
air-drying and partial recrystallization from ethyl acetate to provide the desired
compound as an off-white powder (5.85 g, 0.0216 mol, 59% yield, mp = 165.1-167.0°C).
1

H NMR δ (ppm)(DMSO-d6): 8.73 (1 H, d, J = 2.03 Hz), 8.49 (1 H, d, J = 5.45 Hz), 7.93
(1 H, d, J = 8.80 Hz), 7.83 (1 H, dd, J = 8.83, 2.00 Hz), 7.59 (1 H, br t, J = 5.36 Hz), 6.57
(1 H, d, J = 5.50 Hz), 4.59 (1 H, t, J = 5.05 Hz), 3.56 (2 H, td, J = 6.10, 5.07 Hz), 3.343.37 (solvent signal overlaps m, ~2 H), 1.84 (2 H, apparent p, J = 6.62 Hz).
19

F NMR δ (ppm)(DMSO-d6): -60.3.

3-(6-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate

HN

OMs

F 3C
N

3-(6-(trifluoromethyl)quinolin-4-ylamino)propanol (5.85 g, 21.6 mmol) and triethylamine
(9.1 mL, 6.5 mmol) were taken up in dry chloroform (250 mL) and cooled to below 0°C
on ice/salt, and methanesulfonyl chloride (1.93 mL, 24.8 mmol) was gradually added.
After stirring for 2 hours on ice, TLC indicated that the reaction had gone to completion.
It was therefore rinsed with saturated sodium bicarbonate (150 mL), and the aqueous
layer was extracted 3 times with 15 mL portions of chloroform. The pooled organic
extracts were dried over MgSO4 and evaporated under reduced pressure with warming to
yield an off-white solid (7.57 g, ~100%).
1

H NMR δ (ppm)(DMSO-d6): 8.73 (1 H, d, J = 1.83 Hz), 8.52 (1 H, d, J = 5.44 Hz), 7.95
(1 H, d, J = 8.81 Hz), 7.85 (1 H, dd, J = 8.84, 1.93 Hz), 7.61 (1 H, br t, J = 5.35 Hz), 6.61
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(1 H, d, J = 5.50 Hz), 4.36 (2 H, t, J = 6.19 Hz), 3.42 (2 H, td, J = 6.93, 5.34 Hz), 3.20 (3
H, s), 2.12 (2 H, apparent p, J = 7.03 Hz).
19

F NMR δ (ppm)(DMSO-d6): -59.4.

PL148: N-(3-(4-benzhydrylpiperazin-1-yl)propyl)-6-(trifluoromethyl)quinolin-4amine

HN

N

F 3C

N
N
PL148

3-(6-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (0.98 g, 2.8 mmol), 1benzhydrylpiperazine (0.78 g, 3.1 mmol), and potassium carbonate (0.60 g, 4.3 mmol)
were heated at reflux in anhydrous acetonitrile (15 mL) for 24 hours, whereupon TLC
indicated that reaction was complete. Substantial precipitate had formed in the reaction
mixture. This was recovered by vacuum filtration, rinsing with water, and the resulting
solid was partially recrystallized from a mixture of 95% ethanol and ethyl acetate
(approximately 4:1, total volume 20 mL) to give the desired product as a white,
crystalline solid (1.07 g, 76%, mp = 213-218°C).
1

H NMR δ (ppm)(CHCl3-d): 8.59 (1 H, d, J = 5.36 Hz), 8.20 (1 H, s), 8.05 (1 H, d, J =
8.84 Hz), 7.83 (1 H, dd, J = 8.85, 1.91 Hz), 7.62 (1 H, br t, J = 3.97 Hz), 7.47-7.48 (4 H,
m), 7.24-7.29 (4 H, m), 7.16-7.18 (2 H, m), 6.39 (1 H, d, J = 5.41 Hz), 4.36 (1 H, s), 3.37
(2 H, td, J = 5.69, 4.03 Hz), 2.64 (10 H, br s overlaps t, J = 5.17 Hz), 1.94 (2 H, apparent
p, J = 5.32 Hz).
19

F NMR δ (ppm)(CHCl3-d): 0.5, -59.5.

13

C NMR δ (ppm)(CHCl3-d): 153.1, 151.2, 149.9, 143.1, 130.9, 128.6, 127.9, 127.0,
125.6 (q, JF = 9.96 Hz), 124.7 (q, JF = 3.02 Hz), 119.2 (q, JF = 3.02 Hz), 118.4, 99.4, 75.7,
59.4, 54.3, 51.8, 45.3, 23.3.
HPLC (method C) tR = 11.80 min (98% pure). MS (ESI): m/z 505.2566 M + H
(calculated 505.2574).
19

F NMR δ (ppm)(CHCl3-d): -59.5.
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PL276: 6-trifluoromethyl-N-(3-(4-(pyridin-2-yl)piperazin-1-yl)propyl)quinolin-4amine

HN

N

F 3C

N
N

N

PL276

3-(6-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (1.53 g, 4.39 mmol),
N-(2-pyridyl)piperazine (0.79 g, 4.8 mmol), and potassium carbonate (0.95 g, 6.87 mmol)
were heated at reflux in anhydrous acetonitrile (15 mL) for 24 hours. TLC then indicated
that reaction was complete. Substantial precipitate had formed in the reaction mixture.
This was recovered by vacuum filtration, rinsing with acetonitrile (30 mL), followed by
water (40 mL). The resulting solid was recrystallized from 5 mL 95% ethanol to give the
desired product as a white, crystalline solid (0.82 g, 45%, mp = 168.8-171.0°C).
1

H NMR δ (ppm)(CHCl3-d): 8.61 (1 H, d, J = 5.39 Hz), 8.22-8.24 (1 H, m), 8.15 (1 H, s),
8.03 (1 H, d, J = 8.79 Hz), 7.74 (1 H, dd, J = 8.80, 1.95 Hz), 7.52-7.52 (2 H, m), 6.666.67 (2 H, m), 6.44 (1 H, d, J = 5.44 Hz), 3.69 (4 H, m), 3.44 (2 H, td, J = 5.87, 4.17 Hz),
2.69 (6 H, m), 2.02 (2 H, apparent p, J = 5.51 Hz).
19

F NMR δ (ppm)(CHCl3-d): -61.7.

13

C NMR δ (ppm)(CHCl3-d): 159.5, 153.1, 151.0, 149.9, 148.0, 147.9, 137.6, 130.9,
126.0, 125.8 (q, JF = 32.5 Hz, Q-C6-CF3), 124.7, 118.7, 118.3, 113.6, 107.0, 99.3, 59.0,
53.7, 45.0, 44.7, 23.6.
MS (ESI): m/z 416.2050 M + H (calculated 416.2057).
HPLC (method C) tR = 6.64 min (99% pure).

PL190: N-(dipyridin-2-methylene)piperidin-4-amine (Burgess, 2008; Burgess, 2010)

N
HN

N
N

PL190
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In a round bottomed flask equipped with a Dean and Stark water separator, 4-aminopiperidine
(16.82 g, 0.168 mol), di-2-pyridyl ketone (25.67g, 0.139 mol), and a catalytic amount of paratoluenesulfonic acid were allowed to reflux for 20 hours. TLC then indicated that the reaction
had gone to completion, and the solvent was therefore evaporated under reduced pressure. The
resulting rust-colored solid (41.45 g) was used without further purification.

PL278: 6-trifluoromethyl-N-(3-(4-(dipyridin-2-ylmethyleneamino)piperidin-1yl)propyl)quinolin-4-amine

HN

N

N

F 3C

N

N

N
PL278

3-(6-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (2.00 g, 5.74 mmol),
PL190 (1.76 g, 6.61 mmol; see above), and potassium carbonate (1.19 g, 8.61 mmol)
were heated at reflux in anhydrous acetonitrile (24 mL) for 24 hours. TLC indicated that
reaction was complete, and so the solvent was removed under reduced pressure with
warming, and the residue partitioned between chloroform (50 mL) and water (50 mL).
After separation, the aqueous layer was extracted with further chloroform (3 x 15 mL)
and the pooled organic layers were dried (MgSO4) and evaporated under reduced
pressure with warming. The resulting brown solid was dissolved in a mixture of
dichloromethane and methanol and allowed to evaporate at room temperature; the
resulting crystals were washed with ethyl acetate, followed by 95% ethanol to provide the
desired product as pale yellow, sparkling crystals (0.74 g, 26%, mp = 224-225°C).
1

H NMR δ (ppm)(CHCl3-d): 8.73 (1 H, d, J = 4.93 Hz), 8.60 (1 H, d, J = 5.39 Hz), 8.49
(1 H, d, J = 4.85 Hz), 8.40 (1 H, d, J = 8.01 Hz), 8.18 (1 H, s), 8.05 (1 H, d, J = 8.82 Hz),
7.77-7.82 (2 H, m), 7.58 (1 H, s), 7.31-7.37 (1 H, m), 7.24-7.27 (solvent signal overlaps
m, ~2 H), 6.42 (1 H, d, J = 5.45 Hz), 3.37-3.43 (3 H, m), 2.99-3.04 (2 H, m), 2.60 (2 H,
td, J = 5.10, 1.54 Hz), 2.14 (2 H, m), 1.97-1.99 (4 H, m), 1.81-1.83 (2 H, m).
19

F NMR δ (ppm)(CHCl3-d): -61.5.

13

C NMR δ (ppm)(CHCl3-d): 165.1, 157.3, 155.8, 153.0, 151.2, 149.9, 149.7, 148.6,
136.3, 135.9, 130.8, 125.9 (q, JF = 32.1 Hz, Q-C6-CF3), 124.6, 124.0, 123.4, 123.1,
123.0, 122.3, 118.8, 118.4, 99.3, 59.0, 58.4, 52.1, 44.8, 32.6, 23.9.
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MS (ESI): m/z 519.24868 M + H (calculated 519.24786)
HPLC (method A) tR = 1.58 min (54% pure). (Additional peaks elute at 2.01 min, 6%,
and 9.18 min, 39%).

PL279: 6-trifluoromethyl-N-(3-(4-(dipyridin-2-ylmethylamino)piperidin-1yl)propyl)quinolin-4-amine

HN

N

N

F 3C

N
H
N

N

PL279

PL278 (0.74 g, 1.4 mmol) was taken up in anhydrous methanol (25 mL), and sodium
borohydride (0.16 g, 4.2 mmol) was cautiously added. After stirring 2 hours, additional
sodium borohydride (0.06 g, 2 mmol) was added. After 30 minutes, the solvent was
removed by evaporation under reduced pressure and the resulting solid was allowed to
stir for 1 hour with 15 mL water. This was then extracted with methylene chloride (15
mL followed by 3 x 10 mL), and the pooled organic extracts were dried over MgSO4 and
evaporated under reduced pressure. Recrystallization of the residue from 95% ethanol
(10 mL) gave the product as a golden brown solid (0.34 g, 49%, mp = 128.2-129.8°C).
1

H NMR δ (ppm)(CHCl3-d): 8.58 (1 H, d, J = 5.40 Hz), 8.56-8.56 (2 H, m), 8.10 (1 H, s),
8.03 (1 H, d, J = 8.82 Hz), 7.77 (1 H, dd, J = 8.82, 1.97 Hz), 7.63 (2 H, td, J = 7.66, 1.88
Hz), 7.51 (3 H, d, J = 7.80 Hz), 7.14 (2 H, ddd, J = 7.48, 4.84, 1.23 Hz), 6.40 (1 H, d, J =
5.43 Hz), 5.25 (1 H, s), 3.38 (2 H, td, J = 5.87, 4.06 Hz), 2.96 (2 H, d, J = 11.07 Hz),
2.55-2.58 (3 H, m), 2.08 (2 H, br s), 1.96-2.03 (2 H, m), 1.93 (2 H, apparent p, J = 5.52
Hz), 1.61 (2 H, m).
19

F NMR δ (ppm)(CHCl3-d): -61.4.

13

C NMR δ (ppm)(CHCl3-d): 162.3, 153.0, 151.1, 149.9, 149.1, 149.1, 136.6, 130.8,
125.7 (q, JF = 32.5 Hz, Q-C6-CF3), 124.6, 122.3, 122.1, 118.8, 118.3, 99.3, 66.7, 58.7,
52.9, 52.7, 44.7, 32.5, 23.9.
HPLC (method A) tR = 6.38 min (95% pure).
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PL275: 6-trifluoromethyl-N-(3-(4-(4-fluorophenyl)piperazin-1-yl)propyl)quinolin-4amine

HN

N

F 3C

N
N

PL275

F

3-(6-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (1.53 g, 4.4 mmol),
N-(4-fluorophenyl)piperazine (0.87 g, 4.8 mmol), and potassium carbonate (0.95 g, 6.9
mmol) were heated at reflux in anhydrous acetonitrile (15 mL) for 24 hours, at which
time TLC indicated that reaction was complete. A large amount of precipitate had
formed in the reaction mixture. This was recovered by vacuum filtration, rinsing with
acetonitrile (30 mL), followed by water (40 mL). The solid thus obtained was
recrystallized from 8 mL 95% ethanol to give the desired product as a white, crystalline
solid (1.04 g, 55%, mp = 181.6-183.2°C).
1

H NMR δ (ppm)(CHCl3-d): 8.61 (1 H, d, J = 5.39 Hz), 8.13 (1 H, s), 8.03 (1 H, d, J =
8.79 Hz), 7.75 (1 H, dd, J = 8.80, 1.93 Hz), 7.38 (1 H, t, J = 4.11 Hz), 6.97-7.01 (2 H, m),
6.89-6.90 (2 H, m), 6.43 (1 H, d, J = 5.43 Hz), 3.43 (2 H, td, J = 5.84, 4.20 Hz), 3.25 (4
H, m), 2.73 (4 H, m), 2.70 (2 H, t, J = 5.34 Hz), 2.01 (2 H, apparent p, J = 5.48 Hz).
19

F NMR δ (ppm)(CHCl3-d): 0.5, -60.8, -124.5 (m).

13

C NMR δ (ppm)(CHCl3-d): 158.1, 156.5, 153.0, 151.0, 149.9, 147.6 (d, JF = 2.05 Hz?),
130.9, 127.0, 125.9 (q, JF = 32.1 Hz), 125.2, 124.6, 123.4, 118.7, 118.3, 118.1 (d, JF =
7.66 Hz?),, 115.5 (d, JF = 21.43 Hz?), 99.4, 59.0, 54.0, 50.0, 44.7, 23.6.
MS (ESI): m/z 433.2001 M + H (calculated 433.2010).
HPLC (method C) tR = 9.54 min (>99% pure).
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PL277: 6-trifluoromethyl-N-(3-(4-(4-methoxyphenyl)piperazin-1-yl)propyl)quinolin4-amine

HN

N

F 3C

N
N

PL277

O

3-(6-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (1.53 g, 4.39 mmol),
1-(4-methoxyphenyl)piperazine (0.92 g, 4.8 mmol), and potassium carbonate (0.95 g, 6.9
mmol) were heated at reflux in anhydrous acetonitrile (16 mL) for 24 hours, whereupon
TLC indicated that reaction was complete. Substantial precipitate had formed in the
reaction mixture. This was recovered by vacuum filtration, rinsing with acetonitrile (30
mL), followed by water (40 mL). The resulting solid was recrystallized from 5 mL 95%
ethanol to give the desired product as a white, crystalline solid (0.27 g, 14%, mp = 173.7175.0°C).
1

H NMR δ (ppm)(CHCl3-d): 8.61 (1 H, d, J = 5.40 Hz), 8.14 (1 H, s), 8.04 (1 H, d, J =
8.81 Hz), 7.76 (1 H, dd, J = 8.83, 1.92 Hz), 7.34 (1 H, t, J = 4.16 Hz), 6.92-6.93 (2 H, m),
6.84-6.89 (2 H, m), 6.45 (1 H, d, J = 5.45 Hz), 3.80 (3 H, s), 3.44 (2 H, td, J = 5.85, 4.21
Hz), 3.23 (4 H, m), 2.74 (4 H, m), 2.70 (2 H, t, J = 5.35 Hz), 2.02 (2 H, apparent p, J =
5.47 Hz).
13

C NMR δ (ppm)(CHCl3-d): 153.9, 153.0, 151.0, 149.9, 145.3, 130.9, 125.9, 124.6,
123.0, 118.7, 118.5, 118.3, 114.4, 99.4, 59.0, 55.6, 54.1, 50.5, 44.7, 29.7, 23.6.
19

F NMR δ (ppm)(CHCl3-d): -61.3.

HPLC (method C) tR = 9.22 min (>99% pure). MS (ESI): m/z 445.2200 M + H
(calculated 445.2210).
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A.3.4: 7-trifluoromethylquinolines
7-trifluoromethyl-4-quinolone (Price, 1946; Snyder, 1947)

O

+
F 3C

NH 2

EtO

O

O

OEt

OEt
OEt

O

Dowtherm A F 3C
255oC

N
H

1) 10% NaOH, reflux
2) HCl

O

3) Dowtherm A
255oC

N
H

F 3C

meta-Trifluoromethyl aniline (4.5 g, 27.9 mmol) and diethyl ethoxymethylene malonate
(6.00 mL, 27.9 mmol) in Dowtherm A (100 mL) were allowed to heat gradually, stirring,
to 255°C, at which temperature the reaction was allowed to remain for 1 hour. After
cooling, the reaction mixture was diluted with 30-60º petroleum æther (100 mL) and
vacuum filtered, rinsing with additional 30-60º petroleum æther (250 mL). The resulting
solid (6.64 g) was allowed to reflux in 10% caustic soda (50 mL) for 1 day. After
cooling, the reaction was made acidic by addition of 10% muriatic acid. The resulting
off-white precipitate was recovered by vacuum filtration, followed by drying in a vacuum
dessicator for 1 hour. Without further drying, this material was combined with 20 mL
Dowtherm A and gradually heated to 255ºC, at which temperature it was allowed to
remain for 60 minutes. Upon cooling, the reaction mixture was diluted with 30-60º
petroleum æther (50 mL), and the product was recovered by vacuum filtration (rinsing
with additional 30-60º petroleum æther). The product was a cream-colored, crystalline
solid (4.65 g, 78% from starting aniline). NMR indicated that the product was primarily
the desired 7-trifluoromethyl-4-quinolone, containing approximately 3 % 5trifluoromethyl-4-quionolone.
1

H NMR δ (ppm)(DMSO-d6): Major peaks: 12.01 (1 H, s), 8.28 (1 H, d, J = 8.47 Hz),
8.05 (1 H, s), 7.92 (1 H, s), 7.59 (1 H, dd, J = 8.47, 1.70 Hz), 6.14 (1 H, d, J = 7.47 Hz).
Minor peaks due to the 5-trifluoromethyl regioisomer are also present.
19

F NMR δ (ppm)(DMSO-d6): -61.6 (major peak), -55.9 (minor peak).

4-chloro-7-(trifluoromethyl)quinoline (Price, 1946; Snyder, 1947)

Cl

F 3C

N
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Phosphorus oxychloride (25 mL, 270 mmol) was cautiously added to 7-trifluoromethyl4-quinolone (4.65 g, 21.8 mmol), followed by heating at 110°C for 1 h. After cooling,
the reaction mixture was gradually added to 300 mL ice water. This was allowed to sit
for 16 hours. Without basifying, the aqueous solution was extracted with
dichloromethane (100mL, then 3 x 75 mL). Drying of the pooled organic layers over
MgSO4 followed by evaporation under reduced pressure with warming gave the desired
product as a pale pink solid (1.50 g, 30%, mp = 70.9-72.3°C (lit. 71-72°C (Snyder,
1947)). NMR indicated that the product contained less than 2% of 4-chloro-5trifluoromethylquinoline; this was not removed.
1

H NMR δ (ppm)(CHCl3-d): 8.91 (1 H, d, J = 4.75 Hz), 8.50 (1 H, s), 8.40 (1 H, d, J =
8.82 Hz), 7.86 (1 H, dd, J = 8.82, 1.75 Hz), 7.65 (1 H, d, J = 4.74 Hz).
19

F NMR δ (ppm)(CHCl3-d): -62.9.

3-(7-(trifluoromethyl)quinolin-4-ylamino)propanol

HN

F 3C

OH

N

4-chloro-7-(trifluoromethyl)quinoline (1.5 g, 6.9 mmol) and 3-amino-1-propanol (8.0
mL, 105 mmol) were heated at 90°C for 18 hours. The reaction mixture was then poured
into water (50 mL), and the resulting precipitate was recovered by vacuum filtration,
followed by air-drying to provide the desired compound (1.59 g, 85%, mp = 137.2137.9°C).
1

H NMR δ (ppm)(DMSO-d6): 8.51 (1 H, d, J = 5.41 Hz), 8.46 (1 H, d, J = 8.82 Hz), 8.08
(1 H, s), 7.68 (1 H, dd, J = 8.79, 1.95 Hz), 7.45 (1 H, br t, J = 5.36 Hz), 6.59 (1 H, d, J =
5.47 Hz), 4.61 (1 H, t, J = 5.05 Hz), 3.56 (2 H, m), 3.35 (water signal overlaps m, ~2 H),
1.84 (2 H, m).
19

F NMR δ (ppm)(DMSO-d6): -61.1.

1

H NMR δ (ppm)(CHCl3-d): 8.57 (1 H, d, J = 5.36 Hz), 8.23 (1 H, s), 7.78 (1 H, d, J =
8.77 Hz), 7.52 (1 H, dd, J = 8.75, 1.85 Hz), 6.44 (1 H, d, J = 5.38 Hz), 6.09 (1 H, br t, J =
4.63 Hz), 4.00 (2 H, t, J = 5.38 Hz), 3.48 (2 H, td, J = 6.14, 4.73 Hz), 2.07 (2 H, apparent
p, J = 5.75 Hz).
19

F NMR δ (ppm)(CHCl3-d): -62.7.
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3-(7-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate

HN

F 3C

OMs

N

3-(7-(trifluoromethyl)quinolin-4-ylamino)propanol (1.59 g, 5.9 mmol) and triethylamine
(1.23 mL, 8.8 mmol) in dry dichloromethane (50 mL) were cooled to below 0°C on
ice/salt, and methanesulfonyl chloride (0.53 mL, 6.8 mmol) was gradually added. After
stirring for 17 hours, TLC indicated that the reaction was not complete. Therefore, the
reaction was again cooled to 0ºC and additional triethylamine (1.2 mL, 8.6 mmol) and
methanesulfonyl chloride (0.38 mL, 4.9 mmol) were added. After stirring an additional
18 hours, TLC indicated that reaction was complete. The reaction mixture was rinsed
with saturated sodium bicarbonate (35 mL), and the aqueous layer was extracted 3 times
with 10 mL portions of dichloromethane. The pooled organic extracts were dried over
MgSO4 and evaporated under reduced pressure with warming to yield a yellow solid
(1.96 g, 95%, containing traces of residual triethylamine). This was used without further
purification in the ensuing reactions.
1

H NMR δ (ppm)(DMSO-d6): 8.53 (1 H, d, J = 5.43 Hz), 8.47 (1 H, d, J = 8.82 Hz), 8.09
(1 H, s), 7.72 (1 H, dd, J = 8.79, 1.96 Hz), 7.53 (1 H, s), 6.64 (1 H, d, J = 5.49 Hz), 4.36
(2 H, t, J = 6.19 Hz), 3.42 (2 H, m), 3.20 (3 H, s), 2.08-2.10 (2 H, m).
19

F NMR δ (ppm)(DMSO-d6): -61.3.

PL264: N-(3-(4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)propyl)-7(trifluoromethyl)quinolin-4-amine

HN

F

N
N

F 3C

N
PL264
F

3-(7-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (0.67 g, 1.9 mmol), 1bis-(4-fluorophenyl)methyl piperazine (0.55 g, 1.9 mmol), and triethylamine (0.50 mL,
254

3.6 mmol) were heated at reflux in anhydrous acetonitrile (25 mL) for 18 hours,
whereupon TLC indicated that reaction was complete. The solvent was evaporated under
reduced pressure with warming, and the residue was partitioned between chloroform (35
mL) and water (35 mL). After separation, the aqueous layer was extracted with further
chloroform (3 x 10 mL), and the pooled organic layers were dried (MgSO4) followed by
evaporation under reduced pressure with warming. The resulting brown oil was purified
by chromatography on alumina, eluting with 3:2 hexanes:ethyl acetate. This provided the
desired product as a white, crystalline solid (0.48 g, 47%, mp = 154.8-155.8°C, Rf = 0.8
(basic alumina, 95/5 EA/MeOH v/v)).
1

H NMR δ (ppm)(CHCl3-d): 8.58 (1 H, d, J = 5.29 Hz), 8.24 (1 H, s), 7.95 (1 H, d, J =
8.73 Hz), 7.56 (1 H, br t, J = 4.02 Hz), 7.42 (1 H, dd, J = 8.71, 1.84 Hz), 7.37-7.38 (4 H,
m), 6.98-7.04 (4 H, m), 6.39 (1 H, d, J = 5.36 Hz), 4.38 (1 H, s), 3.38 (2 H, td, J = 5.82,
4.07 Hz), 2.65 (10 H, br s overlaps t, J = 5.28 Hz), 1.95 (2 H, apparent p, J = 5.41 Hz).
19

F NMR δ (ppm)(CHCl3-d): -63.1, -115.8.

13

C NMR δ (ppm)(CHCl3-d): 162.8, 161.1, 152.5, 150.4, 147.7, 137.5, 129.5, 129.4,
115.6, 115.4, 99.5, 74.4, 58.8, 53.9, 51.6, 44.5, 23.3.
HPLC (method C) tR = 12.39 min (99% pure). MS (ESI): m/z 541.2376 M + H
(calculated 541.2385).

PL142: N-(3-(4-benzhydrylpiperazin-1-yl)propyl)-7-(trifluoromethyl)quinolin-4amine
HN

N
N

F 3C

N

PL142

Method 1

HN

OMs

HN

N

KI, K 2CO 3

+
F 3C

N

HN

N

N
CH 3CN, 80oC

F 3C

N

PL142
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3-(7-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (1.09 g, 3.1 mmol), 1benzyhydrylpiperazine (0.83 g, 3.3 mmol), potassium carbonate (0.65 g, 4.7 mmol), and a
catalytic amount of potassium iodide were heated at reflux in anhydrous acetonitrile (30
mL) for 5 days, whereupon TLC indicated that reaction was complete. The reaction
mixture was diluted with 5 mL water and the solvent was removed by evaporation under
reduced pressure with warming. The residue was partitioned between ethyl acetate (25
mL) and water (25 mL). After separation, the aqueous layer was extracted with further
ethyl acetate (3 x 7 mL), and the pooled organic layers were dried over magnesium
sulfate, followed by evaporation and recrystallization of the residue from 95% ethanol;
the desired product was recovered as a white, crystalline solid (0.47 g, 30%, mp = 162.0163.8°C).
1

H NMR δ (ppm)(CHCl3-d): 8.56 (1 H, d, J = 5.30 Hz, Q-C2-H), 8.23 (1 H, s, Q-C8-H?),
7.92 (1 H, d, J = 8.74 Hz, Q-C5-H), 7.72 (1 H, br t, J = 3.96 Hz, Q-C4-NH), 7.42-7.43 (4
H, m, Ph-H ortho), 7.32-7.34 (5 H, m, Ph-H meta overlaps Q-C6-H), 7.23-7.27 (solvent
signal overlaps m, ~2 H, Ph-H para), 6.36 (1 H, d, J = 5.35 Hz, Q-C3-H), 4.48 (1 H, s,
CH(Ph)2), 3.36 (2 H, td, J = 5.78, 4.02 Hz, Q-NH-CH2CH2CH2), 2.65 (10 H, br s overlaps
t, J = 5.34 Hz, Pip-CH2 x 4 and Q-NH-CH2CH2CH2), 1.92-1.96 (2 H, apparent p, J = 5.38
Hz, Q-NH-CH2CH2CH2).
19

F NMR δ (ppm)(CHCl3-d): -62.9.

13

C NMR δ (ppm)(CHCl3-d): 152.4 (Q-C2), 150.4, 147.6, 141.6 (Ph-C ipso), 130.5 (q, JF
= 32.57 Hz, Q-C7), 128.5 (Ph-C meta), 128.2 (Ph-C ortho), 127.4 (q, J F = 4.25 Hz, QC8), 127.2 (Ph-C para), 124.2 (q, JF = 271.81 Hz, CF3), 122.3, 120.8, 119.5 (q, JF = 3.26
Hz, Q-C6), 99.4 (Q-C3), 75.6 (CH(Ph)2), 59.0 (Q-NH-CH2CH2CH2), 54.0 (Pip-C-CNCH(Ph)2), 51.4 (Pip-C-C-NCH(Ph)2), 44.6 (Q-NH-CH2CH2CH2), 23.1 (Q-NHCH2CH2CH2).
MS (ESI): m/z 505.2563 M + H (calculated 505.2574).
HPLC (method C) tR = 11.60 min (98% pure).
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PL142, Method 2 (Based upon Gabriel, 1887; Ing, 1926; Leonardi, 2004; Nishikawa,
1989; Andersag, 1948; Surrey, 1951)
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105-120 oC

4-chloro-7-(trifluoromethyl)quinoline (0.37 g, 1.6 mmol) and phenol (2.11 g, 22 mmol)
were allowed to heat at 105ºC for 1.5 hours. PL151 (0.80 g, 2.6 mmol; see below) was
then added, and the mixture was allowed to heat at 120ºC for 28 hours. The cooled
reaction mixture was diluted with dichloromethane (20 mL) and washed with 1 M caustic
soda (6 x 10 mL), followed by brine (10 mL). The pooled organic layers were dried
(MgSO4) and concentrated under reduced pressure with warming to provide a reddish
brown glass. This material was purified by chromatography on alumina, eluting with
30:70 hexanes:ethyl acetate, followed by 100% ethyl acetate and finally, 95:5 ethyl
acetate:methanol. The desired product was obtained as a tan solid (0.15 g, 19%, Rf = 0.8
(basic alumina, 95/5 EA/MeOH v/v)).

PL151: 3-(4-benzhydrylpiperazin-1-yl)propan-1-amine (Gabriel, 1887; Ing, 1926;
Leonardi, 2004; Nishikawa, 1989)
PL191 (1.47 g, 3.3 mmol; see below) and hydrazine monohydrate (0.48 mL, 9.9 mmol)
were heated in refluxing 95% ethanol (50 mL) for 3 hours, at which time TLC indicated
that the reaction was complete. Upon cooling, crystallization occurred; the reaction was
further chilled in an ice bath, followed by filtration. The white solid obtained was rinsed
with chilled 95% ethanol (3 x 10 mL), followed by chilled diethyl æther (2 x 10 mL). The
filtrate was basified to pH 9 by the addition of 2 M NaOH and concentrated under
reduced pressure with warming. The residue was diluted with water (20 mL) and
extracted with dichloromethane (3 x 10 mL). The pooled organic layers were dried
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(MgSO4) and concentrated under reduced pressure with warming to yield a yellow oil,
which became a waxy solid upon standing. This proved to be the desired product (0.80 g,
79%).
1

H NMR δ (ppm)(CHCl3-d): 7.40-7.42 (4 H, m), 7.22-7.30 (solvent signal overlaps m, ~4
H), 7.14-7.19 (2 H, m), 4.21 (1 H, s), 2.73 (2 H, t, J = 6.83 Hz), 2.41-2.42 (10 H, br s
overlaps t, J = 7.55 Hz), 1.62 (2 H, apparent p, J = 7.23 Hz).

PL191: 2-(3-(4-benzhydrylpiperazin-1-yl)propyl)phthalimide (Gabriel, 1887; Ing,
1926; Leonardi, 2004; Nishikawa, 1989)
1-(Diphenylmethyl)piperazine (11.00 g, 44 mmol), N-3-(bromopropyl)phthalimide (12.84
g, 48 mmol), and potassium carbonate (16.07 g, 120 mmol) were allowed to heat in
anhydrous acetonitrile (210 mL) at reflux under a nitrogen atmosphere for 18 hours, at
which time TLC indicated that reaction was complete. The reaction mixture was
concentrated under reduced pressure with warming, and the residue was diluted with
ethyl acetate (125 mL) and washed with water (75 mL, then 4 x 50 mL), then dried over
magnesium sulfate and concentrated under reduced pressure with warming. The amber
oil thus obtained was divided into two equal portions, each of which was purified by
column chromatography on alumina, eluting with 100% ethyl acetate followed by 95:5
ethyl acetate:methanol. The off-white solid thus obtained contained the residual N-3(bromopropyl)phthalimide in addition to the desired product. This material was
recrystallized from ethyl acetate to obtain the desired product as an off-white, crystalline
solid (7.73 g, 56%, Rf = 0.6 (silica, 95/5 chloroform/methanol v/v)). Note: It was also
possible to perform the ensuing reactions without chromatographic purification of this
material, with comparable results.
1

H NMR δ (ppm)(CHCl3-d): 7.82 (2 H, dd, J = 5.44, 3.05 Hz), 7.71 (2 H, dd, J = 5.46,
3.04 Hz), 7.35-7.37 (4 H, m), 7.12-7.20 (2 H, m), 4.07 (1 H, s), 3.74 (2 H, t, J = 6.94 Hz),
2.41 (10 H, br s overlaps t, J = 7.19 Hz), 1.79-1.87 (2 H, m).

PL287: 7-trifluoromethyl-N-(3-(4-(pyridin-2-yl)piperazin-1-yl)propyl)quinolin-4amine

HN

N
N

F 3C

N

PL287

N
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3-(7-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (3.10 g, 8.9 mmol), 1(2-pyridyl)piperazine (0.92 g, 5.6 mmol), and potassium carbonate (1.85 g, 13 mmol)
were heated at reflux in anhydrous acetonitrile (24 mL) for 5 days. The solvent was
removed by evaporation under reduced pressure with warming, and the residue was
partitioned between dichloromethane (50 mL) and water (25 mL). After separation, the
aqueous layer was extracted with further dichloromethane (3 x 10 mL), and the pooled
organic layers were dried over magnesium sulfate, followed by evaporation under
reduced pressure with warming and recrystallization of the residue from ethyl acetate to
obtain the desired product as beige crystals (0.72 g, 19%, mp = 172.3-173.9°C).
1

H NMR δ (ppm)(CHCl3-d): 8.60 (1 H, d, J = 5.34 Hz), 8.22-8.25 (2 H, m), 7.97 (1 H, d,
J = 8.75 Hz), 7.54 (1 H, ddd, J = 8.53, 7.17, 2.02 Hz), 7.45 (1 H, dd, J = 8.75, 1.88 Hz),
7.42 (1 H, t, J = 4.03 Hz), 6.69-6.70 (2 H, m), 6.44 (1 H, d, J = 5.38 Hz), 3.70 (4 H, m),
3.43 (2 H, td, J = 5.96, 4.23 Hz), 2.69-2.70 (6 H, m), 2.02 (2 H, apparent p, J = 5.49 Hz).
13

C NMR δ (ppm)(CHCl3-d): 159.3, 152.5, 150.3, 148.1, 147.7, 137.7, 130.7 (q, JF = 32.5
Hz, Q-C7-CF3), 127.7, 121.7, 120.8, 119.7, 113.8, 107.2, 99.6, 58.7, 53.5, 45.4, 44.3,
23.6.
MS (ESI): m/z 416.20603 M + H (calculated 416.20566)
HPLC (method A) tR = 6.41 min (>99% pure).

PL230: 7-trifluoromethyl-N-(3-(4-(dipyridin-2-ylmethyleneamino)piperidin-1yl)propyl)quinolin-4-amine

HN

N

N
N

F 3C

N

N

PL230

3-(7-trifluoromethyl-4-ylamino)propyl methanesulfonate (0.32 g, 0.92 mmol), N(dipyridin-2-methylene)piperidin-4-amine (0.36 g, 1.4 mmol), and potassium carbonate
(0.18 g, 1.3 mmol) were allowed to heat at 70ºC in anhydrous acetonitrile (12 mL) for 6
days. TLC then indicated that the reaction was complete. The reaction mixture was
diluted with water (30 mL) and partially evaporated under reduced pressure with
warming, followed by filtration to yield a sticky, light brown solid. This was allowed to
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air dry, then purified by chromatography on basic alumina, eluting with 100% ethyl
acetate. This provided the desired product as a white powder (0.14 g, 29%, mp = 191199°C, Rf = 0.1 (basic alumina, ethyl acetate)).
1

H NMR δ (ppm)(CHCl3-d): 8.75-8.75 (1 H, m), 8.59 (1 H, d, J = 5.34 Hz), 8.52-8.52 (1
H, m), 8.34-8.41 (1 H, m), 8.26 (1 H, s), 8.22 (1 H, d, J = 8.73 Hz), 8.15 (1 H, t, J = 4.03
Hz), 7.82-7.83 (2 H, m), 7.76 (1 H, dd, J = 8.70, 1.88 Hz), 7.36 (1 H, ddd, J = 7.67, 4.91,
1.21 Hz), 7.29-7.29 (2 H, m), 6.40 (1 H, d, J = 5.38 Hz), 3.41-3.42 (3 H, m), 3.06-3.10 (2
H, m), 2.63 (2 H, td, J = 4.98, 1.35 Hz), 2.05-2.09 (4 H, m), 1.96 (2 H, apparent p, J =
5.32 Hz), 1.73-1.98 (2 H, m).
13

C NMR δ (ppm)(CHCl3-d): 165.5, 157.0, 155.6, 152.5, 150.5, 149.7, 148.7, 147.7,
136.5, 136.0, 130.7 (q, JF = 32.1 Hz, Q-C7-CF3), 127.4, 124.2, 123.4, 123.1, 122.6,
122.2, 121.0, 119.7, 115.6, 99.2, 59.0, 58.5, 52.1, 44.7, 32.9, 23.6.
19

F NMR δ (ppm)(CHCl3-d): -63.1. (corrected to Freon 11)

MS (ESI): m/z 519.24828 M + H (calculated 519.24786)
HPLC (method A) tR = 1.59 min (79% pure). (Additional peak elutes at 2.02 min, 19%.)

PL242: 7-trifluoromethyl-N-(3-(4-(dipyridin-2-ylmethylamino)piperidin-1yl)propyl)quinolin-4-amine

HN

N

N
N
H

F 3C

N

N

PL242

PL 230 (0.11 g, 0.21 mmol) was dissolved in anhydrous methanol (10 mL), followed by
the addition of sodium borohydride (0.03 g, 0.79 mmol). After stirring at room
temperature for one hour, equipped with an alumina drying tube, additional sodium
borohydride (0.01 g, 0.26 mmol) was added. After a further 30 minutes, the solvent was
removed by evaporation under reduced pressure with warming. The residue was
combined with water (10 mL) and allowed to stir for 1.5 hours at room temperature,
followed by extraction with dichloromethane (8 x 5 mL). The pooled organic layers were
dried (MgSO4) and evaporated under reduced pressure with warming to yield the desired
product as a pale brown solid (0.11 g, ~100%, mp = 140.5-145.0°C).
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1

H NMR δ (ppm)(CHCl3-d): 8.56-8.59 (3 H, m), 8.23 (1 H, s), 8.03 (1 H, d, J = 8.76 Hz),
7.94 (1 H, t, J = 3.93 Hz), 7.63-7.64 (3 H, m), 7.48 (2 H, d, J = 7.88 Hz), 7.16-7.16 (2 H,
m), 6.38 (1 H, d, J = 5.40 Hz), 5.25 (1 H, s), 3.37 (2 H, td, J = 5.74, 3.89 Hz), 3.00-3.04
(2 H, m), 2.62-2.72 (1 H, m), 2.56-2.61 (2 H, m), 2.00-2.04 (4 H, m), 1.93 (2 H, apparent
p, J = 5.34 Hz), 1.67 (2 H, m).
19

F NMR δ (ppm)(CHCl3-d): -63.3.

13

C NMR δ (ppm)(CHCl3-d): 162.2, 152.4, 150.5, 149.1, 147.7, 136.6, 130.7 (q, JF = 32.8
Hz, Q-C7-CF3), 127.4, 122.4, 122.3, 122.2, 120.9, 119.7, 99.3, 66.5, 58.7, 53.1, 52.8,
44.6, 33.1, 23.6.
MS (ESI): m/z 521.2627 M + H (calculated 521.2635).
HPLC (method C) tR = 6.37 min (98% pure).

PL315: 7-trifluoromethyl-N-(3-(4-(4-fluorophenyl)piperazin-1-yl)propyl)quinolin-4amine

HN

N
N

F 3C

N

PL315

F

3-(7-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (1.33 g, 3.8 mmol),
N-(4-fluorophenyl)piperazine (0.72 g, 4.0 mmol), and potassium carbonate (0.79 g, 5.7
mmol) were heated at 75ºC in anhydrous acetonitrile (15 mL) for 18 hours, whereupon
TLC indicated that reaction was complete. The reaction mixture was diluted with 5 mL
water, followed by removal of the solvent under reduced pressure with warming. The
residue was partitioned between chloroform (20 mL) and water (20 mL). After
separation, the aqueous layer was extracted with additional chloroform (3 x 10 mL), and
the pooled organic layers were dried (MgSO4) and evaporated under reduced pressure
with warming. The resulting brown semisolid was crystallized from chloroform,
followed by recrystallization from ethyl acetate (5 mL) to provide the desired product as
a cream-colored solid (0.17 g, 10%, mp = 182.1-183.3°C).
1

H NMR δ (ppm)(CHCl3-d): 8.60 (1 H, d, J = 5.35 Hz), 8.24 (1 H, s), 7.98 (1 H, d, J =
8.75 Hz), 7.40-7.46 (2 H, m), 7.02-7.03 (2 H, m), 6.93-6.95 (2 H, m), 6.44 (1 H, d, J =
5.38 Hz), 3.43 (2 H, td, J = 5.47, 0.01 Hz), 3.27 (4 H, m), 2.76 (4 H, m), 2.72 (2 H, t, J =
5.39 Hz), 2.02 (2 H, apparent p, J = 5.54 Hz).
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19

F NMR δ (ppm)(CHCl3-d): -63.2, -124.3 (m).

13

C NMR δ (ppm)(CHCl3-d): 158.3, 156.7, 152.5, 147.7, 130.9, 127.6, 121.8, 120.7,
119.5, 117.9, 115.8, 115.6, 99.6, 58.5, 53.6, 50.3, 44.3, 23.5.
MS (ESI): m/z 433.20099 M + H (calculated 433.20122)
HPLC (method A) tR = 8.94 min (99% pure).

PL316: 7-trifluoromethyl-N-(3-(4-(4-methoxyphenyl)piperazin-1-yl)propyl)quinolin4-amine

HN

N
N

F 3C

N

PL316

O

3-(7-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (1.04 g, 3.0 mmol),
N-(p-methoxyphenyl)piperazine (0.29 g, 1.5 mmol), N-(p-methoxyphenyl)piperazine
dihydrochloride (0.44 g, 1.7 mmol), potassium carbonate (1.08 g, 7.8 mmol), and a
catalytic amount of potassium iodide were heated at reflux in anhydrous acetonitrile (25
mL) for 5 days, whereupon TLC indicated that reaction was complete. The solvent was
removed by evaporation under reduced pressure with warming, and the resulting golden
brown, thick oil was partitioned between ethyl acetate (25 mL) and water (25 mL). After
separation, the aqueous layer was extracted with further ethyl acetate (3 x 7 mL), and the
pooled organic layers were dried over magnesium sulfate, followed by evaporation and
recrystallization of the residue from 95% ethanol; the desired product was recovered as
large, colorless crystals (0.52 g, 39%, mp = 155.9-157.2°C).
1

H NMR δ (ppm)(CHCl3-d): 8.60 (1 H, d, J = 5.33 Hz, Q-C2-H), 8.24 (1 H, d, J = 1.70
Hz, Q-C8-H), 8.01 (1 H, d, J = 8.73 Hz, Q-C5-H), 7.54 (1 H, br t, J = 4.19 Hz), 7.43 (1 H,
dd, J = 8.70, 1.88 Hz, Q-C6-H), 6.94-6.97 (2 H, m, Ph-H, ortho to -OCH3), 6.89-6.92 (2
H, m, Ph-H, meta to OCH3), 6.43 (1 H, d, J = 5.37 Hz, Q-C3-H), 3.81 (3 H, s, OCH3),
3.43 (2 H, td, J = 5.89, 4.15 Hz, Q-NH-CH2CH2CH2), 3.24 (4 H, m, Pip-CH2 x 2,
adjacent to Ph), 2.76 (4 H, m, Pip-CH2 x 2, not adjacent to Ph), 2.71 (2 H, t, J = 5.34 Hz,
Q-NH-CH2CH2CH2), 2.01 (2 H, apparent p, J = 5.51 Hz, Q-NH-CH2CH2CH2).
19

F NMR δ (ppm)(CHCl3-d): -63.1.
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13

C NMR δ (ppm)(CHCl3-d): 154.2 (Ph-C ipso to OCH3), 152.5 (Q-C2), 150.3 (Q-C4),
147.8 (Q-C), 145.5 (Ph-C, para to OCH3), 130.7 (q, JF = 31.9 Hz, Q-C7), 127.6 (q, JF =
4.5 Hz, Q-C8), 124.1 (q, JF =175.1 Hz, CF3), 122.0 (Q-C5), 120.8 (Q-C), 119.6 (q, JF =
2.7 Hz, Q-C6), 118.4 (Ph-C, ortho to OCH3), 114.7 (Ph-C, meta to OCH3), 99.6 (Q-C3),
58.7 (Q-NH-CH2CH2CH2), 55.6 (OCH3), 53.8 (Pip-CH2 x 2, not adjacent to Ph), 50.9
(Pip-CH2 x 2, adjacent to Ph), 44.5 (Q-NH-CH2CH2CH2), 23.6 (Q-NH-CH2CH2CH2).
MS (ESI): m/z 445.22082 M + H (calculated 445.22097)
HPLC (method A) tR = 8.60 min (>99% pure).

A.3.5: 8-trifluoromethylquinolines
3-carboxy-8-trifluoromethyl-4-quinolone (Price, 1946; Allais, 1969)

O
+
NH 2
CF 3

EtO

O

O

OEt

OEt
OEt

O

Dowtherm A
255oC

CF 3

N
H

O

1) 10% NaOH,
reflux

O
OH

2) HCl
CF 3

N
H

ortho-Trifluoromethyl aniline (7.19 mL, 58.0 mmol) and diethyl ethoxymethylene
malonate (11.63 mL, 58.0 mmol) in Dowtherm A (80 mL) were allowed to heat
gradually, stirring, to 255°C, at which temperature the reaction was allowed to remain for
20 minutes. After cooling, the reaction mixture was diluted with hexanes (100 mL) and
vacuum filtered, rinsing with additional hexanes (250 mL) followed by acetone (150
mL). The resulting solid was allowed to reflux in 10% caustic soda (200 mL) for 20
hours. After cooling partially, the reaction was made acidic by addition of 3 M muriatic
acid. The resulting off-white precipitate was recovered by vacuum filtration. After air
drying, yield was 7.31 g (49%, possibly containing residual water).
1

H NMR δ (ppm)(CH3OH-d4): 8.68 (1 H, s), 8.58 (1 H, d, J = 8.16 Hz), 8.14 (1 H, d, J =
7.50 Hz), 7.62 (1 H, t (presumably dd), J = 7.85 Hz).
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8-trifluoromethyl-4-quinolone (Price, 1946; Allais, 1969)
O

CF 3

N
H

3-carboxy-8-trifluoromethyl-4-quinolone (7.31 g, 28.4 mmol) was heated in Dowtherm A
(100 mL) at 255°C for 30 minutes. After cooling, NMR indicated that reaction was not
complete; the reaction was therefore returned to reflux for an additional 30 minutes.
After cooling, the reaction mixture was diluted with hexanes (100 mL) and vacuum
filtered, rinsing with additional hexanes (250 mL) to yield the desired product (5.33 g,
88%).

4-chloro-8-(trifluoromethyl)quinoline (Price, 1946; Allais, 1969)

Cl

N
CF 3

Phosphorus oxychloride (25 mL, 268 mmol) was cautiously added to 8-trifluoromethyl4-quinolone (3.76 g, 17.6 mmol), followed by heating at 110°C for 2.5 h. After cooling,
the reaction mixture was gradually poured into ice water with vigorous stirring. After
resting, and without basifying, the aqueous mixture (800 mL) was extracted with
dichloromethane (500mL, then 5 x 100 mL) to provide the desired product as a tan,
crystalline solid (3.80 g, 93%, mp = 79.5-81.2°C (lit. 78°C (Allais, 1969)).
1

H NMR δ (ppm)(CHCl3-d): 8.95 (1 H, d, J = 4.71 Hz), 8.48 (1 H, d, J = 8.55 Hz), 8.15
(1 H, d, J = 7.33 Hz), 7.71 (1 H, t, J = 7.93 Hz), 7.61 (1 H, d, J = 4.71 Hz).
19

F NMR δ (ppm)(CHCl3-d): -60.1.
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3-(8-(trifluoromethyl)quinolin-4-ylamino)propanol

HN

OH

N
CF 3

4-chloro-8-(trifluoromethyl)quinoline (20.49 g, 88.5 mmol) and 3-amino-1-propanol
(43.0 mL, 562 mmol) were allowed to heat at 110°C for 1.5 hours, at the end of which
time TLC indicated that reaction was complete. The hot reaction mixture was therefore
poured into 500 mL deionized water, with vigorous agititation. The resulting precipitate
was recovered by vacuum filtration. Upon drying, the product was an off-white powder
(21.53 g, 90%, mp = 162.6-163.7°C).
1

H NMR δ (ppm)(DMSO-d6): 8.52 (1 H, d, J = 8.53 Hz), 8.49 (1 H, d, J = 5.43 Hz), 8.01
(1 H, d, J = 7.29 Hz), 7.52 (1 H, t, J = 7.88 Hz), 7.42 (1 H, t, J = 5.37 Hz), 6.58 (1 H, d, J
= 5.49 Hz), 4.60 (1 H, t, J = 5.06 Hz), 3.55 (2 H, m), 3.36-3.38 (water signal overlaps m,
~2 H), 1.79-1.87 (2 H, m).
1

H NMR δ (ppm)(CHCl3-d): 8.69 (1 H, d, J = 5.37 Hz), 7.96 (2 H, m), 7.43 (1 H, t, J =
7.89 Hz), 6.50 (1 H, d, J = 5.40 Hz), 6.05 (1 H, br s), 3.98 (2 H, t, J = 5.39 Hz), 3.49 (2 H,
m), 2.06 (2 H, m).
19

F NMR δ (ppm)(DMSO-d6): -58.6.

MS (ESI): m/z 271.10583 M + H (calculated 271.10527)
HPLC (method A) tR = 7.98 min (>99% pure).

3-(8-trifluoromethyl-quinolin-4-ylamino)propyl methanesulfonate

HN

OMs

N
CF 3
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3-(8-(trifluoromethyl)quinolin-4-ylamino)propanol (21.53 g, 79.7 mmol) and
triethylamine (20.0 mL, 140 mmol) in anhydrous chloroform (500 mL) were cooled to
below 0°C on ice/salt, and methanesulfonyl chloride (12.0 mL, 154 mmol) was gradually
added. After stirring 1.5 hours on ice, TLC indicated that reaction was not complete.
Additional methanesulfonyl chloride (1.70 mL, 2.19 mmol) was added; after an
additional hour of stirring, TLC indicated that reaction was complete. The reaction
mixture was shaken with saturated sodium bicarbonate (150 mL), and the aqueous layer
was then extracted with 3 x 20 mL chloroform. Upon standing, a fine, needlelike
precipitate appeared in the pooled organic layers; this was recovered by filtration. NMR
indicated that this material was the desired product (a white, crystalline solid, 5.87 g, mp
= 141.6-142.8°C). The filtrate was dried over magnesium sulfate and evaporated under
reduced pressure with warming to yield a tan solid. NMR indicated that this, too, was the
desired product (20.97 g; total yield 26.84 g, 97%).
1

H NMR δ (ppm)(DMSO-d6): 8.50-8.51 (2 H, m), 8.03 (1 H, d, J = 7.28 Hz), 7.54 (1 H, t,
J = 7.88 Hz), 7.46 (1 H, t, J = 5.41 Hz), 6.62 (1 H, d, J = 5.47 Hz), 4.36 (2 H, t, J = 6.18
Hz), 3.42 (2 H, m), 3.20 (3 H, s), 2.05-2.13 (2 H, m).
19

F NMR δ (ppm)(DMSO-d6): -58.6.

MS (ESI): m/z 349.08340 M + H (calculated 349.08282)
HPLC (method A) tR = 9.28 min (99% pure)
Note: HPLC and MS data are of the precipitate, which is presumed to be of atypically
high purity for a 3-(quinoline-4-ylamino)propyl methanesulfonate produced by this
method.

PL149: N-(3-(4-benzhydrylpiperazin-1-yl)propyl)-8-(trifluoromethyl)quinolin-4amine

HN

N
N

N

PL149

CF 3

3-(8-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (1.67 g, 4.79 mmol),
1-benzyhydrylpiperazine (1.26 g, 4.99 mmol), and potassium carbonate (0.82 g, 5.9
mmol) were heated at reflux in anhydrous acetonitrile (22 mL) for 24 hours, whereupon
TLC indicated that reaction was complete. The solvent was removed by evaporation
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under reduced pressure with warming, and the residue was partitioned between
dichloromethane (35 mL) and water (35 mL). After separation, the aqueous layer was
extracted with further dichloromethane (3 x 10 mL), and the pooled organic layers were
dried over magnesium sulfate followed by evaporation under reduced pressure with
warming. Recrystallization of the residue from 95% ethanol provided the desired product
as a cream-colored solid (0.44 g, 18%, mp = 205-208°C).
1

H NMR δ (ppm)(CHCl3-d): 8.65 (1 H, d, J = 5.36 Hz), 8.10 (1 H, d, J = 8.46 Hz), 7.99
(1 H, d, J = 7.27 Hz), 7.71 (1 H, br t, J = 3.97 Hz), 7.41-7.47 (4 H, m), 7.31 (4 H, m),
7.22-7.27 (solvent signal overlaps m, ~3 H), 6.39 (1 H, d, J = 5.41 Hz), 4.38 (1 H, s), 3.37
(2 H, td, J = 5.78, 4.02 Hz), 2.65 (10 H, br s overlaps t, J = 5.43 Hz), 1.94 (2 H, apparent
p, J = 5.37 Hz).
19

F NMR δ (ppm)(CHCl3-d): 0.5, -60.3.

13

C NMR δ (ppm)(CHCl3-d): 152.0, 150.7, 145.4, 142.1, 130.5, 128.6, 128.1, 127.1,
125.5, 122.2, 119.8, 118.4, 116.2, 98.9, 76.3, 58.9, 54.0, 51.8, 44.5, 23.3.
MS (ESI): m/z 505.25751 M + H (calculated 505.25736)
HPLC (method A) tR = 10.70 min (94% pure).

PL281: 8-trifluoromethyl-N-(3-(4-(pyridin-2-yl)piperazin-1-yl)propyl)quinolin-4amine

HN

N
N

N

PL281

N

CF 3

3-(8-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (1.67 g, 4.79 mmol),
1-(2-pyridyl)piperazine (0.92 g, 5.6 mmol), and potassium carbonate (0.98 g, 7.1 mmol)
were heated at reflux in anhydrous acetonitrile (24 mL) for 2 days. By analogy to other
reactions of this type, the reaction was vacuum filtered to remove precipitated product;
however, after water rinsing, no solid was collected. After allowing the filtrate to stand
overnight, crystallization was noted. These crystals were recovered by filtration, rinsing
with a few drops of 95% ethanol and acetone. NMR indicated that this material was the
desired product (tan crystals, 0.53 g, 27%, mp = 122.8-127.1°C).
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1

H NMR δ (ppm)(CHCl3-d): 8.67 (1 H, d, J = 5.37 Hz), 8.24-8.24 (1 H, m), 8.09 (1 H, d,
J = 8.46 Hz), 7.93 (1 H, d, J = 7.29 Hz), 7.53-7.53 (1 H, m), 7.43 (1 H, br t, J = 4.14 Hz),
7.30 (1 H, dd, J = 8.42, 7.28 Hz), 6.68-6.69 (2 H, m), 6.45 (1 H, d, J = 5.41 Hz), 3.69 (4
H, m), 3.43 (2 H, td, J = 5.93, 4.19 Hz), 2.69-2.70 (6 H, m), 2.02 (2 H, apparent p, J =
5.59 Hz).
13

C NMR δ (ppm)(CHCl3-d): 159.4, 152.0, 150.5, 148.1, 145.4, 137.7, 127.6, 127.5,
124.9, 122.5, 119.8, 113.8, 107.2, 99.1, 58.7, 53.5, 45.4, 44.3, 23.6.
MS (ESI): m/z 416.20568 M + H (calculated 416.20566)
HPLC (method A) tR = 5.31 min (99% pure).

PL268: 8-trifluoromethyl-N-(3-(4-(dipyridin-2-ylmethyleneamino)piperidin-1yl)propyl)quinolin-4-amine

HN

N

N
N

N

N

PL268

CF 3

3-(8-trifluoromethyl-4-ylamino)propyl methanesulfonate (9.50 g, 27 mmol), N(dipyridin-2-methylene)piperidin-4-amine (7.60 g, 29 mmol), and triethylamine (5.70
mL, 41 mmol) were heated in anhydrous acetonitrile (50 mL) at reflux for 2 days, at the
end of which time TLC indicated that the reaction had gone to completion. The solvent
was then removed under reduced pressure with warming and the resulting
inhomogeneous brown solid was then partitioned between chloroform (250 mL) and
saturated sodium bicarbonate (50 mL). The aqueous layer was extracted with additional
chloroform (3 x 50 mL), and the pooled chloroform layers were dried over MgSO4 and
evaporated under reduced pressure with warming. The resulting heterogeneous semisolid
was twice recrystallized from 95% ethanol, yielding a sparkling off-white solid (3.52 g,
25%, mp = 185.5-186.6°C).
1

H NMR δ (ppm)(CHCl3-d): 8.74-8.74 (1 H, m), 8.67 (1 H, d, J = 5.33 Hz), 8.51-8.53 (1
H, m), 8.31-8.33 (1 H, m), 8.25 (1 H, d, J = 8.44 Hz), 8.01 (1 H, d, J = 7.24 Hz), 7.95 (1
H, br t, J = 4.00 Hz), 7.80-7.84 (2 H, m), 7.55 (1 H, t, J = 7.81 Hz), 7.36 (1 H, ddd, J =
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7.69, 4.93, 1.20 Hz), 7.29-7.29 (2 H, m), 6.41 (1 H, d, J = 5.39 Hz), 3.38-3.39 (3 H, m),
3.05-3.08 (2 H, m), 2.60 (2 H, t, J = 5.05 Hz), 2.01-2.13 (4 H, m), 1.95 (2 H, apparent p, J
= 5.35 Hz), 1.77-1.93 (2 H, m).
19

F NMR δ (ppm)(CHCl3-d): -60.7.

13

C NMR δ (ppm)(CHCl3-d): 165.5, 157.1, 155.7, 152.0, 150.8, 149.8, 148.8, 145.4,
136.4, 136.0, 127.5, 125.6, 124.2, 123.4, 123.1, 122.5, 122.2, 120.0, 118.4, 116.2, 98.9,
59.0, 55.8, 52.2, 44.7, 33.0, 23.6.
MS (ESI): m/z 519.24853 M + H (calculated 519.24786)
HPLC (method A) tR = 1.49 min (>99% pure).

PL269: 8-trifluoromethyl-N-(3-(4-(dipyridin-2-ylmethylamino)piperidin-1yl)propyl)quinolin-4-amine

HN

N

N

N

PL269

N
H

N

CF 3

PL 268 (3.44g, 6.63 mmol) was dissolved in anhydrous methanol (40 mL) to which
sodium borohydride (0.70g, 19 mmol) was then cautiously added. After stirring at room
temperature for one hour, TLC indicated that the reaction had not gone to completion,
and so additional sodium borohydride was added in several portions (in total an
additional 0.70 g, 19 mmol) until TLC indicated that the reaction had gone to completion
(after a further hour). After removal of methanol by evaporation under reduced pressure
with warming, 25 mL water was added and stirring was continued 1 hour. The aqueous
mixture was then extracted with chloroform (20 mL followed by three additional 10 mL
portions), and the chloroform layers were dried (MgSO4) and evaporated under reduced
pressure to yield a pale yellow glass (2.88 g, 83%, mp = 157.5-159.7°C).
1

H NMR δ (ppm)(CHCl3-d): 8.64 (1 H, d, J = 5.38 Hz), 8.56-8.59 (2 H, m), 8.12 (1 H, d,
J = 8.49 Hz), 7.97 (1 H, d, J = 7.29 Hz), 7.80 (1 H, br t, J = 3.93 Hz), 7.63 (2 H, td, J =
7.68, 1.77 Hz), 7.44-7.50 (3 H, m), 7.15-7.16 (2 H, m), 6.38 (1 H, d, J = 5.42 Hz), 5.25 (1
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H, s), 3.35-3.36 (2 H, m), 2.98-3.01 (2 H, m), 2.62-2.62 (1 H, m), 2.53-2.60 (2 H, m),
1.98-2.01 (4 H, m), 1.91 (2 H, apparent p, J = 5.37 Hz), 1.63-1.64 (2 H, m).
13

C NMR δ (ppm)(CHCl3-d): 162.1, 151.9, 150.7, 149.1, 145.4, 136.7, 127.4 (q, JF = 30.3
Hz, Q-C8-CF3), 125.4, 123.6, 122.5, 122.4, 122.2, 119.9, 98.8, 66.6, 62.5, 58.6, 52.8,
44.5, 33.0, 23.7, 23.7.
19

F NMR δ (ppm)(CHCl3-d): -60.7.

HPLC (method C) tR = 5.68 min (95% pure). MS (ESI): m/z 521.2626 M + H (calculated
521.2635).

PL267: 8-trifluoromethyl-N-(3-(4-(4-(trifluoromethyl)phenyl)piperazin-1yl)propyl)quinolin-4-amine

HN

N
N

N

PL267

CF 3

CF 3

3-(8-trifluoromethyl-4-ylamino)propyl methanesulfonate (4.81 g, 13.8 mmol) 1-(4trifluoromethylphenylpiperazine (3.19 g, 1.4 mmol), and triethylamine (3 mL, 2.2 mmol)
were heated in refluxing acetonitrile (24 mL) for 2 days. TLC indicated that reaction was
complete. The solvent was removed under reduced pressure with warming, and the
residue was partitioned between chloroform (100 mL) and saturated NaHCO3 (100 mL).
After separation of the organic layer, the aqueous layer was extracted with further
chloroform (3 x 50 mL), and the pooled organic layers were dried (MgSO4) and
evaporated under reduced pressure with warming to yield a brown oil. Partial
recrystallization from 95% ethanol followed by recrystallization from chloroform yielded
the desired product as a white, crystalline solid (0.70 g, 11%, mp = 168.8-170.3°C).
1

H NMR δ (ppm)(CHCl3-d): 8.67 (1 H, d, J = 5.36 Hz), 8.04 (1 H, d, J = 8.46 Hz), 7.93
(1 H, d, J = 7.30 Hz), 7.53 (2 H, d, J = 8.57 Hz), 7.29 (1 H, t, J = 4.21 Hz), 7.26 (1 H, t, J
= 7.90 Hz), 6.97 (2 H, d, J = 8.57 Hz), 6.44 (1 H, d, J = 5.41 Hz), 3.38-3.43 (6 H, m),
2.74 (4 H, m), 2.70 (2 H, t, J = 5.45 Hz), 2.01 (2 H, apparent p, J = 5.60 Hz).
19

F NMR δ (ppm)(CHCl3-d): -60.8, -61.9.
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13

C NMR δ (ppm)(CHCl3-d): 153.1, 152.0, 150.4, 145.4, 127.7 (q, JF = 30.6 Hz, C-CF3),
126.6, 124.8, 122.4, 121.1 (q, JF = 32.9 Hz, C-CF3), 119.7, 114.7, 114.7, 99.1, 58.5, 53.3,
48.2, 44.2, 23.7.
MS (ESI): m/z 483.1976 M + H (calculated 483.1978).
HPLC (method C) tR = 10.63 min (97% pure).

PL262: 8-trifluoromethyl-N-(3-(4-(4-methoxyphenyl)piperazin-1-yl)propyl)quinolin4-amine

HN

N
N

N
CF 3

PL262

O

3-(8-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (1.29 g, 3.70 mmol),
N-(p-methoxyphenyl)piperazine dihydrochloride (1.04 g, 3.92 mmol), and potassium
carbonate (1.29 g, 11.5 mmol) were heated at reflux in anhydrous acetonitrile (25 mL) for
5 days, whereupon TLC indicated that reaction was complete. The solvent was removed
by evaporation under reduced pressure with warming, and the residue was partitioned
between water (35 mL) and dichloromethane (30 mL). After separation, the aqueous
layer was extracted with further dichloromethane (3 x 10 mL), and the pooled organic
layers were rinsed with brine (10 mL), then dried over magnesium sulfate and evaporated
under reduced pressure with warming. The residue was purified by column
chromatography on basic alumina, eluting with 3:2 hexanes:ethyl acetate, followed by
recrystallization from ethyl acetate to give the desired product as a cream-colored solid
(0.42 g, 26%, mp = 123-125°C, Rf = 0.7 (basic alumina, 95/5 EA/MeOH v/v)).
1

H NMR δ (ppm)(CHCl3-d): 8.67 (1 H, d, J = 5.36 Hz), 8.13 (1 H, d, J = 8.45 Hz), 7.93
(1 H, d, J = 7.28 Hz), 7.60 (1 H, t, J = 4.08 Hz), 7.28 (1 H, t, J = 7.86 Hz), 6.95-6.96 (2 H,
m), 6.88-6.91 (2 H, m), 6.43 (1 H, d, J = 5.41 Hz), 3.81 (3 H, s), 3.42 (2 H, td, J = 5.84,
4.10 Hz), 3.24 (4 H, m), 2.76 (4 H, m), 2.71 (2 H, t, J = 5.29 Hz), 2.00 (2 H, apparent p, J
= 5.47 Hz).
19

F NMR δ (ppm)(CHCl3-d): -60.8.
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13

C NMR δ (ppm)(CHCl3-d): 154.2, 152.0, 150.6, 145.5, 145.4, 127.5, 125.3, 122.4,
119.8, 118.3, 114.6, 99.0, 58.8, 55.6, 53.8, 50.9, 44.5, 23.5, 23.5.
MS (ESI): m/z 445.22102 M + H (calculated 445.22097)
HPLC (method A) tR = 8.21 min (>99% pure).

A.3.6: 2,8-ditrifluoromethylquinolines
3-(2,8-bis(trifluoromethyl)quinolin-4-ylamino)propanol

HN

N

OH

CF 3

CF 3

4-chloro-2,8-bis(trifluoromethyl)quinoline (0.96 g, 3.2 mmol, purchased from Oakwood
Chemical Company) and 3-amino-1-propanol (2.0 mL, 2.6 mmol) were allowed to heat at
70°C for 1.5 hours, followed by heating at 100ºC for 1 hour. TLC then indicated that
reaction was complete. The hot reaction mixture was partitioned between water (50 mL)
and ethyl acetate (15 mL, then 3 x 10 mL). The pooled organic layers were dried
(MgSO4) and evaporated under reduced pressure with warming to yield the desired
product as a creamy white solid (0.97 g, 91%, mp = 130.5-131.2°C).
1

H NMR δ (ppm)(DMSO-d6): 8.63 (1 H, d, J = 8.57 Hz), 8.15 (1 H, d, J = 7.30 Hz), 8.00
(1 H, t, J = 5.41 Hz), 7.68 (1 H, t, J = 7.92 Hz), 6.90 (1 H, s), 4.63 (1 H, t, J = 5.07 Hz),
3.55 (2 H, m), 3.46 (2 H, m), 1.79-1.89 (2 H, m).
19

F NMR δ (ppm)(DMSO-d6): -58.9, -67.1.
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3-(2,8-bis(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate

HN

N

OMs

CF 3

CF 3

3-(2,8-bis(trifluoromethyl)quinolin-4-ylamino)propanol (1.13 g, 3.71 mmol) and
triethylamine (0.78 mL, 5.6 mmol) in dry THF (50 mL) were cooled to below 0°C on
ice/salt. Methanesulfonyl chloride (0.33 mL, 4.3 mmol) was added dropwise. After
stirring for 1 hour on ice, TLC indicated that reaction was not complete; therefore,
additional methanesulfonyl chloride (0.02 mL, 0.3 mmol) was added and stirring was
continued for a further 15 hours. The reaction mixture was then washed with 100 mL
saturated sodium bicarbonate. The aqueous layer was extracted with ethyl acetate (3 x 10
mL), and the pooled organic layers were rinsed with 10 mL brine, then dried (MgSO4)
and evaporated under reduced pressure with warming to give the desired product as a
cream-colored solid (1.19 g, 84%).
1

H NMR δ (ppm)(DMSO-d6): 8.63 (1 H, d, J = 8.58 Hz), 8.17 (1 H, d, J = 7.31 Hz), 8.01
(1 H, t, J = 5.44 Hz), 7.70 (1 H, t, J = 7.92 Hz), 6.93 (1 H, s), 4.36 (2 H, t, J = 6.14 Hz),
3.52 (2 H, m), 3.20 (3 H, s), 2.09 (2 H, m).
19

F NMR δ (ppm)(DMSO-d6): -58.9, -67.0.

PL280: N-(3-(4-benzhydrylpiperazin-1-yl)propyl)-2,8-di(trifluoromethyl)quinolin-4amine

HN

N
N

N
CF 3

CF 3
PL280

3-(2,8-di(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (1.21 g, 2.91
mmol), 1-benzyhydrylpiperazine (0.79 g, 3.1 mmol), and potassium carbonate (0.62 g,
4.5 mmol) were heated at reflux in anhydrous acetonitrile (25 mL) for 24 hours. TLC
indicated that reaction was complete, and so the solvent was removed under reduced
pressure with warming, and the residue partitioned between chloroform (50 mL) and
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water (50 mL). After separation, the aqueous layer was extracted with further chloroform
(3 x 15 mL) and the pooled organic layers were dried (MgSO4) and evaporated under
reduced pressure with warming. The resulting tan solid was recrystallized from ethyl
acetate (>20 mL) to provide the desired product as a white, crystalline solid (0.50 g, 30%,
mp = 227-229°C).
1

H NMR δ (ppm)(CHCl3-d): 8.19 (1 H, br t, J = 3.90 Hz), 8.12 (1 H, d, J = 8.51 Hz), 8.04
(1 H, d, J = 7.27 Hz), 7.41-7.47 (4 H, m), 7.30-7.33 (5 H, m), 7.23 (2 H, m), 6.65 (1 H, s),
4.40 (1 H, s), 3.40 (2 H, td, J = 5.26, -0.00 Hz), 2.68 (10 H, br s overlaps t, J = 30.53 Hz),
1.96 (2 H, apparent p, J = 5.26 Hz).
19

F NMR δ (ppm)(CHCl3-d): -59.4, -67.6.

13

C NMR δ (ppm)(DMSO-d6): 152.4, 143.8, 142.9, 129.0, 128.5, 127.5, 126.8, 124.4,
119.4, 94.0, 75.2, 55.4, 53.0, 51.5, 41.0, 24.8.
MS (ESI): m/z 573.24611 M + H (calculated 573.24474)

A.3.7: 5- and 7-chloro-2-(trifluoromethyl)-quinolines
5- and 7-chloro-2-trifluoromethyl-4-quinolone (based upon Conrad, 1887; Conrad,
1891; Reynolds, 1955)

Cl

O

O

+
N
H

CF 3

Cl

N
H

CF 3

Ethyl-4,4,4-trifluoroacetoacetate (11.99 g, 65.1 mmol), meta-chloroaniline (8.40 g, 65.8
mmol), and a catalytic amount of para-toluenesulfonic acid were allowed to heat in
refluxing benzene (75 mL) in a flask equipped with a Dean and Stark water separator
topped with stacked Vigreux condensers. After 18 hours, the solvent was removed by
evaporation under reduced pressure with warming to provide a pale yellow, viscous
liquid. This residue was allowed to heat in Dowtherm A (100 mL) to 230ºC, followed by
cooling to room temperature; after standing 18 hours, the reaction was heated to 255ºC
and allowed to remain at this temperature for 45 minutes. The cooled reaction mixture
was filtered without dilution, rinsing with Dowtherm A followed by 35-60º petroleum
æther. This provided a beige powder that was used without further purification (6.61 g,
presumed to contain a mixture of 5- and 7-chloro regioisomers).
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19

F NMR δ (ppm)(DMSO-d6): -66.7, -67.0.

4,5-dichloro-2-(trifluoromethyl)quinoline and 4,7-dichloro-2(trifluoromethyl)quinoline (based upon Steinacker Dey, 1965):

Cl

Cl

Cl

+
N

CF 3

Cl

N

CF 3

Phosphorus oxychloride (39 mL, 418 mmol) was cautiously added to 5- and 7-chloro-2trifluoromethyl-4-quinolone (6.61 g, 26.7 mmol), and the mixture was heated at 110°C
for 1 hour. After cooling, the reaction mixture was gradually poured into ice water with
vigorous stirring. After resting, the aqueous mixture was basified with solid caustic
potash and diluted with water to 1 L. This mixture was extracted with chloroform (200
mL, then 3 x 20 mL), dried (MgSO4), and concentrated under reduced pressure with
warming to yield a dark, olive green liquid. NMR indicated that this contained both 4,5dichloro-2-(trifluoromethyl)quinoline and 4,7-dichloro-2-(trifluoromethyl)quinoline in a
ratio of approximately 2:3. Crystallization from hexanes afforded 4,5-dichloro-2(trifluoromethyl)quinoline alone. Concentration of the mother liquor yielded a second
crop of the same material (1.09 g from both crystallizations, a white, crystalline solid
having a strong odor similar to that of 4,7-dichloroquinoline, 15%, mp = 95.1-97.1°C).
The mother liquor was further concentrated to yield an additional three crops of 4,5dichloro-2-(trifluoromethyl)quinoline. The remaining mother liquor was then allowed to
evaporate to a brown solid. Upon recrystallizing a portion of this material from hexanes,
a mixture of regioiosomers crystallized (approximately 1:9 4,7-dichloro:4,5-dichloro-2(trifluoromethyl)quinoline). A similar result was obtained by crystallizing a second
portion from ethyl acetate. Automated flash chromatography on alumina, eluting with
100% hexanes, achieved only partial separation. The fractions containing more than 50%
of the 4,7-dichloro-2-(trifluoromethyl)quinoline were further purified by automated flash
chromatography on silica, eluting with 100% hexanes. 4,7-dichloro-2(trifluoromethyl)quinoline was obtained as a viscous, colorless liquid; this was allowed to
stand for several days. After disturbance of the liquid by removal of a sample, abrupt
crystallization occurred. The product, a white, crystalline solid (2.00 g, 28%, mp = 40.941.9ºC), had a faint odor like that of 4,7-dichloroquinoline, but this was far less
pronounced than that of the 4,5-dichloro regioisomer.
Characterization data for 4,5-dichloro-2-(trifluoromethyl)quinoline:
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CF 3 Cl

N

CF 3

White crystals, mp = 95.1-97.1°C
Rf = 0.2 (silica, hexanes), 0.3 (basic alumina, hexanes)
1

H NMR δ (ppm)(CHCl3-d): 8.17 (1 H, dd, J = 8.43, 1.34 Hz, Q-C6-H or Q-C8-H), 7.83
(1 H, s, Q-C3-H), 7.78 (1 H, dd, J = 7.58, 1.35 Hz, Q-C8-H or Q-C6-H), 7.71 (1 H, dd, J
= 8.44, 7.58 Hz, Q-C7-H).
19

F NMR δ (ppm)(CHCl3-d): -68.5.

13

C NMR δ (ppm)(CHCl3-d): 150.1, 147.81 (q, JF = 23.14 Hz), 144.0, 132.8 (Q-C8?)
130.8 (Q-C6?), 130.7 (Q-C7), 130.3, 124.6, 120.8 (q, JF = 1.01 Hz), 120.7 (q, JF = 183.82
Hz?), 118.5, 116.2 (if these last two weak peaks are the center of a quartet, 117.4, J =
231 Hz).
GC/MS: tR = 5.32 min, 265 M+ (35Cl2), 100 %, 196 (M-CF3)+, 42%, 161 (M-CF3-Cl)+,
28%, 99 (C8H3)+, 31%, 69 (CF3)+, 11%.
Characterization data for 4,7-dichloro-2-(trifluoromethyl)quinoline:
Cl

Cl

N

CF 3

White crystals, mp = 40.9-41.9ºC
Rf = 0.3 (silica, hexanes), 0.5 (alumina, hexanes)
1

H NMR δ (ppm)(CHCl3-d): 8.26 (1 H, d, J6,8 ~ 1.62 Hz, Q C8-H) 8.24 (1 H, d, J6,5 ~
8.71 Hz, Q C5-H), 7.82 (1 H, s, Q C3-H), 7.73 (1 H, dd, J5,6 = 8.99, J8,6 = 2.10 Hz, Q C6H). Note: Peaks at 8.26 and 8.24 overlap. The estimated peak positions and coupling
constants are provided.
19

F NMR δ (ppm)(CHCl3-d): -68.3.
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13

C NMR δ (ppm)(CHCl3-d): 148.92 (q, JF = 35.2 Hz), 148.3, 144.8, 138.1, 130.8, 129.5,
125.6, 125.6, 120.79 (q, JF = 275.73 Hz?), 119.0, 117.5 (q, JF = 2.37 Hz), 115.7 (if the
last two weak peaks, 117.5 and 119.0, are part of a quartet, J would be 337.11 Hz).
GC/MS: tR = 5.08 min, 265 M+ (35Cl2), 100 %, 196 (M-CF3)+, 42%, 161 (M-CF3-Cl)+,
28%, 99 (C8H3)+, 31%, 69 (CF3)+, 11%.

3-(5-chloro-2-(trifluoromethyl)quinolin-4-ylamino)propanol

Cl HN

N

OH

CF 3

4,5-dichloro-2-(trifluoromethyl)quinoline (1.09 g, 4.08 mmol) and 3-amino-1-propanol
(1.87 mL, 24.4 mmol) were allowed to heat at 80°C for 17 hours, at the end of which
time TLC indicated that reaction was complete. The hot reaction mixture was therefore
poured into 100 mL water, stirring vigorously. After standing 45 minutes, the resulting
precipitate was recovered by vacuum filtration. Upon drying, the product was an offwhite powder (1.13 g, 91%).
1

H NMR δ (ppm)(DMSO-d6): 8.01 (1 H, br t, J = 4.87 Hz), 7.87 (1 H, dd, J = 8.28, 1.48
Hz), 7.66 (1 H, dd, J = 8.25, 7.68 Hz), 7.60 (1 H, dd, J = 7.55, 1.48 Hz), 6.82 (1 H, s),
4.84 (1 H, t, J = 4.87 Hz), 3.61 (2 H, td, J = 5.74, 4.77 Hz), 3.43 (2 H, td, J = 6.57, 4.92
Hz), 1.87 (2 H, apparent p, J = 6.13 Hz).
19

F NMR δ (ppm)(DMSO-d6): -67.0.

3-(5-chloro-2-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate

Cl HN

N

OMs

CF 3

3-(5-chloro-2-trifluoromethylquinolin-4-ylamino)propanol (1.13 g, 3.71 mmol) and
triethylamine (0.78 mL, 5.6 mmol) in dry THF (50 mL) were cooled to below 0°C on
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ice/salt. Methanesulfonyl chloride (0.33 mL, 4.3 mmol) was added dropwise. After
stirring for 1 hour on ice, TLC indicated that reaction was not complete; therefore,
additional methanesulfonyl chloride (0.02 mL, 0.3 mmol) was added and stirring was
continued for a further 15 hours. The reaction mixture was then washed with 100 mL
saturated sodium bicarbonate. The aqueous layer was extracted with ethyl acetate (3 x 10
mL), and the pooled organic layers were rinsed with 10 mL brine, then dried (MgSO4)
and evaporated under reduced pressure with warming to give the desired product as a
cream-colored solid (1.19 g, 84%).
1

H NMR δ (ppm)(DMSO-d6): 7.89 (2 H, br t overlaps dd, J = 8.29, 1.65 Hz), 7.68 (1 H,
dd, J = 8.21, 7.70 Hz), 7.63 (1 H, dd, J = 7.55, 1.51 Hz), 6.88 (1 H, s), 4.37 (2 H, t, J =
6.00 Hz), 3.54 (2 H, td, J = 6.76, 5.23 Hz), 3.20 (3 H, s), 2.12 (2 H, apparent p, J = 6.49
Hz).

PL303: N-(3-(4-benzhydrylpiperazin-1-yl)propyl)-5-chloro-2(trifluoromethyl)quinolin-4-amine

Cl HN

N
N

N

CF 3
PL303

3-(5-chloro-2-trifluoromethylquinolin-4-ylamino)propyl methanesulfonate (1.19 g, 3.1
mmol), potassium carbonate (0.64 g, 4.6 mmol), 1-(diphenylmethyl)piperazine (0.82 g,
3.2 mmol), and a catalytic amount of potassium iodide were allowed to reflux in
anhydrous acetonitrile (22 mL) for 3 days. TLC then indicated that reaction was
complete. The solvent was removed under reduced pressure with warming, and the
residue was partitioned between chloroform (30 mL) and water (30 mL). After
separation, the aqueous layer was extracted with further chloroform (3 x 7 mL), and the
pooled organic layers were dried (MgSO4) and evaporated under reduced pressure with
warming to yield an amber oil. This material was crystallized from 95% ethanol to yield
the desired product as a white, crystalline solid (1.06 g, 65%, mp = 146.5-147.9°C).
1

H NMR δ (ppm)(CHCl3-d): 7.96 (1 H, dd, J = 8.40, 1.39 Hz), 7.65 (1 H, br t, J = 4.80
Hz), 7.51 (1 H, t, J = 8.02 Hz), 7.40-7.44 (5 H, m), 7.25-7.26 (solvent signal overlaps m,
~4 H), 7.13-7.20 (2 H, m), 6.68 (1 H, s), 4.23 (1 H, s), 3.36 (2 H, m), 2.52 (10 H, br s
overlaps t, J = 7.15 Hz), 1.94 (2 H, apparent p, J = 6.78 Hz).
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19

F NMR δ (ppm)(CHCl3-d): 0.5, -68.5.

13

C NMR δ (ppm)(CHCl3-d): 152.7, 150.3, 142.7, 130.5, 129.3, 128.7, 128.5, 128.0,
127.0, 126.9, 121.2, 116.4, 116.2, 95.3, 76.3, 56.1, 53.7, 51.8, 42.2, 25.4.
MS (ESI): m/z 539.22023 M + H (calculated 539.21839)
HPLC (method A) tR = 20.93 min (95% pure).

3-(7-chloro-2-(trifluoromethyl)-quinolin-4-ylamino)propanol

HN

Cl

N

OH

CF 3

4,7-dichloro(2-trifluoromethyl)quinoline (1.00 g, 3.8 mmol) and 3-amino-1-propanol
(1.72 mL, 23 mmol) were combined in a 2-5 mL Biotage microwave vial and heated at
130°C for 20 minutes, whereupon TLC indicated that reaction was complete. The
colorless, semi-solid reaction mixture was stirred vigorously in water (100 mL), followed
by standing for 30 minutes. Filtration yielded a white, crystalline solid, which was
partially recrystallized from a mixture of 95% ethanol and ethyl acetate (~2:3, 30 mL) to
provide the desired product (a white, crystalline solid, 0.91g, 79% ).
1

H NMR δ (ppm)(DMSO-d6): 8.37 (1 H, d, J = 9.07 Hz), 7.93 (1 H, d, J = 2.22 Hz), 7.88
(1 H, br t, J = 5.39 Hz, NH), 7.61 (1 H, dd, J = 9.00, 2.28 Hz), 6.79 (1 H, s), 4.63 (1 H, t,
J = 5.06 Hz, OH), 3.55 (2 H, td, J = 6.01, 5.09 Hz), 3.42 (2 H, td, J = 7.06, 5.41 Hz), 1.83
(2 H, apparent p, J = 6.58 Hz).
19

F NMR δ (ppm)(DMSO-d6): -66.3.

3-(7-chloro-2-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate

HN

Cl

N

OMs

CF 3
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3-(7-chloro-2-trifluoromethylquinolin-4-ylamino)propanol (0.50 g, 1.6 mmol) and
triethylamine (0.33 mL, 2.4 mmol) in dry THF (100 mL) were cooled to 5°C in an ice
bath. Methanesulfonyl chloride (0.15 mL, 1.9 mmol) was added dropwise. After stirring
for 45 minutes on ice, additional methanesulfonyl chloride (0.05 mL, 0.6 mmol) was
added. After a further 20 minutes, TLC indicated that reaction was not complete;
therefore, additional triethylamine (0.20 mL, 1.4 mmol) and methanesulfonyl chloride
(0.03 mL, 0.4 mmol) were added and stirring was continued for a further 20 minutes. The
reaction mixture was then washed with 35 mL saturated sodium bicarbonate. The
aqueous layer was extracted with ethyl acetate (3 x 10 mL), and the pooled organic layers
were rinsed with 15 mL brine, then dried (MgSO4) and evaporated under reduced
pressure with warming to give the desired product as a white solid (0.63 g, ~100%).
1

H NMR δ (ppm)(DMSO-d6): 8.38 (1 H, d, J = 9.07 Hz), 7.95 (1 H, d, J = 2.22 Hz), 7.90
(1 H, t, J = 5.40 Hz), 7.64 (1 H, dd, J = 8.99, 2.26 Hz), 6.82 (1 H, s), 4.36 (2 H, t, J = 6.12
Hz), 3.48 (2 H, td, J = 7.02, 5.42 Hz), 3.19 (3 H, s), 2.09 (2 H, apparent p, J = 6.54 Hz).
19

F NMR δ (ppm)(DMSO-d6): -66.2.

PL398: 7-chloro-2-(trifluoromethyl)-N-(3-(4-(pyridin-2-yl)piperazin-1yl)propyl)quinolin-4-amine

HN

N
N

Cl

N

CF 3

N

PL398

3-(7-chloro-2-trifluoromethylquinolin-4-ylamino)propyl methanesulfonate (0.61 g, 1.6
mmol), 1-(2-pyridyl)piperazine (0.27 g, 1.6 mmol), potassium carbonate (0.33 g, 2.4
mmol), and a catalytic amount of potassium iodide were heated at reflux in anhydrous
acetonitrile (24 mL) for 18 hours. The reaction mixture was diluted with water (5 mL),
and the solvent was removed under reduced pressure with warming. The residue was
partitioned between chloroform (35 mL) and water (30 mL). After separation, the
aqueous layer was extracted with chloroform (3 x 5 mL), and the pooled organic layers
were dried over magnesium sulfate and evaporated under reduced pressure with warming.
The resulting beige solid was recrystallized from 3 mL ethyl acetate to provide the
desired product as glittering, white crystals (0.34 g, 47%).
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1

H NMR δ (ppm)(CHCl3-d): 8.24 (1 H, m), 8.03 (1 H, d, J = 2.14 Hz), 7.86 (1 H, t, J =
4.11 Hz), 7.82 (1 H, d, J = 8.97 Hz), 7.55 (1 H, ddd, J = 8.47, 7.25, 2.02 Hz), 7.29 (1 H,
dd, J = 8.94, 2.16 Hz), 6.70-6.70 (2 H, m), 6.63 (1 H, s), 3.68-3.69 (4 H, m), 3.47 (2 H,
td, J = 5.87, 4.08 Hz), 2.70-2.71 (6 H, m), 1.97-2.06 (2 H, m).
13

C NMR δ (ppm)(CHCl3-d): 159.3, 152.0, 150.0 (q, JF = 33.1 Hz), 148.2, 148.1, 137.7,
135.9, 129.4, 126.5, 121.9, 121.8 (q, JF = 275 Hz), 117.4, 113.9, 107.2, 94.1 (q, JF = 2.2
Hz), 58.8, 53.5, 45.3, 44.6, 23.2.
19

F NMR δ (ppm)(CHCl3-d): -68.8.

HPLC (method A) tR = 11.81 min (>99% pure).

A.3.8: 7-chloro-2-methylquinolines
3-(2-methyl-7-chloroquinolin-4-ylamino)propanol

HN

Cl

N

OH

CH 3

4,7-dichloro(2-methyl)quinoline (0.50 g, 2.4 mmol, purchased from Sigma Aldrich) and
3-amino-1-propanol (1.7 mL, 22 mmol) were combined in a 2-5 mL Biotage microwave
vial and heated at 130°C for 20 minutes, whereupon TLC indicated that reaction was
complete. The strawberry-colored reaction mixture was poured into water (100 mL) with
vigorous stirring, followed by standing for 20 minutes. Filtration yielded a pale pink
solid, which was partially recrystallized from a mixture of 95% ethanol and ethyl acetate
(~1:9, 5 mL) to provide the desired product (a pinkish mauve, granular solid, 0.32g,
53%).
1

H NMR δ (ppm)(DMSO-d6): 8.18 (1 H, d, J = 8.98 Hz), 7.68 (1 H, d, J = 2.24 Hz), 7.36
(1 H, dd, J = 8.92, 2.27 Hz), 7.14 (1 H, br t, J = 5.30 Hz), 6.38 (1 H, s), 4.58 (1 H, t, J =
5.06 Hz), 3.54 (2 H, td, J = 6.12, 5.04 Hz), 3.31 (water signal overlaps m, ~2 H), 2.45 (3
H, s), 1.82 (2 H, apparent p, J = 6.65 Hz).
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3-(7-chloro-2-methylquinolin-4-ylamino)propyl methanesulfonate

HN

Cl

N

OMs

CH 3

3-(7-chloro-2-methylquinolin-4-ylamino)propanol (0.27 g, 1.1 mmol) and triethylamine
(0.23 mL, 1.6 mmol) in dry THF (100 mL) were cooled to 5°C in an ice bath.
Methanesulfonyl chloride (0.10 mL, 1.3 mmol) was added dropwise. After stirring for 45
minutes on ice, additional methanesulfonyl chloride (0.03 mL, 0.4 mmol) was added.
After a further 20 minutes, TLC indicated that reaction was complete. The reaction
mixture was washed with 35 mL saturated sodium bicarbonate. The aqueous layer was
extracted with ethyl acetate (3 x 10 mL), and the pooled organic layers were dried
(MgSO4) and evaporated under reduced pressure with warming to give the desired
product as a white solid (0.24 g, 72%).
1

H NMR δ (ppm)(DMSO-d6): 9.17 (1 H, br t, J = 5.52 Hz), 8.52 (1 H, d, J = 9.09 Hz),
7.91 (1 H, d, J = 2.12 Hz), 7.75 (1 H, dd, J = 9.01, 2.12 Hz), 6.83 (1 H, s), 4.35 (2 H, t, J
= 6.08 Hz), 3.60 (2 H, td, J = 6.98, 5.48 Hz), 3.21 (3 H, s), 2.65 (3 H, s), 2.12 (2 H,
apparent p, J = 6.55 Hz).

PL399: 7-chloro-2-methyl-N-(3-(4-(pyridin-2-yl)piperazin-1-yl)propyl)quinolin-4amine

HN

N
N

Cl

N

CH 3

N

3-(7-chloro-2-methylquinolin-4-ylamino)propyl methanesulfonate (0.24 g, 0.73 mmol),
1-(2-pyridyl)piperazine (0.12 g, 0.73 mmol), potassium carbonate (0.15 g, 1.1 mmol),
and a catalytic amount of potassium iodide were heated at reflux in anhydrous
acetonitrile (24 mL) for 18 hours. After dilution of the reaction mixture with water (5
mL), the solvent was removed under reduced pressure with warming; the residue was
partitioned between chloroform (25 mL) and water (20 mL) and separated. The aqueous
layer was then extracted with chloroform (3 x 5 mL), and the pooled organic layers were
dried over magnesium sulfate and evaporated under reduced pressure with warming. The
resulting pale amber oil was taken up in 1 mL ethyl acetate. Upon standing,
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crystallization occurred; vacuum filtration provided the desired product as white crystals
(0.07 g, 24%).
1

H NMR δ (ppm)(CHCl3-d): 8.24 (1 H, m), 7.86 (1 H, d, J = 2.14 Hz), 7.73 (1 H, d, J =
8.89 Hz), 7.52-7.53 (1 H, m), 7.18 (1 H, dd, J = 8.86, 2.16 Hz), 7.11 (1 H, t, J = 4.21 Hz),
6.69 (2 H, m), 6.26 (1 H, s), 3.67 (4 H, m), 3.41 (2 H, td, J = 5.96, 4.30 Hz), 2.65-2.70 (6
H, m), 2.59 (3 H, s), 1.99 (2 H, apparent p, J = 5.64 Hz).
13

C NMR δ (ppm)(CHCl3-d): 160.9, 159.4, 150.4, 149.0, 148.1, 137.7, 134.7, 128.0,
124.1, 121.6, 116.1, 113.8, 107.1, 98.8, 58.6, 53.5, 45.3, 44.2, 25.8, 23.8.
HPLC (method A) tR = 2.01 min (85%), 1.54 min (14%).

A.4: 7-hydroquinolines
3-carbethoxy-4-quinolone (Price, 1946; Hauser, 1950)

O

O
OEt

N
H

Aniline (10.0 mL, 110 mmol) and diethyl ethoxymethylene malonate (21.99 mL, 110
mmol) were heated in refluxing Dowtherm A (100 mL) for 30 minutes. After cooling,
the reaction mixture was diluted with hexanes (150 mL) and vacuum filtered, rinsing with
further hexanes (200 mL), followed by acetone (100 mL). The product was obtained as
grayish beige, powdery solid (13.87 g, 58%).
1

H NMR δ (ppm)(DMSO-d6): 12.31 (1 H, s), 8.54 (1 H, s), 8.16 (1 H, dd, J = 8.09, 1.47
Hz), 7.71 (1 H, ddd, J = 8.27, 6.99, 1.54 Hz), 7.62 (1 H, dd, J = 8.24, 1.07 Hz), 7.42 (1 H,
ddd, J = 8.08, 6.99, 1.17 Hz), 4.22 (2 H, q, J = 7.10 Hz), 1.28 (3 H, t, J = 7.10 Hz).
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3-carboxy-8-chloro-4-quinolone (Price, 1946; Hauser, 1950)
O

O
OH

N
H

3-carbethoxy-4-quinolone (13.87 g, 63.9 mmol) was heated at reflux in 200 mL of 10%
caustic soda for 18 hours. The hot reaction mixture was poured into 300 mL water, then
made acidic by the addition of concentrated muriatic acid. After cooling, vacuum
filtration followed by air-drying provided the desired product as a white solid (12.20 g,
containing residual water). This material was used without further drying in the ensuing
reaction.
1

H NMR δ (ppm)(DMSO-d6): 15.36 (1 H, br s), 13.48 (1 H, br s), 8.90 (1 H, s), 8.31 (1
H, d, J = 8.15 Hz), 7.90 (1 H, m), 7.84 (1 H, d, J = 8.35 Hz), 7.62 (1 H, m).

4-quinolone (Price, 1946; Hauser, 1950)
O

N
H

3-carboxy-4-quinolone from the above reaction (12.06 g, containing residual water) was
heated in Dowtherm A (100 mL) at reflux for 40 minutes. After cooling, the reaction
mixture was diluted with 100 mL hexanes and allowed to sit for 48 hours, followed by
vacuum filtration, rinsing with further hexanes (300 mL) to provide the product as an offwhite, powdery solid (9.28 g, ~100% from 3-carbethoxy-4-quinolone).
1

H NMR δ (ppm)(DMSO-d6): 11.74 (1 H, s), 8.09 (1 H, dd, J = 8.08, 1.47 Hz), 7.89 (1 H,
dd, J = 7.39, 5.89 Hz), 7.64 (1 H, ddd, J = 8.34, 6.94, 1.56 Hz), 7.54 (1 H, d, J = 8.31 Hz),
7.31 (1 H, ddd, J = 8.09, 6.94, 1.12 Hz), 6.03 (1 H, dd, J = 7.38, 1.22 Hz).
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4-chloroquinoline (Price, 1946; Hauser, 1950)

Cl

N

4-quinolone (9.28 g, 63.9 mmol) and phosphorus oxychloride (35 mL, 375 mmol) were
heated at 110ºC for 2.5 hours, whereupon TLC indicated that the reaction was complete.
After cooling, the reaction mixture was poured cautiously onto ice, stirring vigorously.
After resting, the aqueous mixture was made basic to litmus by the addition of solid
caustic potash (final volume 800 mL). After cooling, this mixture was extracted with
chloroform (200 mL followed by 3 x 20 mL), and the pooled organic layers were dried
(MgSO4) and evaporated under reduced pressure with warming to yield the desired
product as a viscous, aromatic liquid. After offgassing for several days, followed by
storage for several years in a closed vial, this became a beige solid (9.42 g, 90%, mp =
25.9-28.1°C (lit. 34-35°C; Hauser, 1950)).
1

H NMR δ (ppm)(CHCl3-d): 8.80 (1 H, d, J = 4.70 Hz), 8.25 (1 H, dd, J = 8.42, 1.38 Hz),
8.14 (1 H, dd, J = 8.48, 1.11 Hz), 7.79 (1 H, ddd, J = 8.49, 6.89, 1.44 Hz), 7.66 (1 H, ddd,
J = 8.42, 6.90, 1.23 Hz), 7.51 (1 H, d, J = 4.70 Hz).

3-(quinolin-4-ylamino)propanol

HN

OH

N

4-chloroquinoline (3.00 g, 18.3 mmol) and 3-amino-1-propanol (8.42 mL, 110 mmol)
were heated at 70°C in a Carius vessel for 24 hours. TLC indicated that the reaction was
not complete. The temperature was increased to 90°C, and heating was continued for a
further 6 days. Reaction was found to be complete by TLC, and the thick reaction
mixture was poured without cooling into water (300 mL). After resting for 20 minutes,
the resulting precipitate was recovered by vacuum filtration to give the desired product as
a creamy white, sparkling solid (3.60 g, 97%, mp = 148.7-149.7°C).
1

H NMR δ (ppm)(DMSO-d6): 8.38 (1 H, d, J = 5.30 Hz), 8.18 (1 H, dd, J = 8.42, 1.33
Hz), 7.76 (1 H, dd, J = 8.37, 1.26 Hz), 7.59 (1 H, ddd, J = 8.39, 6.77, 1.37 Hz), 7.40 (1 H,
ddd, J = 8.40, 6.77, 1.35 Hz), 7.13 (1 H, t, J = 5.39 Hz), 6.44 (1 H, d, J = 5.35 Hz), 4.59
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(1 H, t, J = 5.06 Hz), 3.55 (2 H, m), 3.32-3.36 (water signal overlaps m, ~2 H), 1.83 (2 H,
apparent p, J = 6.65 Hz).
MS (ESI): m/z 203.11814 M + H (calculated 203.11789)
HPLC (method A) tR = 6.47 min (99% pure).

3-(quinolin-4-ylamino)propyl methanesulfonate

HN

OMs

N

3-(quinolin-4-ylamino)propanol (0.50 g, 2.5 mol) and triethylamine (0.52 mL, 3.7 mmol)
were taken up in 50 mL anhydrous dichloromethane and chilled to below 0°C in an icesalt bath. Methanesulfonyl chloride (0.22 mL, 2.8 mmol) was gradually added and
stirring on ice was continued for 1 hour. TLC indicated that the reaction was not
complete. The flask was sealed and stored at 5°C for 18 hours. Further triethylamine
(1.00 mL, 7.2 mmol) and methanesulfonyl chloride (0.12 mL, 1.5 mmol) were then
added. After thirty minutes, TLC indicated that reaction was complete. The reaction
mixture was washed with saturated NaHCO3 (25 mL), and the aqueous layer was then
extracted with dichloromethane (3 x 7 mL). The pooled organic layers were dried over
magnesium sulfate and evaporated under reduced pressure with warming to yield a cream
colored solid (0.61 g, 88%).
1

H NMR δ (ppm)(DMSO-d6): 8.40 (1 H, d, J = 5.31 Hz), 8.20 (1 H, dd, J = 8.45, 1.31
Hz), 7.78 (1 H, dd, J = 8.39, 1.25 Hz), 7.61 (1 H, ddd, J = 8.42, 6.78, 1.31 Hz), 7.42 (1 H,
ddd, J = 8.42, 6.78, 1.33 Hz), 7.17 (1 H, br t, J = 5.45 Hz), 6.48 (1 H, d, J = 5.36 Hz),
4.35 (2 H, t, J = 6.21 Hz), 3.39 (2 H, m), 3.20 (3 H, s), 2.08 (2 H, apparent p, J = 6.61
Hz).
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PL374: N-(3-(4-(dipyridin-2-ylmethyleneamino)piperidin-1-yl)propyl)quinolin-4amine

HN

N

N
N

N

N

PL374

3-(quinolin-4-ylamino)propyl methanesulfonate (1.17 g, 4.2 mmol), PL190 (1.28 g, 4.8
mmol), potassium carbonate (0.87 g, 6.3 mol), and a catalytic amount of potassium iodide
were allowed to reflux in anhydrous acetonitrile (50 mL) for 24 hours, at which time TLC
indicated that reaction was complete. The reaction mixture was diluted with water (5
mL) and evaporated under reduced pressure with warming. The residue was partitioned
between water (25 mL) and chloroform (50 mL). After separation, the aqueous layer was
further extracted with chloroform (3 x 10 mL). The pooled organic layers were dried
(MgSO4) and evaporated under reduced pressure with warming. The resulting thick,
amber oil was purified by flash chromatography on basic alumina, eluting with a gradient
of 100% hexanes to 3/2 hexanes/ethyl acetate (v/v). The resulting tan solid was taken up
in boiling ethyl acetate (40 mL) and the solution was allowed to evaporate at room
temperature to 10 mL. Filtration afforded the desired product as tan crystals (0.63 g,
34%, mp = 171.0-172.5°C).
1

H NMR δ (ppm)(CHCl3-d): 8.73-8.75 (1 H, m), 8.54 (1 H, d, J = 5.26 Hz), 8.51 (1 H,
m), 8.34 (1 H, m), 8.01 (1 H, d, J = 8.37 Hz), 7.97 (1 H, m), 7.81 (2 H, m), 7.63 (1 H, m),
7.57 (1 H, t, J = 4.11 Hz), 7.52 (1 H, m), 7.35 (1 H, m), 7.28 (2 H, m) , 6.35 (1 H, d, J =
5.31 Hz), 3.39 (3 H, m), 3.06 (2 H, m), 2.58 (2 H, td, J = 5.25, 1.20 Hz), 2.13 (2 H, m),
2.03 (2 H, br m), 1.94 (2 H, apparent p, J = 5.39 Hz), 1.83 (2 H, m).
13

C NMR δ (ppm)(CHCl3-d): 165.4, 157.2, 155.8, 151.3, 150.6, 149.7, 148.7, 148.5,
136.4, 136.0, 129.8, 128.9, 124.2, 124.1, 123.4, 123.0, 122.2, 120.8, 119.2, 98.2, 59.0,
58.8, 52.2, 44.4, 33.0, 24.0.
MS (ESI): m/z 451.26047 M + H (calculated 451.26102)
HPLC (method A) tR = 1.15 min (49%), 2.26 min (1%), 9.20 min (50%).
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PL375: N-(3-(4-(dipyridin-2-ylmethylamino)piperidin-1-yl)propyl)quinolin-4-amine

HN

N

N
N
H

N

N

PL375

PL374 (0.58 g, 1.3 mol) was dissolved in anhydrous methanol (40 mL). Sodium
borohydride (0.18 g, 4.8 mmol) was added and the reaction was allowed to stir at room
temperature, equipped with a calcium chloride drying tube, for 1 hour. Additional
sodium borohydride was then added (0.09 g, 2.4 mmol), and stirring was continued for 14
hours, whereupon TLC indicated that the reaction was complete. After removal of the
solvent under reduced pressure with warming, the residue was stirred with water (35
mL), then shaken with 35 mL dichloromethane. After separation, the aqueous layer was
extracted with further dichloromethane (3 x 10 mL), dried (MgSO4), and evaporated
under reduced pressure with warming to yield a pale yellow glass. This material was
allowed to stand overnight, followed by heating at 50ºC in the vacuum oven for 1 hour to
remove residual solvent. The desired product was obtained as a pale yellow glass (0.57
g, 96%, mp = 93.0-98.8°C).
1

H NMR δ (ppm)(CHCl3-d): 8.57-8.57 (2 H, m), 8.52 (1 H, d, J = 5.32 Hz), 7.95 (1 H,
dd, J = 8.43, 1.20 Hz), 7.89 (1 H, dd, J = 8.40, 1.32 Hz), 7.63-7.63 (3 H, m), 7.46-7.48 (4
H, m), 7.15 (2 H, ddd, J = 7.46, 4.88, 1.19 Hz), 6.33 (1 H, d, J = 5.37 Hz), 5.25 (1 H, s),
3.37 (2 H, td, J = 5.88, 4.16 Hz), 2.93-3.05 (2 H, m), 2.54-2.59 (3 H, m), 1.94-1.96 (6 H,
m), 1.66-1.68 (2 H, m).
13

C NMR δ (ppm)(CHCl3-d): 162.1, 151.1, 150.6, 149.1, 148.3, 136.6, 129.6, 128.9,
124.3, 122.4, 122.2, 120.6, 119.1, 98.1, 66.6, 60.4, 58.6, 52.8, 44.3, 33.0, 24.0.
MS (ESI): m/z 453.27612 M + H (calculated 453.27655)
HPLC (method A) tR = 2.41 min (81% pure). (An additional major peak elutes at 1.57
minutes, 16%.)
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A.5: Methylquinolines
A.5.1: 6-Methylquinolines
3-carbethoxy-6-methyl-4-quinolone (Price, 1946; Burckhalter, 1948)
O

O

H 3C

OEt
N
H

para-Toluidine (4.97 g, 46 mmol) and diethyl ethoxymethylene malonate (10.04 g, 46
mmol) were allowed to heat in Dowtherm A (80 mL) to 255ºC. After 20 minutes at this
temperature, the reaction was removed from the heat. Upon cooling, the reaction mixture
was diluted with hexanes (100 mL), and the solid was recovered by vacuum filtration,
rinsing with hexanes (200 mL) followed by acetone (100 mL) to provide the product as a
pinkish tan, powdery solid (5.79 g, 54%).

3-carbethoxy-6-methyl-4-quinolone (Price, 1946; Burckhalter, 1948
O
H 3C

O
OH

N
H

3-carbethoxy-6-methyl-4-quinolone from the above reaction (5.79 g, 25 mmol) was
allowed to heat in 10% sodium hydroxide (200 mL) at reflux for 46 hours. After cooling,
the reaction mixture was diluted to 500 mL and made acidic by the addition of
concentrated muriatic acid. The resulting precipitate was recovered by vacuum filtration
and allowed to air dry (7.25 g, presumed to contain residual water).
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6-methyl-4-quinolone (Price, 1946; Burckhalter, 1948)
O
H 3C
N
H

3-carboxy-6-methyl-4-quinolone from the above reaction (7.25 g, presumed to contain
residual water) was allowed to heat in Dowtherm A (30 mL) to 255ºC, at which
temperature it was allowed to remain for 30 minutes. Upon cooling, the reaction mixture
was diluted with hexanes and the solid material was recovered by vacuum filtration (an
off-white powder, 6.00 g). The product was used without purification in the ensuing
reaction.
1

H NMR δ (ppm)(DMSO-d6): 11.74 (1 H, s), 7.84-7.90 (2 H, m), 7.45-7.47 (2 H, m),
6.00 (1 H, d, J = 7.35 Hz), 2.40 (3 H, s).

4-chloro-6-methylquinoline (Price, 1946; Burckhalter, 1948)

Cl
H 3C
N

6-methyl-4-quinolone (6.00 g) and phosphorus oxychloride (40 mL, 430 mmol) were
allowed to heat at 110ºC for 3 days. After cooling, the reaction mixture was poured
cautiously onto ice (final volume 1.4 L). After resting, the mixture was made basic by
the addition of solid caustic potash, followed by extraction with chloroform (100 mL,
followed by 3 x 50 mL). The pooled chloroform layers were dried over magnesium
sulfate and evaporated under reduced pressure with warming to provide the desired
product as a golden brown, crystalline solid (3.90 g, 48% from para-toluidine, mp =
49.8-53.8°C (lit. 55°C; Burckhalter, 1948)).
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3-(6-methylquinolin-4-ylamino)propanol

HN

OH

H 3C
N

4-chloro-6-methylquinoline (1.96 g, 11 mmol) and 3-amino-1-propanol (5.07 mL, 66
mmol) were heated at 90°C for 24 hours in a Carius vessel, at the end of which time TLC
indicated that the reaction had gone to completion. The hot reaction mixture was poured
into water (200 mL), and after standing 1 hour the resulting precipitate was recovered by
vacuum filtration, followed by air-drying to provide the desired compound (2.20 g, 92%).
1

H NMR δ (ppm)(DMSO-d6): 8.32 (1 H, d, J = 5.27 Hz), 7.98 (1 H, s), 7.66 (1 H, d, J =
8.49 Hz), 7.43 (1 H, dd, J = 8.50, 1.80 Hz), 6.99 (1 H, br t, J = 5.35 Hz), 6.40 (1 H, d, J =
5.31 Hz), 4.59 (1 H, br t, J = 4.99 Hz), 3.55 (2 H, m), 2.47 (3 H, s), 1.80-1.85 (2 H, m).

3-(6-methylquinolin-4-ylamino)propyl methanesulfonate

HN

OMs

H 3C
N

3-(6-methylquinolin-4-ylamino)propanol (2.20 g, 10 mmol) and triethylamine (1.54 g, 15
mmol) in dry tetrahydrofuran (100 mL) were cooled to below 0°C on ice/salt, and
methanesulfonyl chloride (0.91 mL, 12 mmol) was gradually added. After stirring for 2
hours on ice, TLC indicated that the reaction had not gone to completion. Additional
triethylamine (0.51 g, 5.0 mmol) and methanesulfonyl chloride (0.39 mL, 5.0 mmol)
were therefore added. The reaction was sealed and stored at 5ºC for three days, then
diluted with ethyl acetate (50 mL) and rinsed with saturated sodium bicarbonate (50 mL).
The aqueous layer was extracted with further ethyl acetate (3 x 10 mL), and the pooled
organic extracts were washed with brine (10 mL), dried over magnesium sulfate, and
evaporated under reduced pressure with warming to yield the desired product (2.08 g,
containing residual ethyl acetate and triethylamine). This material was used without
further purification in the ensuing reaction.
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PL383: N-(3-(4-benzhydrylpiperazin-1-yl)propyl)-6-methylquinolin-4-amine

HN

N

H 3C

N
N

PL383

3-(6-quinolin-4-ylamino)propyl methanesulfonate (1.04 g, 3.5 mmol), 1benzhydrylpiperazine (0.88 g, 3.5 mmol), potassium carbonate (0.73 g, 5.3 mmol), and a
catalytic amount of potassium iodide were heated at reflux in anhydrous acetonitrile (50
mL) for 4 days, whereupon TLC indicated that reaction was complete. The solvent was
removed under reduced pressure with warming, and the residue was partitioned between
chloroform (50 mL) and water (50 mL), followed by extraction of the aqueous layer with
additional chloroform (3 x 10 mL). The pooled organic layers were dried over
magnesium sulfate and evaporated under reduced pressure with warming. The solid
residue was recrystallized from ethyl acetate/95% ethanol (approximately 9:1). The
desired product was obtained as small, beige crystals (0.34 g, 7.5% from 3-(6methylquinolin-4-ylamino)propanol, mp = 168.9-171.3°C).
1

H NMR δ (ppm)(CHCl3-d): 8.46 (1 H, d, J = 5.24 Hz), 7.87 (1 H, d, J = 8.55 Hz), 7.70
(1 H, s), 7.47 (1 H, dd, J = 8.59, 1.82 Hz), 7.44 (4 H, m), 7.28 (4 H, m), 7.18 (2 H, m),
7.15 (1 H, br t, J = 4.15 Hz), 6.30 (1 H, d, J = 5.29 Hz), 4.31 (1 H, s), 3.35 (2 H, td, J =
5.43, 0.01 Hz), 2.58-2.69 (13 H, br s overlaps s, 2.69 ppm, and t, 2.61 ppm, J = 5.51 Hz),
1.92 (2 H, apparent p, J = 5.49 Hz).
13

C NMR δ (ppm)(CHCl3-d): 150.4, 150.1, 146.9, 142.8, 133.6, 130.9, 129.6, 128.6,
127.8, 127.1, 119.5, 119.0, 98.4, 76.7, 58.9, 54.0, 52.2, 44.5, 23.8, 22.1.
MS (ESI): m/z 451.28603 M + H (calculated 451.28562)
HPLC (method A) tR = 10.40 min (89% pure). (Additional peaks elute at 9.58 minutes,
10%, and 8.03 minutes, 1%.)
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A.5.2: 8-Methylquinolines
3-carbethoxy-8-methyl-4-quinolone (Price, 1946; Burckhalter, 1948)
O

O
OEt

CH 3

N
H

ortho-Toluidine (9.78 mL, 92 mmol) and diethyl ethoxymethylene malonate (18.53 mL,
92 mmol) were allowed to heat in Dowtherm A (200 mL) to 255ºC. After 20 minutes at
this temperature, the reaction was removed from the heat. Upon cooling, the reaction
mixture was diluted with hexanes, and the solid was recovered by vacuum filtration,
rinsing with hexanes followed by acetone (an off-white powder, 19.53 g, 92%).

3-carboxy-8-methoxy-4-quinolone (Price, 1946; Burckhalter, 1948)
O

O
OH

CH 3

N
H

3-carbethoxy-8-methyl-4-quinolone from the above reaction (19.53 g) was allowed to
heat in 10% sodium hydroxide (215 mL) at reflux for 18 hours. After cooling, the
reaction mixture was diluted to 600 mL and made acidic by the addition of concentrated
muriatic acid. The resulting precipitate was recovered by vacuum filtration and allowed
to air dry (15.77 g, containing residual water).
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8-methyl-4-quinolone (Price, 1946; Burckhalter, 1948)
O

CH 3

N
H

3-carboxy-8-methyl-4-quinolone from the above reaction (15.77 g, presumed to contain
residual water) was allowed to heat in Dowtherm A (175 mL) to 255ºC, at which
temperature it was allowed to remain for 25 minutes. Upon cooling, the reaction mixture
was diluted with hexanes and the solid material was recovered by vacuum filtration (a
gray powder, 13.82 g). This material was used without purification in the ensuing
reaction.
1

H NMR δ (ppm)(DMSO-d6): 11.09 (1 H, s), 7.96 (1 H, d, J = 8.12 Hz), 7.82 (1 H, dd, J
= 7.41, 6.09 Hz), 7.49 (1 H, d, J = 7.13 Hz), 7.21 (1 H, t, J = 7.61 Hz), 6.06 (1 H, d, J =
7.39 Hz), 2.48 (3 H, s).

4-chloro-8-methylquinoline (Price, 1946; Burckhalter, 1948)

Cl

N
CH 3

8-methyl-4-quinolone (13.82 g, no more than 84 mmol) and phosphorus oxychloride (40
mL, 430 mmol) were allowed to heat at 110ºC for 3 hours. After cooling, the reaction
mixture was poured cautiously onto ice. After resting, the mixture was made basic by the
addition of solid caustic potash (end volume 1.4 L), followed by extraction with
chloroform (100 mL, followed by 3 x 50 mL). The pooled chloroform layers were dried
over magnesium sulfate and evaporated under reduced pressure with warming to provide
a cream-colored solid (12.35 g, 76% from para-toluidine, mp = 96.3-97.2°C (lit. 99°C;
Burckhalter, 1948).
1

H NMR δ (ppm)(CHCl3-d): 8.80 (1 H, d, J = 4.66 Hz), 8.11 (1 H, dd, J = 8.43, 1.35 Hz),
7.63 (1 H, dd, J = 7.02, 1.33 Hz), 7.54 (1 H, dd, J = 8.40, 7.06 Hz), 7.50 (1 H, d, J = 4.66
Hz), 2.82 (3 H, s).
294

3-(8-methylquinolin-4-ylamino)propanol

HN

OH

N
CH 3

4-chloro-8-methylquinoline (4.00 g, 1.9 mmol) and 3-amino-1-propanol (10.33 mL, 140
mmol) were heated at 90°C for 9 days in a Carius vessel, at the end of which time TLC
indicated that the reaction had gone to completion. The hot reaction mixture was poured
into water (200 mL), and after standing 1 hour the resulting precipitate was recovered by
vacuum filtration, followed by air-drying and recrystallization from ethyl acetate to
provide the desired compound as golden tan crystals (4.58 g, 92%).
1

H NMR δ (ppm)(DMSO-d6): 8.41 (1 H, d, J = 5.28 Hz), 8.01 (1 H, d, J = 8.46 Hz), 7.46
(1 H, d, J = 6.93 Hz), 7.28 (1 H, dd, J = 8.44, 6.93 Hz), 7.05 (1 H, br t, J = 5.39 Hz), 6.46
(1 H, d, J = 5.34 Hz), 4.59 (1 H, t, J = 5.05 Hz), 3.55 (2 H, m), 3.32 (water signal
overlaps m, ~2 H), 2.61 (3 H, s), 1.78-1.86 (2 H, m).

3-(8-methylquinolin-4-ylamino)propyl methanesulfonate

HN

OMs

N
CH 3

3-(8-methylquinolin-4-ylamino)propanol (1.00 g, 4.6 mmol) and triethylamine (1.0 mL,
7.2 mmol) in dry tetrahydrofuran (100 mL) were cooled to below 0°C on ice/salt, and
methanesulfonyl chloride (0.42 mL, 5.4 mmol) was gradually added. After stirring for 2
hours on ice, TLC indicated that the reaction had not gone to completion. Additional
triethylamine (0.40 mL, 2.9 mmol) and methanesulfonyl chloride (0.20 mL, 2.6 mmol)
were therefore added. After stirring for a further hour, TLC indicated that reaction was
complete. The reaction mixture was diluted with ethyl acetate (50 mL) and rinsed with
saturated sodium bicarbonate (50 mL), followed by extraction of the aqueous layer by
further ethyl acetate (3 x 10 mL). The pooled organic extracts were washed with brine
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(10 mL), dried over magnesium sulfate, and evaporated under reduced pressure with
warming to yield an off-white, crystalline solid (1.00 g, 74%).
1

H NMR δ (ppm)(DMSO-d6): 8.43 (1 H, d, J = 5.27 Hz), 8.03 (1 H, d, J = 8.49 Hz), 7.48
(1 H, d, J = 6.92 Hz), 7.30 (1 H, dd, J = 8.45, 6.93 Hz), 7.10 (1 H, br t, J = 5.43 Hz), 6.50
(1 H, d, J = 5.32 Hz), 4.35 (2 H, t, J = 6.20 Hz), 3.39-3.41 (water signal overlaps m, ~2
H), 3.19 (3 H, s), 2.08 (2 H, apparent p, J = 6.60 Hz).

PL394: N-(3-(4-benzhydrylpiperazin-1-yl)propyl)-8-methylquinolin-4-amine

HN

N
N

N
CH 3

PL394

3-(8-quinolin-4-ylamino)propyl methanesulfonate (0.50 g, 1.7 mmol), 1benzyhydrylpiperazine (0.44 g, 1.7 mmol), potassium carbonate (0.35 g, 2.5 mmol), and a
catalytic amount of potassium iodide were heated at reflux in anhydrous acetonitrile (50
mL) for 24 hours, whereupon TLC indicated that reaction was complete. The solvent
was removed under reduced pressure with warming, and the residue was partitioned
between chloroform (50 mL) and water (50 mL), followed by extraction of the aqueous
layer with additional chloroform (3 x 10 mL). The pooled organic layers were dried over
magnesium sulfate and evaporated under reduced pressure with warming. The resulting
amber oil was crystallized from ethyl acetate (initially taken up in 20 mL, then allowed to
evaporate to 10 mL at room temperature). The desired product was obtained as glittering,
colorless crystals (0.55 g, 72%, mp = 154.3-156.0°C).
1

H NMR δ (ppm)(CHCl3-d): 8.56 (1 H, d, J = 5.26 Hz), 7.76 (1 H, d, J = 8.44 Hz), 7.50
(1 H, d, J = 6.98 Hz), 7.42-7.47 (4 H, m), 7.26-7.34 (5 H, m), 7.18-7.26 (3 H, m), 6.34 (1
H, d, J = 5.31 Hz), 4.33 (1 H, s), 3.35 (2 H, td, J = 5.87, 4.20 Hz), 2.77 (3 H, s), 2.53-2.62
(10 H, br s overlaps t, J = 5.84 Hz), 1.92 (2 H, apparent p, J = 5.55 Hz).
13

C NMR δ (ppm)(CHCl3-d): 150.8, 150.0, 147.4, 142.4, 137.2, 129.1, 128.5, 128.0,
127.0, 123.6, 118.8, 118.8, 98.2, 76.5, 58.7, 53.9, 51.9, 44.4, 23.7, 18.9.
MS (ESI): m/z 451.28600 M + H (calculated 451.28562)
HPLC (method A) tR = 10.45 min (98% pure).
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PL393: 8-methyl-N-(3-(4-(pyridin-2-yl)piperazin-1-yl)propyl)quinolin-4-amine

HN

N
N

N
CH 3

N
PL393

3-(8-quinolin-4-ylamino)propyl methanesulfonate (0.50 g, 1.7 mmol), N-(2pyridyl)piperazine (0.32 g, 1.9 mmol), potassium carbonate (0.35 g, 2.5 mmol), and a
catalytic amount of potassium iodide were heated at reflux in anhydrous acetonitrile (50
mL) for 5 days. TLC then indicated that reaction was complete. The reaction mixture
was diluted with water (5 mL) followed by evaporation of the solvent under reduced
pressure with heating, and the residue was partitioned between chloroform (50 mL) and
water (50 mL), followed by extraction of the aqueous layer with additional chloroform (3
x 10 mL). The pooled organic layers were dried over magnesium sulfate and evaporated
under reduced pressure with warming. The residue was taken up in boiling ethyl acetate
(30 mL) and allowed to evaporate gradually to 10 mL at room temperature. Vacuum
filtration afforded the desired product as large, colorless crystals (0.37 g, 60%, mp =
175.5-177.5°C).
1

H NMR δ (ppm)(CHCl3-d): 8.59 (1 H, d, J = 5.26 Hz), 8.23-8.23 (1 H, m), 7.73 (1 H, d,
J = 8.44 Hz), 7.52 (1 H, ddd, J = 8.54, 7.16, 2.02 Hz), 7.44 (1 H, d, J = 6.98 Hz), 7.20 (1
H, dd, J = 8.40, 6.97 Hz), 7.05 (1 H, t, J = 4.29 Hz), 6.66-6.67 (2 H, m), 6.39 (1 H, d, J =
5.30 Hz), 3.68 (4 H, m), 3.41 (2 H, td, J = 6.01, 4.37 Hz), 2.75 (3 H, s), 2.65-2.66 (6 H,
m), 1.99 (2 H, apparent p, J = 5.75 Hz).
13

C NMR δ (ppm)(CHCl3-d): 159.5, 150.7, 150.0, 148.1, 147.5, 137.6, 137.3, 129.2,
123.9, 118.8, 118.2, 113.6, 107.1, 98.4, 58.6, 53.5, 45.3, 44.1, 24.0, 18.9.
MS (ESI): m/z 362.23440 M + H (calculated 362.23392)
HPLC (method A) tR = 4.42 min (99% pure).
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A.6: Methoxyquinolines
A.6.1: 6-Methoxyquinolines
3-carbethoxy-6-methoxy-4-quinolone (Price, 1946; Ramsey, 1947)
O

O

MeO

OEt
N
H

para-Anisidine (12.32 g, 100 mmol), diethyl ethoxymethylene malonate (21.68 g, 100
mmol), and Dowtherm A (100 mL) were heated to reflux, at which temperature the
reaction was allowed to remain for 30 minutes. Upon cooling, the reaction mixture was
diluted with hexanes and vacuum filtered, rinsing with further hexanes, followed by
acetone. This afforded a tan, powdery solid (15.08 g, 61%).

3-carboxy-6-methoxy-4-quinolone (Price, 1946; Ramsey, 1947)
O
MeO

O
OH

N
H

3-carboxy-6-methoxy-4-quinolone (15.08 g, 61 mmol) was heated for 5 hours in
refluxing 10% caustic soda (250 mL). The hot reaction mixture was poured into 300 mL
water and made acidic by the addition of concentrated muriatic acid. After standing 20
hours, vacuum filtration afforded 3-carboxy-6-methoxy-4-quinolone as a white, powdery
solid (13.30 g, ~100%).
1

H NMR δ (ppm)(DMSO-d6): 15.55 (1 H, s), 13.43 (1 H, s), 8.83 (1 H, s), 7.80 (1 H, d, J
= 9.08 Hz), 7.65 (1 H, d, J = 2.91 Hz), 7.54 (1 H, dd, J = 9.07, 2.92 Hz), 3.91 (3 H, s).
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6-methoxy-4-quinolone (Price, 1946; Ramsey, 1947)
O
MeO
N
H

3-carbethoxy-6-methoxy-4-quinolone (13.30 g, 61 mmol) was heated in 100 mL
refluxing Dowtherm A for 40 minutes. Upon cooling, the reaction mixture was diluted
with 100 mL hexanes and vacuum filtered, rinsing with additional hexanes followed by
acetone. This afforded 6-methoxy-4-quinolone as an off-white solid (10.30 g, 97%).

4-chloro-6-methoxyquinoline (Price, 1946; Ramsey, 1947)

Cl
MeO
N

6-methoxy-4-quinolone (10.30 g, 59 mmol) was heated in phosphorus oxychloride (40
mL, 43 mmol) at 110°C for 2.5 hours. After cooling, the dark reaction mixture was
poured gradually onto ice with vigorous stirring. After standing overnight, the mixture
was made basic by the gradual addition of solid caustic potash. The resulting aqueous
mixture was extracted with chloroform (150 mL, followed by 5 x 20 mL), and the pooled
organic layers were dried (MgSO4) and evaporated under reduced pressure with warming
to yield a dark brown, crystalline solid with a pronounced odor of Dowtherm A. This
was taken up in boiling hexanes and decanted from an insoluble black residue, which was
twice rinsed with boiling hexanes; the pooled hexanes were returned to a boil and
concentrated to 50 mL. Upon cooling, the product was recovered as gleaming, pale
caramel-colored needles (6.93 g, 61%, mp = 79.1-79.9°C (lit. 77-79°C; Ramsey, 1947)).
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3-(6-methoxyquinolin-4-ylamino)propanol

HN

OH

MeO
N

6-methoxy-4-chloroquinoline (2.94 g, 15 mmol) and 3-amino-1-propanol (6.97 mL, 91
mmol) were heated at 80°C in a Carius vessel for 48 hours. TLC indicated that the
reaction was not complete. The temperature was increased to 120°C and heating was
continued for one hour, following which the reaction was poured without cooling into
water (100 mL), stirring well. An oil separated. After standing 24 hours, the resulting
mixture was extracted with dichloromethane (200 mL). The dichloromethane layer was
washed with water (3 x 20 mL). After drying over MgSO4 and evaporation under
reduced pressure with warming, the resulting yellow oil was taken up in boiling ethyl
acetate and allowed to evaporate slowly at room temperature for several days. Filtration
afforded the desired product as tan crystals (0.42 g, 12%, mp = 140.2-141.6°C).
1

H NMR δ (ppm)(DMSO-d6): 8.26 (1 H, d, J = 5.25 Hz), 7.69 (1 H, d, J = 9.11 Hz), 7.54
(1 H, d, J = 2.76 Hz), 7.24 (1 H, dd, J = 9.11, 2.71 Hz), 6.97 (1 H, t, J = 5.43 Hz), 6.41 (1
H, d, J = 5.32 Hz), 4.60 (1 H, t, J = 5.03 Hz), 3.88 (3 H, s), 3.56 (2 H, q, J = 5.61 Hz),
3.34 (water overlaps m, ~2 H), 1.83 (2 H, apparent p, J = 6.73 Hz).
1

H NMR δ (ppm)(CHCl3-d): 8.43 (1 H, d, J = 5.25 Hz), 7.89 (1 H, d, J = 9.17 Hz), 7.26
(solvent signal may overlap s, ~1 H), 6.94 (1 H, d, J = 2.71 Hz), 6.39 (1 H, d, J = 5.28
Hz), 5.59 (1 H, s), 3.96 (2 H, t, J = 5.50 Hz), 3.89 (3 H, s), 3.48 (2 H, td, J = 6.26, 4.93
Hz), 2.05 (2 H, apparent p, J = 5.84 Hz).
Note: No further compounds were successfully made from this material. For the 3(quinolin-4-ylamino)propanol compounds containing a methoxy substituent, the
mesylation reaction that had been used successfully with other compounds of this type
did not work well. After many attempts using various solvents, temperatures, and
repeated additions of methanesulfonyl chloride and triethylamine, it was discovered that
the optimal method was to work up the partially complete reaction and use the crude
mixture in the next step. The unreacted 3-(quinolin-4-ylamino)propanol could then be
removed by chromatography. Reversed chloroquine type compounds were made from the
7- and 8-methoxy substituted 3-(quinolin-4-ylamino)propanol using this method, but time
did not permit a 6-methoxy analogue to be made.
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A.6.2: 7-Methoxyquinolines
3-carbethoxy-7-methoxy-4-quinolone (Price, 1946; Lauer, 1946)

O

O
OEt

MeO

N
H

meta-Anisidine (9.05 g, 74 mmol), diethyl ethoxymethylene malonate (14.73 mL, 74
mmol), and 75 mL Dowtherm A were heated to 255ºC. After remaining at this
temperature for 25 minutes, the reaction was removed from the heat. Upon cooling, the
reaction mixture was filtered, rinsing with 3 small portions of Dowtherm A, followed by
hexanes and finally, acetone. This afforded the desired product as a tan, powdery solid,
with no trace of the 5-methoxy regioisomer (10.57 g, 58%). The absence of the 5methoxy regioisomer in the product of this reaction has been reported previously (Lauer,
1946).
1

H NMR δ (ppm)(DMSO-d6): 12.10 (1 H, s), 8.48 (1 H, s), 8.05 (1 H, dd, J = 8.13, 1.66
Hz), 6.98-7.03 (2 H, m), 4.20 (2 H, q, J = 7.10 Hz), 3.87 (3 H, s), 1.27 (3 H, t, J = 7.10
Hz).

3-carboxy-7-methoxy-4-quinolone (Price, 1946; Lauer, 1946)
O

O
OH

MeO

N
H

3-carbethoxy-7-methoxy-4-quinolone (10.57g, 43 mmol) in 20% caustic soda (250 mL)
was heated at 80ºC for 18 hours, followed by 1 hour at reflux. Upon cooling to room
temperature, the reaction mixture was poured into water (300 mL) and acidified by the
addition of concentrated muriatic acid. After cooling, the resulting white solid was
recovered by vacuum filtration, followed by air-drying. This material was used without
further drying in the following reaction.
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7-methoxy-4-quinolone (Price, 1946; Lauer, 1946)
O

MeO

N
H

3-carboxy-7-methoxy-4-quinolone (containing residual water) was heated for 25 minutes
at 255ºC in Dowtherm A. Upon cooling, the reaction mixture was diluted with hexanes
(100 mL) and vacuum filtered, rinsing with further hexanes; the resulting solid was then
allowed to reflux in hexanes (100 mL) for 1 hour. Filtration afforded the desired product
as a beige solid (7.56 g).
1

H NMR δ (ppm)(DMSO-d6): 11.60 (1 H, s), 7.98 (1 H, d, J = 8.82 Hz), 7.80 (1 H, t, J =
6.33 Hz), 6.90-6.91 (2 H, m), 5.94 (1 H, d, J = 7.40 Hz), 3.85 (3 H, s).

4-chloro-7-methoxyquinoline (Price, 1946; Lauer, 1946)

Cl

MeO

N

7-methoxy-4-quinolone (7.56 g, 43 mmol) was heated at 100°C for 2.5 hours in
phosphorus oxychloride (50 mL, 540 mmol). TLC then indicated that reaction was
complete. After cooling, the reaction mixture was poured gradually onto ice with
vigorous stirring. After standing, the mixture was basified by the gradual addition of
50% caustic soda. The resulting aqueous mixture was diluted to 800 mL with water and
divided into three portions, each of which was extracted with chloroform (100 mL,
followed by 5 x 20 mL). The pooled organic layers from all three extractions were dried
(MgSO4) and evaporated under reduced pressure with warming to yield the desired
product as a beige solid (6.58 g, 79%, mp = 87.1-88.4°C (lit. 82-83°C; Lauer, 1946)).
1

H NMR δ (ppm)(CHCl3-d): 8.70 (1 H, d, J = 4.79 Hz), 8.12 (1 H, d, J = 9.22 Hz), 7.43
(1 H, d, J = 2.55 Hz), 7.35 (1 H, d, J = 4.79 Hz), 7.29 (1 H, dd, J = 9.23, 2.55 Hz), 3.97 (3
H, s).
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3-(7-methoxyquinolin-4-ylamino)propanol

HN

MeO

OH

N

7-methoxy-4-chloroquinoline (3.25 g, 16.8 mmol) and 3-amino-1-propanol (7.73 mL,
101 mmol) were heated at 90°C in a Carius tube for 3 days. TLC indicated that no
quinoline starting material remained, and the reaction was therefore poured without
cooling into 200 mL water, stirring well. After standing for 30 minutes, the resulting
precipitate was isolated by vacuum filtration as a beige, sparkling solid. This material
was recrystallized from 9:1 ethyl acetate:ethanol (20 mL) to give a beige, crystalline solid
(3.32 g, 85%, mp =147.8-148.5°C).
1

H NMR δ (ppm)(CHCl3-d): 8.45 (1 H, d, J = 5.39 Hz), 7.59 (1 H, d, J = 9.17 Hz), 7.30
(1 H, d, J = 2.64 Hz), 7.03 (1 H, dd, J = 9.15, 2.64 Hz), 6.31 (1 H, d, J = 5.41 Hz), 5.74 (1
H, s), 3.95 (2 H, t, J = 5.50 Hz), 3.91 (3 H, s), 3.46-3.47 (2 H, m), 1.99-2.07 (2 H, m).

3-(7-methoxyquinolin-4-ylamino)propyl methanesulfonate

HN

MeO

OMs

N

3-(7-methoxyquinolin-4-ylamino)propanol (0.60 g, 2.6 mmol) was dissolved in
anhydrous THF (100 mL), and triethylamine (0.36 mL, 2.6 mmol) was added. The
solution was cooled to 10 ºC, and methanesulfonyl chloride (0.20 mL, 2.6 mmol) was
added dropwise. After 50 minutes, the reaction mixture was diluted with ethyl acetate
(50 mL) and washed with saturated sodium bicarbonate (100 mL). The aqueous layer
was extracted with additional ethyl acetate (3 x 10 mL), and the pooled organic layers
were rinsed with brine (15 mL), dried over magnesium sulfate, and evaporated under
reduced pressure with warming to yield a yellow oil. This material contained
approximately 50% unreacted starting material by NMR, but was used without further
purification in the ensuing reaction (for reasons noted previously; see the synthesis of 3(6-methoxyquinolin-4-ylamino)propanol).
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PL391: 7-methoxy-N-(3-(4-(pyridin-2-yl)piperazin-1-yl)propyl)quinolin-4-amine

HN

N
N

MeO

N

PL391

N

3-(7-methoxyquinolin-4-ylamino)propyl methanesulfonate (impure product from the
above reaction, containing no more than 2.6 mmol quinoline material), 1-(2pyridyl)piperazine (0.44 g, 2.7 mmol), potassium carbonate (0.53 g, 3.9 mmol), and a
catalytic amount of potassium iodide were heated at reflux in acetonitrile (22 mL) for 18
hours. The solvent was then removed under reduced pressure with warming, and the
residue was partitioned between chloroform (40 mL) and water (40 mL). After
separation, the aqueous layer was extracted with additional chloroform (3 x 10 mL), and
the pooled organic layers were rinsed with brine (10 mL) and dried over magnesium
sulfate. The dried solution was partially evaporated under reduced pressure with
warming, followed by adsorption onto basic alumina. Flash chromatography was
performed with basic alumina as the stationary phase, eluting with a gradient of 100%
hexanes to 35/65 hexanes/ethyl acetate (v/v) over 55 minutes; NMR indicated that the
product-containing fractions also contained unreacted 1-(2-pyridyl)piperazine. Flash
chromatography on basic alumina was repeated, with a gradient of 100% hexanes to 80%
hexanes/20% ethyl acetate (v/v) over 45 minutes, increasing the proportion of ethyl
acetate to 60% over an additional 55 minutes. The desired product was then obtained as
a colorless solid (0.06 g, 6% yield from 3-(7-methoxyquinolin-4-ylamino)propanol, mp =
114.5-118.6°C, Rf = 0.4 (basic alumina, 9/1 MeOH/EtOAc v/v)).
1

H NMR δ (ppm)(CHCl3-d): 8.46 (1 H, d, J = 5.37 Hz), 8.23-8.23 (1 H, m), 7.75 (1 H, d,
J = 9.17 Hz), 7.52-7.52 (1 H, m), 7.30 (1 H, d, J = 2.62 Hz), 7.01 (1 H, br t, J = 4.36 Hz),
6.94 (1 H, dd, J = 9.13, 2.63 Hz), 6.67-6.68 (2 H, m), 6.29 (1 H, d, J = 5.41 Hz), 3.89 (3
H, s), 3.67 (4 H, m), 3.42 (2 H, td, J = 6.01, 4.36 Hz), 2.64-2.70 (6 H, m), 1.96-2.01 (2 H,
m).
13

C NMR δ (ppm)(CHCl3-d): 160.2, 159.4, 151.6, 150.5, 150.3, 148.1, 137.7, 121.6,
116.6, 113.7, 113.5, 108.2, 107.1, 97.4, 58.5, 55.4, 53.5, 45.4, 44.0, 24.0.
MS (ESI): m/z 378.22946 M + H (calculated 378.22884)
HPLC (method A) tR = 5.50 min (98% pure).
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A.6.3: 8-Methoxyquinolines
3-carbethoxy-8-methoxy-4-quinolone (Price, 1946; Lauer, 1946)

O

O
OEt

OMe

N
H

ortho-Anisidine (11.30 g, 92 mmol), diethyl ethoxymethylene malonate (18.40 mL, 92
mmol), and 75 mL Dowtherm A were heated to reflux. After remaining at reflux for 20
minutes, the reaction was removed from the heat. Upon cooling, the reaction mixture
was diluted with 75 mL hexanes and filtered, rinsing with further hexanes (200 mL) and
acetone (75 mL). This afforded the desired product as a creamy white, crystalline solid.
1

H NMR δ (ppm)(DMSO-d6): 11.92 (1 H, s), 8.34 (1 H, s), 7.71 (1 H, dd, J = 7.36, 2.00
Hz), 7.31-7.37 (2 H, m), 4.21 (2 H, q, J = 7.10 Hz), 4.01 (3 H, s), 1.27 (3 H, t, J = 7.09
Hz).

3-carboxy-8-methoxy-4-quinolone (Price, 1946; Lauer, 1946)
O

O
OH

OMe

N
H

The above product was heated for 72 hours in 250 mL refluxing 10% caustic soda. The
hot reaction mixture was poured into 300 mL water and acidified by the addition of
concentrated hydrochloric acid. Vacuum filtration of the cooled solution afforded the
desired product as a creamy white, powdery solid (11.17 g, 0.0510 mol, 56% from two
steps).
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8-methoxy-4-quinolone (Price, 1946; Lauer, 1946)
O

OMe

N
H

3-carboxy-8-methoxy-4-quinolone (11.17 g, 51 mmol) was heated for 1 hour in refluxing
Dowtherm A. Upon cooling, a small sample was analyzed by NMR and it was
determined that the reaction was no more than 50% complete. The reaction was therefore
heated again at reflux for an additional hour. Upon cooling, dilution with 100 mL
hexanes, and resting for 20 hours, the reaction mixture became a tarry, intractable block.
Samples analyzed by NMR and GC/MS indicated that reaction was complete. The
reaction mixture was briefly heated to 130°C, whereupon it became liquid; after cooling
to 50°C, this was poured into a beaker and diluted with additional hexanes. After again
resting for 20 hours, filtration afforded the product as a powdery, tan solid (8.68 g, 97%).

4-chloro-8-methoxyquinoline (Price, 1946; Lauer, 1946)
Cl

N
OMe

8-methoxy-4-quinolone (8.68 g, 50 mmol) was heated at 95°C for 20 hours in phosphorus
oxychloride (30 mL, 320 mmol). After cooling, the dark reaction mixture was poured
gradually onto ice with vigorous stirring. The mixture was allowed to stand for 30
minutes, then made basic by the gradual addition of solid caustic potash. The resulting
aqueous mixture was extracted with chloroform (150 mL, followed by 5 x 20 mL), and
the pooled organic layers were dried (MgSO4) and evaporated under reduced pressure
with warming to yield a golden brown liquid that crystallized upon standing. This was
recrystallized from a mixture of ethyl acetate and hexanes to yield a tan, crystalline solid
(3.30 g, 0.0170 mol, 34%, mp = 81.8-82.6°C (lit. 79-80°C; Lauer, 1946)).
1

H NMR δ (ppm)(CHCl3-d): 8.79 (1 H, d, J = 4.65 Hz), 7.81 (1 H, dd, J = 8.54, 1.13 Hz),
7.57 (1 H, dd, J = 8.53, 7.80 Hz), 7.53 (1 H, d, J = 4.65 Hz), 7.12 (1 H, dd, J = 7.80, 1.08
Hz), 4.11 (3 H, s).
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3-(8-methoxyquinolin-4-ylamino)propanol

HN

OH

N
OMe

8-methoxy-4-chloroquinoline (2.03 g, 0.0105 mol) and 3-amino-1-propanol (4.81 mL,
0.0629 mol) were heated at 90°C in a Carius tube for 48 hours. TLC indicated that no
quinoline starting material remained, and the reaction was therefore poured without
cooling into 150 mL water, stirring well. After standing for 24 hours, the resulting
precipitate was isolated by vacuum filtration (water rinsing) as a dull yellow, sparkling
solid; partial recrystallization from 95% ethyl acetate, 5% ethanol yielded the product as
a sparkling, ochre solid (1.95 g, 78%, mp = 170.6-171.4°C).
1

H NMR δ (ppm)(CHCl3-d): 8.57 (1 H, d, J = 5.25 Hz), 7.30-7.33 (2 H, m), 7.27 (solvent
signal may overlap compound signal, ~1 H, see DMSO-d6 spectrum below), 6.99 (1 H, d,
J = 7.48 Hz), 6.46 (1 H, d, J = 5.27 Hz), 5.73 (1 H, t, J = 4.73 Hz), 4.05 (3 H, s), 3.94 (2
H, t, J = 5.51 Hz), 3.47 (2 H, td, J = 6.29, 4.82 Hz), 2.04 (2 H, apparent p, J = 5.87 Hz).
1

H NMR δ (ppm)(DMSO-d6): 8.33 (1 H, d, J = 5.25 Hz), 7.69 (1 H, d, J = 8.52 Hz), 7.31
(1 H, t, J = 8.10 Hz), 7.05 (1 H, d, J = 7.70 Hz), 7.00 (1 H, t, J = 5.37 Hz), 6.47 (1 H, d, J
= 5.31 Hz), 4.61 (1 H, s), 3.89 (3 H, s), 3.55 (2 H, m), 3.30-3.32 (water signal overlaps m,
~2 H), 1.82 (2 H, apparent p, J = 6.64 Hz).
MS (ESI): m/z 233.12869 M + H (calculated 233.12845)
HPLC (method A) tR = 7.67 min (95% pure).

3-(8-methoxyquinolin-4-ylamino)propyl methanesulfonate

HN

OMs

N
OMe
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3-(8-methoxyquinolin-4-ylamino)propanol (0.40 g, 1.7 mmol) was dissolved in
anhydrous THF (100 mL) by warming at 50ºC in a flask equipped with a Vigreux
condenser and calcium chloride drying tube. This solution was allowed to cool to room
temperature, whereupon precipitation was observed. Triethylamine (0.24 mL, 1.7 mmol)
was added, followed by cooling to 7ºC and addition of methanesulfonyl chloride (0.13
mL, 1.7 mmol). After 1 hour, TLC indicated that starting material remained; further
methanesulfonyl chloride was added (0.40 mL, 5.1 mmol). After a further hour, the
reaction was sealed and stored at 8ºC for 18 hours. The reaction mixture was then
washed with saturated sodium bicarbonate (75 mL), followed by extraction of the
aqueous layer with ethyl acetate (3 x 15 mL). The pooled organic layers were rinsed with
brine (20 mL), dried over magnesium sulfate, and evaporated under reduced pressure
with warming to yield a yellow oil. This contained approximately 20% unreacted starting
material by NMR. This material was used without further purification in the ensuing
reaction (for reasons noted previously, see the synthesis of 3-(6-methoxyquinolin-4ylamino)propanol).

PL390: 8-methoxy-N-(3-(4-(pyridin-2-yl)piperazin-1-yl)propyl)quinolin-4-amine

HN

N
N

N
OMe

N
PL390

3-(8-methoxyquinolin-4-ylamino)propyl methanesulfonate (impure product from the
above reaction, containing no more than 1.7 mmol quinoline material), 1-(2pyridyl)piperazine (0.30 g, 1.8 mmol), potassium carbonate (0.36 g, 2.6 mmol), and a
catalytic amount of potassium iodide were heated at reflux in acetonitrile (25 mL) for 18
hours. The solvent was then removed under reduced pressure with warming, and an
attempt was made to partition the residue between ethyl acetate (50 mL) and water (30
mL). Some material remained undissolved and was left in the reaction flask. After
separation of the ethyl acetate and water layers, the aqueous layer was extracted with
additional ethyl acetate (3 x 5 mL), and the pooled organic layers were rinsed with brine
(10 mL) and allowed to dry over magnesium sulfate for 18 hours. The undissolved
material from ethyl acetate extraction was now taken up in chloroform (30 mL), in which
it was fully soluble, and washed with the aqueous layer from the ethyl acetate extraction.
After separation, the aqueous layer was extracted with additional chloroform (3 x 5 mL),
and the chloroform layer was dried over magnesium sulfate. The combined dried organic
extracts were then partially evaporated under reduced pressure with warming, and
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adsorbed onto 3.5 g basic alumina. Flash chromatography on basic alumina was
performed, eluting with a gradient of 100% hexanes to 100% ethyl acetate over 35
minutes; the product-containing fractions from this also contained 1-(2pyridyl)piperazine. Flash chromatography on basic alumina was repeated, with a
gradient of 100% hexanes to 70% ethyl acetate over 30 minutes, to provide the desired
product as a pale yellow solid (0.13 g, 20% yield from 3-(8-methoxyquinolin-4ylamino)propanol, mp = 147.9-150.0°C, Rf = 0.4 (Alumina, 9/1 MeOH/EtOAc v/v)).
1

H NMR δ (ppm)(CHCl3-d): 8.57 (1 H, d, J = 5.25 Hz), 8.23-8.23 (1 H, m), 7.52 (1 H,
ddd, J = 8.58, 7.13, 2.01 Hz), 7.42 (1 H, d, J = 8.48 Hz), 7.22 (1 H, t, J = 8.10 Hz), 7.06
(1 H, br t, J = 4.30 Hz), 6.94 (1 H, d, J = 7.72 Hz), 6.67-6.68 (2 H, m), 6.41 (1 H, d, J =
5.29 Hz), 4.04 (3 H, s), 3.69 (4 H, m), 3.42 (2 H, td, J = 5.95, 4.26 Hz), 2.66-2.67 (6 H,
m), 2.00 (2 H, apparent p, J = 5.68 Hz).
13

C NMR δ (ppm)(CHCl3-d): 159.4, 155.9, 150.3, 150.1, 148.1, 140.4, 137.6, 124.2,
119.9, 113.6, 112.0, 107.1, 107.1, 99.1, 58.6, 55.9, 53.5, 45.3, 44.1, 23.9.
MS (ESI): m/z 378.22947 M + H (calculated 378.22884)
HPLC (method A) tR = 4.64 min (95% pure).

A.7: Bis-quinolines
A.7.1: Bis-quinoline starting materials not described above
PL16: 3-(7-dichloroquinolin-4-ylamino)propanol (Burgess, 2006; Burgess, 2008;
Burgess, 2010)
HN

OH
PL16

Cl

N

PL16 was synthesized without deviating from methods previously described by Steven
Burgess (a pale tan solid, mp = 148.5-151.0°C).
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PL29: 3-(7-chloroquinolin-4-ylamino)propyl methanesulfonate (Burgess, 2006;
Burgess, 2008; Burgess, 2010):

HN

OMs
PL29

Cl

N

PL16 (1.88 g, 7.9 mmol), triethylamine (1.66 mL, 1.2 mmol), and anhydrous THF (100
mL) were cooled below 0°C on ice/salt, and methanesulfonyl chloride (0.71 mL, 9.1
mmol) was added dropwise. After stirring for an hour on ice, TLC indicated that reaction
was not complete, and therefore additional triethylamine (0.83 mL, 6.0 mmol) and
methanesulfonyl chloride (0.36 mL, 6.0 mmol) were added. After a further hour, TLC
indicated that no quinoline starting material remained. The reaction mixture was diluted
with ethyl acetate (30 mL) and shaken with saturated sodium bicarbonate (30 mL),
followed by extraction of the aqueous layer with additional ethyl acetate (3 x 10 mL).
The pooled ethyl acetate layers were washed with brine (10 mL), dried over magnesium
sulfate, and evaporated under reduced pressure with warming to obtain a pale yellow,
fluffy solid; this was allowed to stand overnight (1.86 g, 81%).
1

H NMR δ (ppm)(CHCl3-d): 8.53 (1 H, d, J = 5.37 Hz, ClQ-C2-H), 7.95 (1 H, d, J = 2.18
Hz, ClQ-C8-H), 7.72 (1 H, d, J = 8.97 Hz, ClQ-C5-H), 7.38 (1 H, dd, J = 8.94, 2.18 Hz,
ClQ-C6-H), 6.42 (1 H, d, J = 5.40 Hz, ClQ-C3-H), 5.55 (1 H, br t, J = 5.75 Hz, NH), 4.42
(2 H, t, J = 5.66 Hz, CH2O), 3.58 (2 H, td, J = 6.34, 5.77 Hz, CH2N), 3.06 (3 H, s, CH3),
2.18 (2 H, apparent p, J = 5.98 Hz, CH2).
1

H NMR δ (ppm)(DMSO-d6): 8.42 (1 H, d, J = 5.39 Hz, ClQ-C2-H), 8.26 (1 H, d, J =
9.04 Hz, ClQ-C5-H), 7.79 (1 H, d, J = 2.24 Hz, ClQ-C8-H), 7.47 (1 H, dd, J = 8.98, 2.27
Hz, ClQ-C6-H), 7.33 (1 H, br t, J = 5.39 Hz, Q-C4-NH), 6.51 (1 H, d, J = 5.45 Hz, ClQC3-H), 4.35 (1 H, t, J = 6.19 Hz, HNCH2CH2CH2), 3.30-3.45 (water signal overlaps m,
~1 H, HNCH2CH2CH2), 3.19 (1 H, s, CH3), 2.07-2.09 (1 H, apparent p, J = 6.56 Hz,
HNCH2CH2CH2).
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PL376: Ethyl 4-((7-chloroquinolin-4-yl)amino)piperidine-1-carboxylate

O
N

OEt

HN
PL376
Cl

N

4,7-dichloroquinoline (2.00 g, 10 mmol), ethyl-4-amino-1-piperidine carboxylate (1.83 g,
11 mmol), and phenol (5.70 g, 61 mol) were heated at 90ºC in a sealed Carius vessel for
48 hours. TLC indicated that unreacted 4,7-dichloroquinoline remained, and therefore
additional ethyl-4-amino-1-piperidine carboxylate (0.39 g, 2.3 mmol) was added. The
vessel was again sealed and heated for a further 7 days, whereupon TLC indicated that no
unreacted quinoline remained. The reaction mixture was diluted with chloroform (50
mL) and rinsed with 10% caustic soda (6 x 10 mL), followed by further rinsing with
brine (3 x 10 mL). The organic layer was dried over MgSO4 and concentrated under
reduced pressure with warming to yield a thick, tan liquid containing some solid material.
After standing 14 hours, this was taken up in boiling solvent (50/50 ethyl acetate/95%
ethanol (v/v)) and allowed to cool and concentrate at room temperature. The crystals
thus formed were recovered from the remaining 5 mL of solvent by vacuum filtration
(off-white crystals, 1.18 g, 35%, mp = 197.3-198.8°C).
1

H NMR δ (ppm)(CHCl3-d): 8.54 (1 H, d, J = 5.36 Hz), 7.96 (1 H, d, J = 2.17 Hz), 7.66
(1 H, d, J = 8.98 Hz), 7.37 (1 H, dd, J = 8.94, 2.19 Hz), 6.46 (1 H, d, J = 5.41 Hz), 4.92 (1
H, br d, J = 7.25 Hz), 4.16 (4 H, br s overlaps q, J = 7.13 Hz), 3.68-3.69 (1 H, m), 3.04 (2
H, td, J = 12.56, 2.82 Hz), 2.11-2.20 (2 H, m), 1.51-1.53 (2 H, m), 1.28 (3 H, t, J = 7.11
Hz).
MS (ESI): m/z 334.13271 M + H (calculated 334.13168)
HPLC (method A) tR = 10.55 min (99% pure).
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PL294: 7-chloro-N-(piperidin-4-yl)quinolin-4-amine

NH
HN
PL294
Cl

N

PL376 (2.45 g, 7.3 mmol, the product of multiple reactions), 95% ethanol (100 mL), and
10% caustic soda (4.5 mL) were allowed to heat, stirring, at reflux for 4 days. As TLC
indicated that the reaction was not complete, 50% caustic soda (0.5 mL) was added, and
reflux was continued for a further 3 days. TLC then indicated that the reaction was
complete. The reaction solvent was removed under reduced pressure with warming, and
the residue was partitioned between chloroform (20 mL) and water (50 mL). After
separation, the aqueous layer was extracted with additional chloroform (3 x 10 mL), and
the pooled organic layers were dried (MgSO4) and concentrated under reduced pressure
with warming to yield a tan solid (1.05 g). A cream colored solid was also isolated from
the aqueous layer by vacuum filtration (1.04 g). NMR indicated that both solids obtained
were the desired product (total yield 1.83 g, 96%, mp = 166.3-169.4°C).
1

H NMR δ (ppm)(CHCl3-d): 8.52 (1 H, d, J = 5.39 Hz), 7.96 (1 H, d, J = 2.18 Hz), 7.65
(1 H, d, J = 8.96 Hz), 7.37 (1 H, dd, J = 8.93, 2.19 Hz), 6.45 (1 H, d, J = 5.42 Hz), 4.87 (1
H, br d, J = 7.35 Hz), 3.61-3.62 (1 H, m), 3.19 (2 H, dt, J = 12.68, 3.70 Hz), 2.79-2.81 (2
H, m), 2.15-2.19 (2 H, m), 1.50-1.50 (2 H, m).
MS (ESI): m/z 262.11116 M + H (calculated 262.11065)
HPLC (method A) tR = 2.74 min (94% pure).

PL377: Ethyl 4-(quinolin-4-ylamino)piperidine-1-carboxylate
O
N

OEt

HN
PL377
N
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4-chloroquinoline (2.00 g, 12 mmol), ethyl-4-amino-1-piperidine carboxylate (3.16 g, 32
mmol), and phenol (6.90 g, 73 mmol) were heated at 90ºC in a sealed Carius vessel for 6
days. TLC indicated that unreacted 4,7-dichloroquinoline remained, and therefore
additional ethyl-4-amino-1-piperidine carboxylate (1.00 g, 1.0 mmol) was added. The
vessel was again sealed and heated for a further 2 days, whereupon TLC indicated that
reaction was complete. The reaction mixture was diluted with chloroform (50 mL) and
rinsed with 10% caustic soda (5 x 10 mL), followed by further rinsing with water (3 x 10
mL). The organic layer was dried over MgSO4 and concentrated under reduced pressure
with warming to yield a brown semisolid. This material was taken up in boiling ethyl
acetate (70 mL) and allowed to cool and concentrate at room temperature (to
approximately 15 mL). Vacuum filtration provided the desired product as a sparkling,
tan, crystalline solid (2.81 g, 77%, mp = 209-210°C).
1

H NMR δ (ppm)(CHCl3-d): 8.56 (1 H, d, J = 5.31 Hz), 7.99 (1 H, dd, J = 8.44, 1.20 Hz),
7.72 (1 H, dd, J = 8.43, 1.25 Hz), 7.64 (1 H, ddd, J = 8.46, 6.85, 1.31 Hz), 7.44 (1 H, ddd,
J = 8.40, 6.86, 1.29 Hz), 6.47 (1 H, d, J = 5.35 Hz), 4.90 (1 H, br d, J = 7.27 Hz), 4.17 (4
H, br s overlaps q, J = 7.11 Hz), 3.70-3.71 (1 H, m), 3.06 (2 H, td, J = 12.54, 2.73 Hz),
2.13-2.22 (2 H, m), 1.52-1.54 (2 H, m), 1.28 (3 H, t, J = 7.11 Hz).
MS (ESI): m/z 300.17103 M + H (calculated 300.17065)
HPLC (method A) tR = 9.81 min (99% pure).

PL378: N-(piperidin-4-yl)quinolin-4-amine
NH
HN
PL378
N

PL377 (1.77 g, 5.9 mmol), 95% ethanol (40 mL), and 50% caustic soda (2.00 mL) were
allowed to heat, stirring, at reflux for 20 hours. As TLC indicated that the reaction was
not complete, additional 50% caustic soda (1.0 mL) was added, and reflux was continued
for a further 3 days. TLC then indicated that the reaction was complete. The reaction
solvent was removed under reduced pressure with warming, and the residue was
partitioned between chloroform (25 mL) and water (25 mL). After separation, the
aqueous layer was extracted with additional chloroform (3 x 7 mL). The pooled organic
layers were vacuum filtered to remove solid material, followed by drying (MgSO4) and
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concentration under reduced pressure with warming to yield the desired product as a
white powder (0.65 g, 48%, mp = 112.5-124°C).
1

H NMR δ (ppm)(CHCl3-d): 8.55 (1 H, d, J = 5.33 Hz), 7.98 (1 H, dd, J = 8.45, 1.22 Hz),
7.72 (1 H, dd, J = 8.42, 1.26 Hz), 7.63 (1 H, ddd, J = 8.45, 6.85, 1.33 Hz), 7.43 (1 H, ddd,
J = 8.39, 6.85, 1.30 Hz), 6.47 (1 H, d, J = 5.36 Hz), 4.89 (1 H, br d, J = 7.32 Hz), 3.633.64 (1 H, m), 3.19 (2 H, dt, J = 12.67, 3.73 Hz), 2.80-2.81 (2 H, m), 2.17-2.20 (2 H, m),
1.44-1.56 (2 H, m).
MS (ESI): m/z 228.14987 M + H (calculated 228.14952)
HPLC (method A) tR = 1.58 min (78% pure). (Second largest peak elutes at 2.00
minutes, 17%.)

PL332: Ethyl 4-((8-(trifluoromethyl)quinolin-4-yl)amino)piperidine-1-carboxylate
O
N

OEt

HN
PL332
N
CF 3

4-chloro-(8-trifluoromethyl)quinoline (1.50 g, 6.5 mmol), ethyl-4-amino-1-piperidine
carboxylate (1.02 g, 5.9 mmol), and phenol (3.04 g, 32 mol) were heated at 82ºC in a
sealed Carius vessel for 20 hours. Additional ethyl-4-amino-1-piperidine carboxylate
(0.20 g, 1.2 mmol) was added. The vessel was again sealed and heated for a further 3
days at 100ºC. whereupon TLC indicated that no unreacted quinoline remained. The
reaction mixture was diluted with chloroform (25 mL) and rinsed with 10% caustic soda
(5 x 10 mL), followed by further rinsing with brine (2 x 10 mL). The organic layer was
dried over MgSO4 and concentrated under reduced pressure with warming to yield a
thick, brown oil. This was diluted with dichloromethane and adsorbed onto silica, then
purified by flash chromatography on silica, eluting with a gradient of 100% hexanes to
100% ethyl acetate. The desired product was obtained as a beige solid (0.63 g, 27%, Rf =
0.4 (silica, ethyl acetate)). The quinoline phenolate was also isolated from
chromatography (a sparkling, white, crystalline solid, 0.94 g, 50%, mp = 175.4-181.0ºC,
Rf = 0.7 (silica, ethyl acetate)).
19

F NMR δ (ppm)(CHCl3-d): -60.8.
314

MS (ESI): m/z 368.15863 M + H (calculated 368.15804)
HPLC (method A) tR = 10.69 min (96% pure).

PL368: N-(piperidin-4-yl)-8-(trifluoromethyl)quinolin-4-amine

NH
HN
PL368
N
CF 3

PL332 (0.62 g, 1.7 mmol), 95% ethanol (50 mL), and 10% caustic soda (4 mL) were
allowed to heat, stirring, at reflux for 18 hours. As TLC indicated that the reaction was
not complete, 50% caustic soda (0.5 mL) was added, and reflux was continued for a
further 24 hours. TLC then indicated that the reaction was complete. After removal of
the solvent under reduced pressure with warming, the residue was partitioned between
chloroform (25 mL) and water (50 mL). After separation, the aqueous layer was
extracted with additional chloroform (3 x 10 mL), and the pooled organic layers were
dried (MgSO4) and concentrated under reduced pressure with warming to provide a pale
yellow solid (0.18 g, 36%, mp = 186.8-189.6°C).
1

H NMR δ (ppm)(CHCl3-d): 8.69 (1 H, d, J = 5.40 Hz), 8.00 (1 H, d, J = 7.33 Hz), 7.93
(1 H, d, J = 8.49 Hz), 7.46 (1 H, dd, J = 8.45, 7.34 Hz), 6.56 (1 H, d, J = 5.43 Hz), 4.93 (1
H, br d, J = 7.30 Hz), 3.63-3.64 (1 H, m), 3.20 (2 H, m), 2.79-2.80 (2 H, m), 2.16-2.20 (2
H, m), 1.49-1.50 (2 H, m).
MS (ESI): m/z 296.13763 M + H (calculated 296.13691)
HPLC (method A) tR = 2.85 min (92% pure). (Additional peaks elute at 1.81 minutes,
2%, and 7.54 minutes, 1%.)
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A.7.2: Bis-quinoline final products
PL241: 7-chloro-N-(3-(4-((7-chloroquinolin-4-yl)amino)piperidin-1yl)propyl)quinolin-4-amine
Primary method (for original method, see section A.7.3):

NH
HN

OMs

Cl

N

HN

HN

N

KI, K 2CO 3

+
Cl

N

CH 3CN,

80oC

NH
Cl

N

PL241
N

Cl

PL29 (1.20 g, 3.8 mmol), PL294 (1.05 g, 4.0 mmol), potassium carbonate (5.7 mmol,
0.79 g), a catalytic amount of potassium iodide, and 50 mL anhydrous acetonitrile were
allowed to heat for 48 hours at reflux, whereupon TLC indicated that the reaction was
complete. The reaction mixture was diluted with water (50 mL) and vacuum filtered.
The filtrate was concentrated under reduced pressure with warming, and the reaction
mixture was partitioned between 50/50 dichloromethane/chloroform (20 mL) and 10 mL
saturated sodium bicarbonate, followed by further extraction with three 10 mL portions
dichloromethane. The pooled organic layers were dried over anhydrous magnesium
sulfate and concentrated under reduced pressure. The resulting solid was combined with
the material filtered from the reaction mixture and recrystallized from 95% ethanol,
which afforded the desired product as a pale yellow, crystalline solid (1.30 g).
Concentration of the mother liquor yielded a further crop of crystals (0.06 g, total yield
71%, mp = 224-227°C (dec)).
1

H NMR δ (ppm)(CHCl3-d): 8.56 (1 H, d, J = 5.33 Hz, Q1-C2-H), 8.53 (1 H, d, J = 5.33
Hz, Q2-C2-H), 7.99 (1 H, d, J = 2.16 Hz, Q1-C5-H), 7.97 (1 H, d, J = 2.14 Hz, Q2-C5-H),
7.78 (1 H, d, J = 8.90 Hz, Q2-C8-H), 7.71 (1 H, d, J = 8.95 Hz, Q1-C8-H), 7.43 (1 H, dd, J
= 8.89, 2.18 Hz, Q1-C6-H), 7.35 (1 H, dd, J = 8.87, 2.16 Hz, Q2-C6-H), 7.02 (1 H, br t, J
= 4.27 Hz, Q1-C4-NH), 6.47 (1 H, d, J = 5.37 Hz, Q1-C3-H), 6.38 (1 H, d, J = 5.37 Hz,
Q2-C3-H), 4.92 (1 H, br d, J = 6.78 Hz, Q2-NH), 3.65 (1 H, m, Pip-CH), 3.42 (2 H, td,
JCH2 = 6.01, JNH = 4.35 Hz, Q1-NHCH2CH2CH2), 3.06 (2 H, m, piperidine-CH x 2
adjacent to alkyl chain), 2.67 (2 H, t, JCH2 = 5.64 Hz, Q1-NHCH2CH2CH2), 2.33 (2 H, m,
piperidine-CH x 2 adjacent to alkyl chain), 2.28 (2 H, m, piperidine CH x 2 adjacent to
CH-NH-Q2), 1.99 (2 H, apparent p, JCH2x2 = 5.75 Hz, Q1-NHCH2CH2CH2), 1.75 (water
signal overlaps m, ~2 H, piperidine CH x 2 adjacent to CH-NH-Q2).
13

C NMR δ (ppm)(CHCl3-d): 152.3 (Q1-C2), 152.0 (Q2-C2), 150.4, 149.4, 149.3, 148.4,
135.1, 134.7, 129.1 (Q-C5), 129.0 (Q-C5), 125.6 (Q1-C6), 124.8 (Q2-C6), 121.7 (Q2-C8),
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120.7 (Q1-C8), 117.5, 117.2, 99.6 (Q1-C3), 98.8 (Q2-C3), 58.2 (Q1-NHCH2CH2CH2),
52.5 (piperidine-C adjacent to alkyl chain), 49.5 (piperidine-CH-NH- Q2), 43.9 (Q1NHCH2CH2CH2), 32.0 (piperidine-C adjacent to CH-NH-Q2), 24.4 (Q1-NHCH2CH2CH2).
Note: Q1 and Q2 denote respectively the quinoline ring system on the left and that on the
right of the structure as shown above. For the quinoline ring system numbering, see
Figure 5, Chapter 1. Spectra are provided in Appendix C (Example spectra: PL241).
MS (ESI): m/z 480.17456 M + H (calculated 480.17163)
HPLC (method A) tR = 6.93 min (97% pure).

PL338: 7-chloro-N-(1-(3-(quinolin-4-ylamino)propyl)piperidin-4-yl)quinolin-4amine

HN

N
NH

N

PL338
N

Cl

3-(quinolin-4-ylamino)propyl methanesulfonate (0.61 g, 2.2 mol), PL294 (0.60 g, 2.3
mol), K2CO3 (0.45 g, 3.3 mol), and a catalytic amount of potassium iodide were heated
for 5 days in refluxing acetonitrile (25 mL), at which point TLC indicated that reaction
was complete. The solvent was removed under reduced pressure with warming (after
dilution with 10 mL water), and the residue was combined with water (50 mL) and
chloroform (80 mL). A large amount of material remained undissolved and was
recovered by vacuum filtration (a cream colored solid). The filtrate was placed in a
separatory funnel and separated, and the aqueous layer was extracted thrice with 10 mL
portions of chloroform. The pooled chloroform layers were dried (MgSO4) and
evaporated under reduced pressure with warming to yield a cloudy, pale yellow oil, 0.07
g. NMR indicated that the oil from extraction contained both product and starting
material, whereas the solid recovered from filtration was the desired product with very
little impurity. The latter was taken up in excess boiling 95% ethanol, and allowed to
evaporate gradually (at room temperature) to ~10 mL. Filtration afforded the desired
product as beige crystals (0.79 g, 81%, mp = 240-250°C (dec)).
1

H NMR δ (ppm)(DMSO-d6): 8.37-8.41 (3 H, m), 8.19 (1 H, d, J = 8.41 Hz), 7.77-7.79 (2
H, m), 7.61 (1 H, ddd, J = 8.43, 6.73, 1.31 Hz), 7.42-7.46 (2 H, m), 7.30 (1 H, br t, J =
5.24 Hz), 6.99 (1 H, br d, J = 7.49 Hz), 6.55 (1 H, d, J = 5.54 Hz), 6.48 (1 H, d, J = 5.37
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Hz), 3.50-3.53 (1 H, m), 3.41-3.46 (2 H, m), 2.95-2.98 (2 H, m), 2.46 (2 H, t, J = 6.79
Hz), 2.06-2.12 (2 H, m), 1.98-2.01 (2 H, m), 1.85 (2 H, apparent p, J = 6.68 Hz), 1.631.72 (2 H, m).
13

C NMR δ (ppm)(DMSO-d6): 151.8, 150.6, 149.9, 149.2, 149.1, 148.2, 133.3, 128.9,
128.6, 127.4, 124.4, 123.8, 123.7, 121.5, 118.8, 117.4, 99.1, 98.0, 55.7, 52.3, 49.6, 40.9,
30.9, 25.3.
MS (ESI): m/z 446.21096 M + H (calculated 446.21060)
HPLC (method A) tR = 6.07 min (99% pure).

PL337: 7-chloro-N-(3-(4-(quinolin-4-ylamino)piperidin-1-yl)propyl)quinolin-4amine

HN

N
NH

Cl

N

PL337
N

PL29 (0.83 g, 0.00264 mol), PL378 (0.63 g, 0.00277 mol), K2CO3 (0.55 g, 0.00396 mol),
and a catalytic amount of potassium iodide were heated for 24 hours in refluxing
acetonitrile (50 mL), at which point TLC indicated that reaction was complete. After
dilution with 10 mL water, the solvent was removed under reduced pressure with
warming. The residue was combined with additional water (30 mL in total) and
chloroform (30mL). A cream colored solid remained undissolved, and was recovered by
vacuum filtration. The filtrate was separated into two layers, and the aqueous layer was
extracted with chloroform (3 x 10 mL). The pooled organic layers were dried (MgSO4)
and evaporated under reduced pressure with warming to yield a waxy, yellow solid. This
solid, together with the solid obtained from filtration, was dissolved in excess boiling
95% ethanol (100 mL) and allowed to evaporate gradually (at room temperature) to ~ 10
mL. Filtration afforded the desired product as a beige solid (0.66 g, 56%, mp = 224228°C).
1

H NMR δ (ppm)(CHCl3-d): 8.58 (1 H, d, J = 5.28 Hz), 8.54 (1 H, d, J = 5.34 Hz), 8.01
(1 H, dd, J = 8.43, 1.20 Hz), 7.97 (1 H, d, J = 2.14 Hz), 7.77-7.81 (2 H, m), 7.68 (1 H,
ddd, J = 8.46, 6.84, 1.29 Hz), 7.51 (1 H, ddd, J = 8.38, 6.84, 1.30 Hz), 7.37 (1 H, dd, J =
8.88, 2.16 Hz), 7.11 (1 H, br t, J = 4.14 Hz), 6.49 (1 H, d, J = 5.35 Hz), 6.38 (1 H, d, J =
5.38 Hz), 4.93 (1 H, br d, J = 6.80 Hz), 3.66-3.69 (1 H, m), 3.43 (2 H, td, J = 5.97, 4.29
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Hz), 3.05-3.08 (2 H, m), 2.68 (2 H, t, J = 5.61 Hz), 2.30 (4 H, d, J = 14.10 Hz), 1.99 (2 H,
apparent p, J = 5.72 Hz), 1.72-1.81 (2 H, m).
13

C NMR δ (ppm)(DMSO-d6): 151.9, 150.7, 150.1, 149.1, 149.0, 148.5, 133.3, 129.0,
128.7, 127.5, 124.1, 124.0, 123.6, 122.0, 118.9, 117.4, 98.6, 98.6, 55.7, 52.4, 49.5, 41.0,
31.1, 25.3.
MS (ESI): m/z 446.21091 M + H (calculated 446.21060)
HPLC (method A) tR = 6.35 min (93% pure). (An additional peak elutes at 6.94 minutes,
6%.)

PL339: N-(3-(4-(quinolin-4-ylamino)piperidin-1-yl)propyl)quinolin-4-amine

HN

N
NH

N
PL339
N

3-(quinolin-4-ylamino)propyl methanesulfonate (0.76 g, 0.00271 mol), PL378 (0.65 g,
0.00285 mol), K2CO3 (0.56 g, 0.00407 mol), and a catalytic amount of potassium iodide
were heated for 24 hours in refluxing acetonitrile (40 mL), at which point TLC indicated
that reaction was complete. After dilution with 10 mL water, the acetonitrile was
removed by evaporation under reduced pressure with warming, and the residue was
combined with dichloromethane (30 mL) and water (30 mL). An undissolved tan solid
was removed by filtration, rinsing with dichloromethane and water. The
dichloromethane and water layers were separated, and the aqueous layer was extracted
with dichloromethane (3 x 10 mL), followed by drying of the pooled organic layers
(MgSO4) and evaporation under reduced pressure with warming to yield a yellow solid.
NMR indicated that this was primarily starting material, whereas the solid from filtration
was primarily the desired product. The latter was dissolved in excess boiling 95%
ethanol, and allowed to evaporate gradually (at room temperature) to approximately 10
mL. Filtration afforded a tan solid (0.80 g). This material was further purified by
automated flash chromatography on alumina, eluting with a gradient of 100% hexanes to
100% ethyl acetate. The desired product was obtained as a white solid (0.29 g, 26%, mp
=190.2-191.8°C, Rf =0.14 (alumina, 10/90 MeOH/EA v/v)).
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1

H NMR δ (ppm)(CHCl3-d): 8.56-8.58 (2 H, m), 7.95-8.04 (2 H, m), 7.87 (1 H, dd, J =
8.38, 1.31 Hz), 7.77 (1 H, dd, J = 8.41, 1.25 Hz), 7.65-7.65 (2 H, m), 7.49-7.49 (1 H, m),
7.41-7.41 (1 H, m), 7.01 (1 H, br t, J = 4.25 Hz), 6.49 (1 H, d, J = 5.35 Hz), 6.40 (1 H, d,
J = 5.34 Hz), 4.95 (1 H, br d, J = 6.91 Hz), 3.66-3.66 (1 H, m), 3.43 (2 H, td, J = 6.02,
4.41 Hz), 3.04-3.10 (2 H, m), 2.66-2.68 (2 H, m), 2.22-2.35 (4 H, m), 1.99 (2 H, p, J =
5.79 Hz), 1.77-1.80 (2 H, m).
MS (ESI): m/z 412.25005 M + H (calculated 412.24957)
HPLC (method A) tR = 4.06 min (97% pure).

PL335: 7-chloro-N-(1-(3-((8-(trifluoromethyl)quinolin-4-yl)amino)propyl)piperidin4-yl)quinolin-4-amine

HN

N
NH

N
CF 3

PL335

N

Cl

3-(8-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (0.50 g, 0.00144
mol), PL294 (0.39 g, 0.00151 mol), K2CO3 (0.20 g, 0.00145 mol), and a catalytic amount
of potassium iodide were heated for 5 days in refluxing acetonitrile (40 mL), at which
point TLC indicated that reaction was complete. After dilution with 10 mL water, the
acetonitrile was removed by evaporation under reduced pressure with warming, and the
residue was combined with chloroform (30 mL) and water (30 mL). A beige solid
remained undissolved and was removed by filtration, rinsing with chloroform and water.
After separation of the chloroform and water layers, the aqueous layer was extracted with
chloroform (3 x 7 mL), and the pooled organic layers were dried (MgSO4) and
evaporated under reduced pressure with warming to yield a pale yellow, waxy solid,
0.09g. NMR indicated that the solid from filtration was primarily the desired product.
This was dissolved in excess boiling 95% ethanol, and allowed to evaporate gradually (at
room temperature) to approximately 10 mL. Filtration afforded the desired product as
sparkling, beige crystals (0.52 g, 70%, mp = 225-233°C (dec)).
1

H NMR δ (ppm)(DMSO-d6): 8.49-8.52 (2 H, m), 8.36-8.39 (2 H, m), 8.03 (1 H, d, J =
7.29 Hz), 7.78 (1 H, d, J = 2.25 Hz), 7.53-7.57 (2 H, m), 7.45 (1 H, dd, J = 9.01, 2.28
Hz), 6.98 (1 H, br d, J = 7.48 Hz), 6.62 (1 H, d, J = 5.50 Hz), 6.55 (1 H, d, J = 5.57 Hz),
3.44-3.53 (1 H, m), 3.35-3.36 (2 H, m), 2.96 (2 H, m), 2.44-2.47 (2 H, m), 2.09 (2 H, t, J
= 11.56 Hz), 1.99 (2 H, m), 1.86 (2 H, apparent p, J = 6.74 Hz), 1.62-1.71 (2 H, m).
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13

C NMR δ (ppm)(DMSO-d6): 151.9, 151.4, 150.3, 149.3, 149.1, 144.9, 133.4, 127.4,
126.7, 124.4, 123.9, 123.1, 122.4, 119.4, 117.5, 99.1, 99.0, 55.6, 52.3, 49.6, 40.9, 31.0,
25.3.
MS (ESI): m/z 514.19866 M + H (calculated 514.19798)
HPLC (method A) tR = 6.53 min (99% pure).

PL341: 8-(trifluoromethyl)-N-(3-(4-((8-(trifluoromethyl)quinolin-4yl)amino)piperidin-1-yl)propyl)quinolin-4-amine

HN

N
NH

N
CF 3

PL341
N
CF 3

3-(8-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (0.66 g, 1.9 mmol),
PL368 (0.59 g, 2.0 mmol), K2CO3 (0.39 g, 2.8 mmol), and a catalytic amount of
potassium iodide were heated for 27 hours in refluxing acetonitrile (50 mL), at which
point TLC indicated that reaction was complete; however, heating at reflux was
continued for an additional 18 hours. The solvent was removed by evaporation under
reduced pressure with warming, and the resulting golden brown solid was combined with
chloroform (30 mL) and water (30 mL). A large amount of solid material remained
undissolved and was removed by filtration, rinsing with chloroform and water (a white
solid). This material was dissolved in excess boiling ethyl acetate, followed by gradual
evaporation at room temperature to induce crystallization. The fine, off-white crystals
thus obtained proved to be the desired product (0.20 g, 19%).
1

H NMR δ (ppm)(CHCl3-d): 8.72 (1 H, d, J = 5.35 Hz), 8.69 (1 H, d, J = 5.35 Hz), 8.038.07 (2 H, m), 7.96-8.00 (2 H, m), 7.52 (1 H, dd, J = 8.41, 7.33 Hz), 7.42 (1 H, dd, J =
8.41, 7.27 Hz), 7.09 (1 H, br t, J = 4.24 Hz), 6.58 (1 H, d, J = 5.41 Hz), 6.48 (1 H, d, J =
5.41 Hz), 4.97 (1 H, br d, J = 6.71 Hz), 3.66-3.69 (1 H, m), 3.44 (2 H, td, J = 6.01, 4.30
Hz), 3.06-3.09 (2 H, m), 2.68 (2 H, t, J = 5.59 Hz), 2.28-2.33 (4 H, m), 1.99-2.05 (2 H,
apparent p, J = 5.69 Hz), 1.73-1.82 (2 H, m).
13

C NMR δ (ppm)(CHCl3-d): 152.0, 151.7, 150.4, 148.3, 145.6, 145.5, 127.7, 127.4,
124.6, 123.5, 123.2, 122.3, 119.8, 119.4, 100.1, 99.3, 58.2, 52.5, 43.9, 32.0, 24.3.
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MS (ESI): m/z 548.22434 M + H (calculated 548.22519)
HPLC (method A) tR = 6.93 min (99% pure).

PL340: 7-chloro-N-(3-(4-((8-(trifluoromethyl)quinolin-4-yl)amino)piperidin-1yl)propyl)quinolin-4-amine

HN

N
NH

Cl

N
PL340

N
CF 3

PL29 (0.59 g, 1.9 mmol), PL368 (0.58 g, 2.0 mmol), K2CO3 (0.39 g, 2.8 mmol), and a
catalytic amount of potassium iodide were heated for 24 hours in refluxing acetonitrile
(50 mL), at which point TLC indicated that reaction was complete. The solvent was
removed by evaporation under reduced pressure with warming, and the resulting ochre
solid was combined with chloroform (30 mL) and water (30 mL). A large amount of
solid material remained undissolved and was removed by filtration, rinsing with
chloroform and water. The chloroform and water layers of the filtrate were separated,
and the aqueous layer was extracted with chloroform (3 x 10 mL), dried (MgSO4), and
evaporated under reduced pressure with warming. This material was combined with the
insoluble material from extraction (above), and taken up in excess boiling 95% ethanol.
This was allowed to cool and evaporate gradually at room temperature. The crystals that
formed were recovered by filtration and further purified by automated flash
chromatography on basic alumina, eluting with a gradient of 100% hexanes to 100%
ethyl acetate. The desired product was obtained as a beige solid (0.38 g, 40%, mp = 205207°C, Rf = 0.2 (alumina, EA)).
1

H NMR δ (ppm)(CHCl3-d): 8.72 (1 H, d, J = 5.35 Hz), 8.54 (1 H, d, J = 5.35 Hz), 8.04
(1 H, d, J = 7.31 Hz), 7.99 (1 H, d, J = 8.53 Hz), 7.97 (1 H, d, J = 2.15 Hz), 7.78 (1 H, d, J
= 8.92 Hz), 7.53 (1 H, dd, J = 8.44, 7.30 Hz), 7.35 (1 H, dd, J = 8.88, 2.17 Hz), 7.03 (1 H,
br t, J = 4.28 Hz), 6.58 (1 H, d, J = 5.41 Hz), 6.38 (1 H, d, J = 5.39 Hz), 4.98 (1 H, br d, J
= 6.79 Hz), 3.66-3.68 (1 H, m), 3.43 (2 H, td, J = 5.99, 4.32 Hz), 3.06-3.09 (2 H, m), 2.68
(2 H, t, J = 5.59 Hz), 2.28-2.35 (4 H, m), 1.99 (2 H, apparent p, J = 5.69 Hz), 1.71-1.80 (2
H, m).
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13

C NMR δ (ppm)(DMSO-d6): 151.9, 151.3, 150.1, 149.3, 149.0, 145.0, 133.3, 127.4,
127.1, 125.8, 124.0, 123.9, 122.1, 119.3, 117.4, 99.5, 98.5, 55.6, 52.3, 49.6, 40.9, 30.9,
25.3.
MS (ESI): m/z 514.19879 M + H (calculated 514.19798)
HPLC (method A) tR = 6.95 min (>99% pure).
A.7.3: Original method used to synthesize PL241 (for primary method, see page
316)
PL67: N-(3-(4-aminopiperidin-1-yl)propyl)-7-chloroquinolin-4-amine (Burgess,
2008):
HN

Na2CO3

OSO2CH3
PL 29

NH2
HN

N

O

Dean and Stark
water separator,
reflux, 1h

HN

Cl

HN

N

N
85 oC, 24 h

N
Cl

N

5/95 H2O/isopropanol
25oC, 1h
HN

N
NH2

Cl

N

PL 67

Methyl isobutyl ketone, 125 mL, was allowed to reflux in a round bottom flask equipped
with a Dean and Stark water separator. After 30 minutes, sodium carbonate (0.74 g, 7.0
mmol) and 4-aminopiperidine (0.580 mL, 5.5 mmol) were added and reflux was
continued for 1 hour, at the end of which time TLC indicated that no more of the amine
starting material was present. The reaction was allowed to cool to 85°C, and PL29 (1.45
g, 4.6 mmol) was added. After 16 hours had elapsed, TLC indicated that no more PL29
was present. The reaction mixture was washed with water (50 mL) to remove sodium
carbonate, and the solvent was then evaporated under reduced pressure. The resulting
amber oil was stirred for 1.5 hours in a mixture of 50 mL isopropanol and 5 mL water,
and the solvent was then evaporated under reduced pressure. The resulting liquid was
partitioned between ethyl acetate (20 mL) and saturated sodium bicarbonate (25 mL), and
the aqueous layer was extracted with additional ethyl acetate (3 x 10 mL). During this
procedure, a yellow oil remained insoluble; NMR indicated that this was pure product.
After removal of water therefrom by heating under reduced pressure, this material was
used without further purification.
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PL241, original method (Based upon Andersag, 1948; Surrey, 1951; Burgess, 2008):

HN

N

HN

Cl

Phenol

NH2
Cl

N

+

120 oC, 40 h
N

Cl

N
NH

Cl

N
N

Cl

PL 67 (0.30 g, approximately 0.94 mmol), 4,7-dichloroquinoline (0.59g, 3.00 mmol), and
1.3 g phenol were heated for 40 hours at 120°C. The resulting dark brown oil was taken
up in dichloromethane (20 mL) and washed with 1.0 M caustic soda (6 x 10 mL),
followed by brine (10 mL). The organic layer was dried over anhydrous magnesium
sulfate and evaporated under reduced pressure to yield a brown oil. This was purified by
column chromatography on alumina, eluting with ethyl acetate and then with 95/5 ethyl
acetate/methanol (v/v). The resulting solid was recrystallized using a Craig tube from 4:1
ethyl acetate:methanol, which afforded the desired product as a beige solid (0.034g, 7%,
Rf = 0.6 (basic alumina, EA/MeOH, 85/15, v/v)).
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APPENDIX B: Tables of antiplasmodial activity and cytotoxicity
Table B1: Ring-modified Reversed Chloroquine type compounds and their in vitro
activity against P. falciparum malaria
Note: Organized by reversal agent moiety.
Code
number

Quinoline
ring system
substitution
5

4

6
8

(purchased)

Structure
D6

Dd2

7G8

3

7

CQ

IC50 (nM)

N
1

2

7-Cl

6.9

102

106
Cl

PL127
(Steven
Burgess)

None (H)

90

>250

N

HN

N
N

HN

>250

N

PL64
(Steven
Burgess)

HN

N
N

None (H)

0.88

5.0

N
HN

PL06
(Steven
Burgess)

N
N

7-Cl

1.9

2.6

11
N

Cl

HN

N

Cl

PL270

6-Cl

3.4

7.9

N

29
N
HN

N
N

PL271

8-Cl

66

>250

>250
N
Cl
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HN

N
N

PL305

7,8-diCl

108

491

1360
N

Cl
Cl

Cl HN

PL379

N
N

5,7-diCl

10

41

32
N

Cl

HN

N

F

PL285

6-F

10

16

N

23
N
HN

N
N

PL310

7-Br

1.2

<2.5

<2.5
Br

N

HN

N

Br

PL308

6-Br

<2.5

<2.5

N

6.8
N

HN

N

I

PL317

6-I

1.7

5.0

N

2.5
N
HN

N
N

PL147/301

2-CF3

402

639

1103
N

CF3

HN

N
N

PL142

7-CF3

1.5

3.9

5.9
N

F3C

HN

PL148

6-CF3

3.7

10.4

14

N

F3C

N
N
HN

N
N

PL149

8-CF3

>250

>250

>250
N
CF3

326

HN

N
N

PL280

2,8-diCF3

>250

>250

>250
N

CF3

CF3

Cl HN

N
N

PL303

2-CF3-5-Cl

690

1250

1420
N

CF 3

HN

PL383

N
N

6-CH3

2.5

9

4.5
N

HN

PL394

N
N

8- CH3

14

74

41
N

PL68
(Steven
Burgess)

7-Cl

16

30

HN

12

N

N
Cl

PL374

N

N

None (H)

420

>2500

N

HN

>2500

N

N

N

N
N

PL230

7-CF3

7.3

8.7

HN

43

6-CF3

20

>250

>250

N

N
F3C

PL278

N

N

N

HN

N

N

F3C

N

N
N

HN

PL268

8-CF3

>250

>250

>250

N

N
N

N

N
CF3

327

PL69
(Steven
Burgess)

7-Cl

0.9

2.2

HN

1.8

N

N
H
Cl

PL375

N

N

None (H)

28

789

N

HN

261

N

N

N

N
H
N

PL242

7-CF3

2.4

1.3

HN

1.1

6-CF3

5.2

11

7.9

N

N
H
F3C

PL279

N

N

N

HN

N

N

F3C

N

N
H
N

HN

PL269

8-CF3

>250

>250

N

N

>250

N

N
H
N
CF3

PL106
(Bornface
Gunsaru)

HN

7-Cl

3.0

6.0

N
N

6.1

N

N

Cl

HN

PL283

6-Cl

9.2

22

25

N

Cl

N
N

N

HN

PL284

8-Cl

465

>2500

N
N

1570

N

N
Cl

PL367

Cl HN

5,7-diCl

33

67

N

83
Cl

6,7-diCl

<2.5

<2.5

6.8

Cl
Cl

N

N
HN

PL307

N

N
N

N

N

328

HN

PL306

7,8-diCl

217

990

N
N

1320
Cl

N

N
Cl

PL286

6-F

22

61

49

HN

N

F

N
N

N
HN

PL311

7-Br

2.2

4.4

N
N

7.2
Br

N

N
HN

PL309

6-Br

8.6

18

30

N

Br

N
N

N

HN

PL318

6-I

2.6

5.2

6

N

I

N
N

N
HN

PL392

7-I

<2.5

<2.5

N
N

<2.5
I

N

N
HN

PL302

2-CF3

>2500

1294

N
N

394
N

N

CF3

HN

PL287

7-CF3

2.5

11

N
N

8.6

N

N

F3C

HN

PL276

6-CF3

7.2

12

23

N

F3C

N
N

N

HN

PL281

8- CF3

>250

>250

N
N

>250

N

N
CF3

HN

PL399

2-CH3-7-Cl

12

38

N
N

29
Cl

N
HN

PL398

2-CF3-7-Cl

660

540

N

CH 3
N
N

65
Cl

N

CF 3

N

329

HN

PL282

6-NO2

11

15

N

O2N

11

N
N

N

HN

PL393

8-CH3

350

1830

N
N

950

N

N
HN

PL391

7-OCH3

21

53

N
N

58

N

N

O

HN

N
N

PL390

8-OCH3

240

930

950

N

N
O

PL156
(Bornface
Gunsaru)

HN

7-Cl

1.4

<0.2

N

<0.2
Cl

N
HN

PL397

6-Cl

-

29

N

7

F
N

Cl

N
N
HN

PL275

6-CF3

-

-

1.4

F
N

F3C

N
N

HN

PL315

7-CF3

<2.5

3.8

N

1.5
N

F3C

PL157
(Bornface
Gunsaru)

HN

7-Cl

1

<0.2

-

-

N
N

Cl

6-Cl

F

<0.2
N
HN

PL382

F

N

5.3

OCH3
N

Cl

N
N
HN

PL277

6-CF3

-

-

2.6

OCH3
N

F3C

N
N
HN

PL316

7-CF3

1.7

2.6

1.4

O
N
N

F3C

N

O
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>2500 >2500
PL262

>2500

HN

N
N

8-CF3
N

O

CF3

PL158
(Bornface
Gunsaru)

HN

7-Cl

1

N

<0.2
Cl

1020
PL267

<0.2
2630

N

N

1080

HN

CF 3
N
N

8-CF3
N

CF3

CF3

HN

PL08
(Steven
Burgess)

F

N
N

7-Cl

15

19

-

Cl

N

F

-

-

-

HN

F

N
N

PL264

7-CF3

F3C

N

F

331

Table B2: Comparison of in vitro activity of 6- and 7- substituted compounds
(against P. falciparum)
Structure

Quinoline Code
ring system number
substitution
(R)
5

7G8

4

6

3

7
8

N
1

7-Cl

2

CQ

N

HN

Cl

IC50 (nM)
D6
Dd2

6.9

102

108

1.9
3.4
1.2
<2.5
1.5
3.7
2.4

2.6
7.9
<2.5
<2.5
3.9
10.4
1.3

11
29
<2.5
6.8
5.9
14
1.1

5.2

11

7.9

3.0
9.2
2.2
8.6
<2.5
2.6
2.5
7.2
<2.5
1.4
<2.5
1
1.7

6.0
22
4.4
18
<2.5
5.2
11
12
<2.5
<0.2
29
3.8
<0.2
2.6

6.1
25
7.2
30
<2.5
6
8.6
23
6.8
<0.2
7
1.5
1.4
<0.2
5.3
2.6
1.4

N
HN

7-Cl
6-Cl
7-Br
6-Br
7-CF3
6-CF3
7-CF3
6-CF3

N
N

R
N

HN

N

N
N
H

R

PL06
PL270
PL310
PL308
PL142
PL148
PL242
PL279

N

N
HN

N
N

R

N

N

HN

N
N

R
N
HN

F
N
N

R
N

OCH3

7-Cl
6-Cl
7-Br
6-Br
7-I
6-I
7-CF3
6-CF3
6,7-diCl
7-Cl
6-Cl
7-CF3
6-CF3
7-Cl
6-Cl
7-CF3
6-CF3

PL106
PL283
PL311
PL309
PL392
PL318
PL287
PL276
PL307
PL156
PL397
PL315
PL275
PL157
PL382
PL277
PL316
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Table B3: Comparison of in vitro activity of chloro-, bromo-, and fluoro- substituted
compounds (against P. falciparum)
Structure

Quinoline Code
ring system number
substitution
(X)
5

8

7G8

N
1

6.9

102

108

2

7-Cl

CQ

7-Cl
7-Br

PL06
PL310

N

HN

N

HN

N
N

N
HN

N

X

N
N
HN

N
N

X

Dd2

3

7

X

D6

4

6

Cl

IC50 (nM)

N

N
HN

X

N

1.9

2.6

11

1.2

<2.5

<2.5

16
7.9
<2.5
5.0
6.0
4.4
<2.5
61

23
29
6.8
2.5
6.1
7.2
<2.5
49

22
18
5.2

25
30
6

6-F
6-Cl
6-Br
6-I

PL285
PL270
PL308
PL317

7-Cl
7-Br
7-I

PL106
PL311
PL392

6-F

PL286

10
3.4
<2.5
1.7
3.0
2.2
<2.5
22

6-Cl
6-Br
6-I

PL283
PL309
PL318

9.2
8.6
2.6

N
N

N
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Table B4: Comparison of in vitro activity of chloro-, trifluoromethyl-, and nitrosubstituted compounds (against P. falciparum)
Structure

Quinoline
ring system
substitution
(R)
5

IC50 (nM)
7G8

4

6

3

7
8

N
1

2

Code
Number

D6

Dd2
108

N

HN

Cl

N
HN

N
N

R
N

HN

N

N
N
H

R
N
N
R

N

N

HN

N
N

R
N
HN

F
N
N

R
N

CQ
PL06
PL142
PL270
PL148
PL69
PL242

6-CF3
7-Cl
7-CF3
6-Cl
6-CF3
6-NO2
7-Cl
7-CF3
6-Cl
6-CF3
7-Cl
7-CF3
6-Cl
6-CF3

PL279
PL106
PL287
PL283
PL276
PL282
PL156
PL315
PL397
PL275
PL157
PL277
PL382
PL316

N

N
HN

CQ
7-Cl
7-CF3
6-Cl
6-CF3
7-Cl
7-CF3

OCH3

6.9
1.9
1.5
3.4
3.7
0.9
2.4

102
2.6
3.9
7.9
10.4
2.2
1.3

11
5.9
29
14
1.8
1.1

5.2

11

7.9

3.0
2.5
9.2
7.2
11
1.4
<2.5
1
1.7

6.0
11
22
12
15
<0.2
3.8
29
<0.2
2.6

6.1
8.6
25
23
11
<0.2
1.5
7
1.4
<0.2
2.6
5.3
1.4
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Table B5: Comparison of in vitro activity of chloro-, des-chloro-, methyl, and
methoxy- substituted compounds (against P. falciparum)
Structure

Quinoline
ring system
substitution
(R)
5

3

7
8

N
1

CQ
N

None (H)

R
N
HN

7-Cl

R

N
N

N

Code
Number
CQ
PL127
(Steven
Burgess)

N

None (H)
6-Cl
6-CH3
8-Cl
8-CH3
7-Cl
7-OCH3
8-Cl
8-CH3
8-OCH3

D6
6.9

Dd2
102

108

90

>250

>250

1.9

2.6

11

(Steven
Burgess)

0.88

5.0

-

PL270
PL383
PL271
PL394
PL106
PL391
PL284
PL393
PL390

3.4
2.5
66
14
3.0
21
465
350
241

7.9
9
>250
74
6.0
53
>2500
1825
930

29
4.5
>250
41
6.1
58
1570
951
946

(Steven
Burgess)

PL64

N

R

2

PL06

N
N

HN

7G8

4

6

HN

IC50 (nM)
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Table B6: In vitro activity of bis-quinoline compounds
Code
number

D6

IC50 (nM)
Dd2
7G8

Structure

HN

PL241

0.063

0.054

0.014

N
NH

Cl

N
N
HN

Cl

N
NH

PL340

<2.5

-

<2.5

Cl

N
N
CF 3

HN

PL335

<2.5

-

N
NH

<2.5
N
CF 3

N

HN

Cl

N
NH

PL341

35

-

259

N
CF 3

N
CF 3
HN

PL337

<2.5

-

<2.5

N
NH

Cl

N
N
HN

PL338

<2.5

-

<2.5

N
NH

N
N
HN

PL339

17

-

28

Cl

N
NH

N
N
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Table B7: In vitro cytotoxicity data against mouse spleen lymphocytes
Compound

Cytotoxicity (LC50 in nM)

Chloroquine

12400

Structure
N

HN

Cl

PL06

1100

N
HN

N
N

N

Cl

PL64

1600

HN

N
N

N

PL69

6500
HN

N

N

N

N
H
Cl

PL106

N

13300

HN

N
N

PL142

12500

N

N

Cl

HN

N
N

N

F3C

PL148

4900

HN

N

F3C

N
N

PL149

11000

HN

N
N

N
CF3

337

PL242

4800
HN

N

N
N
H

F3C

PL241

190

N

N

HN

N
NH

Cl

N
N

Cl
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APPENDIX C: Sample NMR spectra: PL241
The following spectra were run at 600 MHz. The solvent used was CDCl3, except where
noted (it was necessary to run an additional 1H spectrum in DMSO-d6 to confirm the
suspected integration of one peak that was overlapped by the water signal in CDCl3).
TMS was used as a reference. The one-dimensional spectra shown here were processed
using DataChord Spectrum Analyst 4.1.rc39, while the two-dimensional spectra were
processed using Bruker Topspin 2.1.

HN

N
NH

Cl

N
PL241

N

Cl

Spectral assignments (see also Appendix A, p. 310):
1

H NMR δ (ppm)(CHCl3-d): 8.56 (1 H, d, J = 5.33 Hz, Q1-C2-H), 8.53 (1 H, d, J = 5.33
Hz, Q2-C2-H), 7.99 (1 H, d, J = 2.16 Hz, Q1-C8-H), 7.97 (1 H, d, J = 2.14 Hz, Q2-C8-H),
7.78 (1 H, d, J = 8.90 Hz, Q2-C5-H), 7.71 (1 H, d, J = 8.95 Hz, Q1-C5-H), 7.43 (1 H, dd, J
= 8.89, 2.18 Hz, Q1-C6-H), 7.35 (1 H, dd, J = 8.87, 2.16 Hz, Q2-C6-H), 7.02 (1 H, br t, J
= 4.27 Hz, Q1-C4-NH), 6.47 (1 H, d, J = 5.37 Hz, Q1-C3-H), 6.38 (1 H, d, J = 5.37 Hz,
Q2-C3-H), 4.92 (1 H, br d, J = 6.78 Hz, Q2-NH), 3.65 (1 H, m, Pip-CH), 3.42 (2 H, td,
JCH2 = 6.01, JNH = 4.35 Hz, Q1-NHCH2CH2CH2), 3.06 (2 H, m, piperidine-CH x 2
adjacent to alkyl chain), 2.67 (2 H, t, JCH2 = 5.64 Hz, Q1-NHCH2CH2CH2), 2.33 (2 H, m,
piperidine-CH x 2 adjacent to alkyl chain), 2.28 (2 H, m, piperidine CH x 2 adjacent to
CH-NH-Q2), 1.99 (2 H, p, JCH2x2 = 5.75 Hz, Q1-NHCH2CH2CH2), 1.75 (water signal
overlaps m, ~2 H, piperidine CH x 2 adjacent to CH-NH-Q2).
13

C NMR δ (ppm)(CHCl3-d): 152.3 (Q1-C2), 152.0 (Q2-C2), 150.4, 149.4, 149.3, 148.4,
135.1, 134.7, 129.1 (Q-C8), 129.0 (Q-C8), 125.6 (Q1-C6), 124.8 (Q2-C6), 121.7 (Q2-C5),
120.7 (Q1-C5), 117.5, 117.2, 99.6 (Q1-C3), 98.8 (Q2-C3), 58.2 (Q1-NHCH2CH2CH2),
52.5 (piperidine-C adjacent to alkyl chain), 49.5 (piperidine-CH-NH- Q2), 43.9 (Q1NHCH2CH2CH2), 32.0 (piperidine-C adjacent to CH-NH-Q2), 24.4 (Q1-NHCH2CH2CH2).
Note: Q1 and Q2 denote the quinoline ring system on the left and right of the figure,
respectively. For quinoline ring numbering system, see Figure 5, Chapter 1.
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List of spectra:
Figure C1: 1H NMR spectrum of PL241 in CDCl3, full view.
Figure C2: 1H NMR spectrum of PL241 in CDCl3, expansion 1 of 3 (aromatic region,
part 1).
Figure C3: 1H NMR spectrum of PL241 in CDCl3, expansion 2 of 3 (aromatic region,
part 2).
Figure C4: 1H NMR spectrum of PL241 in CDCl3, expansion 3 of 3 (aliphatic region,
part 1).
Figure C5: 13C NMR spectrum of PL241 in CDCl3, full view.
Figure C6: 13C NMR spectrum of PL241 in CDCl3, aliphatic region only.
Figure C7: COSY spectrum of PL241 in CDCl3.
Figure C8: HSQC spectrum of PL241 in CDCl3.
Figure C9: HMBC spectrum of PL241 in CDCl3.
Figure C10: NOESY spectrum of PL241 in CDCl3.
Figure C11: 1H NMR spectrum of PL241 in DMSO-d6.
Figure C12: 1H NMR spectrum of PL241 in DMSO-d6, aliphatic region only.
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Figure C1: 1H NMR spectrum of PL241 in CDCl3, with integrals (see figures C2, C3, and C4 for
expanded views).

6
Figure C2: 1H NMR spectrum of PL241 in CDCl3, expansion 1 of 3 (aromatic region, part 1).
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Figure C3: 1H NMR spectrum of PL241 in CDCl3, expansion 2 of 3 (aromatic region, part 2).

Figure C4: 1H NMR spectrum of PL241 in CDCl3, expansion 3 of 3 (aliphatic region).
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Figure C5: 13C NMR spectrum of PL241 in CDCl3 (see figure C6 for expanded aromatic region).

Figure C6: 13C NMR spectrum of PL241 in CDCl3, aromatic region only.
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Figure C7: COSY spectrum of PL241 in CDCl3, showing direct proton to proton interactions.
344

Figure C8: HSQC spectrum of PL241 in CDCl3, showing direct proton to carbon interactions
(split into two expanded regions to show detail).
345

Figure C9: HMBC spectrum of PL241 in CDCl3, showing 13C - 1H multiple bond correlations.
346

Figure C10: NOESY spectrum of PL241 in CDCl3, showing proton to proton interactions through
space.
347

Figure C11: 1H NMR spectrum of PL241 in DMSO-d6, with integrals (see figure C12 for
expanded aliphatic region). This spectrum was used to confirm the suspected integration of a
peak overlapped by the water signal in the CDCl3 spectrum (here at 1.68 ppm).

Figure C12: 1H NMR spectrum of PL241 in DMSO-d6, aliphatic region.
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